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Abstract 
Photobiomodulation refers to low-intensity light therapy, utilising wavelengths in 
the near-infrared region of the electromagnetic spectrum to elicit biological 
effects. 
The principle aim of this investigation was to explore signalling pathways 
initiated by IR1072, with particular focus on heat shock proteins (HSPs), a 
family of proteins known to target cellular aggregates which are involved in the 
maintenance of cellular homeostasis. This was further examined by exploring 
the role of age and sex in the magnitude of biological effects induced. Another 
aim of this study was to explore the cytoprotective potential of IR1072 in 
conjunction with Alzheimer’s disease-related insults. 
The results of this study show chronic IR1072 exposure altered the expression 
of a number of HSPs in both CD-1 and TASTPM mice; including HSP105, 
HSP70, HSP27, and αB crystallin. The magnitude of effect differed with age and 
sex of CD-1 and TASTPM mice respectively; these differences coincided with 
altered endogenous activity of electron transport chain components. Acute 
exposure of CAD neuronal cultures provided significant neuroprotection against 
oxidative-stress and β-amyloid insults. 
Further characterisation of the CD-1 and TASTPM strains during ageing was 
established. CD-1 mice demonstrated reduced TARP γ2 with age, which may 
underlie learning deficits that become apparent during ageing. Chronic IR1072 
exposure significantly increased TARP γ2 in 7 and 13 month old CD-1 mice, 
perhaps explaining improved working-memory reported following IR1072 
exposure. Acute treatments of CD-1 mice altered Complex I and II activity in 
mitochondria. 
Chronic IR1072 exposure Caenorhabditis elegans was shown to consistently 
extend lifespan. This model system aided in establishing pathways essential for 
biological effects of IR1072, demonstrating the importance of HSF1 driven 
pathways, in particular those requiring HSP70. In conclusion, this research 
revealed mechanisms initiated by photobiomodulation at IR1072 that act to re-
establish homeostasis, profoundly reduce amyloid load, prevent cell stress and 
cell death. 
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 Chapter 1: Literature Review and Aims 
 
1.1 Photobiomodulation and Infrared Light 
1.1.1 Electromagnetic Spectrum and Infrared Light 
The electromagnetic spectrum, EM, is composed of different categories of light, 
as shown in figure 1.1. These ‘categories’ of light differ due to the unique 
properties of the individual photons which make up each wavelength within 
these groupings of light. The photons at a specific wavelength possess different 
properties, both magnetic and electrical, to photons which comprise other 
wavelengths (Enwemeka, 2004, Hamblin and Demidova, 2006). Wavelengths in 
the infrared category are longer than wavelengths of visible light and are thus 
not visible to the human eye. 
 
 
Figure 1.1. Electromagnetic Spectrum of Light, demonstrating the subcategories that infrared 
light is split into. 
 26 
Infrared radiation accounts for 40% of the solar radiation that reaches the 
earth’s surface (Frank et al., 2004). Near Infrared (NIR) light, typically defined 
as 600-1500 nm, has been shown to have a wide range of biological actions 
and therapeutic benefits. A great deal of research has been undertaken to 
establish the optimal parameters; whether that be wavelength, fluence, dosage 
or light source, for optimal biological effect (Laser or LEDs; Hamblin and 
Demidova, 2006, Tsai et al., 2001).  
There are advantages and disadvantages for the use of both lasers and LEDs 
(Light Emitting Diodes) in the clinical application of NIR to biological tissues. 
LASERs (Light Amplification by the Stimulated Emission of Radiation) have 
advantages over LEDs as they are able to specifically emit monochromatic light 
and typically have an easily tuneable wavelength; whereas LEDs have a typical 
bandwidth of approximately 25 nm. Lasers have other limitations; they emit a 
large amount of heat, potentially causing tissue damage, they usually have a 
small beam width making the treatment of large areas of tissue difficult, as well 
as a risk of blinding to the user if correct safety measures are not taken 
(Desmet et al., 2006, Karu, 1999, Whelan et al., 2001, Wong-Riley et al., 2005).  
LEDs offer an efficient alternative to lasers; they are easily able to be configured 
to emit a range of wavelengths, particularly important as some data show 
combined wavelengths are required for optimal beneficial effects (Whelan et al., 
2001). They are also more affordable, portable and are able to be arranged in a 
variety of array conformations for the treatment of large or complex areas; they 
produce very little heat and have been reported to penetrate to a depth of 
approximately 23 cm in human tissue, depending on the use of an appropriate 
wavelength (Desmet et al., 2006, Whelan et al., 2001, Wong-Riley et al., 2005). 
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1.1.2 Photobiomodulation 
Photobiomodulation is the use of a low energy light source to elicit biological 
effects. It is also commonly referred to as Low-Level Light Therapy, LLLT, or 
Low-Intensity Light Therapy, LILT. Following the development of the laser by 
Theodore Maiman in 1960, a mechanism was available to study the effects of 
monochromatic, or coherent light, on biological tissues (Enwemeka, 2004). 
Work with NIR began in Budapest, Hungary, in 1967 with Endre Mester. Using 
a laser emitting infrared light, Mester undertook experiments to investigate the 
effects of the laser on tumour cells in mice. Mester implanted cancer cells 
underneath the skin of the mice, to determine whether laser stimulation would 
cause the proliferation or eradication of the cells. Surprisingly, Mester found that 
following irradiation with his ruby laser, the cells did not form tumours, nor did 
the irradiation kill the cancer cells. Mester did discover that the incisions made 
to introduce the cancer cells, healed more quickly in irradiated animals. Also, 
the dorsal hair removed prior to the incisions grew back at a significantly faster 
rate in irradiated mice (Enwemeka, 2004, Hamblin and Demidova, 2006).  
LLLT is frequently termed as having a ‘biphasic dose response’, whereby levels 
above or below the optimum exposure conditions result in diminished biological 
effects, suggesting the magnitude of effect is determined by the fluence, energy 
density over a given area, of the light therapy. LLLT appears to follow the Arndt-
Schulz law, if insufficient energy is applied no effect will be observed, and if too 
much energy is supplied, ‘bio-inhibition’ occurs (Hamblin and Demidova, 2006, 
Huang et al., 2009). 
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An important factor to consider is the potential depth of tissue infiltration by NIR 
before proposing therapeutic use. Depth of tissue penetration is proportional to 
absorption and scattering coefficients, which are intrinsically linked to the 
structure and function of tissues. As LLLT passes through tissue, some will be 
absorbed by chromophores, this is dependent on wavelength and on the 
density of chromophores, for example blood-rich tissues absorb more infrared 
light at certain wavelengths due to high haemoglobin level and some NIR is lost 
through scattering due to organelles in the cell. Investigation of photon-
scattering in a number of tissues from the rat, found that mitochondria content 
was proportional to the degree of scattering during NIR exposure (Beauvoit et 
al., 1995). The fact that defined action spectra can be constructed for specific 
cellular responses confirms light absorption by specific molecular chromophores 
(Huang et al., 2009). 
Spectroscopic data investigating propagation of NIR through human tissue is 
under investigation. NIR, ranging from 630-800 nm, has been shown to have 
high tissue penetrability; investigations using muscle in the forearm and calf 
have shown NIR can travel up to 23 cm through the skin into the muscle tissue. 
The magnitude of infiltration differs depending on tissue type, wavelength and 
fluence; a great deal of investigation is still required in this area in order to 
exploit the full biological effect of LLLT (Beauvoit et al., 1994, Whelan et al., 
2001). 
In order for LLLT to have biological action in neurodegenerative disorders, it 
must be able to infiltrate the head. It has been hypothesised that NIR follows an 
arc of transmission through the human head; with the theory that the light will 
pass through the scalp, bone, dura and tissues and return to the point of 
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transmission. Young, 2000, investigated the elliptical transmission of NIR 
(776.5, 819, 871 and 909 nm) through the human head of patients undergoing 
elective neurosurgery procedures. Metal probes were fitted to the skulls of 
patients in two conditions, shown in figure 1.2. The transmission of NIR was 
investigated at ‘baseline’ levels, shown on the left, and the manner of layer 
removal is shown on the right. The experimenters found that the detectable 
optical density of the light returning to the detector was greatly reduced when 
the bone was removed (14-fold reduction), and much smaller, but significant, 
reductions in detected intensity were observed following the removal of the CSF 
(cerebral spinal fluid) and dura. The experimenters therefore concluded that the 
skull is able to act as an optical channel, providing a preferential path for NIR to 
enter the head. These data provide evidence to support the previously held 
concept that bone is seen as ‘translucent’ to NIR, with CSF and CBF (cerebral 
blood flow) acting as useful NIR propagators. Such data suggest that 
photobiomodulation in these tissues is conceivable and that photons are able to 
travel sufficiently to penetrate the brain (Okada et al., 1997, Owen-Reece et al., 
1996, Young et al., 2000). 
 
Figure 1.2. NIR emitter and detector settings, indicating how transmission of infrared light was 
measured through the heads of patients undergoing elective neurosurgery procedures  (From 
Young et al., 2000). 
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1.1.3 Photoacceptors 
In order for any wavelength of LLLT to have a therapeutic effect, photons of that 
wavelength must be absorbed by a photoacceptor or a molecular chromophore. 
Chromophores typically occur in one of two forms; metal complexes or 
conjugated pi electron systems, with examples including haemoglobin, 
cytochrome c oxidase and porphyrins (Gao and Xing, 2009, Hamblin and 
Demidova, 2006, Huang et al., 2009, Karu, 1999). A second important factor to 
consider is the diffraction and absorption properties of the tissue which is being 
irradiated and the overall wavelength in the infrared range. Haemoglobin, the 
primary photoacceptor in biological tissue; and melanin, have high absorption at 
wavelengths lower than 600 nm and water absorbs strongly at wavelengths 
longer than 1300 nm. This resulted in the coinage of the term ‘optical window’ 
(figure 1.3.), which ranges from approximately 650 – 1200 nm, wavelengths that 
have low absorption by haemoglobin and melanin and therefore higher tissue 
propagation. The NIR absorption properties of biological tissues vary 
considerably depending on the constituents; water, fat, collagen etc., with high 
water containing tissues typically having an NIR absorption spectra similar to 
the absorption profile of water (Hamblin and Demidova, 2006, Huang et al., 
2009, Karu, 1999, Tsai et al., 2001). Temperature, ion concentration and ion 
content can also affect intrinsic absorption spectra, but under homeostasis they 
vary to a typically vary to a very small degree (Tsai et al., 2001). Photoacceptor 
molecules are believed to act through either directly absorbing the energy of 
photons, becoming electrically excited and then directly partaking in chemical 
reactions, or by the transference of energy of the absorbed photon to another 
molecule, which is then able to induce chemical reactions and ultimately a 
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biological effect (Karu, 1999). Absorption is likely to occur via internal 
conversion, the first excited singlet state of the chromophore undergoes a 
transition to a lower electronic state and this energy is then given off as 
vibration, causing localised heating and altered biochemical activity (Hamblin 
and Demidova, 2006, Karu et al., 1995, Karu et al., 1994). 
 
 
Figure 1.3. Optical Window of Near Infrared Light (Hamblin and Demidova, 2006) 
Abbreviations: Hb, Haemoglobin, HbO2, Oxyhaemoglobin. 
 
1.1.4 Molecular Mechanism of Action - Electron Transport Chain (ETC) 
Mitochondria are an important intracellular organelle; they are integral to the cell 
and the maintenance of cell homeostasis; through involvement in signal 
transduction, energy production, apoptosis, amino acid, lipid, nucleotide and 
steroid metabolism. Therefore the manipulation of a single factor within the 
Water 
Hb 
HbO2 
Melanin 
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mitochondrion can have a dramatic effect on a significant number of cellular 
processes (Chinnery and Schon, 2003, Nicholls and Budd, 2000).  
Mitochondria are composed of an outer membrane which is separated from the 
matrix by an inner mitochondrial membrane (IMM), which is made up of very 
small folds called cristae, which increase membrane surface area, with an 
intermembrane space in between the inner and outer membranes (Scheffler, 
2001). Each complex of the electron transport chain is made up of multiple 
subunits, located at the cristae of the IMM. Each chain comprises of five 
enzymatic-membrane bound subunits, Complexes I-V, see figure 1.4., through 
which electrons pass to generate ATP with the help of soluble electron carriers; 
ubiquinone (Co-enzyme Q) which shuttles electrons from Complex I to Complex 
II and III, and Cytochrome c which transports electrons between Complex III 
and IV. These carriers are also assisted by iron sulphur proteins (Chinnery and 
Schon, 2003, Nicholls and Budd, 2000, Ow et al., 2008). 
The principle function of mitochondria in actively respiring eukaryotic cells is 
aerobic catabolism (metabolic reactions that cause the release of energy). This 
process utilises three stages, the first is glycolysis, which broadly speaking 
converts glucose into pyruvate. At the second stage, pyruvate dehydrogenase 
transports the pyruvate into the mitochondrial matrix. Here, one carbon 
molecule is removed from pyruvate by oxidative decarboxylation, creating acetyl 
CoA. Acetyl CoA then enters the Kreb’s cycle, where it becomes fully oxidised, 
generating carbon dioxide, water and NADH (reduced nicotinamide adenine 
dinucleotide). NADH then enters stage three, oxidative phosphorylation 
(Chinnery and Schon, 2003, Nicholls and Budd, 2000, Scheffler, 2001).  
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NADH oxidation to NAD (nicotinamide adenine dinucleotide) transfers electrons 
to Complex I, which is the largest of the ETC components with over 40 subunits. 
Complex II gains electrons through oxidation of FADH2 (reduced flavin adenine 
dinucleotide) to FAD (flavin adenine dinucleotide), which are then transferred to 
ubiquinone. Ubiquinone then carries the electrons to Complex III and Complex 
III donates the electrons to Cytochrome c. These electrons are then moved to 
cytochrome c oxidase, Complex IV, where they are donated to oxygen, 
generating H2O, see figure 1.4 (Chinnery and Schon, 2003, Nicholls and Budd, 
2000, Scheffler, 2001).  
 
 
Figure 1.4. The Electron Transport Chain. Complex I (NADH-ubiquinone reductase), Complex II 
(succinate-ubiquinone reductase), Complex III (ubiquinone-cytochrome c reductase), Complex 
IV (cytochrome c oxidase) and Complex V (ATP synthase). 
Abbreviations: ADP, adenosine diphosphate; ATP, adenosine triphosphate; e
-
, electron; H
+
, 
hydrogen ion, FAD, flavin adenine dinucleotide; NAD, nicotinamide adenine dinucleotide; Pi, 
Inorganic phosphate; Q, ubiquinone; IMM, inner mitochondrial membrane. 
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The transfer of electrons through the ETC yields a highly exergonic reaction 
which enables protons to be pumped out of the matrix, via Complexes I, III and 
IV, and this generates a mitochondrial membrane potential, Δѱm, which is 
heavily negative to the cytosol, at approximately 150-180 mV (Duchen, 2004, 
Nicholls and Budd, 2000). The generation of this proton motive force drives 
ADP phosphorylation, as protons passively move through the proton pore in 
Complex V (ATP Synthase) into the matrix (Nicholls and Budd, 2000, Ow et al., 
2008). ATP is the energy source for essentially all metabolically active 
processes in the cell; it is exchanged for ADP by the ANT, adenine nucleotide 
translocator, and released from the mitochondria into the cytosol (Chinnery and 
Schon, 2003, Duchen, 2004). 
It has been previously reported that mitochondria are sensitive to NIR 
wavelengths, with up to 50% of NIR absorbed by mitochondrial chromophores, 
including cytochrome c oxidase (Beauvoit et al., 1995, Beauvoit et al., 1994). 
Absorption of light by cytochrome c oxidase has been reported to increase 
mitochondrial membrane potential, ATP production and reactive oxygen species 
(ROS) production, all of which can result in induction of signalling pathways and 
increased energy availability (Reviewed - Gao and Xing, 2009). It has been 
reported that LLLT increased ATP production and oxygen consumption in 
mitochondria isolated from the rat, with reports specifically stating that LLLT 
increased the activity of respiratory chain components, Complex II and 
cytochrome c oxidase and altered proton motive force following LLLT 
(Passarella et al., 1984, Silveira et al., 2007). 
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1.1.5 Cytochrome c Oxidase – NIR Photoacceptor? 
Mitochondrial respiratory chain components are believed to be required for the 
absorption of red to NIR light. Absorption of NIR, results in changes in the 
oxidation state of metals within cytochrome c oxidase, increasing electron 
transfer and subsequently increased ROS (reactive oxygen species) production, 
ATP and/or cAMP (cyclic adenosine monophosphate) levels resulting in the 
initiation of signalling cascades which are able to promote cell proliferation and 
cytoprotection. However, cytochrome c oxidase is only able to act as the 
primary photoacceptor for NIR when it is of mixed valence and not when the 
metals it contains (two copper sites, two haem moieties, and a magnesium and 
a zinc site, shown in figure 1.5) are fully reduced or fully oxidised (Gao and 
Xing, 2009, Karu, 1999, Karu et al., 2004, Karu et al., 2005). Action spectra of 
mitochondria have been determined for specific biochemical reactions. These 
show which wavelengths of light are absorbed most effectively for a variety of 
cellular processes, demonstrating absorption of light by a photoacceptor, and 
which wavelengths are potentially able to modulate processes including DNA 
and RNA synthesis rates and cell adhesion (Huang et al., 2009, Karu and 
Kolyakov, 2005, Karu et al., 2005). 
Absorption spectra of cytochrome c oxidase, in a variety of oxidation states, 
were found to be analogous to that of a generalised spectrum created by Tiina 
Karu for a variety of biological materials, including HeLa cells (Karu et al., 
2005). It was then discovered that the transfer of electrons between metals 
complexed within the cytochrome c oxidase, altering the oxidation state of these 
metals, was responsible for different peaks in the action spectra, metals are 
shown in figure 1.5. However, the upper limit of the wavelengths examined was 
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860 nm, therefore critical information regarding the role of cytochrome c oxidase 
in the absorption of infrared light at 1072 nm is unavailable and it is difficult to 
draw conclusions regarding absorption of IR1072, the wavelength used in this 
investigation (Hamblin and Demidova, 2006, Huang et al., 2009, Karu et al., 
2004, Karu et al., 2005). During respiration, the pair of CuA residues of 
cytochrome c oxidase accept electrons from the cytochrome c molecule, where 
internal electron transfer between CuA and haem a (Oxidised CuA accepts at 
825 nm, reduced CuA accepts at 620 nm), and the haem a3-CuB centre 
(Oxidised CuB accepts at 680 nm, reduced CuB accepts at 760 nm) utilises a 
minimum of seven redox intermediates to reduce molecular oxygen (Gao and 
Xing, 2009, Karu, 1999, Karu et al., 2005). 
 
 
Figure 1.5. Structure of Cytochrome c oxidase, denoting how electrons are transferred between 
metal residues and donated to molecular oxygen to generate water. Adapted from (Karu, 1999). 
Abbreviations; Cyt c, Cytochrome c; Cu, copper; e
-
, Electron; IMM, inner mitochondrial 
membrane; Mg, magnesium; Zn, zinc. 
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It has been postulated that the electron transfer between haem a and haem a3-
CuB, normally the rate limiting step of respiration, is sped up during LLLT and 
this makes more electrons available to reduce molecular oxygen (Karu et al., 
2005). This may occur through structural changes in cytochrome c oxidase 
following NIR absorbance (Karu et al., 2004) 
Uncoupled mitochondria do not show sensitivity to LLLT, nor does purified 
cytochrome c oxidase, suggesting an intact electron transport chain is required 
for absorption of NIR. Indeed, beneficial effects of NIR can be attenuated by the 
use of the potent cytochrome c oxidase inhibitor, potassium cyanide (Karu et 
al., 2005). Frank et al. (2004), reported that IR (700 - 4000 nm) was able to 
induce cytochrome c release from the mitochondria; however IR exposure was 
found not to disrupt the mitochondrial membrane and release did not result in 
activation of caspases or caspase-independent cell proteins which normally 
drive cell death following cytochrome c release (detailed in section 1.3.2). The 
recorded partial release of cytochrome c oxidase, without deleterious effects, 
suggests IR is capable of mobilising loosely-bound cytochrome c that is 
sensitive to electrostatic changes. Release of cytochrome c oxidase may occur 
due to transient opening of mitochondria permeability transition pore (MPTP) 
due to calcium release (detailed in 1.1.6). This release triggers upregulation of 
pro-apoptotic proteins, including BAX (BCL2 associated athanogene), in the 
short term, but was shown to be swiftly followed by the increased expression of 
anti-apoptotic proteins Bcl-2 (B-Cell Lymphoma 2) and BCL-XL (B Cell 
Lymphoma-Extra Large) over a longer time period. High levels of these anti-
apoptotic proteins are able to temporarily reduce ΔѰm, leading to a more 
reduced state of the cell and potentially leaving the cell more sensitive to further 
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irradiation (detailed in 1.1.6). As the ΔѰm returns to normal, anti-apoptotic 
proteins were shown to accumulate, resulting in a cell more resistant to stress. 
This release of cytochrome c has been shown to occur in a number of cell 
types, including human dermal and lung fibroblasts (Frank et al., 2004). 
 
1.1.6 Secondary Effects – Cell Signalling 
The magnitude of the secondary biological effects are dependent upon the 
redox state of the tissue that is being irradiated, cells with a more reduced state 
are more sensitive to irradiation as reduced forms of cytochrome c oxidase 
promote electron transport. This increase in activity has a potential downside, 
with a higher rate of electron flow, the likelihood of superoxide anion production 
increases. This would in turn result in increased hydrogen peroxide levels and 
other free radicals, an increase in pH and cause the release of calcium, 
amongst other processes. However, in relatively small concentrations, the 
combination of these molecules are capable of modulating the redox state of 
the cell and potentially perpetuating any biological effects via this apparent 
mitochondrial-nuclear retrograde signalling (Butow and Avadhani, 2004, Gao 
and Xing, 2009, Hamblin and Demidova, 2006, Karu, 1999, Karu, 2008, Karu et 
al., 2005). Signalling is believed to be a two part reaction; with primary redox 
changes increasing electron transfer which is followed by secondary ‘dark’ 
biochemical reactions inducing cell signalling (Karu et al., 2004). 
Several signal transduction pathways have been implicated in the therapeutic 
effects of LLLT; including ERK (extracellular signal-regulated protein kinase), 
MAPK (mitogen associated protein kinase), PI3K (phosphoinositide 3 kinase) 
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and even ATP-related signalling pathways (For a review of these data see Gao 
and Xing, 2009). Examples of mitochondrial retrograde signalling pathways 
initiated following LLLT are shown in figure 1.6. 
ATP has recently received attention as a signalling molecule, in addition to 
acting as an energy source. Even small changes in ATP can significantly alter 
cellular metabolism. The discovery of specific receptors for ATP, P2 family of 
receptors, and receptors for its final breakdown product, adenosine, P1 receptor 
family, enabled further understanding of intercellular communication. Binding of 
ATP to P2X receptors forms a channel for Na
+ and Ca2+ to enter the cell and 
binding to P2Y receptors triggers intracellular cascades, releasing internal 
calcium stores. Altered calcium and ROS levels within the mitochondria would 
also have impact on mitochondrial membrane potential, thus mitochondrial 
activity, mitochondrial proliferation, and ultimately ATP production via a 
mitochondrial-nuclear retrograde signalling mechanism, see figure 1.6 (Karu, 
2010a, Karu, 2008, 2010b, Khakh and Burnstock, 2009). 
Mitochondria also play an important role in calcium storage and release; the 
organelles are able to accumulate Ca2+, which can be important for protecting 
the cell when cytosolic levels rise to critical concentrations. Alterations in Ca2+ 
concentrations have also been reported following LLLT; increased levels of 
intracellular Ca2+ have been reported in hepatocytes and mast cells with 
intramitochondrial levels reported to be three to eight times greater following 
NIR (Reviewed - Butow and Avadhani, 2004, Karu, 2008, Scheffler, 2001). 
Sustained increased levels of Ca2+ in the mitochondria has been shown to have 
both a direct impact on the Krebs cycle (stage effected depends on the cellular 
location of the free calcium; Wan et al., 1989), Δѱm, and thus indirectly on the 
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pool of available ATP/ADP. Ca2+ is believed to be the principal effector of the 
mitochondrial-retrograde signalling mechanisms, see figure 1.6. Disruption of 
ΔѰm causes the release of Ca2+ cytosolically, increasing the intracellular 
concentration and therefore increase activities NF-κB (nuclear factor κB), a 
number of kinases, amongst other signalling pathways for the cell ultimately 
leading to activation of nuclear genes (Butow and Avadhani, 2004, Karu, 2008, 
Nicholls and Budd, 2000). 
Increased intramitochondrial Ca2+ can trigger the opening of the MPTP, directly 
or indirectly as a result of altered ΔѰm. This can cause the release of calcium 
and protons into the cytosol which lead to membrane depolarisation. In a 
transient ‘spike’ opening manner this is beneficial to the cell and the principal 
mechanism through which NIR initiates its response. The involvement of MPTP 
in LLLT may explain why previous reports have shown cytochrome c release 
following NIR without deleterious effects (Frank et al., 2004, Nicholls and Budd, 
2000). 
Production of ROS has also been a reported secondary signalling molecule 
following LLLT. ROS at high levels can be detrimental, but its production is a 
normal by-product of respiration. It is estimated that between 2-5% of electrons 
that pass through the ETC actually leak from brain mitochondria and result in 
the production of ROS, including hydrogen peroxide and superoxide anions 
(Hurtado et al., 2003). A shift in cellular redox state towards oxidation following 
LLLT results in increased ROS production (Hamblin and Demidova, 2006, 
Huang et al., 2009). ROS has the capability to modulate a range of cellular 
processes, including protein synthesis and nucleic acid production. ROS has 
been shown to have influence over a range of transcription factors; including 
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NF-κB (nuclear factor κB), AP-1 (activator protein-1), Ref-1 (redox factor-1), 
CREB (cAMP response element binding protein) and p53 (Reviewed - Hamblin 
and Demidova, 2006, Huang et al., 2009). ROS can also activate TNFα and 
vice versa, the initiation of such factors is thought to be responsible for a 
number of the secondary effects observed following LLLT (Brookes et al., 
2002). 
 
Figure 1.6. Putative mitochondrial retrograde signalling pathways believed to be initiated 
following LLLT. 
 
NO· and N3 are widely reported physiologic modulators of cytochrome c oxidase 
activity and thus important regulators of intra-mitochondrial signalling. NO· is 
able to competitively bind cytochrome c oxidase, dislodging oxygen and to a 
degree inhibiting respiration in stressed cells. NO· is also able to prevent 
increasing levels of free radicals, including hydrogen peroxide, by inhibiting 
Abbreviations: ROS, Reactive Oxygen 
Species; ΔѰm, Mitochondrial 
membrane potential; AP-1, Activator 
protein-1; NFκB, Nuclear factor kappa 
B; Eh, Redox potential; Em, plasma 
membrane potential. Subscript m and i 
refer to mitochondria or intracellular 
locations, respectively. 
Established pathways: 
Theoretical pathways: 
 (Adapted from Karu, 2008) 
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respiration. Cytochrome c oxidase shares responsibility for ATP production with 
other oxidative phosphorylation machinery, and rarely has more than 20% 
control over respiratory activity (Reviewed - Brookes et al., 2002, Karu, 2008, 
Karu et al., 2004). Notably, NIR at 670 nm was able to reverse the inhibition of 
cytochrome c oxidase of nitric oxide occupying the oxygen binding site 
(Trimmer et al., 2009, Zhang et al., 2009). Binding of NO· to cytochrome c 
oxidase has been shown to induce ROS production in the mitochondria and 
initiate signalling pathways; it is thought that increased NO· levels may also be 
able to initiate signalling through altering the Δѱm (Butow and Avadhani, 2004, 
Karu, 2008). A proposed overall mechanism of action is shown in figure 1.7. 
 
1.1.7 Experimental Findings 
Photobiomodulation or LLLT, has also been reported to have beneficial effects 
in reducing the oxidative stress associated with diabetes in an animal model of 
the disease (Henshel et al., 2009, Tsai et al., 2001), restorative action towards 
axonal transport deficits seen in Parkinson’s disease through increasing ATP 
(adenosine triphosphate) levels and mitochondrial velocity (Trimmer et al., 
2009), as well as accelerating wound healing and tissue regeneration (Desmet 
et al., 2006, Medrado et al., 2008, Whelan et al., 2001). LLLT has also been 
reported to protect against retinal toxicity (Desmet et al., 2006, Eells et al., 
2003) and protect against apoptosis of visual cortical neurons (Liang et al., 
2006). Of a large range of wavelengths that have been tested in vitro and in 
vivo, the most beneficial and effective wavelengths parallel the absorption 
spectra of cytochrome c oxidase, which peaks at 670 and 830 nm and 
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beneficial effects are observed at doses ranging from 1-6 J/cm2 (Hamblin and 
Demidova, 2006). LLLT has been found to modulate the expression of a range 
of genes which control critical cellular functions, including DNA 
(deoxyribonucleic acid) repair proteins, molecular chaperones, trafficking and 
degradation driving proteins, antioxidant enzymes and proteins that drive cell 
growth and maintenance (Desmet et al., 2006). 
Neurite outgrowth, neuronal maturation and protection against oxidative stress 
have all been demonstrated to occur in PC12 cells following NIR exposure at 
670 nm (Giuliani et al., 2009). In an in vitro model of Alzheimer’s disease, NIR 
at 670 nm has also been found to reduce the quantity of β-amyloid aggregates 
in HeLa neuroblastoma cells, clearance which occurred at the expense of a 
great deal of cellular ATP although the direct mechanism remains unclear. This 
study also found the NIR at 670 nm was able to facilitate in the uptake of drugs 
into the HeLa cell line. The study also reported increased levels of ATP in the 
absence of β-amyloid. These data provide an interesting new therapeutic angle 
of functional interplay, as well a mechanism to explore potential synergistic 
effects of NIR and drugs for the treatment of neurological disorders (Sommer et 
al., 2012). 
Medrado (2008) investigated the effects of LLLT on connective tissue 
remodelling during the healing of subcutaneous wounds in the rat. The research 
found that laser irradiation at 670 nm improved the differentiation and deposition 
of collagen fibres, resulting in more efficient re-establishment of the appropriate 
tensile strength and fibre organisation in healed tissue, when compared to 
control treated wounds (Medrado et al., 2008). 
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Whelan, 2001, reported significant therapeutic effects of NIR on wound healing. 
Using LLLT with combined wavelengths (670, 728 and 880 nm), skin-based 
wound healing rates increased by 50% and skeletal muscle-based wounds 
increased by 40% in human subjects, with up to 200% increases in cell growth 
reported in mouse fibroblasts, rat osteoblasts, rat skeletal muscle cells, and 
human epithelial cells that were exposed to the combined wavelengths. These 
data suggest that there is a great deal of potential to optimise the parameters of 
LLLT to promote wound healing in a number of tissues. Alterations in electron 
transport chain activity have been reported by Silveira et al. (2007) following 
NIR. The researchers were investigating the effect of NIR for 10 days on the 
rate of wound healing in rats. They found that LLLT resulted in wound healing 
occurring faster than in control treated animals, and irradiation at 904 nm, dose 
per session of 3 J/cm2, not only increased the activity of cytochrome c oxidase 
(Complex IV), but for the first time increased Complex II (Succinate-Ubiquinone 
Reductase) activity were also reported. No change in the levels of soluble 
succinate dehydrogenase was reported, confirming tight coupling of the 
mitochondria membrane following irradiation, further supporting the consensus 
of mitochondrial involvement in photobiomodulation (Silveira et al., 2007). 
Additionally, increased ATP production, mitochondrial membrane potential and 
proton gradient were all reported following irradiation of isolated liver 
mitochondria from Wistar rats exposed to 633 nm. The authors propose that 
absorption of NIR by the mitochondria increases the proton motive force, and 
this drives an increased level of ATP production (Passarella et al., 1984). 
Investigations of NIR at 830 nm have also reported increased ATP production in 
the rat brain. Through holes made in the skull, an area of the cerebral cortex 
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was irradiated whilst the animals were anaesthetised. It was found that a 15 
minute irradiation period was sufficient to significantly increase the 
concentration of ATP determined to be in the tissue, with no significant 
alteration in ADP (adenosine diphosphate) levels. Interestingly, 15 minute 
irradiation at 652 nm had no effect on ATP or ADP levels (Mochizuki-Oda et al., 
2002), emphasising the importance of wavelength choice. 
A single exposure of 40 seconds at 810 nm was able to restore the sporadic 
axonal transport in Parkinson’s disease cybrid neurites to that of control levels. 
LLLT was also found to restore mitochondrial mobility, something reported as 
essential for neuronal survival (Trimmer et al., 2009). Due to their high 
metabolic rate, neurons require a large, continuous supply of ATP which is 
sourced through the electron transport chain within the mitochondria. However, 
mitochondria are not static and are transported around the cell to where they 
are required via microtubule-based anterograde transport, but this process itself 
is dependent on ATP. The compromise of this transport mechanism may 
underlie the progressive loss of neurons associated with neurodegenerative 
disorders, such as Alzheimer’s disease and Parkinson’s disease, as without 
normal mitochondrial fission, fusion and movement; neurons are unable to 
survive (De Vos et al., 2008, Mattson and Liu, 2003). 
Investigations have also noted that the more protective wavelengths parallel the 
action spectra of more oxidised cytochrome c oxidase which had been 
previously reported (Karu, 1999). Photobiomodulation at 670 nm using LEDs 
has also been shown to directly protect neurons against exposure to toxins; 
moreover, particular wavelengths were more effective than others (Wong-Riley 
et al., 2005). Investigations with NIR and visual cortical neurons also found a 
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protective effect. Pre-treatment of the visual cortical neurons with LEDs emitting 
670 nm reduced apoptosis by up to 50% when the neurons were exposed to 
potassium cyanide, demonstrating potassium cyanide and NIR compete for 
cytochrome c oxidase. Liang et al. (2006) proposed the mechanism of this 
protection was via prevention of caspase-driven apoptosis; utilising reduced 
ROS (reactive oxygen species) levels and down-regulation of pro-apoptotic 
proteins, together with upregulation of anti-apoptotic proteins (Liang et al., 
2006). Further work using 670 nm by Eells et al., (2003), found that three brief 
exposures (144 seconds in total) was able to dissipate the toxicity of methanol-
derived formate, a toxin detrimental to mitochondria, which induces damage to 
the retina. Mitochondrial dysfunction/damage is believed to be a significant 
factor in ocular disease/injury; these data suggest LLLT may be of therapeutic 
benefit in such conditions (Eells et al., 2003). Microarray analysis has shown 
670 nm exposure can directly induce upregulation of a number of genes which 
are expressed in pathways involved in mitochondrial energy production (Eells et 
al., 2004, Giuliani et al., 2009). 
LLLT has also been shown to protect human fibroblasts from UVB (Ultraviolet-
B) toxicity; this effect was accompanied by alterations in mitochondrial 
membrane potential, partial cytochrome c release, and increased expression of 
HSP27, an established inhibitor of apoptosome formation (detailed in section 
1.3.2.; Frank et al., 2004). 
The majority of these studies report an increase in mitochondrial membrane 
potential; some report an increase of up to 30% (Reviewed -Karu, 2008), 
accompanied by heightened ATP and ROS production, Complex II and 
Cytochrome c oxidase (Complex IV) activity (Desmet et al., 2006, Gao and 
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Xing, 2009, Silveira et al., 2007, Tsai et al., 2001, Wong-Riley et al., 2005), and 
some even report increased mitochondrial velocity (Trimmer et al., 2009) 
following NIR exposure. The magnitude of the effect of NIR on mitochondria 
depends on the wavelength used and how this wavelength correlates to the 
action spectra of cytochrome c oxidase, for example LLLT at 725 nm which 
does not correlate to a peak in the action spectra, has actually been shown to 
result in decreased ATP production, further signifying the importance of 
wavelength selection to elicit therapeutic benefit (Gordon and Surrey, 1960). 
 
1.1.8 Applications and Therapeutic Effects of IR1072 
The strong absorption of NIR at long wavelengths by water generally limits the 
infiltration of light into deep tissue. NIR at 1072 nm represents a peak in the 
transmission of the infrared spectrum through the water molecule, therefore NIR 
at 1072 nm requires less energy and less intensity to safely enter biological 
matter, without causing thermal stress, than wavelengths 1300 nm and beyond 
(Bradford et al., 2005, Burroughs, 2010, Tsai et al., 2001). 
A recent clinical trial conducted by Dougal & Kelly, found that a single five 
minute exposure to IR1072 significantly reduced the healing time of herpes 
labialis flair-ups by four days for patients, when compared to treatment with 
acyclovir five times daily. The clinicians do not propose a mechanism of action 
for this improved recovery time but do also state that the NIR did not appear to 
attenuate the virulence of the herpes labialis; it is therefore possible that the 
LLLT may be affecting the integrity of the cell membrane. The more resistant 
the cell membrane, the greater difficulty the virus will have in infecting cells and 
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in doing so an enhanced local immune response could be mounted (Dougal and 
Kelly, 2001). 
Experiments conducted by our group (Bradford et al., 2005), demonstrated 
protective action of IR1072 on lymphocytes isolated from human whole blood 
that were subsequently exposed to UVA (Ultraviolet-A). This study showed that 
exposure of lymphocytes to IR1072 provided a rapid and long-lasting protective 
effect, possibly elicited through iNOS (inducible Nitric Oxide Synthase) 
upregulation, a rapidly produced, easily diffusible signalling molecule which 
does not require the presence of calcium for activity. The study also reported 
that upregulation of iNOS levels occurred in a wavelength-dependent manner; 
with IR1072 the only wavelength demonstrating a significantly increased level of 
expression (660, 880, 950 and 1267 nm were all also tested). This is particularly 
important as iNOS is believed to play a role in the prevention of apoptosis via 
prevention of the activation of or by inhibiting caspase-3-like proteases 
(Bradford et al., 2005). Our group has also demonstrated that six minute 
exposures to IR1072 for 10 consecutive days had no detrimental effect on 
anxiety or exploratory behaviour in CD-1 mice (4 months and 12 months of age) 
in a 3D radial maze test; a strain which develops premature learning deficits 
(Ennaceur et al., 2008, Michalikova et al., 2008). The working memory of 
middle-aged (12 month) CD-1 mice was actually found to significantly improve 
following IR1072 exposure. Furthermore, the middle-aged IR treated mice 
showed the most beneficial effect in the ‘acquisition phase’ of the behavioural 
experiment, with more consideration taken over decision making, resulting in a 
cognitive performance similar to that observed in young (4 month) CD-1 mice 
(Michalikova et al., 2008). The use of IR1072 as a treatment for Alzheimer’s 
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disease was investigated with recruitment of patients initiated in December 
2010 (double-blind, placebo-controlled clinical trial). The results of these trials 
will enable statistically valid conclusions to be drawn, sanctioning the use of 
IR1072 in a clinical neurological setting. 
 
Figure 1.7. Proposed overall mechanism of action. Abbreviations: ATP, adenosine 5’ 
triphosphate; BDNF, brain-derived neurotrophic factor; DNA, deoxyribonucleic acid; HSP, heat 
shock protein; MAPK, mitogen-associated protein kinase; PI3K, phosphoinositide 3-kinase; 
RNA, ribonucleic acid; ROS, reactive oxygen species. 
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1.1.9 Experimental Limitations - Questions relating to the use of LLLT 
clinically 
A range of wavelengths are currently in use clinically; longer wavelengths (up to 
1300 nm) have deeper tissue infiltration distances and shorter wavelengths 
(typically around 600 nm) are used for more superficial tissue treatments. It has 
been reported that a combination of wavelengths may have an additive effect 
which could prove useful in treating complex disorders. However, there remains 
a great deal of work to do to define the optimal parameters for NIR in particular 
conditions (Hamblin and Demidova, 2006). LLLT is currently applied to a 
diverse range of clinical situations; including wound healing and treatment of 
herpes labialis, using a varied assortment of wavelengths and parameters, light 
sources, and treatment protocols. However, despite mechanistic questions, a 
significant limitation to the progression of LLLT into conventional medical 
practice is the lack of adequately controlled clinical trials. The reported biphasic 
dose-response that is commonly observed with NIR treatment of biological 
tissue also raises the question of dosage. The fluence of NIR and the total 
energy conveyed differ greatly between studies, as do the reported effects of 
pulsed or continuous wave light. Work to further understand the best 
boundaries for using NIR as a clinical treatment need to be investigated. 
 
1.2 Alzheimer’s disease 
Alzheimer’s disease is the leading cause of dementia in the world, it is a 
progressive dementia characterised by the deposition of β-amyloid (Aβ), found 
in large extracellular structures known as senile plaques (SPs), which are 
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thought to induce toxicity through affecting the stability of the cell membrane 
and therefore reducing synaptic transmission (Kamenetz et al., 2003) and 
impairing synaptic plasticity (Shankar et al., 2008). Aβ also acts intracellularly 
as small oligomers, which are believed to be the more toxic Aβ structure. 
Oligomers of Aβ are thought to dissociate from large SPs, move into the cell 
and, as their structure has exposed hydrophobic moieties, and sequester 
proteins essential for cell homeostasis. Senile plaques are thought to act as 
pools of ‘available’ Aβ with oligomers able to dissociate and cause neuronal 
death at locations away from their originating SP. SPs have also been shown to 
be a magnet for free metals and aggregates, exacerbating their toxicity to 
neurons within their vicinity. 
Aβ was first purified in 1984 by Glenner & Wong, who identified the substance 
as a 4.2 kDa peptide, composed of 40 or 42 amino acids but it wasn’t until 
1987, when Kang et al. cloned the amyloid precursor protein, that Aβ was 
established as a cleavage product of a larger protein, although this was 
previously hypothesised to be the case (Glenner and Wong, 1984, Kang et al., 
1987). The exact physiological function of APP remains unclear, although roles 
have been established in synaptic pruning, neuronal plasticity and synaptic 
physiology/processing (Abramov et al., 2009, Kamenetz et al., 2003, O'Brien 
and Wong, 2011). Over expression appears to have a positive effect on cell 
growth and health. Deletion of APP doesn’t induce a severe phenotype, but 
mice ‘fail to thrive’ (O'Brien and Wong, 2011, Zheng et al., 1995). APP is a 
ubiquitously expressed single transmembrane domain protein, APP can be 
cleaved following the α-secretase pathway, which does not generate Aβ, or via 
the β-secretase pathway which does generate Aβ (Reviewed - Hardy, 1997). In 
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order to produce Aβ, APP is sequentially cleaved by β-secretase and γ-
secretase, depending on where APP is cleaved determines the length of 
fragment created. Cleavage by γ-secretase can produce a number of Aβ 
variants, including Aβ37, Aβ38, Aβ40, Aβ42 and Aβ43, with Aβ40 and Aβ42 the most 
common (subscript number denoting the amino acid length; Reviewed - 
Benilova et al., 2012, Hardy, 1997, O'Brien and Wong, 2011). γ-secretase is 
crucial for the sequential intramembranous cleavage of a number of 
transmembrane proteins, and itself is comprised of presenilin 1, presenilin 2, 
nicastrin and two transmembrane proteins (Bergmans and De Strooper, 2010). 
The pathology of sporadic AD is very similar to that of autosomal dominant AD 
and there have been a number of mutations identified in the APP gene which 
act to alter the β- or γ-secretase cleavage site and mutations in Presenilin 
genes which alter the amino acids in their transmembrane domains. There are 
other genetic mutations that attribute risk to the development of late onset AD, 
including the presence of the APOE (apolipoprotein) ε4 allele (other non-risk 
associated variants of APOE are ε2 and ε3) which is believed to be present in 
up to 70% of sporadic AD in aged individuals, with Apoε4 reducing Aβ 
clearance and increasing Aβ deposition (Avramopoulos, 2009, Huang and 
Mucke, 2012, O'Brien and Wong, 2011). 
In the disease state, production of the aggregation prone Aβ42 is increased (it 
accounts for approximately 5% of Aβ generated in the physiological state) and 
its levels can be elevated through mutations in the aforementioned genes, while 
reduced clearance can arise from lessened expression of factors responsible 
for its removal, such as HSPs and IDE (insulin degrading enzyme; Gandy, 
2005) and reduced clearance across the blood brain barrier. Aβ oligomers can 
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cause aberrant neuronal network communication, synaptic dysfunction and alter 
related signalling pathways, leading to impaired LTP (long term potentiation). 
The presence of Aβ leads to altered neuronal activity and can cause 
excitotoxicity, via impairing interneurons, stimulating glutamate receptors and 
causing release of neurotoxic intermediates from adjacent glial cells (Benilova 
et al., 2012, Gandy, 2005, Haass and Selkoe, 2007, Hardy, 1997, Huang and 
Mucke, 2012, LaFerla, 2010, O'Brien and Wong, 2011). As well as 
accumulating cellular proteins and free metals as mentioned previously 
(Kamenetz et al., 2003, Shankar et al., 2008), the formation of fibrillar amyloid 
senile plaques causes distortion and displacement of neuronal processes. 
Deposition of Aβ can also occur vascularly, resulting in impairment of nutrient 
supply and waste product removal. This in turn can cause infarcts, activate 
microglia and exacerbate existing excitotoxicity. An overview of these 
mechanisms is shown in figure 1.8 (Huang and Mucke, 2012). 
Another key characteristic is the presence of NFTs, which are primarily 
intracellular structures, composed of hyperphosphorylated tau. Phosphorylation 
of tau results in its dissociation from the microtubule cytoskeleton, ultimately 
destabilising the neuron and these tangles then commandeer fundamental 
proteins and intracellular Aβ (Benilova et al., 2012, Fandrich et al., 2011, Guo 
and Lee, 2011, Haass and Selkoe, 2007, LaFerla, 2010). Tau is a microtubule 
associated protein which a significant role in the outgrowth of neuronal 
processes, stabilisation of microtubule and their dynamics. Tau is abundantly 
expressed in the CNS, principally in axons and is also required for membrane 
interactions and axonal transport of organelles to and from terminal boutons 
(Ittner and Gotz, 2011, Reddy, 2011). The loss of cytoskeletal associated tau 
 54 
also results in the reduced transport of mitochondria, resulting in defective 
mitochondria function; increased ROS and decreased ATP production, and in 
itself exacerbating neuronal damage (Eckert et al., 2011, Reddy, 2011, Schmitt 
et al., 2012). 
 
 
Figure 1.8. Complex basis of Alzheimer’s disease. Accumulation and aggregation of Aβ, shown 
in pink, may result from reduced clearance, lower levels of degrading enzymes or increased Aβ 
production. Aβ plaques disrupt neuronal processes and Aβ oligomers impair synaptic function, 
both altering neuronal activity and triggering release of neurotoxic substances. Apoε4 increases 
Aβ deposition and reduces its removal; it also acts to impair mitochondrial activity and stability 
of the cytoskeleton. Tau becomes phosphorylated, mislocalised to dendrites and begins to form 
NFTs. P-Tau can be released extracellularly, affecting adjacent neurons (Figure obtained from 
Huang and Mucke, 2012). 
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The neuronal loss associated with Alzheimer’s disease is not specific to one 
type of neurotransmitter; serotonergic, cholinergic, dopaminergic, noradrenergic 
and peptide neurotransmitter systems are all affected, but neuronal loss does 
appear to be anatomically determined (Hardy and Allsop, 1991, Pearson and 
Powell, 1989). The onset of memory impairment is one of the earliest symptoms 
of Alzheimer’s disease, this is followed by language impairment and once the 
substantia nigra and striatum become damaged in the latter stages of disease, 
motor dysfunction (hypertonic-hyperkinetic syndrome) becomes apparent 
(Reviewed - Braak and Braak, 1991, 1995, Braak and Braak, 1997, Forstl and 
Kurz, 1999, Hardy and Allsop, 1991). Braak & Braak, 1991, defined six stages 
of Alzheimer’s disease progression, each distinguishable by location of amyloid 
and NFT deposition and the severity of that deposition, a summary of which is 
shown in figure 1.9.  
 
 
 
 
 
 
Figure 1.9 Distribution of amyloid and tau neurofibrillary tangles in Alzheimer’s disease. 
Shading represents density/severity of deposition. (Figure modified from Braak and Braak, 
1991). 
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The initial, clinically silent, transentorhinal stages I-II are characterised by 
development of intraneuronal lesions found in poorly myelinated areas of the 
neocortex and typically these changes do not contain amyloid deposits. Stages 
III-IV involve the limbic system, with the entorhinal, transentorhinal regions and 
the hippocampus affected. Amyloid deposition becomes apparent, starting in 
the CA1 (cornu ammonis) region and radiating throughout the hippocampus. 
The extent of damage that occurs at this stage results in the appearance of 
clinical symptoms, as the limbic region is crucial in the conversion of sensory 
information to memories. Stages V-VI are characterised by profound destruction 
of the all sections of the cerebral cortex by the presence of NFTs, SPs and 
amyloid, deposits also apparent in the striatum, hypothalamus and thalamic 
nuclei (Braak and Braak, 1991, 1995, 1997). Stages V-VI signify fully developed 
Alzheimer’s disease, with patients demonstrating impaired motor skills and long 
term memory, as well as behavioural changes including aggression, apathy and 
loss of vocabulary (Reviewed - Forstl and Kurz, 1999, Hardy and Allsop, 1991). 
Despite Alois Alzheimer first publishing the histological pathology of this 
dementia in 1907, a great deal remains unknown about the pathology of the 
disease (Balducci and Forloni, 2011, O'Brien and Wong, 2011). 
 
1.3 Roles of Heat Shock Proteins in cell maintenance and disease 
1.3.1 Overview of Heat Shock Proteins 
There are more than 100 different proteins that comprise the chaperone protein 
family found in mammalian cells. Chaperones are a widely expressed and 
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highly conserved protein family, and have been reported to constitute 
approximately 5% of cellular proteins (Koren et al., 2009, Soti and Csermely, 
2003). The primary role of this family is to protect proteins against stress and 
aid in the correct folding of nascent proteins. It is only as a final resort do they 
function to direct proteins toward degradation mechanisms, see figure 1.10. 
Chaperones are crucial in the assembly and disassembly of multimeric 
complexes, regulation of vesicular transportation, as well as interaction with 
signalling and translocation of proteins across cellular membranes (Reviews - 
Koren et al., 2009, Ohtsuka and Suzuki, 2000, Voisine et al., 2010). 
Chaperones do not usually increase speed of folding, but by binding they 
extend the folding time and increase the yield of the final protein (Soti and 
Csermely, 2000). 
 
 
Figure 1.10. Basic Chaperone Roles (Based on Ohtsuka and Suzuki, 2000). 
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Ellis, et al., 1991, defined heat shock proteins as ‘a family of unrelated classes 
of protein that mediate the correct assembly of other polypeptides, but are not 
themselves components of the final structure’. As more detail concerning 
chaperone function was discovered this definition was later extended by 
Hendrick & Hartl, 1993, who define a heat shock protein as ‘a molecular 
chaperone protein that binds to and stabilises an otherwise unstable conformer 
of another protein – and by controlled binding and release of the substrate 
protein, facilitates its correct fate in vivo: be it folding, oligomerise assembly, 
transport to a particular subcellular compartment, or a controlled switching 
between active/inactive conformations’ (Ellis and van der Vies, 1991, Hendrick 
and Hartl, 1993). 
Inducible transcription of heat shock protein genes is initiated through the 
translocation of HSFs, heat shock factors, into the nucleus where they bind 
HSEs, heat shock responsive elements, which then activate gene transcription 
(Samali et al., 1999, Yenari et al., 1999). Under normal cellular conditions, 
HSF1 activity is repressed by a HSP90 complex (containing HSP90, HSP40, 
HSP70, p23 and cyclophilin) by maintaining it in an inactive conformation 
(Reviewed - Turturici et al., 2011) which can only be activated by a multifaceted 
process involving many modification steps. Under stress, these HSFs 
dissociate, trimerise and are then able to enter the nucleus to initiate 
transcription. During stress, HSPs act as a negative feedback mechanism to 
HSF1 activity, ensuring gene expression is tightly coupled to the cell 
environment, the more vacant chaperones there are available, the greater the 
number of HSP90 molecules binding to HSF1, thus preventing transcription of 
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more chaperones than required and vice versa, see figure 1.11 (Anckar and 
Sistonen, 2011, Calderwood et al., 2009, Sherman and Goldberg, 2001). 
 
Figure 1. 11. Regulation of HSF1. Accumulation of damaged proteins results in the release of 
HSF1 from complexes which normally suppress its action. These consist of HSP90 and co-
chaperones which include p23 and cyclophilins. HSF1 then trimerises and locates to the 
nucleus, where it binds HSEs, ultimately resulting in HSP expression. HSF1, Heat Shock Factor 
1, HSE, Heat shock Elements, HSP, Heat shock protein, CY, cyclophilin. Based on figure from 
(Calderwood et al., 2009). 
It is beneficial for the cell to remove misfolded proteins quickly, as formation of 
aggregates can act as ‘seeds’ for more misfolded or unfolded proteins to begin 
to associate with. Nascent protein production can be impacted upon by the 
presence of aggregates and reduced control of protein production can result in 
cell death. Neurons are particularly vulnerable to the effects of aggregation as 
they are post-mitotic, and it is essential to remove aggregated proteins as they 
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cannot dilute their build-up through cell division (Chen and Brown, 2007, 
Sherman and Goldberg, 2001). 
Chaperone molecules do not typically act alone; they commonly associate with 
another molecule or molecules, which may be another chaperone, such as 
HSP90 or HSP70, or they may associate with co-chaperones such as HSP40 or 
CHIP (Carboxy terminus of HSC70/HSP70-binding protein; Connell et al., 2001, 
Macario and Conway de Macario, 2005, Soo et al., 2008, Soti and Csermely, 
2003). 
The ability for cells to remove/handle cellular aggregates appears to become 
dampened with age. Interestingly, the level of HSF1 has not been found to alter 
with age; however it has been reported that the binding of HSF1 to HSEs is 
reduced in aged animals, although the mechanism of this reduction is not 
known (Calderwood et al., 2009, Soti and Csermely, 2000). This results in the 
reduced induction of heat shock proteins and more aggregates forming 
following initial ‘seeding’ of misfolded proteins, congruently, protein degradation 
pathways have also been reported to become diminished. Impairment of both 
pathways ultimately leading to neurodegeneration. A particularly reduced 
response has been reported in aged individuals that are exposed to high 
oxidative stress, evident in degenerative disorders, in mammalian, 
Drosophila melanogaster and Caenorhabditis elegans systems (Reviewed - 
Sherman and Goldberg, 2001).  
Current thinking suggests that the chaperone system primarily revolves around 
the ATPase activities of HSP70 and HSP90; which are thought to be the two 
major chaperone scaffolds. Other chaperones and co-chaperones work by 
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manipulating the ATPase activities of HSP70 and HSP90, enabling the 
refolding/folding of the bound protein or leading to its degradation (Koren et al., 
2009). A brief overview of HSP roles is shown in figure 1.10 and 1.12. HSPs 
have a well established role in the interference of apoptosis; by preventing JNK 
(c-Jun N-terminal kinase), AIF (Apoptosis Inducing Factor) and APAF-1 
(Apoptosis protease activating factor-1) recruitment, also interfering with 
procaspase-9, procaspase-3 activation and Cytochrome c release amongst 
other roles (Reviewed - Olsson et al., 2004, Yenari et al., 2005). 
The importance of heat shock proteins is emphasised via chaperonopathies, 
any pathological condition whereby a defective or absent chaperone is an 
aetiological factor. Depending on the number of clients which bind the 
chaperone the cost to the cell can be significant if the chaperone family is 
defective. Defective chaperones may still bind proteins but this can result in the 
formation of large precipitates and affect a complex number of cellular 
processes, the effects of which become more profound with the age of the 
organism (Macario and Conway de Macario, 2005, 2007). 
 
1.3.2 Heat Shock Proteins and Cell death 
The capacity of HSPs to prevent cell death relies on their ability to inhibit 
caspase activation and apoptosis, rather than being heavily influenced by their 
chaperone capabilities. Apoptosis occurs via two main pathways, intrinsic and 
extrinsic. The intrinsic and extrinsic pathways usually occur independently of 
each other, but the intrinsic pathway is also able to trigger the extrinsic pathway 
at the stage of mitochondria involvement. The intrinsic pathway is characterised 
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by permeabilisation of the outer mitochondria membrane. This causes the 
release of SMAC/DIABLO (second mitochondrial-derived activator of caspases 
and the Drosophila melanogaster homologue), AIF and Cytochrome c, this 
binds APAF-1 which recruits and activates procaspase-9 to form the 
apoptosome. Apoptosome formation in turn activates more procaspase-9 
molecules and procaspase-3, beginning degradation of substrates (Beere, 
2004, 2005, Benn and Woolf, 2004). 
Caspases (cysteine aspartic specific proteases) are generally categorised by 
their mechanism of activation; there are initiator caspases, including caspases 
2, 8 and 9, and executioner caspases, such as caspases 3, 6 and 7 (Beere, 
2004, 2005). Initiator caspases dimerise with adaptor molecules to become 
catalytically active; these active initiator caspases are then able to cleave the 
executioner caspases and in turn activate them. Executioner caspases are able 
to cleave Initiator caspases, but the reason for this is debated; it may serve to 
stabilise their structure or result in their regulation (Beere, 2005, Thornberry, 
1998). 
The extrinsic pathway is initiated through the binding of specific ligands to 
‘death receptors’ located on the cell membrane, with the major death receptor 
family being TNFR (Tumour necrosis factor receptors); members including 
apoptosis antigen-1 (FAS) and TNFR1, and main binding partners include TNF-
related apoptosis-inducing ligand (TRAILR1) and FAS ligand (Benn and Woolf, 
2004). The binding of FAS ligand to FAS in the neuron engages the FAS-
associated death domain (FADD) and activates procaspase-8. Caspase-8 can 
then cleave BID (BH3 interacting domain death agonist) to tBID (truncated BID). 
As a pro-apoptotic member of the Bcl-2 (B-cell lymphoma 2) family, tBID 
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oligomerises BAX (Bcl-2 associated X protein) and BAK (Bcl-2 antagonist/killer) 
to form pores in the outer mitochondria membrane, thus causing cytochrome c 
release. Caspase-8 is then also able to activate executioner caspases including 
caspase-3. JNK (c-Jun N-terminal kinase) pathway is also activated by FAS, 
through the recruitment of DAXX (death domain associated protein) and ASK1 
(apoptosis-signal regulating kinase 1). JNK then phosphorylates and inactivates 
the anti-apoptotic members of the Bcl-2 family, BCL2 and BCL-XL (B-cell 
lymphoma-extra large), whilst converting BID to jBID (BID cleavage product). 
jBID is then able to recruit SMAC/DIABLO which further activates caspases and 
induces apoptosis (Beere, 2004, 2005, Benn and Woolf, 2004). HSP 
involvement is summarised in figure 1.12. 
Several HSPs have been implicated in protection of the cell from apoptosis, 
including HSP27 and members of the HSP70 family. Pivotal roles of HSPs have 
been found in both the intrinsic and extrinsic pathways providing an essential 
mechanism to protect cells at times of severe cellular stress. HSP70 has been 
shown to inhibit the release of cytochrome c from the mitochondria, although 
whether this mechanism is direct or upstream of the mitochondria is debated, 
through directly effecting mitochondrial membrane integrity or through 
prevention of MPTP formation (Beere, 2004, 2005, Mosser et al., 2000). HSP70 
has also been shown to prevent TNFR induced release of Cytochrome c 
through inhibition of caspase-8 driven BID activation, as well as prevention of 
BAX translocation to the mitochondria membrane. In conjunction with 
interference of the intrinsic pathway, HSP70 is also capable of preventing the 
formation of a functional apoptosome via binding to APAF-1. This in turn, limits 
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activation of procaspase-9 (Beere, 2004, 2005, Benn and Woolf, 2004, 
Calabrese et al., 2002). 
 
Figure 1.12. An Overview of HSP Involvement in the Prevention of Apoptosis. Abbreviations: 
αB Crys, αB Crystallin; AIF, apoptosis inducing factor; APAF-1, apoptotic protease activating 
factor 1; ASK1, apoptosis signal-regulating factor 1; BAX, Bcl-associated X protein; Bcl-2, B cell 
lymphoma 2; B cell lymphoma-extra large; BID, BH3 interacting domain death agonist; DAXX, 
death domain associated protein; FADD, FAS-associated death domain; FAS, apoptosis 
antigen-1; FASL, FAS ligand, HSP27, heat shock protein 27; HSP70, heat shock protein 70; P, 
phosphorylation; SMAC/DIABLO, second mitochondrial-derived activator of caspases and the 
Drosophila melanogaster homologue. 
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HSP70 and HSP27 have been specifically implicated in the regulation of the 
extrinsic pathway, via the inhibition of ASK1 by HSP70 and through HSP27 
binding to DAXX, arresting JNK pathway progression. HSP27 has also been 
shown to prevent BID translocation to the outer mitochondria membrane 
preventing release of Cytochrome c, it has also been shown to sequester 
Cytochrome c once it has been released, preventing apoptosome formation. 
Indeed, αB Crystallin has also been implicated in promotion of cell survival 
through an ability to suppress the activities of caspase-3 and caspase-8 by 
preventing their complete processing (Beere, 2004, 2005, Benn and Woolf, 
2004, Calabrese et al., 2002, Stetler et al., 2009). 
HSPs have been implicated in the regulation of TRAIL, FAS and TNF driven 
apoptotic pathways, but the mechanisms are complex with several studies 
providing conflicting evidence as to whether the effect of HSP intervention is 
positive or negative regarding long term cell maintenance, for example; cells 
may be stopped from undergoing apoptosis through HSP intervention when in 
some instances this may be to the organism’s detriment rather than advantage 
(Beere, 2005). An outline of major HSP roles in apoptosis are shown in figure 
1.12. 
 
1.3.3 Altered Expression of HSPs in Disease 
Induction of the heat shock protein response has been frequently found to 
become impaired with age in a variety of tissues, including neurons. A decline in 
protein quality control occurs as cells lose the ability to activate the 
transcriptional pathways required for HSP synthesis, potentially due to reduced 
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DNA binding capabilities (Calderwood et al., 2009, Soti and Csermely, 2003, 
Winklhofer et al., 2008). 
 
Figure 1.13. Established roles of chaperones in protein toxicity diseases. Abbreviations: ER, 
endoplasmic reticulum; ERAD, endoplasmic reticulum associated degradation; HSP, heat shock 
protein; LAMP, lysosomal associated membrane protein; ROS, reactive oxygen species; TF, 
transcription factor (Figure from Muchowski and Wacker, 2005). 
 
HSF1, Heat shock factor 1, is the required transcription factor for heat shock 
protein induction when cells become stressed. HSF1 is constitutively expressed 
in most tissues, and can be found in both the nucleus and cytoplasm, but during 
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stress it becomes highly concentrated in the nucleus. High constitutive levels of 
HSF1 activity are tightly linked to increased longevity in both nematodes and 
flies (Calderwood et al., 2009, Hsu et al., 2003). 
Altered HSP expression has been reported in Alzheimer’s disease (AD); Yoo et 
al., (2001) reported aberrant expression of multiple HSPs; including αB 
crystallin, HSP70, HSC70 and HSP60, in a range of regions of the human brain 
(Yoo et al., 2001). Compared to control patients, Alzheimer’s disease sufferers 
demonstrated increased HSP27 and αB crystallin levels in the cerebral cortex 
(Shinohara et al., 1993) and higher HSP70 expression in the temporal cortex 
(Perez et al., 1991). 
Chaperones have been found to co-localise with the Aβ plaques and PHFs 
(paired helical filaments) of Alzheimer’s disease, they have also been reported 
to induce conformational changes in and encourage the removal of Aβ via 
transport over the blood-brain-barrier or through phagocytosis (Wilhelmus et al., 
2007). A summary of the direct and indirect processes that have been attributed 
to chaperones in protein-based toxicity are summarised in figure 1.13. 
 
1.3.4 HSP70 
HSP70 family has two major members, HSC70 (heat shock cognate), a 
constitutively expressed form, and HSP70, an inducible form. HSC70 is the 
major chaperone expressed in healthy cells and HSP70 is the predominant 
inducible-heat shock protein. HSC70 and HSP70 share approximately 95% 
sequence homology and have similar biochemical functions (Welch, 1992). 
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HSP70 family proteins are found in most intracellular compartments, and also 
include an ER localised member, GRP78 (glucose regulated protein 78), and a 
mitochondrial localised member, MtHSP75 (mitochondrial heat shock protein 
75), which are both also constitutively expressed (Turturici et al., 2011). The 
HSP70 family is important for the correct folding of nascent proteins, promotion 
of ubiquitination/lysosome mediated autophagy, interaction with signal 
transduction proteins and translocation of proteins through the intracellular 
membrane. The HSP70 family are able to do this as they possess both an NES 
(nuclear export signal) and an NLS (nuclear localisation signal), so they are 
able to move between the nucleus and cytoplasm (Reviewed - Mayer and 
Bukau, 2005, Muchowski and Wacker, 2005, Saito et al., 2007, Turturici et al., 
2011). 
HSP70 binds exposed hydrophobic regions of misfolded/damaged proteins in 
an ATP-dependent manner. Binding of ATP to the ATP-domain at the N-
terminal is required before the substrate binding domain at the C-terminal can 
be active (Mayer and Bukau, 2005, Yenari et al., 1999). The precise mechanism 
of how HSP70 enables folding of a protein into its native state is unknown. 
There are two principle theories; ‘kinetic partitioning’ in which HSP70 plays a 
passive role in binding free substrates in order to reduce their concentration 
sufficiently to prevent aggregation and to allow correct folding to occur naturally, 
and ‘local unfolding’, in which HSP70 repeatedly binds and releases sections of 
the misfolded substrate, refolding small areas until the native confirmation can 
arise (Reviewed - Mayer and Bukau, 2005). 
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Figure 1.14. Overview of Chaperone Families and Their Roles – Core families HSP70, HSP90 
and TRiC (T-Complex Protein 1 Ring Complex). Small HSPs and HSP100 (referred to as 
HSP105/110 in text). Cochaperones are shown as coloured circles, attached to the blue 
hexagon of HSP70 (Voisine et al., 2010). 
 
Chaperones and the ubiquitin-proteasome systems have been shown to work 
competitively and synergistically in directing proteins for degradation. Proteins 
that HSC70/HSP70 cannot refold can be sent for degradation, which occurs 
through the association with CHIP and BAG-1 (BCL2 Associated Athanogene 
1). CHIP is an ubiquitin E3 ligase, which adds an ubiquitin molecule to the 
lysine residue(s) of the substrate, assuring the substrates degradation (Lanneau 
et al., 2010). A number of HSP70 driven roles are shown in figure 1.14. 
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Overexpression of HSP70 has been found to protect against insults in both 
peripheral and hippocampal neurons, with the suggestion that expression of 
HSP70 in glia is able to be transferred to neurons, directly aiding in neuronal 
protection (Guzhova et al., 2001, Yenari et al., 1999, Yenari et al., 2005). 
Indeed HSP70 has been shown to directly reduce the toxicity of intracellular Aβ 
in neurons (Magrane et al., 2004). The ability for HSPs to not only act 
intracellularly, is supported by a wide range of reports that demonstrate that 
HSC70/HSP70 can be released from glial cells and internalised in its active 
form by other cell types, including neurons; taken into the cytoplasm and 
nucleus to support the probability of cell survival, presumably through 
chaperone capabilities and proteasome activation (Guzhova et al., 2001, 
Magrane et al., 2004). HSP70 can also act extracellularly, with roles including 
cytokine release, microglia activation and clearance of Aβ - potentially through 
microglial-driven phagocytosis (Evans et al., 2006, Kakimura et al., 2002), 
amongst other potential roles as HSP70 does not express a secretion 
sequence. The precise mechanism of release and uptake of HSP70 remains 
undetermined, although current thinking suggests release occurs via secretory 
vesicles, secretory lysosomal endosomes or even via calcium induced 
interaction with lipid rafts and uptake may occur via TLRs (Toll-Like Receptors). 
Notably, TLR2 and TLR4 on antigen presenting cells are believed to be 
involved, suggesting immune system interplay and CD40 is also thought to act 
as a receptor for HSP70 (Calderwood et al., 2007, Mayer and Bukau, 2005, 
Muchowski and Wacker, 2005, Novoselova et al., 2006, Turturici et al., 2011). 
However, the neuroprotective capabilities of HSP70 have been reported to be 
limited by the levels of co-chaperone HSP40, as well as by the severity and 
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type of insult as mentioned previously (Turturici et al., 2011). Although there is 
evidence for HSP70 to function in a beneficial manner in the absence of HSP40 
(Oh et al., 1999). 
High expression of HSP70 has been found to occur in a range of pathological 
conditions, including neurodegenerative diseases, epilepsy and ischemia. 
HSP70 is predominately expressed in endothelial cells, but is also found in glia 
and in the majority of neuronal subtypes - neurons typically contain high levels 
of HSC70 and low levels of HSP70 (Sharp et al., 1999, Yenari et al., 1999). 
HSC70 levels differ between neuronal types; for example neurons of the 
hippocampus and entorhinal cortex have higher expression levels than 
expression levels in neurons of the substantia nigra, but neurons of other areas, 
such as the spinal cord, have constitutively much higher levels still. It has been 
hypothesised that neurons with high constitutive levels of HSC70, have a 
greater ability to buffer against the accumulation of misfolded proteins. Areas of 
the brain damaged in disorders characterised by misfolded proteins/aggregates 
are sequentially affected by their chaperone expression levels, explaining why 
the substantia nigra is often the first affected area, followed by the cortex and 
hippocampus (Chen and Brown, 2007). 
Increased synthesis of HSP70, interaction of HSP70 with intracellular Aβ and 
prevention of Aβ accumulation have all been observed in models of AD and 
patient samples from Alzheimer’s disease sufferers (Magrane et al., 2004, 
Perez et al., 1991). Indeed, Hoshino, et al., 2011, have also shown that high 
expression levels of HSP70 suppress the Alzheimer’s disease phenotype and 
cognitive defects in APPsw (Swedish APP mutation) mice. The experimenters 
found high HSP70 levels had no effect on Aβ production, but reduced levels of 
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Aβ, plaque deposition and Aβ-associated neurotoxicity, potentially via 
extracellular/intracellular HSP70 stimulating microglia. Upregulation of IDE 
(Insulin Degrading Enzyme), an Aβ degrading enzyme, and TGF-β1 
(Transforming Growth Factor β1) were both observed and are both expressed 
by microglia (Hoshino et al., 2011). In conjunction with HSP90, HSP70 has 
been shown to interact with cytosolic Aβ, preventing early stages of aggregation 
and interaction of Aβ with cell survival proteins, resulting in neuroprotection 
(Koren et al., 2009, Magrane et al., 2004). 
HSP70 has also been found to attenuate tau toxicity, of all six isoforms, by 
facilitating its degradation and by binding to tau and preventing aggregation. 
HSP70 has not been shown to be effective at decreasing fibrillar tau fibre 
formation, effective at reducing the ability of tau to oligomerise as it binds tau 
oligomers more readily, potentially due to greater exposure of hydrophobic 
binding regions. Tau and HSP70 levels demonstrate an inverse relationship to 
levels of tau aggregation (Dou et al., 2003, Voss et al., 2012) HSP70, 
independent of ATP binding, is then able to remove tau monomers from the 
ends of aggregates, as well as directly aid in the refolding of tau and in 
transferring tau to other chaperones for refolding (Patterson et al., 2011, Voss 
et al., 2012). HSP70 is also able to promote partitioning of tau to microtubules 
and its solubilisation, preventing insoluble tau from affecting fast axonal 
transport (Dou et al., 2003, Voss et al., 2012). It has been suggested that this 
ability of HSP70 also requires the presence of co-chaperone HSP40 (Sahara et 
al., 2007). 
Evans, et al., (2006), found that HSP70/40 and HSP90 were both able to 
directly prevent polymerisation of Aβ monomers in vitro and the HSPs were able 
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to manipulate pre-formed Aβ oligomers and reduce their aggregation, also 
thought to be due to the exposed hydrophobic regions enabling HSP binding. 
High HSP70/40 and HSP90 levels had no significant effect on pre-formed fibrils; 
however this could be explained through a lack of exposed hydrophobic 
residues due to the compact nature of their structure. But the presence of co-
chaperones are not essential for function, however they do increase the 
potency of the main chaperone (Evans et al., 2006, Muchowski and Wacker, 
2005). 
 
1.3.5 HSP105 
The HSP105/110 family of heat shock proteins are a group of mammalian 
proteins that have been shown to be related to the main HSP family, HSP70. 
However, there are significant differences between the two groups. HSP105 is 
sometimes referred to as HSP110; there is no consistent format used in the 
literature, thus in the remainder of this report the chaperone will be referred to 
as HSP105. 
HSP105 has been shown to be the most strongly expressed member of the 
HSP105/110 family, and expression is significantly higher in the brain compared 
to other regions (Reviewed - Hylander et al., 2000). However, expression levels 
vary across the brain, Hylander, et al., 2000, showed that neurons are the 
predominate cell type expressing HSP105 throughout brain hemispheres, with 
the exception of the cerebellum where very little expression was detected, bar 
Purkinje fibres located in this area which showed strong expression (Hylander 
et al., 2000).  
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The members of the HSP105/110 family are HSP105α and HSP105β, and the 
group also includes HSPA4L (heat shock 70 kDa protein 4-like, also called 
Apg1) and HSP94 (Apg2) but the latter proteins only share ~60% homology 
with the former HSP105α and β members (Hylander et al., 2000). 
The two principle members of the HSP105/110 family are HSP105α, a 
constitutively expressed form which is upregulated in response to a variety of 
stresses, and HSP105β, a protein specifically induced following mild heat stress 
(Ishihara et al., 1999). HSP105α is 858 amino acids in length, whereas 
HSP105β is thought to be an alternatively spliced version at 814 amino acids 
(Yasuda et al., 1995). HSP105α has been found to be predominately expressed 
in the cytoplasm, whereas HSP105β is expressed in the nucleus exclusively. 
This differential expression pattern has been attributed to the presence of a 
NLS in both isoforms, but the extra 44 amino acids in HSP105α encode a NES 
and mask the NLS (Saito et al., 2007, 2009). The combination of this sequence 
and the strong interaction of HSP105α with microtubules cause the protein to be 
retained in the cytoplasm, suggesting the isoforms may have minor differences 
in function (Saito et al., 2007). 
HSP105 overexpression has been shown to confer cellular heat resistance and 
to prevent protein aggregation by keeping misfolded proteins in a folding-
competent state, apparently to a greater magnitude than HSC70/HSP70 (Oh et 
al., 1999). HSP105α, in particular, has been shown to protect against stress 
induced cell death through interaction with HSP70 to refold proteins (Yamagishi 
et al., 2011). HSP105 has an ATP binding domain, like HSC70/HSP70, but ATP 
is not required to be bound for the chaperone to act in a ‘holding’ manner, but 
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the ATP domain is believed to be required for HSP105 to refold proteins 
although this has not yet been investigated in great depth (Oh et al., 1999). 
Perhaps unsurprisingly, considering their close evolutionary lineage, HSP105 (α 
and β) are able to exist in high molecular mass complexes with HSC70/HSP70 
and HSP70 in mammalian cells, the dissociation of which is not dependent on 
binding ATP. This led to the suggestion that HSC70/HSP70 may have 
functional support from HSP105, such as regulation of HSC70/HSP70 by 
HSP105 or vice versa under both normal and stressed cellular conditions 
(Hatayama and Yasuda, 1998). 
HSP105α in particular has been identified as a repressor of HSC70/HSP70 
activity, and may act as a modulator of its chaperone capabilities. HSP105α has 
been reported to interfere with the chaperone function of HSC70/HSP70 
through inhibiting the ATP-dependent refolding of substrates. HSP105α was not 
found to prevent the interaction of HSC70 with misfolded proteins but in the 
presence of HSC70, HSP105α is able to bind ATP and hydrolyse it to ADP, thus 
reducing the ATP concentration, reducing the ability for HSC70/HSP70 to bind 
substrates rapidly, with low affinity. The ADP-bound HSC70/HSP70 is able to 
bind substrates but this occurs more slowly, with a higher affinity for the 
substrate. In these conditions, HSC70/HSP70 becomes a ‘holding’ chaperone 
with the HSP105 family acting as nucleotide exchange factors (Particularly 
HSP105α; Reviewed - Yamagishi et al., 2003, Yamagishi et al., 2011). In the 
presence of ADP or ATP, HSP105 is still able to suppress protein aggregation 
and its ability to modulate HSC70/HSP70 activity can be removed by 
phosphorylation of HSP105α at Ser509 by protein kinase CK2 (Casein Kinase 
II; Yamagishi et al., 2004, Yamagishi et al., 2000). When a cell becomes 
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severely compromised and the HSP70 main family of chaperones are unable to 
function, the HSP105 family are able to efficiently suppress aggregation of 
proteins in ATP depleted conditions in order to protect the cell until normal 
function can be regained. In the absence of ATP, HSP105 can direct 
aggregates to CHIP (Yamagishi et al., 2004) but ATP is required for HSP105 to 
function in conjunction with other chaperones (Yamagishi et al., 2000). 
Nuclear-located HSP105β has been shown to be capable of inducing HSP70 
expression, but not of other HSPs, in mammalian cells whereas HSP105α is 
unable to influence HSP70 expression (Saito et al., 2009). HSP105β was found 
to be able to do this by binding to STAT3 (Signal Transducer and Activator of 
Transcription-3) rather than via HSFs, which are the usual mechanism of HSP 
upregulation (Yamagishi et al., 2009). STAT3 is monomeric until specific 
tyrosine phosphorylation by JAK (Janus Kinase), causing trimerisation and 
migration to the nucleus and activation of gene expression. STAT3 then binds 
the hsp70 promoter at a position different to that which HSF1 binds. The 
mechanism through which increased HSP105β causes increase 
phosphorylation remains unknown. HSP105α is also thought to have an 
important anti-apoptotic role through preventing JNK activation in stressed cells 
(Hatayama et al., 2001); illustrating the significant role HSP105α may play in 
neuronal protection. HSP105 has also been shown to reduce signalling to 
activate procaspase-3 (Meares et al., 2008). 
HSP105α and HSP105β also been shown to suppresses aggregate formation 
and cytotoxicity in poly-Q expressing cell lines, through the induction of HSP70 
and under these circumstances, HSP105α was able to localise in the nucleus. 
This suggests that under certain critical circumstances, the NES of HSP105α is 
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able to be overcome and the NLS is dominant (Yamagishi et al., 2010). Indeed, 
using hsp105-/- mice, tau hyperphosphorylation and accumulation of Aβ have 
been shown to be increased. This study also demonstrated that HSP70 and 
HSP105 have a critical role in maintaining tau in an unphosphorylated state, as 
hyperphosphorylation of tau leads to the loss of microtubule stability and the 
formation of NFTs (neurofibrillary tangles), as seen in Alzheimer’s disease. The 
loss of HSP105, in conjunction with APP over-expression (in murine models), 
also appeared to have a dramatic impact on APP (amyloid precursor protein) 
processing, resulting in the formation of Aβ(1-42) peptide and Aβ deposition 
(Eroglu et al., 2010). 
These studies provide important understanding and models to further 
understand mechanisms involved in neurodegenerative disease but also give 
valuable insights into potential therapeutic targets. 
The HSP105β protein is thought of only being induced upon heat-stress to 
42oC, as the preliminary work that identified this protein only found its 
expression occurs under the heating conditions and not following other stresses 
– ethanol, copper sulphate, sodium arsensite, puromycin or canavanine 
(Hatayama et al., 1986). However, this work was only completed in HeLa cells 
and as the majority of work on HSP105 has been done by one laboratory, little 
else has been looked at, including the expression of HSP105 (α and β) in 
neurodegenerative disorders. 
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1.3.6 Small Heat Shock Proteins (sHSPs) 
There are currently 10 known small heat shock proteins (sHSPs) in the human 
chaperone family, they are between 12-43 kDa in size, do not require ATP to 
stabilise and refold their substrates and they function by forming dynamic 
oligomers which can be heterogeneous in nature and up to 1 MDa in size. 
Under normal conditions in the cell, sHSPs are stored as large assemblies, 
upon the onset of stress; these assemblies are broken down into functional 
oligomers by protein kinases (Eyles and Gierasch, 2010, Koren et al., 2009, 
Sun and MacRae, 2005, Wilhelmus et al., 2006a). The dodecamer is the most 
common conformation of sHSPs in normal cellular conditions, in this dynamic 
configuration the sHSPs are unable to bind substrates, but act as a reserve of 
subunits should they be required (Eyles and Gierasch, 2010). 
Much like larger molecular weight HSPs, sHSPs are able to act as ‘holdases’ or 
‘holding’ chaperones, binding partially folded proteins, preventing the 
aggregation of the misfolded proteins until the HSP90/HSP70 machinery can 
refold the misfolded protein or target it for degradation (Eyles and Gierasch, 
2010). The C- and N- terminal extensions of the sHSPs are essential to their 
function, enabling the formation of large sHSP oligomers and arbitrate the 
recognition of substrates (Jaya et al., 2009). 
The function of sHSPs is able to be altered by post-translational modifications, 
such as phosphorylation. These modifications are typically reversible and are a 
response to particular stress, such as cytokines or mitogens. The 
phosphorylation of sHSPs leads to an altered ability of monomers to 
oligomerise, smaller oligomers form following a greater degree of 
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phosphorylation. This modification of function allows a range of transcriptional 
pathways to adapt sHSP function (Arrigo et al., 2007, Garrido et al., 2012, 
Parcellier et al., 2005). The phosphorylation of sHSPs also results in the 
formation of more specialised conformations, which are able to target specific 
substrates. The nature of this capability means sHSPs are able to target an 
ample range of proteins (Garrido et al., 2012), indeed some have reported up to 
300 different sHSP:substrate interactions (Eyles and Gierasch, 2010). 
A variety of sHSPs have also been shown to directly interact with the 
proteasome, ubiquitin ligase complexes, cell redox (reduction/oxidation) 
potential and apoptotic proteins when required. sHSPs, including HSP27 and 
αB crystallin, also interact with the cytoskeleton – actin, microtubules and 
intermediate filaments (including desmin and GFAP (glial fibrillary acidic 
protein)). But some of these interactions require direct phosphorylation of the 
sHSP; P-HSP27 is needed for HSP27 to interact with actin (Reviewed - Ecroyd 
and Carver, 2009, Garrido et al., 2012, Nicholl and Quinlan, 1994). 
sHSPs are not only expressed in stress conditions, they are expressed in cells 
throughout development and during adulthood. Their cellular location differs in 
response to the environmental conditions (Sun and MacRae, 2005). HSP27 and 
αB crystallin are the two main sHSPs, their expression often associated with 
tissues which have high rates of oxidative metabolism, such as the brain, heart 
and skeletal muscle fibres (type I and IIa), although both proteins are not 
expressed at the same concentration. These sHSPs protect against ischemic 
and reperfusion damage due to blood flow occlusion, with αB crystallin 
predominately known as a major constituent of the eye lens, with αB crystallin 
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(and αA) important in preventing cataract formation (Arrigo et al., 2007, Sun and 
MacRae, 2005).  
In neurodegenerative disorders, including Alzheimer’s and Parkinson’s 
diseases, the upregulation of HSP27 and αB crystallin at damaged neurons and 
astrocytes has been observed and are frequently associated with amyloid 
deposits (Ecroyd and Carver, 2009, Sun and MacRae, 2005). Their role in 
Alzheimer’s disease will be explored in sections dedicated to each sHSP, 
particular expression of sHSPs in AD is thought to be as a result of the cell 
recognising the formation of amyloid fibrils as a stress and responding 
appropriately. 
 
1.3.7 HSP27 and Phosphorylated HSP27 
HSP27 expression is induced following cellular stress, forming stable dimers 
which can also form oligomers of up to 32 subunits (~800 kDa), but these are 
typically unstable (Garrido, 2002). Dephosphorylation promotes oligomer 
formation, whereas phosphorylation promotes dimer formation, one particular 
kinase associated with HSP27 phosphorylation is MAPKAPK2 (mitogen-
activated protein kinase-activated protein kinase 2). HSP27 is modified via 
phosphorylation at serine sites, and therefore differential oligomerisation, 
following exposure to a range of stressors, results in a very specific ability to 
control the function of HSP27 (Garrido, 2002, Read and Gorman, 2009, Stetler 
et al., 2009). 
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HSP27 is able to act as a chaperone when it is present as large 
unphosphorylated oligomers, usually of 24 subunits. The chaperone capability 
is down-regulated upon phosphorylation, with this phosphorylation most 
commonly resulting in the formation of short rod-shaped tetramers. 
Phosphorylation was not initially thought to be as advantageous to the cell as it 
diminishes the chaperone capabilities of HSP27, but it has been suggested that 
phosphorylation of HSP27 acts as a mechanism to remove proteins that cannot 
be successfully refolded from the cell. P-HSP27 targets these proteins towards 
ubiquitination, acting as an E4 factor. Ubiquitination is an enzyme based, 
multistep process, interaction with E4 factors can cause the association of E3 
ligases to substrates and act as functional bridging for ubiquitin moieties, 
stabilising the aggregates before their removal. This interaction increases the 
efficiency and speed of the transference of ubiquitin chains from the E3 ligase 
to the misfolded substrate. The rapid adaptability of large HSP27 oligomers, via 
phosphorylation and dephosphorylation, enables fast, dynamic responses to a 
variety of cellular stresses (Reviewed - Lanneau et al., 2010, Rogalla et al., 
1999, Sahara et al., 2007, Stetler et al., 2009). 
Through the chaperone function of HSP27 cell fate can be influenced to a 
degree, but HSP27 is also associated with cell survival through the stabilisation 
of the actin cytoskeleton and inhibition of apoptotic pathways. Known as a 
powerful anti-apoptotic protein, HSP27 at high levels is able to suppress 
caspase activation, Cytochrome c release (Samali et al., 2001) and the 
translocation of other molecules required for apoptosis. But the direct site of 
HSP27 interaction in apoptosis initiation is debated, HSP27 is able to bind to 
cytochrome c after it is released from the mitochondria, preventing apoptosome 
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formation, it has also been shown to bind to DAXX preventing FAS driven cell 
death, see figure 1.12, but HSP27 is also thought to be able to act upstream of 
the mitochondria, interfering with caspase recruitment (Reviewed - Beere, 2005, 
Garrido, 2002, Read and Gorman, 2009, Stetler et al., 2009). 
Reduction of HSP27 expression has been associated with the onset of neuronal 
cell death and elevated levels of HSP27 have been frequently found in 
individuals with neurodegenerative disorders, such as Alzheimer’s disease, 
widely hypothesised to be part of a chaperone driven protective response to 
enhance protein folding capacity of the affected neurons (Read and Gorman, 
2009, Sherman and Goldberg, 2001, Shimura et al., 2004). 
Expression of HSP27 varies across different cell types, with constitutive 
expression level varying; it is highest in the spinal ganglia and brain stem with 
neurons expressing HSP27 at a relatively low level and prominent expression in 
glia cells (Reviewed - Stetler et al., 2009). Despite differential expression of 
HSP27 across neuronal populations; neurons that express both proteins 
(HSP70 and HSP27) have a higher ‘defence’ capacity against misfolded 
proteins (Chen and Brown, 2007). 
Expression of HSP27 has been reported to be increased by approximately 20% 
in the Alzheimer’s disease brain (Bjorkdahl et al., 2008); expression has been 
frequently associated with degenerating hippocampal neurons, 
hyperphosphorylated tau, senile plaques and NFTs, as well as proliferating and 
astrocytes (Bjorkdahl et al., 2008, Wilhelmus et al., 2006b). 
HSP27 has also been shown to prevent the deformation and limited dynamics 
of mitochondria that arise when exposed to Aβ, both of which are commonly 
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linked to Alzheimer’s pathology (King et al., 2009). HSP27 can positively 
reinforce the activity of ATP-dependent chaperones, such as HSP70, through 
an ability to maintain mitochondrial membrane potential, ensuring ATP 
production through increasing and maintaining glutathione levels at times of 
cellular stress (Preville et al., 1999). 
HSP27 has been widely reported to bind to fibrillar amyloid plaques and to 
inhibit de novo fibrillisation (Koren et al., 2009, Wilhelmus et al., 2007), this is 
thought to be possible through HSP27 targeting the ‘seeding’ step of fibril 
formation, with less impact of HSP27 found on established fibrils (Kudva et al., 
1997). HSP27 is also associated with senile plaques and degenerating neurons 
in the brains of AD patients, particularly localised found in temporal, parietal and 
frontal lobes (Shinohara et al., 1993). This has been directly reported in 
cerebrovascular cells; HSP27 was shown to bind Aβ, prevent its aggregation 
and accumulation at the cell surface, promoting cell survival (Wilhelmus et al., 
2006a). Despite limited neuronal endogenous expression levels, HSP27 
expression by glia and transference to neurons has been proposed as a 
mechanism of how this protection is elicited (King et al., 2009). 
P-HSP27 has not been shown to bind ‘normal’ tau and preferentially binds to 
hyperphosphorylated tau (including PHFs), and targets it for dephosphorylation 
or removal in conjunction with HSP70 and CHIP by altering its confirmation, but 
the sHSP also appears to be able to remove hyperphosphorylated tau 
independently of the HSP70/CHIP ubiquitin pathway, although the mechanisms 
of this have not been established. It has been suggested to directly feed p-tau 
into the proteasome, suppressing cell death (Koren et al., 2009, Shimura et al., 
2004), through acting as an E4 factor (Lanneau et al., 2010). HSP27 and P-
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HSP27 have both been shown to bind tau in Alzheimer’s disease, but HSP27 is 
only able to target tau for removal if it itself is not phosphorylated, P-HSP27 has 
been shown to actually stabilise tau structures (Abisambra et al., 2010, 
Bjorkdahl et al., 2008). P-HSP27 has been found in the nucleus and cytoplasm 
of the cell, potentially its small size enabling shuttling between both locations. 
This enables P-HSP27 to target both, cytosolic and nuclear proteins for 
degradation (Lanneau et al., 2010), cycling enables HSP27 to hand P-tau to P-
HSP27 to degrade via ubiquitination, emphasising the importance of the 
dynamic cycling of HSP27 and P-HSP27 (Abisambra et al., 2010). 
 
1.3.8 αB Crystallin 
A range of studies have shown that αB crystallin interacts predominately in the 
early stages of protein folding, with amorphous, intermediately folded 
aggregates, resulting in the formation of a large, stable complex that is less 
likely to aggregate with other nascent proteins (Ecroyd and Carver, 2009). 
Despite lacking the ability to refold aggregates, during times of cellular stress 
when cellular levels of ATP are low this can be advantageous. The lack of 
ability to refold aggregates can be advantageous at times of cell stress, when 
ATP levels are low sHSPs can incapacitate misfolded aggregates thus limiting 
further cell stress through the build up of aggregates until cellular conditions 
become more favourable and ATP levels increase. At this point, the aggregates 
can be refolded through the action of HSP70. It has been suggested that 
HSP70 and αB crystallin act synergistically in vivo (Ecroyd and Carver, 2009, 
Haslbeck et al., 2005). 
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Examination of αB crystallin expression in the Alzheimer’s disease brain has 
shown that some areas show up to 30% higher expression than in control 
patients (Bjorkdahl et al., 2008). Increased expression was identified in several 
areas including in the hippocampal gyrus, temporal cortex, cingulated cortex 
and superior frontal cortex, with particular expression noted in microglia that 
were associated with NFTs and SPs (senile plaques), suggesting expression 
associated with Aβ deposition (Mao et al., 2001, Renkawek et al., 1994, Yoo et 
al., 2001). Strong αB crystallin expression has been noted in neurons in areas 
strongly associated with damage in Alzheimer’s disease, levels increasing 
proportionally to neuronal loss, with the highest concentration found in layers III 
and V of the cerebral cortex (Mao et al., 2001, Renkawek et al., 1994), 
Accumulation was also noted in astrocytes, microglia and degenerated neurons 
(Wilhelmus et al., 2006b). It has been suggested that αB crystallin is involved in 
the latter stages of disease progression, levels consistently correlate with the 
formation of intracellular NFTs which ultimately lead to neuronal death, and the 
formation of extracellular NFTs (Mao et al., 2001). 
αB Crystallin has been reported to prevent formation of mature Aβ(1-40) fibrils in 
vitro, however, presence of αB crystallin also increased the toxic effect of Aβ(1-
40) through encouraging the formation of smaller aggregates and the formation 
of β-pleated sheet rich structures in which αB crystallin is complexed with Aβ(1-
40) (Stege et al., 1999, Yoo et al., 2001), verified by Thioflavin T assays and Far-
UV circular dichroism (Liang, 2000) and believed to be the more toxic Aβ 
structure. The formation of these types of structures has been reported to occur 
due to Aβ interfering with the normally dynamic structure of αB crystallin 
oligomers. The αB crystallin oligomers are made of monomers that rapidly 
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associate and dissociate with the larger structure, the presence of Aβ prevent 
monomers re-associating, so the forming Aβ structure becomes coated in αB 
crystallin monomers (Liang, 2000). Oxidation of Met35, found on side chains of 
Aβ(1-40), limits the ability of Aβ to structurally form fibrils and acts to promote 
oligomer formation, which is thought to be the principle reason for the increased 
toxicity of Aβ in the presence of αB crystallin (Narayanan et al., 2006). Met35 
oxidation induces increased neurotoxicity; this facilitates the propagation of free 
radical production among adjacent residues (Kanski et al., 2002). Narayanan, et 
al., 2006, also found that fibril formation in the presence of αB crystallin was 
restricted due to the sHSP competing for Aβ(1-40) monomer interactions. 
Shammas, et al., 2011, further investigated this suggestion through looking at 
the effect of αB crystallin on pre-formed fibrils in vitro. αB crystallin was shown 
to tightly bind Aβ(1-42) and whilst bound, impede fibril elongation. High 
concentrations of αB crystallin were not found to impede Aβ(1-42) fibril formation 
de novo (Narayanan et al., 2006, Shammas et al., 2011), pre-incubation of 
neurons with αB crystallin, was also found to increase the toxicity of Aβ upon 
exposure (Stege et al., 1999). 
Wilhelmus, et al., (2006), have also shown αB crystallin to promote protofibril 
formation, but in cerebrovascular cells this structure was not toxic and indeed 
protected cells from the toxicity of Aβ through limiting the availability of Aβ at the 
cell surface. These data suggest the mechanism and regulation of Aβ toxicity 
may vary between cell types (Wilhelmus et al., 2006a).  
Others have suggested that the prevention of fibril formation through interaction 
of αB crystallin with Aβ, is able to directly reduce the toxicity of Aβ on the cell 
(Dehle et al., 2010). However, the work by Dehle, et al., 2010, did not 
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investigate oligomer formation and utilised MTT (3-(4,5-dimethylthiazol-2-yl)-
2,5-diphenyltetrazolium bromide), a marker of mitochondrial dehydrogenase 
activity and a commonly used dye, for assessment of neuronal viability. Aβ has 
been shown to directly reduce this dye, providing false positive absorbances 
when the dye intensity is measured. MTT is a widely used dye, but there are 
now significant questions regarding its validity when used with Aβ, suggesting 
direct markers of cell apoptosis/death should be used (Benilova et al., 2012, 
Wogulis et al., 2005). Further support for the role in HSP27 and αB crystallin in 
prevention of fibril formation, come from evidence that the levels of these 
sHSPs negatively correlate to the concentrations of ROS and NO˙, both of 
which are produced abundantly as fibrils are formed (Reviewed - Ecroyd and 
Carver, 2009). 
αB crystallin has also been linked to increased tau degradation, possibly via 
ubiquitination. The sHSP has also been shown to bind tau and NFTs, 
preventing their phosphorylation with via interacting with kinases or through 
enhancing dephosphorylation by phosphatises and potentially acting through 
ubiquitin ligase capabilities. These data suggest αB crystallin may have a 
beneficial role in attempting to prevent disease progression (Bjorkdahl et al., 
2008). Interestingly, and in contrast to a significant quantity of data obtained 
using samples from Alzheimer’s disease patients, mouse models and C. 
elegans (Link, 2006), work with another AD mouse model has shown levels of 
αB crystallin to decrease with age and disease progression (Ojha et al., 2011). 
Such data raise important questions regarding selection of appropriate models 
and appropriate promoters for the study of complex disorders, such as AD. 
These data emphasis the impact of species/strain background choices as well 
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as particular methodological approaches on experimental conclusions that are 
drawn. Despite a wealth of research into the role of αB crystallin in Alzheimer’s 
disease and amyloid fibril formation, a definitive positive/negative role remains 
to be established. Results for the majority of groups agree that αB crystallin 
limits fibril formation but the toxicity of the alternately formed products is 
debated. There remains no standard method for fibril production in vitro, the 
appropriate molar concentration of Aβ to use culture, the use of Aβ(1-40) or Aβ(1-
42), and methods used to assess neurotoxicity. The range of experimental 
differences limits the conclusions that can be applied in understanding the 
disease state (Ecroyd and Carver, 2009). 
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1.4 Primary Hypothesis  
Beneficial effects of IR1072 in multiple model systems of ageing and 
neurodegeneration are generated via a complex protein-based signalling 
cascade. 
This hypothesis has been formulated following a series of key findings 
regarding the biological effects of IR1072. As detailed in the introduction, 
mitochondria are believed to be critical in absorption and key initiators of the 
biological effects of infrared light. Previously undertaken research in the 
laboratory established altered activity of Complex II following IR1072 exposure 
in CD-1 mice. Therefore it was critical to investigate this property in further 
detail in the present study. Research conducted by our laboratory had also 
previously established that chronic IR1072 exposure reduced the number of 
small amyloid plaques present in the TASTPM brain (Grillo et al., 2013). 
Therefore it was logical to examine the heat shock protein family, a family of 
proteins known to be responsible for the removal of cellular aggregates, 
including β-amyloid. Another component of this primary hypothesis was to 
examine molecular changes underpinning observed improved working memory 
in CD-1 mice exposed to IR1072 (Michalikova et al., 2008). Research 
conducted using lymphocytes had previously demonstrated protective effects of 
IR1072 against UVA-induced cytotoxicity (Bradford et al., 2005); the primary 
hypothesis for this present study also required examination of whether IR1072 
was able to protect neurons against disease related cytotoxicity; induced 
through oxidative-stress and β-amyloid exposure. 
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1.4.1 Key aims to address the primary hypothesis 
1. Determine whether IR1072 exposure is sufficient to protect against toxic, 
disease-related insults in an in vitro neuronal culture system, assess the 
effects on cell proliferation and ATP production as a measure of 
mitochondria activity. 
2. Determine whether the oxidative phosphorylation activity of electron 
transport chain components are altered by IR1072 exposure. 
3. Assess the effects of IR1072 exposure on the levels of heat shock 
proteins and disease-related proteins via in a premature ageing mouse 
model, CD-1, and an Alzheimer’s disease mouse model, TASTPM, via 
western blotting and immunohistochemistry. 
4. Investigate the effect of age and sex on the photomodulatory effects of 
IR1072 in CD-1 mice and TASTPM mice, respectively through western 
blotting and immunohistochemistry. 
5. Examine the effects of ageing on the expression levels of chaperone 
proteins and disease-related proteins in both the CD-1 and TASTPM 
strains to further understand the disease state. 
6. Utilise the nematode Caenorhabditis elegans to understand/elucidate 
pathways essential to the biological effects of IR1072 and to understand 
how this information interplays with mammalian data. 
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Chapter 2: Methods and Materials 
 
2.1 Animals 
All mouse (Mus musculus) strains used in experiments were maintained in the 
Life Sciences Support Unit (LSSU), within Durham University. All mice had 
unrestricted access to food and water and were kept in a quiet same sex 
environment, under a 12 hour light/dark cycle. All procedures, including 
experimental, animal husbandry and breeding, were conducted in agreement 
with the UK Animal (Scientific Procedures) Act of 1986. PPL number: 40/3390. 
CD-1 mice are the in-house mouse strain maintained at the Life Science 
Support Unit of Durham University. 
TASTPM mice (heterozygous double transgenic mice (TASTPM) with the 
Swedish Amyloid Precursor Protein (K670N; M671L) double familial mutation 
(Thy-1-APP695Sw, Line 10 (TAS10) plus the PS1 (M146V) mutation (Thy-1-
PS-1M146V) were backcrossed onto a pure C57BL/6 background originally 
obtained from GlaxoSmithKline (Harlow, Essex, UK) where a breeding 
programme was set up within the LSSU at Durham University. 
 
2.2 In vivo IR Treatments and Apparatus 
The treatment apparatus is comprised of LED arrays which emit infra red light at 
1072 nm ± 25 nm. The arrays are fitted together to form a box in which the 
animal is enclosed for the duration of the exposure. This manner of treatment 
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ensures the animal will be exposed to IR1072 from every direction. The LEDs 
are pulsed at 600 Hz, with a duty cycle of 300 microseconds, 5 mW/cm2. 
Thermal drift was prevented by the fitting of a standard cooling fan to the 
equipment, thus room temperature was maintained, temperature was monitored 
at all times. LED arrays at the same specification were used for in vitro work 
and work with C. elegans. Sham treatments were conducted using replica 
equipment which was fitted with LED arrays but did not emit any light, of any 
wavelength, when turned on. LED arrays were supplied by Virulite Distribution 
Ltd, UK and were validated by both Dr Gordon Dougal (Virulite Distribution Ltd, 
UK) and the Durham University Physics Department (Dr Andrew Beeby). 
 
2.2.1 Acute IR1072 Treatments 
CD-1 or TASTPM mice were exposed to IR1072 or Sham treatments, for six 
minutes per day, over a 10 day period. Tissue (liver and/or brain) was then 
immediately taken for preparation for use in mitochondrial studies, 
immunoblotting or immunohistochemistry. 
 
2.2.2 Chronic IR1072 Treatments 
CD-1 or TASTPM mice were exposed to IR1072 or Sham exposures for six 
minutes a day, for two consecutive days, twice a week over a 5-6 month period. 
The weights of the mice were monitored during this time period. Tissue (liver 
and/or brain) was taken to be prepared for immunoblotting, 
immunohistochemistry or mitochondrial respiratory studies. 
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2.3 Immunoblotting 
2.3.1 Sample Preparation 
CD-1 or TASTPM mice were stunned and sacrificed humanely using a 
Schedule 1 technique, brain tissue dissected, the left hemisphere removed and 
snap frozen at –20°C. Brains were homogenised individually in a glass/glass 
dounce homogeniser using 5 ml homogenisation buffer (50 mM Tris-Base, 5 
mM ethylenediaminetetraacetic acid (EDTA), 5 mM ethyleneglycotetraacetic 
acid (EGTA) and 150 μM Protease Inhibitor Cocktail III, pH 7.4). 
Protein concentrations were determined using a Lowry Protein Assay (Lowry et 
al., 1951) using bovine serum albumin (BSA) as a protein standard. A stock 
solution of BSA (10 mg/ml) was diluted using distilled water to give a range of 
protein concentrations, 0-100 μg/ml, in triplicate. Protein samples of 5 μl and 10 
μl aliquots, made up to 100 μl using distilled water, were also assayed in 
triplicate. Lowry reagent A (2% (w/v) sodium carbonate, 0.1 M sodium 
hydroxide, 5% (w/v) sodium dodecyl sulphate (SDS)), Lowry reagent B (2% 
(w/v) sodium potassium tartrate) and Lowry reagent C (1% (w/v) copper 
sulphate) were mixed to a ratio of 100:1:1, respectively. 
0.5 ml of the Lowry reagent mixture was added to each sample and to the BSA 
protein standards; each was vortexed and incubated for 10 minutes at room 
temperature. 50 μl of Folin-Ciocalteau phenol reagent (1:1, Folin:dH2O (distilled 
water)) was added to each sample and standards, each eppendorf vortexed 
and incubated for 30 minutes at room temperature in the dark. After this time, 
0.5 ml of distilled water was added to each eppendorf to terminate the reaction. 
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A Jenway Genova spectrophotometer was used to measure absorbance at 
λ=770 nm for each sample. A standard curve was plotted of λ=770 nm 
absorbance for BSA standards which was then used to determine unknown 
protein concentrations. 
Samples were prepared for immunoblotting in 3x sample buffer (30 mM 
NaH2PO4, 30% (v/v) glycerol, 0.05% (w/v) Bromophenol blue, 7.5% (w/v) SDS, 
in dH2O), DTT (Dithiothreitol, 23.5 mM final concentration, from a 200 mM stock 
solution made with dH2O) with 10-50 μg of protein and made up to a final 
volume of 15 μl with dH2O. 
Samples were thoroughly vortexed, centrifuged at 13,000 rpm for one minute, 
incubated for five minutes at 95°C, centrifuged at 13,000 rpm for one minute 
and thoroughly vortexed again. Samples were then stored at -20°C or applied to 
an SDS-PAGE (polyacrylamide gel electrophoresis) gel for electrophoresis. 
 
2.3.2 Immunoblotting 
Samples underwent SDS-PAGE (Bradford et al., 2005), wells were formed for 
loading samples using a 0.75 mm 10 well comb and formed from 6.5% SDS-
PAGE stacking gel (56.0% (v/v) distilled water, 24.7% stacking gel buffer (0.5 
mM Tris-base, 8 mM EDTA, 0.4% (w/v) SDS), 16.1% (v/v) acrylamide (40% 
stock, 29:1, acrylamide:bis-acrylamide), 2% ammonium persulphate (stock 1 
mM made up with dH2O) and 0.25% TEMED (Tetramethylethylenediamine 
(v/v)). After stacking gel had set, the comb was removed and the wells washed 
with water. 
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10% acrylamide resolving gels (49.73% (v/v) dH2O, 24.86% (v/v) acrylamide 
(40%, 29:1, acrylamide:bis-acrylamide), 24.86% (v/v) running gel buffer (1.5 
mM Tris-base, 8 mM EDTA, 0.4% (w/v) SDS), 0.5% ammonium persulphate (1 
mM stock made with dH2O) and 0.05% TEMED); 15% acrylamide resolving gels 
(37.3% (v/v) dH2O, 37.29% (v/v) acrylamide (40%, 29:1, acrylamide:bis-
acrylamide), 24.86% (v/v) running gel buffer (1.5 mM Tris-base, 8 mM EDTA, 
0.4% (w/v) SDS), 0.5% ammonium persulphate (1 mM stock made with dH2O) 
and 0.05% TEMED), or 7.5% acrylamide resolving gels (55.94% (v/v) dH2O, 
18.65% (v/v) acrylamide (40%, 29:1, acrylamide:bis-acrylamide), 24.86% (v/v) 
running gel buffer (1.5 mM Tris-base, 8 mM EDTA, 0.4% (w/v) SDS), 0.5% 
ammonium persulphate (1 mM stock made with dH2O) and 0.05% TEMED) 
were used. 
 Resolving gels were left to set for 30 minutes prior to use, following this gels 
were placed in Hoefer Mighty Small II SE 260 vertical slab gel electrophoresis 
tanks (Hoefer, Germany) and the tanks were filled with electrode buffer (50 mM 
Tris-base, 384 mM glycine, 1.8 mM EDTA, 0.1% SDS (w/v) pH 8.8). Previously 
prepared 15 μl samples and pre-stained standard (10-250 kDa) were loaded 
into stacking gel wells using a 50 μl Hamilton syringe. 
Electrophoresis was conducted at 180 V and 10 mA, until samples had entered 
the resolving gel, after which mA were increased to 15 mA until the 10 kDa 
marker reached the bottom of the gel. 
Protein within the resolving gel was transferred onto nitrocellulose membrane 
by using a transfer cassette composed of sponge, two sheets of blotting card, 
nitrocellulose membrane (0.45 μm pore size), SDS-PAGE gel, two sheets of 
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blotting card and another sponge, all of which were soaked in transfer buffer 
previously, bar the SDS-PAGE gel. Air bubbles were removed during the 
construction of the cassette by rolling a 50 ml Falcon tube over each layer, bar 
directly rolling the nitrocellulose and acrylamide. Transfer of proteins onto 
nitrocellulose membrane was performed using transfer buffer (25 mM Tris-
Base, 192 mM Glycine, 20% Methanol (v/v)) and a Hoefer TE Series transfer 
unit (Hoefer, Germany), set at 50 V, <200 mA, for 2.5 hours (or less, depending 
on protein size) kept cold using ice and cool packs. 
Following transfer, the nitrocellulose was incubated in 10 ml blocking buffer (5% 
(w/v) dried milk powder, 0.2% (v/v) Tween-20, 100 μl 2 M NaOH, in TBS (Tris 
Buffered Saline (50 mM Tris-base, 0.9% (w/v) sodium chloride, pH 7.4)), for one 
hour at room temperature, with gentle agitation. 
Nitrocellulose was the incubated with primary antibody (see table 2.1) in 
incubation buffer (TBS pH 7.4, 2.5% dried milk powder) at 4°C for antibody 
specific incubation times (see table 2.1) with gentle agitation. Following the 
incubation period, the nitrocellulose was washed four times for 10 minutes 
each, in 10 ml wash buffer (TBS pH 7.4, 2.5% dried milk powder, 0.2% Tween-
20) at room temperature with gentle agitation. Nitrocellulose was then incubated 
for one hour at room temperature in incubation buffer containing 1:2000 dilution 
of HRP (horseradish peroxidase) linked anti-mouse or anti-rabbit (see table 2.1) 
antibody with gentle agitation. Excess secondary antibody was removed by 
washing as described previously. Nitrocellulose was then rinsed in TBS and 
incubated in 10 ml luminol solution (Solution A: Solution B 1:1, (Solution A, 100 
mM Tris-base pH 8.5, 25 mM luminol, 396 μM p-Coumaric acid. Solution B, 100 
mM Tris-base pH 8.5, 6.27 mM H2O2). Luminol was then drained from the 
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nitrocellulose and wrapped in cling film, after which it was taped into a film 
cassette. The nitrocellulose was then exposed to Hyperfilm™ for various times, 
the hyperfilm was then developed using Kodak-D19 developer and fixed for five 
minutes in Kodak Unifix fixative. 
The immunoreactive signals from each lane were quantified using ImageJ 
(version 1.43, National Institute of Health, USA). Optical density of the labelled 
bands was normalised against the background density. Protein levels were 
standardised using anti-mouse β-actin primary antibody (1:2000 dilution, Sigma, 
UK). 
 
2.3.3 Protocol for Phosphorylated Antibodies 
Method was followed as stated previously in 2.3.2, until the end of the transfer 
stage when membranes were blocked in 10 ml blocking solution (5% (w/v) BSA, 
0.1% (v/v) Tween-20, in TBS) for one hour at room temperature. Subsequently 
antibodies were incubated with membrane in a 2.5% (w/v) BSA, 0.1% (v/v) 
Tween-20 TBS solution for 3 days at 4oC, with gentle agitation. Membranes 
were then subjected to four 10 minute washes using a 0.1% (v/v) Tween-20 
TBS solution. Secondary antibody was incubated at 1:1000 dilution of HRP 
linked anti-mouse or anti-rabbit (see table 2.1) antibody, in a 2.5% (w/v) BSA, 
0.1% (v/v) Tween-20 TBS solution for one hour at room temperature, with 
gentle shaking. Excess secondary antibody was removed by washing the 
membrane four times, each for 10 minutes in 0.1% (v/v) Tween-20 TBS buffer. 
Nitrocellulose membrane was then incubated for five minutes in Pierce® 
SuperSignal West Pico Chemiluminescent Substrate, mixed 1:1. Excess 
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developing solution was then removed from the membrane, the membrane 
enclosed in cling film and taped into a cassette, exposed to Hyperfilm™, 
developed using Kodak-D19 developer, then fixed for five minutes in Kodak 
Unifix fixative. 
Membranes were rinsed in stripping buffer (200 mM glycine, 0.1% SDS (w/v), 
1% Tween-20 (v/v), pH 2.2) before incubation in 10 ml stripping buffer for 10 
minutes with gentle shaking. Following this, the membrane was washed twice, 
each for 10 minutes in TBS. Subsequently, membranes were washed twice with 
0.1% (v/v) Tween-20 TBS solution for five minutes per wash. Following this the 
membrane was blocked for one hour, at room temperature with gentle shaking, 
in 10 ml blocking buffer (5% (w/v) dried milk powder, 0.02% (v/v) Tween-20, 
100 μl 2 M NaOH, in TBS. The membrane was then incubated with anti-mouse 
β-actin primary antibody (1:5000 dilution, Sigma Aldrich, UK) to standardise 
protein levels, following the method described in 2.3.2. 
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Table 2.1. Antibody Concentrations and Conditions 
Antibody 
Predicted 
Weight (kDa) 
Acrylamide 
Gel % 
Monoclonal/ 
polyclonal 
Concentration Secondary 
Incubation 
(Days) 
Source 
Peptide 
Blocking Agent 
APP 90 10 Polyclonal 1:1000 Rabbit 2 Cell Signaling Marvel 
AT8 79 10 Monoclonal 1:50 Mouse 2 ThermoFisher  BSA 
GluA2 (N19) 100 7.5 Polyclonal 1:2000 Goat (1:5000) 1 Santa Cruz Chicken Albumin 
GSK-3β 50 10 Polyclonal 1:10,000 Rabbit 1 Sigma Aldrich Marvel 
HSF1 66 10 Polyclonal 1:200 Rabbit 2 ProteinTech Marvel 
HSP105 105 7.5 Polyclonal 1:250 Rabbit 2 Cell Signaling Marvel 
HSP70 70 10 Polyclonal 1:125 Rabbit 2 Cell Signaling Marvel 
HSP27 28 15 Polyclonal 1:100 Rabbit 3 Cell Signaling Marvel 
PS1 53 10 Polyclonal 1:300 Rabbit 2 AbCam BSA 
P-HSP27 (Ser82) 27 15 Polyclonal 1:100 Rabbit 3 Cell Signaling BSA 
P-Tau (Ser519) 50 10 Monoclonal 1:5000 Rabbit 1 AbCam BSA 
SDHC 19 15 Polyclonal 1:1000 Rabbit 2 ProteinTech Marvel 
TARP γ2 37 10 Polyclonal 0.25 μg/ml Rabbit 1 In house Marvel 
TARP γ8 50 10 Polyclonal 0.25 μg/ml Rabbit 1 In house Marvel 
THY-1 22 15 Polyclonal 1:200 Rabbit 2 Cell Signaling BSA 
αB Crystallin 20 15 Monoclonal 1:100 Mouse 2 Roy Quinlan Marvel 
β-amyloid(1-40) 87 10 Polyclonal 1:500 Rabbit 3 AbCam BSA 
β-amyloid(1-42) 87 10 Polyclonal 1:200 Rabbit 3 AbCam BSA 
β-actin 43 - Monoclonal 1:2000 Mouse 1 Sigma Aldrich Marvel 
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2.4 Immunohistochemistry 
2.4.1 Tissue Preparation 
CD-1 or TASTPM mice were stunned, decapitated and brains rapidly dissected. 
The right hemisphere was removed and placed in a paraformaldehyde fixative 
solution (4% paraformaldehyde, 0.1 M Na2PO4, 0.1 M NaH2PO4, pH 7.4) for one 
week. After which the brains were primarily dehydrated in 10% sucrose 
overnight followed by 20% sucrose and 30% sucrose sequentially, made up 
with PBS (phosphate buffered saline, diluted from 10x stock solution, pH 7.4). 
Once the tissue was dehydrated, the brains were snap-frozen in isopentane at -
70°C for one minute, and then stored at -80°C. Hemispheres were cut using a 
Leica model CM 3050S Cryostat at -25°C into 25 μm sagittal sections. The 
sections were then transferred into 24-well plates containing TBS 0.02% (w/v) 
sodium azide and stored at 4°C. 
 
2.4.2 Immunohistochemical Protocol 
To prevent endogenous peroxidase activity, samples were incubated at room 
temperature for 30 minutes in a solution of TBS, 10% (v/v) methanol and 3% 
(v/v) hydrogen peroxide (30% stock). Samples were then washed three times 
for five minutes in TBS-T, 0.2% (v/v) Triton X-100 in TBS. After this time 
sections were incubated for 30 minutes at room temperature in 0.2% (w/v) 
glycine, made in TBS. This was performed to quench excess 
paraformaldehyde. 
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Sections were subsequently blocked for one hour in 10% FCS (v/v) (Foetal Calf 
Serum) made in TBS-T. This was followed by incubation with the primary 
antibody in 1% (v/v) FCS and TBS solution; anti-GSK-3β was used at 1 μg/ml 
and kept at 4°C overnight. Following incubation with the primary antibody, 
sections were allowed to reach room temperature for one hour. Sections were 
then washed three times, each for five minutes in TBS-T. Consequently, 
sections were incubated at room temperature for two hours with 50 μl 
biotinylated anti-rabbit secondary antibody (Vector Laboratories, UK, part of 
VectorStain ABC Kit) in a solution of 1% (v/v) FCS and TBS. Sections were 
then washed three times, each for five minutes in TBS-T. ABC reagent (Vector 
Laboratories) was mixed 30 minutes before use and constituted of 100 μl of 
reagent A, 100 μl reagent B in 5 ml TBS. Sections were incubated in ABC 
reagent for one hour at room temperature. Sections were subsequently washed 
three times for five minutes each in TBS-T. This was followed by two 
subsequent washes for five minutes in TBS. 
Samples were developed using 3,3’-Diaminobenzidine (DAB) solution (200 μl 
Buffer solution, 100 μl DAB and 100 μl H2O2 in 5 ml dH2O; DAB peroxidase 
substrate kit, Vector Laboratories). After this point, developing was stopped by 
the addition of dH2O and DAB solution removed. Sections were then rinsed 
three times in dH2O. Sections were mounted, air-dried and coverslipped using 
DPX mountant and glass coverslips. 
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2.4.3 Protocol for Mouse on Mouse antibodies 
For the anti-AT8 antibody (ThermoScientific, Fisher, UK), a Vector® M.O.M™ 
Kit (Vector Laboratories) was used as the primary antibody had been raised in a 
mouse and mouse tissue was being probed. 
The initial steps were similar to the standard method; 2.4.2 was followed until 
the blocking stage. After which antigen retrieval was then performed on sections 
by incubating sections for 30 minutes in 50 mM Sodium Citrate, pH 8.4 and 
room temperature. This was followed by incubation with fresh 50 mM Sodium 
Citrate, pH 8.4, at 80°C for 30 minutes. Sections were then washed for 15 
minutes with TBS-T. Samples were blocked for one hour using M.O.M™ Mouse 
Ig Blocking Reagent (4% (v/v) stock solution, diluted in TBS) with gentle 
shaking. Sections were washed twice for two minutes using TBS before 
incubation in M.O.M™ working diluent (8% (v/v) supplied protein concentrate 
stock solution in TBS) for five minutes. Anti-AT8 antibody was diluted to give a 
concentration of 1 μg/ml in the M.O.M™ working diluent and incubated 
overnight at 4°C, with gentle agitation. Subsequently, sections were washed 
twice for two minutes in TBS and incubated for 10 minutes with biotinylated 
secondary antibody (0.4% (v/v) M.O.M™ Biotinylated Anti-Mouse IgG, 8% (v/v) 
supplied protein concentrate stock solution in TBS). Samples were again 
washed twice for two minutes in TBS before application of ABC reagent (Vector 
Laboratories, 4% (v/v) Reagent A, 4% (v/v) Reagent B in TBS) which was 
created 30 minutes before use and allowed to mix. Sections were incubated in 
ABC reagent for five minutes at room temperature and consequently washed 
twice for two minutes in TBS before developing. 
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Samples were developed using DAB solution (4% (v/v) Buffer solution, 2% (v/v) 
DAB and 2% (v/v) H2O2 in dH2O; DAB peroxidase substrate kit (Vector 
Laboratories, UK)). After this point, developing was stopped by the addition of 
dH2O and DAB solution removed. Sections were then rinsed three times in 
dH2O. Sections were mounted, air-dried and coverslipped using DPX mountant 
and glass coverslips. Sections were viewed on a Nikon Eclipse E400 
microscope, where images were photographed using Progen Eyepiece 3 mega-
pixel camera in TSView 7, Tuscen Image Technology Co., Ltd., China. 
 
2.5 Mitochondrial Respiratory Studies 
2.5.1 Mitochondrial Isolation 
Mice were stunned and decapitated, brain tissue removed and kept cold on ice 
in isolation buffer (220 mM mannitol, 60 mM sucrose, 5 mM Tris-base, 1 mg/ml 
BSA (essentially fatty acid free), 0.5 mM EGTA, pH 7.4). Liver tissue was also 
removed, kept cold on ice and in a separate isolation buffer (250 mM Sucrose, 
3.4 mM Tris-base, pH 7.4). Tissues were rinsed three times in their respective 
isolation buffers to remove excess blood. Tissues were roughly chopped using 
scissors and subsequently rinsed twice in a small volume (<5 ml) of isolation 
buffer using a Pasteur pipette. Tissue was homogenised gently three-four times 
using a loose pestle in a 7 ml dounce glass/glass homogeniser containing 5 ml 
of ice-cold isolation buffer. A smooth suspension was gained by further 
homogenising the tissue using a tight pestle seven-eight times. Brain and liver 
homogenates were then transferred to clean JA20 tubes, balanced with 
isolation buffer, and centrifuged using a Beckman JA20 rotor at 2000 rpm for 10 
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minutes, at 0-4°C. Subsequently, the pellet was discarded and the supernatant 
further centrifuged at 10,000 rpm for 10 minutes, at 0-4°C. 
The liver preparation supernatant was discarded and the pellet resuspended in 
chamber buffer (220 mM mannitol, 60 mM Sucrose, 5 mM Tris-Base, 1 mg/ml 
BSA (essentially fatty acid free) pH 7.4) at 10,000 rpm for 10 minutes at 0-4°C. 
After this, the supernatant was discarded and the remaining pellet resuspended 
gently in approximately 0.5 ml chamber buffer at room temperature, ready for 
oxidative phosphorylation experiments. 
For the brain suspension, the pellet was resuspended in approximately 9 ml of 
ice-cold Percoll® solution (250 mM Sucrose, 5 mM Tris-HCl, 0.1 mM EGTA, 
18% Percoll®, pH 7.4). The brain tissue was then centrifuged at 10,000 rpm for 
45 minutes. 
After centrifugation two layers were visible in the JA20 tube, the top layer 
containing synaptosomes and the bottom containing a loose mitochondrial 
pellet. Using a Pasteur pipette, the top layer was removed and placed in a clean 
JA20 tube. The loose mitochondrial pellet was then removed using a Pasteur 
pipette and placed in a clean JA20 tube. Both were resuspended in room 
temperature chamber buffer and centrifuged at 10,000 rpm for 10 minutes in 
order to remove Percoll®. Subsequently, the supernatant was removed and 
discarded from both JA20 tubes. The pellets were individually resuspended 
gently using Pasteur pipettes in approximately 8 ml of chamber buffer and 
centrifuged for 10 minutes at 10,000 rpm. Finally, the supernatant was 
removed, leaving approximately 200 μl of synaptosomes and mitochondria. 
Synaptosomes were frozen and the mitochondria were used immediately in 
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oxidative phosphorylation studies. Protein concentrations were determined 
spectrophotometrically using the Lowry Protein Assay (See 2.3.1.; Lowry et al., 
1951). 
 
2.5.2 Oxidative Phosphorylation Protocol 
A Clark-type oxygen electrode was used to polarographically measure 
mitochondrial oxygen consumption (Sweetman and Weetman, 1969) with a 
maximum bath volume of 1 ml (Rank Bros, Bottisham, UK). A Kipp and Zonen 
flat bed recorder was calibrated to provide a chart speed of 0.5 mm/sec and a 
full-scale deflection of 10 mV to record changes in oxygen consumption. 
The reaction chamber had a final volume of 0.3 ml, made up of chamber buffer 
plus 5 mM KH2PO4, saturated with oxygen (139 ng O atoms/ml). The 
experiment began with the addition of liver (0.9-1.2 mg) or brain (0.3-0.5 mg) 
mitochondria protein to measure oxidative respiration and the chamber sealed. 
Endogenous respiration was measured for one minute, after this time substrate 
was added to the chamber and the chamber re-sealed. Substrates were 5 mM 
succinate or 5 mM glutamate plus 5 mM malate, added to measure state 4 
respiration, where the mitochondria respire in the presence of excess oxygen 
and excess substrate, in the absence of ADP.  
After recording state 4 respiration for 1 minute, ADP (167 μM) was added in 
order to measure state 3 respiration, at this point substrate, oxygen and ADP 
are all in excess. As the ADP becomes phosphorylated, state 4 respiration 
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returns, leaving oxygen and substrate in excess only (Chance and Williams, 
1956a). 
RCI (Respiratory Control Index) was calculated by dividing state 3 respiration 
rate by return to state 4 respiration rate, giving a measure of the integrity of 
mitochondria and of oxidation coupling to ATP synthesis in the respiratory 
chain. Values greater than 3 and 2 for substrates, glutamate plus malate and 
succinate respectively, indicate tightly coupled mitochondria (Chance and 
Williams, 1956a). 
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Glutamate (5 mM) plus Malate (5 mM)     Succinate (5 mM) 
 
 
 
 
 
 
 
Figure 2.1. Examples of Oxidative Phosphorylation traces for Complex I and II. Traces 
generated by measuring the endogenous respiration, mitochondria only, for one minute before 
the addition of any substrate, one minute after adding glutamate (5 mM) plus malate (5 mM; 
Complex I) or succinate (5 mM; Complex II) which is noted as state 4 respiration. State 3 
respiration is measured following the addition of ADP (167 μM) and as ADP becomes 
phosphorylated, respiration returns to state 4, respiration is measured until it has completely 
returned to State 4 and is then also recorded for one minute. 
 
2.6 Neuronal Cultures 
2.6.1 Cell maintenance 
CAD (Cath.a differentiated) murine CNS (central nervous system) 
catecholaminergic cell line were maintained in 75 cm3 (Sarstedt, UK) flasks in 
Gibco® DMEM (Dulbecco’s Modified Eagle’s Medium) /F12 +GlutaMAX® +10% 
FCS. 
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2.6.2 In vitro IR1072 Treatments 
The treatment apparatus is composed of LED arrays which emit infra red light at 
1072 nm ± 25 nm. The arrays are fitted together to be held above the cell 
culture plate being irradiated, see figure 2.2. The LEDs are pulsed at 600 Hz, 
with a duty cycle of 300 microseconds, 5 mW/cm2. 
 
 
 
 
 
 
 
Figure 2.2. IR1072 treatment apparatus used in tissue culture experiments 
 
2.6.2.1 In vitro IR1072 preconditioning 
CAD cells were seeded in 96 well plates (Sarstedt, UK) and grown at 37°C, 5% 
CO2, for 72 hours before use. 
Cells were exposed to five sets of three minute treatments of IR1072 or Sham 
treatments, with 30 minutes between each exposure. Cells were then exposed 
to hydrogen peroxide for four hours at a final concentration of 100, 75 or 50 μM, 
Cell culture 
dish 
LEDs 
Sham treated side of 
culture dish 
Power supply 
with fan 
Mirrored sheet 
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with PBS as a volume control. After this a MTT assay was performed (see 
2.6.3). 
 
2.6.2.2 In vitro IR1072 exposure plus Hydrogen Peroxide insult 
CAD cells were seeded in 96 well plates (Sarstedt, UK) and grown at 37°C, 5% 
CO2, for 72 hours before use. Cells were exposed to 150 or 50 μM H2O2 in 
DMEM/F12 + GlutaMAX® + 10% FCS or to a PBS volume control in 
DMEM/F12 + GlutaMAX® + 10% FCS. Immediately after the addition of the 
media containing H2O2 or PBS, cells were exposed to five sets of three minute 
IR1072 treatments, 30 minutes apart, for Sham treated. Four hours after the 
addition of the media containing H2O2, an MTT assay was performed (see 
2.6.3).  
 
2.6.3 MTT Assay 
MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) uses 
mitochondrial dehydrogenase activity as a measure of cell viability. 10 μl of MTT 
(5 mg/ml, in PBS, sterile filtered) was added to each well and incubated for 2.5 
hours at 37°C. After this time, the media containing MTT was removed and 100 
μl of isopropanol added to each well. Following dissolution of the formazan 
crystals, the density of each well was measured spectrophotometrically at 595 
nm using a Multiskan Ascent Plate Reader, Version 2.6. Isopropanol alone was 
used as a density control. 
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2.6.4 CytoTox 96 Non-radioactive Assay (Promega, UK) 
CytoTox 96 assay kit quantifies LDH (lactate dehydrogenase) levels as a 
measure of cell lysis (necrosis).  
Media was removed from cells and centrifuged at 13,000 rpm for two minutes. 
The supernatant containing the LDH was retained and the pellet resuspended in 
PBS, using the same volume removed from the cells, and placed back into the 
respective well of the 24 well plate. The 24 well plate was then frozen for two 
hours at -20°C to lyse all remaining cells. Cells were subsequently thawed and 
centrifuged at 13,000 rpm for two minutes; again the supernatant was retained 
as a measure of total remaining LDH. Dilutions; 1:10 and 1:20, were made of 
each supernatant using PBS as the diluent with DMEM/F12 plus 10% FCS used 
to calibrate the assay. 50 μl of substrate mix was added to 50 μl of each dilution 
prior to incubation for 30 minutes at room temperature in the dark. Neat, 1:10 
and 1:20 dilutions were all completed in triplicate. Following this, 50 μl of stop 
solution was added to each well and the absorbance measured at 490 nm on a 
Multiskan Ascent Plate Reader, Version 2.6. Cell lysis, via LDH release in the 
media supernatant, was calculated as a percentage of the sum of total LDH 
absorbance, combining the absorbance of positive control freeze-thawed cells 
and absorbance of media containing LDH. 
 
2.6.5 ATP Determination Assay (A22066, Invitrogen, USA) 
Using 24 well plates, CAD cells were passaged and maintained in DMEM/F12 
+GlutaMAX® +10% FCS and maintained at 37°C, 5% CO2, for 72 hours. After 
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this time, cells were exposed to IR conditioning, consisting of five sets of three 
minute IR1072 or sham exposures with 30 minutes between each treatment. 
ATP was either assayed immediately after the final IR1072 exposure or the 
cells were returned to the incubator for four hours. Media was removed and 
replaced with 300 μl of cell lysis buffer (100 mM Tris-HCl, pH 7.7, 2 M NaCl, 20 
mM EDTA, 0.2% (v/v) Triton-X100) and stored at 4°C for one hour. Buffer from 
each well was then centrifuged for 15 minutes at 13,200 rpm to remove cell 
debris. A standard reaction solution was made, as directed in the assay 
instructions. Using white Greiner® 96 well CellStar® UClear Bottom plates, 10 
μl of the supernatant from each sample was added to 90 μl of this solution and 
incubated for 15 minutes. After this time the luminescence was measured on a 
MicroBeta® 1450 TriLux Luminescence Counter Workstation Version 3.2 and 
ATP concentration determined from a standard curve of [ATP] vs. 
luminescence, performed each time an assay was completed as instructed by 
the assay kit. 
 
2.6.6 Immunocytofluorescence 
Using 24 well plates, sterile 13 mm glass coverslips were poly-d-lysine (Sigma, 
UK) coated at room temperature for 12 hours, under UV light in sterile 
conditions. Wells were rinsed twice with sterile PBS and CAD cells passaged 
into 24 well plates in DMEM/F12 +10% FCS and maintained for at 37°C, 5% 
CO2, for 72 hours. 
After 72 hours, cells reached 70% confluence; media was replaced and cells 
were exposed to IR conditioning. This consisted of five sets of three minute 
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IR1072 or sham exposures with 30 minutes between each treatment. Following 
the final treatment, cells were returned to the incubator for four hours. After this 
time, the media was removed from the wells and coverslips washed with PBS-T 
(PBS with 0.05% (v/v) Tween-20) for five minutes, twice. Cells were fixed in 4% 
paraformaldehyde for 15 minutes and then washed twice, as stated previously.  
Cells were then permeabilised using 0.5% (v/v) Triton X-100 in PBS for 10 
minutes and washed a further time. Cells were then blocked using PBG (1% 
BSA (w/v; Fraction V, minimum 96% lyophilized powder), 0.5% (v/v) cold water 
fish skin gelatin in PBS, pH 7.4) for 15 minutes, after which the primary antibody 
was diluted in PBG; 1:400 anti-Ki67, and cells were incubated with the primary 
antibody for one hour at room temperature. Cells were then washed three times 
using PBS-T, each for five minutes and then incubated with the secondary 
antibodies (1:100 anti-DAPI (4’,6-diamidino-2-phenylindole) and 1:500 anti-
rabbit Alexa fluor 488) for one hour. Cells were then washed five times with 
PBS-T, as previously stated, mounted with Mowiol (Calbiochem, UK) and left to 
dry overnight at room temperature in the dark, before storage at 4oC. Cells were 
inspected using a Carl Zeiss Axioskop 2 microscope equipped for 
epifluorescence. Images were captured using a Hamamatsu Orca 285 CCD 
camera controlled by Improvision Volocity software version 6. 
 
2.6.7 Preparation of β-amyloid Structures for use in Neuronal Cultures 
Human β-amyloid(1-42) peptide, Ascent Scientific, UK, was dissolved in DMSO 
(dimethyl sulphoxide) at 1 mg/ml and stored at -80°C until use. 
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Prior to use, the molar concentration of the peptide was calculated and diluted 
to 200 μM using sterile PBS. The peptide was then incubated for 72 hours at 
37°C, 5% CO2, without agitation. The peptide was then diluted to the required 
concentration using DMEM/F12 plus GlutaMAX® +10% FCS, inverted and 
gently added to neuronal cultures, with DMSO in DMEM/F12 plus GlutaMAX® 
+10% FCS as a control volume in control neuronal cultures. 
 
2.6.7.1 IR1072 Exposure of Cultures and Aβ 
24 hours after seeding in 24 well plates, cells were exposed to five sets of 3 
minute IR1072 treatments or sham treated, with 30 minutes between each 
exposure. 24 hours later, medium was removed and replaced with that 
containing Aβ or DMSO:PBS, five sets of three minute IR1072 or sham 
exposures immediately followed. 24 hours after media change, cells were 
exposed to five sets of 3 minute IR1072 treatments or sham treated, with 30 
minutes between each exposure. 24 hours after this the CytoTox 96 non-
radioactive assay was performed (see 2.6.4). Between each exposure and after 
each set of exposures cells were returned to the incubator and maintained at 
37°C, 5% CO2. 
 
2.6.8 Electron Microscopy 
Electron micrographs were obtained (figure 2.3) to determine the structure of 
the β-amyloid peptide following fibril formation as described in 2.6.7. A sample 
of 200 μM β-amyloid(1-42) peptide was removed, prior to the use of the peptide in 
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neuronal cultures. Samples were negative stained with 2% uranyl acetate (w/v), 
in distilled water, onto 400 mesh formvar coated copper grids and air dried. 
Samples were viewed using a Hitachi H7600 Transmission Electron 
Microscope. Mrs Christine Richardson conducted all electron microscopy in the 
Histology laboratory within the University of Durham. 
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Figure 2.3. Representative electron micrographs of β-amyloid (1-42) fibrils/oligomers. 
Fibrils/Oligomers formed by the method stated in 2.6.7 and imaged as in 2.6.8. Scale bar on 
image A) 100 nm, B) 500 nm. Labelling of fibrils is defined in nm. 
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2.7 Statistical Analysis 
All data were analysed using Microsoft Excel 2007 and GraphPad Prism 
Version 5, GraphPad Software Inc. All data were verified to be normally 
distributed. All data are displayed as mean ± standard error of the mean (SEM). 
For CD-1 and TASTPM timeline data, data were subjected to one-way ANOVA 
analysis of variance, with a Bonferroni post-hoc test.  
For comparing sham and IR1072 conditions, data were subjected to an 
unpaired two-tailed Student’s T-test. 
When examining the effect of IR1072 exposure and β-amyloid concentration on 
cell death in CAD cells; a two-way ANOVA analysis of variance was conducted, 
with a Bonferroni post-hoc test. 
Significance denoted as p<0.1 representing a trend towards a significant 
difference between conditions, whereas *p<0.05, **p<0.01, ***p<0.001 
represent a significant difference between conditions. 
 
2.8 Nematode Strains and Maintenance 
A Leica Model MZ9.5 was used for all light microscopy.  
SS104, glp-4 (bn2)I, nematodes were used for lifespan experiments and protein 
extraction assays. The SS104 are fertile at 15°C, but infertile when kept at 
25°C. 
 
 11
7
 
 Table 2.2. Summary of Nematode Strains Used in This Investigation 
Strain Name Genotype Gene/Protein Effected Mutation/Modification Cutorial Remarks 
CL2070 dvIs70 Is[hsp-
16.2::gfp; rol-
6(su1006)] 
HSP16.2 HSP16.2 expressed 
via a GFP-tagged 
promoter 
Used for lifespan studies and to determine 
if IR1072 exposure initiated HSP16.2 via 
imaging GFP levels 
GR1307 daf-16 (mgDf50) I daf-16 Eliminates gene 
coding region 
Used for lifespan studies 
N2 - - - Wild type strain, used for lifespan studies 
PS3551 hsf-1(sy441) I hsf-1 Substitution, cytosine 
for thymine in coding 
sequence 
HSF-1 expressed is non-functional, used 
for lifespan experiments 
RB1104 hsp-3 (ok1083) X hsp-3 Homozygous for hsp-
3 deletion 
Used for lifespan studies 
SJ4005 zcIs4 (hsp-4::GFP) HSP4 HSP4 expressed via 
a GFP-tagged 
promoter 
Used determine if IR1072 exposure 
initiated HSP4 via imaging GFP levels 
SJ4100 zcIs13 hsp-6::gfp HSP6 HSP6 expressed via 
a GFP-tagged 
promoter 
Used for lifespan studies and to determine 
if IR1072 exposure initiated HSP6 via 
imaging GFP levels 
SS104 glp-4 (bn2)I Abnormal germ line 
proliferation 
Temperature-induced 
sterility 
Nematodes are fertile at 15°C, but infertile 
when kept at 25°C, used for lifespan 
studies and protein extraction 
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2.8.1 Nematode Growth Medium 
NGM (nematode growth medium) was made using 1.5 g/l NaCl, 2.5 g/l peptone 
(NZ- Soy BL7, enzymatic hydrolysate) and 17 g/l agar in distilled water. 
Following sterilisation, 1 ml/l cholesterol (5 mg/ml in ethanol) was added 
followed by freshly sterilised 1 ml/l 1 M calcium chloride, 1 ml/l 1 M magnesium 
sulphate and 25 ml/l 1 M potassium phosphate (pH 6.0). 
5 ml NGM was aliquoted per 35 mm plate under sterile conditions and allowed 
to set, prior to storage at 4°C until use. 
 
2.8.2 M9 Buffer 
M9 buffer was used in all bacterial viability assays and egg preparation (2.8.6), 
the solution was freshly produced and sterilised (via autoclaving) before each 
use. M9 (22 mM KH2PO4, 41 mM Na2HPO4.2H2O, 85 mM NaCl) was separated 
into 250 ml aliquots, autoclaved and allowed to cool. 1 ml of 1 M MgSO4 was 
added, per 250 ml aliquot, under sterile conditions prior to use. 
 
2.8.3 Bacterial maintenance 
All strains of OP50 bacteria (E. coli) were maintained in cultures kept at 4°C. 
Fresh bacterial cultures were grown by adding 35 ml LB (Luria-Bertani) media 
(10 g/l tryptone, 5 g/l yeast extract, 10 g/l sodium chloride, made up with dH2O 
and autoclaved) to a 50 ml falcon tube. In sterile conditions, an inoculating loop 
was used to taken a sample of OP50 from either frozen or clean, refrigerated 
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cultures. These were then grown overnight at 37°C, whilst being continually 
agitated at 215 rpm. 
 
2.8.4 Seeding plates 
60 mm plates were seeded with 100 μl of OP50 under sterile conditions. The 
plates were then left to dry overnight at room temperature. This was performed 
2-3 days before the use of the plates. 
 
2.8.5 Chunking/strain maintenance 
In order to maintain a high number of worms, plates were initially seeded, as 
described in 2.8.4. Following seeding, a sterile environment was created using 
a Bunsen burner, a small cube of agar was cut from starved plates of 
nematodes using a sterilised scalpel. These cubes were then transferred, worm 
side down, onto plates seeded 1-2 days previously. The cubes were placed 
adjacent to the bacterial lawn and then transferred to an incubator. 
 
2.8.6 Egg Bleaching 
This was performed using gravid worms. Individual plates were washed with 2 
ml of M9 buffer; this was then pipetted into eppendorfs using a large pipette tip. 
The adult worms were then left for two minutes to settle into a loose pellet in the 
eppendorf, the excess solution was then removed leaving approximately 200 μl 
of solution and the loose worm pellet. 125 μl of bleach solution (7:8, Sodium 
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hypochlorite:4 M NaOH) was added to each eppendorf. The eppendorfs were 
then shaken continually for approximately five minutes, cessation of shaking 
occurred when loss of definition of the worms was observed. Eppendorfs were 
then filled to 1 ml with M9 buffer and centrifuged for 2,400 rpm for 90 seconds. 
After this time, the supernatant was removed and M9 used to fill the eppendorf 
to 1.5 ml, this was then vigorously shaken to dislodge the pellet. Again, the 
eppendorfs were centrifuged for 90 seconds at 2,400 rpm. The supernatant was 
removed, leaving approximately 50 μl of solution. The number of eggs was 
judged by eye under the microscope and more M9 buffer added to the 
eppendorf or the solution aliquoted onto seeded plates, dependent on the 
observable egg number. Plates were then stored at 15°C. 
 
2.8.7 Egg Lay 
Worms which had undergone method step 2.8.6 were grown until gravid, at this 
point gravid worms were transferred onto plates which had been previously 
seeded and stored at 25°C (15°C for SS104, glp-4 (bn2)l strain) for four hours. 
Subsequently the gravid worms were removed and the plates now containing 
eggs were kept at 25°C, except for work completed with the SS104 strain 
whereby the plates containing eggs were kept at 15°C for two to three days and 
then shifted to 25°C to induce sterility for timeline experiments. When the 
worms reached late L3/early L4 stages (as shown in figure 7.2) they were 
picked and transferred onto fresh plates for the lifespan protocol. 
In non-sterile strains, the nematodes were transferred onto fresh, seeded 60 
mm plates daily for a period of seven days following the initiation of egg laying 
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in the nematodes selected for the lifespan, in order to minimise the interference 
of progeny. 
 
2.9 IR1072 Exposure of C. elegans 
2.9.1 Apparatus and Protocol 
Initial experiments were conducted using IR1072 apparatus consisting of 1072 
nm near infrared LED array, which enclosed the 35 mm petri dishes, containing 
a known number of C. elegans. Irradiation was facilitated using 1072 nm LEDs 
pulsing at 600 Hz and a duty cycle of 300 microseconds, 5 mW/cm2. 
Temperature was monitored and the apparatus was fitted with a standard 
cooling fan, to ensure thermal drift from peak wavelength was not achieved and 
as to not to heat shock C. elegans. Initial experiments were conducted using 
three, six and 12 minute cycles of exposure. 
Further IR1072 experiments were conducted using a second apparatus; this 
consisted of six individual 1072 nm near infrared LED arrays fixed together 
horizontally. The 60 mm plates were positioned beneath the arrays and upon 
mirrored sheets to facilitate irradiation from every possible direction. Irradiation 
was again administered using 1072 nm LEDs pulsing at 600 Hz and a duty 
cycle of 300 microseconds, 5 mW/cm2. Each array was fitted with an individual 
standard cooling fan. All experiments were conducted at 25°C within an LTE 
Qualicool™ incubator (LTE Scientific Ltd, Oldham, UK) and temperature was 
also monitored using a digital thermometer. Exposure cycle was 12 minutes 
every three hours for 24 hours. This was then repeated every three days. For 
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experimental set up, see figure 2.4. Both apparatus were supplied by Virulite 
Distribution Limited, County Durham, UK. 
 
2.9.2 Preliminary Chronic IR Treatment Protocol 
Initial experiments conducted with C. elegans included exposure to IR1072 
treatments for three, six or 12 minutes daily until the C. elegans reached the 
end of their lifespan. Sham treatments conducted involved wrapping the petri 
dishes containing the C. elegans in aluminium foil, and exposing the C. elegans 
to IR1072 for three, six or 12 minute sessions. During the daily exposures the 
temperature of the internal box was monitored. 
 
2.9.3 Secondary Chronic IR Treatment Protocol 
Secondary C. elegans experiments were conducted using 12 minute exposure 
times every four hours, for 24 hours, conducted every three days until the end 
of the C. elegans lifespan. Again, the Sham treated dishes were wrapped in 
aluminium foil for the exposure duration. These experiments were undertaken 
within an incubator, maintained at 25°C. 
 
2.9.4 Tertiary Chronic IR Treatment Protocol 
Tertiary C. elegans lifespans were conducted using an alternate treatment 
protocol to limit any potential interference of intermittent heating of the 
nematodes caused by the equipment. This protocol consisted of a cycle of 50 
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seconds of IR exposure followed by a 100 second period of no exposure. This 
cycle was repeated for 24 hours, every three days for the duration of the 
lifespan. 
 
 
Figure 2. 4. C. elegans IR1072 treatment apparatus 
 
2.9.5 Lifespan and Data Analysis 
In all lifespan experiments the C. elegans were counted every second day, 
following the first week of the experiment and transferred to fresh 60 mm 
peptone plates every three to four days to prevent the onset of starvation and to 
limit effects of agar dehydration. All lifespan experiments were conducted at 
25°C in a temperature controlled incubator. Lifespan data were analysed using 
JMP® Version 8.02 statistical software, (SAS Institute Inc, USA), where 
applicable data was fitted to the Kaplan-Meier survival model, with statistical 
significance determined using Log-Rank and Wilcoxon analysis. 
 
Worms on E.coli  
lawn 
Peptone agar plate 
LEDs 
       Control plate 
Power supply with 
 fan 
Mirrored sheet 
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2.9.6 Kanamycin Treated OP50 IR1072 Treatment Protocol 
These experiments were carried out in the same manner as the above protocol, 
however C. elegans were transferred onto kanamycin treated OP50 (80 μl 10 
mM kanamycin on 100 μl OP50 lawn, as described by Garigan et al., 2002) for 
the duration of the lifespan. Lifespans were conducted as described in 2.9.5. 
 
2.10 IR1072 and Bacterial Viability 
2.10.1 Experimental Design 
Six 60 mm NGM plates were seeded with 100 μl of OP50 bacteria. 24 hours 
later, two plates were treated with IR1072 irradiation for the following 24 hours 
at 25°C, two plates were treated with 80 μl of kanamycin (10 mM) and kept at 
25°C and the remaining two plates were controls and also kept at 25°C for 24 
hours. 
 
2.10.2 Determining Viability 
All six plates were removed from 25°C incubator and 1 ml of M9 (plus MgSO4) 
added to each plate surface, under sterile conditions. A sterilised glass 
spreader was used to scrape the E. coli lawn into the buffer solution. The 
solution was then removed from the plate surface and aliquoted into an 
eppendorf. This was repeated for each plate and a freshly sterilised glass 
spreader was used each time. 
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The stock bacterial solutions were also diluted one in five, in duplicate for each 
plate, in order to determine the approximate number of colony forming units 
(CFUs) of the OP50 from each plate in each condition. The optical density at 
λ=600 nm was measured using a Jenway Genova spectrophotometer, where 
an absorbance of 1 = 8x108 CFU per ml. 
The stock solutions were then diluted to approximately the same concentration 
of CFUs using M9 (plus MgSO4) and then a range of dilutions were created; 10
-
2, 10-4, 10-6, 10-7, 10-8, 10-9, 10-10, in duplicate, for each plate. These dilutions 
were each vortexed and 100 μl from each dilution was pipetted onto a fresh 60 
mm NGM plate and spread using a sterilised glass spreader. Two additional 60 
mm plates were used to aliquot 100 μl of M9 (plus MgSO4) buffer. See table 
2.3. The 60 mm plates were then stored at 37°C overnight, 18 hours later the 
plates were removed and the number of colonies on each plate were counted. 
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 Table 1.3. Bacterial Viability Assay Dilutions 
= 3 conditions (14 total dilutions per original plate x 2 original plates) + 2 M9 (plus MgSO4) 
control plates; total of 86 plates 
 
2.11 Nematode protein extraction for Spectrophotometer Analysis 
40 x 60 mm plates of NGM were seeded with 100 μl OP50 bacteria and left for 
48 hours, subsequently the plates were chunked onto (as described in 2.8.5) 
using plates with established SS104, glp-4 (bn2)l populations. The plates were 
then left at 15°C for five days. 
After five days, the nematodes were washed into falcon tubes using M9 buffer 
(see 2.8.2) and gently centrifuged for two minutes to form a loose pellet. Excess 
M9 buffer was removed and nematode pellets snap frozen in liquid nitrogen for 
five minutes. Pellets were then thawed quickly in a 60°C water bath, and once 
thawed the falcons were immediately placed onto ice and lysis buffer (50 mM 
Tris HCl, 50 mM KCl, 10 mM EDTA, 1:100 Protease inhibitor cocktail III, 10 mM 
Na3VO4, 5 mM NaF, pH 8.0) added in an equal volume to that of the pellet. 
Worm pellets were then separated into 200 μl aliquots, kept on ice, and 
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sonicated three times for 10 second periods. Homogenate was left to stand on 
ice for 30 minutes and then centrifuged for 30 minutes at 13,200 rpm at 4oC. 
Supernatant was subsequently removed and retained. Protein content of 
extraction was measure using a Lowry assay, described as in (2.3.1), with the 
exception that in using the lysis buffer in the preparation of the standards, the 
buffer was diluted 10 times due to high Tris HCl and EDTA content of buffer. 
A Shimadzu UV-3600 UV-VIS-NIR Spectrophotometer (Shimadzu U.K. Ltd, 
Milton Keynes, UK) was calibrated using lysis buffer as a baseline. The 
absorbance spectra of samples, diluted to 1 mg/ml, were then measured from 
1500 nm-600 nm. The spectrum of each sample was measured three times, 
with the sample being carefully resuspended before each reading. 
 
2.12 Mitochondria extraction for Spectrophotometer Analysis 
2.12.1 Absorbance Profile of Isolated Irradiated Mitochondria 
Mitochondria were isolated from the liver and brain of four male, CD-1 mice at 5 
months of age, as described in 2.5.1. A Lowry was performed on the isolated 
mitochondria, as described in 2.3.1, and the pure mitochondrial preparations 
were diluted to 1 mg/ml using ice-cold Chamber buffer and kept on ice at all 
times. A Shimadzu UV-3600 UV-VIS-NIR Spectrophotometer was calibrated 
using chamber buffer (see 2.5.1) as a baseline. The absorbance spectra of 
samples were then measured from 1500 nm-600 nm. The spectrum of each 
sample was measured three times, with the sample being carefully 
resuspended before each reading. 
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The mitochondria preparations were then exposed to five 6 minute exposures of 
IR1072, timed 30 minutes apart. The irradiation was carried out by aliquoting 
the mitochondria preparation to a 35 mm petri dish. Between IR1072 
exposures, the mitochondria were returned to a cuvette and kept on ice. The 
absorbance profile of the mitochondria was recorded three times immediately 
prior to the following IR exposure. This was repeated for both the brain and liver 
mitochondrial preparations. Using Microsoft Excel 2007 the absorbances were 
corrected for baseline readings and the average of each reading plotted. 
 
2.12.2 Absorbance Profile of Mitochondria Irradiated for 10 days in vivo 
4 male three month old CD-1 mice were irradiated for six minutes a day for a 
period of 10 days, as described in 2.2.1. Mitochondria were isolated from the 
liver and brain, as described in 2.5.1.  
A Lowry was performed on the isolated mitochondria, as described in 2.3.1, and 
the pure mitochondrial preparations were diluted to 1 mg/ml using ice-cold 
Chamber buffer and kept on ice at all times. A Shimadzu UV-3600 UV-VIS-NIR 
Spectrophotometer was calibrated using Chamber buffer (see 2.5.1) as a 
baseline. The absorbance spectra of samples were then measured from 1500 
nm - 600 nm. The spectrum of each sample was measured three times, with the 
sample being carefully resuspended before each reading. 
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Chapter 3: Acute IR1072 Treatments - Effects in vitro using murine 
neuronal-derived cultures 
 
3.1 Introduction 
3.1.1 In vitro model system – neuronal cultures 
Neuronal cultures provide a useful, simplified model system to enable direct 
investigation of a biological system under controlled and reproducible conditions 
which can only be controlled to a limited extent in whole animal models. The 
defined system allows for any variations in outcome to be attributed to particular 
components of the system which can be manipulated. In vitro systems provide a 
relatively low-cost, non-time consuming method with high replicability; they also 
enable the ability to work at high n numbers, resulting in a reduced need for 
animals in scientific procedures, allaying some ethical issues associated with 
biological research (Hartung et al., 2002, Qi et al., 1997). 
Neuronal culture systems present a unique method to study every facet of 
neural processes; including synapse formation, differentiation, functionality, and 
to apply these investigations in understanding/manipulating potential therapies. 
For the purpose of these investigations, CAD (Cath.a-differentiated) cells were 
used. CAD cells are a catecholaminergic cell line, derived from the Cath.a cell 
line which was procured from a brain tumour that had developed in a transgenic 
mouse model. Cath.a cells express a range of neuronal markers including 
synaptophysin and Na+, Ca2+ and K+ voltage gated channels, synapse specific 
markers including SNAP25 (synaptosomal-associated protein 25), and have 
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been shown to produce dopamine and noradrenaline (Qi et al., 1997). CAD 
cells differ from Cath.a cells as they spontaneously lost their oncogene, SV40 T 
antigen, during propagation after the cells had committed to a neuronal 
phenotype (Qi et al., 1997). 
Differentiation is able to be induced in the CAD cell line through the withdrawal 
of serum from culture media, and cells will not fully differentiate in serum-
containing culture media, they proliferatively double in 18-22 hours. They do 
partially differentiate in serum-containing media, but do not show significant 
numbers of processes. The CAD cell line express markers associated with 
mature neurons and ultrastructurally resemble neurites (Qi et al., 1997). 
 
3.1.2 Hydrogen Peroxide and β-amyloid as Neuronal Insults 
Production of reactive oxygen species, including hydrogen peroxide, are a 
natural by-product of oxidative phosphorylation and at low levels can act as 
signalling molecules for a variety of cellular processes (See Introduction, 1.8). 
However high levels of ROS are detrimental and Aβ oligomers have been 
reported to cause oxidative damage via production of hydrogen peroxide and 
Aβ structures form. This in turn further damages the cell and mitochondrial 
membrane potential, disrupting the ETC and ultimately resulting in the release 
of Cytochrome c and apoptosis (Beere, 2005, Tabner et al., 2005); therefore 
using hydrogen peroxide to induce neuronal damage was chosen to model this 
aspect of Alzheimer’s disease. 
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The Aβ peptide is the predominate protein aggregate associated with 
Alzheimer’s disease but a great deal remains to be determined about its role in 
neuronal death, including whether its presence continually drives cell death or if 
a certain concentration needs to be reached to trigger apoptosis. A number of 
model systems have been established to investigate the effect of Aβ on 
neuronal systems, including hippocampal slices, primary cultures and 
continuous cell lines. A number of methods are used for the creation of toxic Aβ 
structures from synthetic peptides, with a wide range of permutations exacted to 
push structure formation towards fibrillar or oligomeric. An aim for this 
investigation was to create an Alzheimer’s disease model system in vitro to 
explore whether IR1072 had any effect on Aβ induced cell toxicity. A wide 
number of studies were reviewed before the protocol for Aβ fibril/oligomer 
production was decided upon that is described in 2.6.7 (El-Agnaf et al., 2001, 
Isobe et al., 2000, Kayed et al., 2003, King et al., 2009, Kranenburg et al., 2005, 
Kudva et al., 1997, Lorenzo and Yankner, 1994). 
For this investigation, a treatment protocol was devised based upon work by 
Bradford, 2005, who tested a range of IR treatment protocols on cell viability in 
human lymphocytes, and found that cells irradiated with IR1072 using a 5 x 3 
min treatment protocol showed a significantly higher viability than that of cells 
irradiated with other IR wavelengths using the same protocol (Bradford et al., 
2005). Burroughs & Chazot, (unpublished), also found the same treatment 
protocol was sufficient to elicit 90% protection against mild excitotoxic glutamate 
insults in rat primary neuronal cultures. Another aim of this investigation was to 
determine whether IR1072 exposure could also protect against hydrogen 
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peroxide based insults and to determine whether IR1072 exposure alone had 
any effect on neuronal viability. 
 
3.2 Results 
All data were processed using Microsoft Office Excel 2007 and statistical 
analyses were carried out using GraphPad Prism Version 5, GraphPad 
Software Inc. 
 
3.2.1 IR1072 Preconditioning, followed by H2O2 exposure 
CAD cells were maintained as described in 2.6.1. CAD cells were either sham 
treated or treated with five sets of 3 minute IR1072 exposures, 30 minutes 
apart. Immediately after this time, hydrogen peroxide was added to the media to 
give final concentrations of 50 μM, 75 μM or 100 μM, with PBS used as a 
volume control. The cells were then incubated for four hours at 37°C, 5% CO2. 
After this time a MTT assay was performed (see 2.6.3). Figure 3.1. Part A) 
shows 100 μM H2O2, Part B) shows 75 μM H2O2 and Part C) shows 50 μM 
H2O2. 
 
3.2.1.1 Exposure of IR1072 Preconditioned CAD cells to 100 μM Hydrogen 
Peroxide 
In the presence of 100 μM hydrogen peroxide, figure 3.1, part A, sham-
preconditioned neuronal cultures displayed a 32.69% decrease in cell viability 
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compared to control sham cultures which received PBS. In the presence of 100 
μM hydrogen peroxide, IR1072-preconditioned neuronal cultures displayed a 
26.18% decrease in cell viability, compared to control IR1072 cultures that 
received PBS. A 6.64% trend for increased cell viability was found in IR1072-
preconditioned neuronal cultures which received PBS compared to sham-
preconditioned cultures that also received PBS. A 16.19% increase in cell 
viability in IR1072-preconditioned neuronal cultures which received 100 μM 
hydrogen peroxide was found compared to sham-preconditioned cultures that 
also received hydrogen peroxide. 
Data compared using an unpaired two tailed Student’s T-test. Data represent 
mean ± SEM. 
 
3.2.1.2 Exposure of IR1072 Preconditioned CAD cells to 75 μM Hydrogen 
Peroxide 
In the presence of 75 μM hydrogen peroxide, figure 3.1, part B, sham-
preconditioned neuronal cultures displayed a 31.70% decrease in cell viability, 
compared to control sham cultures which received PBS. In the presence of 75 
μM hydrogen peroxide IR1072-preconditioned neuronal cultures displayed a 
19.30% decrease in cell viability, compared to control IR1072 cultures that 
received PBS. A 3.24% trend for increased cell viability in IR1072-
preconditioned neuronal cultures which received PBS was found, compared to 
sham-preconditioned cultures that also received PBS. A 17.99% increase in cell 
viability in IR1072-preconditioned neuronal cultures which received 75 μM 
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hydrogen peroxide was found compared to sham-preconditioned cultures that 
also received hydrogen peroxide. 
Data compared using an unpaired two tailed Student’s T-test. Data represent 
mean ± SEM. 
 
3.2.1.3 Exposure of IR1072 Preconditioned CAD cells to 50 μM Hydrogen 
Peroxide 
In the presence of 50 μM hydrogen peroxide, figure 3.1, part C, sham-
preconditioned neuronal cultures displayed a 27.39% decrease in cell viability, 
compared to control sham cultures which received PBS. In the presence of 50 
μM hydrogen peroxide IR1072-preconditioned neuronal cultures displayed a 
10.59% trend for decreased cell viability, compared to control IR1072 cultures 
that received PBS. No difference in cell viability in IR1072-preconditioned 
neuronal cultures which received PBS was found compared to sham-
preconditioned cultures that also received PBS. A significant 29.05% increase 
in cell viability in IR1072-preconditioned neuronal cultures which received 50 
μM hydrogen peroxide was found compared to sham-preconditioned cultures 
that also received hydrogen peroxide. 
Data compared using an unpaired two tailed Student’s T-test. Data represent 
mean ± SEM. 
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Figure 3.1. Preconditioning CAD Cells with IR1072 A) 100 μM hydrogen peroxide; B) 75 μM 
hydrogen peroxide, C) 50 μM hydrogen peroxide. Cell viability determined using an MTT assay, 
(Sham cultures, without hydrogen peroxide represent 100%). Mean values ± SEM, n= 24 from 
one culture, for A) and C); n=72, from 3 cultures, for B); *p<0.05, **p<0.01, ***p<0.001. 
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3.2.2 Exposure of CAD Cultures to H2O2, Followed by IR1072 Treatment 
CAD cells were passaged into 24 well plates, as described in 2.6.1. DMEM/F12 
+GlutaMAX® +10% FCS was removed from the cells and replaced with fresh 
media containing hydrogen peroxide at a range of concentrations (150 μM or 50 
μM), or PBS as a control. Cells were then immediately exposed to five sets of 3 
minute IR1072 treatments, 30 minutes apart or Sham-treated. Cells were then 
incubated at 37°C, 5% CO2 for four hours, after which an MTT assay was 
performed (see 2.6.3). 
 
3.2.2.1 Exposure of CAD Cultures 150 μM Hydrogen Peroxide, Followed by 
IR1072 Conditioning 
In the presence of 150 μM hydrogen peroxide, figure 3.2, part A, sham-treated 
neuronal cultures displayed a 69.11% decrease in cell viability compared to 
control sham cultures which received PBS. In the presence of 150 μM hydrogen 
peroxide, IR1072-treated neuronal cultures displayed a 72.07% decrease in cell 
viability compared to control IR1072 cultures that received PBS (Figure 3.2, part 
A). No difference in cell viability in IR1072-treated neuronal cultures which 
received PBS was found compared to sham-treated cultures that also received 
PBS. No significant difference was found between IR1072-treated cultures 
which received 150 μM hydrogen peroxide was found compared to sham-
treated cultures that also received hydrogen peroxide. 
Data compared using an unpaired two tailed Student’s T-test. Data represent 
mean ± SEM. 
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3.2.2.2 Exposure of CAD Cultures 50 μM Hydrogen Peroxide, Followed by 
IR1072 Conditioning 
In the presence of 50 μM hydrogen peroxide, figure 3.2, part B, sham-treated 
neuronal cultures displayed a 17.23% decrease in cell viability compared to 
control sham cultures which received PBS. In the presence of 50 μM hydrogen 
peroxide, IR1072-treated neuronal cultures displayed a 17.28% trend for 
decreased cell viability, compared to control IR1072 cultures that received PBS. 
A 21.27% increase in viability was found between IR1072-treated CAD cultures 
and Sham-treated cultures which both received PBS. A 25.65% increase in cell 
viability was also found in IR1072-treated neuronal cultures, in the presence of 
50 μM hydrogen peroxide, compared to sham-treated cultures that also 
received 50 μM hydrogen peroxide. 
Data compared using an unpaired two tailed Student’s T-test. Data represent 
mean ± SEM. 
 
138 
A)
Sham IR Sham + H2O2 IR + H2O2
0
20
40
60
80
100
120
140
***
***
IR Treatment
C
e
ll
 S
u
rv
iv
a
l 
(%
)
B)
Sham IR Sham + H2O2 IR + H2O2
0
20
40
60
80
100
120
140
160
180
***
***
**
***
IR Treatment
C
e
ll
 S
u
rv
iv
a
l 
(%
)
 
Figure 3.2. CAD Cells Sham-treated or IR1072 treated, following the addition of hydrogen 
peroxide. A) 150 μM hydrogen peroxide; B) 50 μM hydrogen peroxide. Cell viability determined 
using an MTT assay, (sham cultures, without hydrogen peroxide, represent 100%). Mean 
values ± SEM, n= 24 from one culture, for A); n=48, from two cultures, for B); **p<0.01, 
***p<0.001. 
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3.2.3 Effect of IR1072 Exposure on CAD Cell Viability 
As CAD cultures were seeded from the same stock solution of cells, cell density 
was identical at the time of passage. Therefore the observation of increased 
and trends towards increased MTT absorbance in IR1072 exposed cultures, 
shown in 3.2.1 and 3.2.2, compared to sham-treated controls was unexpected. 
This was explored further by sham-treating or exposing new CAD cultures to 
five sets of 3 minute IR1072 treatments, 30 minutes apart. The cells were then 
incubated for four hours at 37°C, 5% CO2. After this time a MTT assay was 
performed (see 2.6.3). A highly significant difference was observed between 
Sham treated control cultures and IR treated cultures which show a 17.68% 
increase in cell survival, see figure 3.3. 
Data compared using an unpaired two tailed Student’s T-test. Data represent 
mean ± SEM. 
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Figure 3.3. Cell viability of CAD Cells Sham-treated or IR1072 treated, viability determined 
using an MTT assay. Sham cultures represent 100% viability. Mean values ± SEM, n= 384 from 
eight cultures; ***p<0.001. 
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3.2.4. The Effect of IR1072 Exposure on CAD Cell Proliferation 
In order to determine whether the increased number of viable cells found in 
3.2.3, following exposure to IR1072 was due to LLLT preventing cell death/cell 
turnover or causing cells to actively proliferate immunocytofluorescence was 
performed as described in 2.6.6. Cells were stained with Ki67, a protein strictly 
associated with cell proliferation. Ki67 is present during all active phases of the 
cell cycle but is not present in resting cells. After the breakdown of the nuclear 
membrane, Ki67 can be found at low levels in the cytoplasm but at interphase, 
Ki67 is exclusively and densely found in the nucleus and during mitosis found 
on the surface of the chromosomes (Scholzen and Gerdes, 2000). 
CAD cells were grown for 72 hours in 24 well plates and treated as described in 
2.6.5. IR1072-treated neuronal cultures displayed no significant difference in the 
percentage of cells that stained positive for Ki67 when compared to sham-
treated neuronal cultures. A total of 6236 cells were counted in the Sham-
treaded condition, with 818 staining for Ki67. In the IR1072 exposed condition a 
total of 5701 cells were counted with 873 staining positive for Ki67. Examples of 
immunocytofluorescence for both conditions are shown in figure 3.4, with figure 
3.5 showing statistical analysis of staining. 
Data compared using an unpaired two tailed Student’s T-test. Data represent 
mean ± SEM. 
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Figure 3.4. A) Sham treated CAD cells B) Magnified image of cells highlighted in the white box 
in figure A, arrows indicate Ki67 positive cells. C) IR Treated CAD cells D) Magnified image of 
cells highlighted by the white box in figure C. Figures A and C, scale bar 100 μm. Figures B and 
D, scale bar 20 μm. 
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Figure 3.5. Graph to compare the effect of IR1072 exposure on cell proliferation against that of 
Sham-treated cultures, using Ki67 as a marker. Values are given as percentages of the total 
number of cells counted. There is no significant difference between the conditions. Data shown 
mean value ± SEM, n=6 replicates. 
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3.2.5 Effect of IR1072 Exposure on ATP Production in CAD Cells 
A number of studies into the effects of photobiomodulation of biological systems 
suggest that mitochondria act as the primary photoacceptors for NIR. This has 
been supported by reports of increased activity of members of the electron 
transport chain; cytochrome c oxidase and Complex II, increased ATP and ROS 
production, increased mitochondrial membrane potential and mitochondrial 
velocity in response to LLLT (Desmet et al., 2006, Gao and Xing, 2009, Karu, 
2008, Silveira et al., 2007, Trimmer et al., 2009, Tsai et al., 2001, Wong-Riley et 
al., 2005). 
Altered activity of components of the ETC in the mitochondria following IR1072 
is reported later in this document, see Chapter 4, thus the CAD cell system was 
utilised to investigate whether IR1072 had any specific effects on ETC activity 
via measuring ATP levels, the product of the electron transport chain. 
CAD cell cultures were grown and treated as described in 2.6.5, ATP 
concentrations were determined from a standard curve constructed from the 
concentration of known ATP standards. ATP concentrations were normalised 
against approximate cell density, calculated by performing LDH assays, see 
2.6.4, on adjacent wells. This was performed as IR1072 exposure had been 
found to prevent cell death/turnover previously, see 3.2.3. 
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3.2.5.1 Measurement of ATP Concentrations Immediately Following IR1072 
Exposure 
CAD Cultures were passaged into 24 well plates and grown for 72 hours. After 
this time, cultures were either Sham-treated of exposed to five sets of 3 minute 
IR1072 exposures, 30 minutes apart. Immediately after this time, an ATP assay 
was performed on six wells in each condition; see 2.6.5, and an LDH assay, see 
2.6.4, on the remaining six wells in each condition. ATP luminescence values 
were normalised against the absorbance values of LDH of freeze-thawed cells 
only (LDH measurements of the media were not accounted for as this is a 
measure of dead cells, freeze-thawed LDH absorbances refer to cells alive at 
the start of the assay, therefore those cells capable of ATP production). 
There was no significant difference in ATP concentration in IR-treated CAD 
cultures compared to Sham-treated controls (n=6 for both conditions). This is 
shown in figure 3.6., part A. Data compared using an unpaired two tailed 
Student’s T-test. Data represent mean ± SEM. 
 
3.2.5.2 Measurement of ATP Concentration Four Hours after IR1072 
Exposure 
CAD Cultures were passaged into 24 well plates and grown for 72 hours. After 
this time, cultures were either Sham-treated of exposed to five sets of 3 minute 
IR1072 exposures, 30 minutes apart. After the final exposure, cells were 
returned to the incubator and kept at 37°C, 5% CO2, for four hours. After this 
time, an ATP assay was performed on six wells in each condition; see 2.6.5, 
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and an LDH assay, see 2.6.4, on the remaining six wells in each condition. ATP 
luminescence values were normalised against the absorbance values of LDH of 
freeze-thawed cells only. 
There was no significant difference in ATP concentration in IR-treated CAD 
cultures compared to Sham-treated controls (n=6 for both conditions). This is 
shown in figure 3.6., part B. Data compared using an unpaired two tailed 
Student’s T-test. Data represent mean ± SEM. 
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Figure 3.6. Column graphs to show that exposure of cultures to IR1072 has no significant effect 
on ATP concentration, compared to the ATP concentration in Sham-treated control cultures. A) 
shows [ATP] measured immediately after IR or sham exposures p=0.914. B) Shows [ATP] four 
hours after IR/Sham exposures, p=0.463. n=6 replicates from one culture for both A) and B). 
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3.2.6 IR1072 Exposure Protects CAD Cells From β-amyloid Induced 
Toxicity 
24 hours after cells were passaged into 24 well plates they were exposed to five 
sets of three minute IR1072 or Sham treatments, 30 minutes apart, cells then 
were returned to the incubator. 24 hours after this time, media was removed 
and replaced with DMEM/F12 +GlutaMAX® +10% FCS containing the β-
amyloid(1-42) (Aβ) peptide. Peptide Aβ was prepared as described in 2.6.7, the 
formation of a mixture of fibrils and oligomers confirmed through transmission 
electron microscopy (as described in 2.6.8), figure 2.3 shows example electron 
micrographs of Aβ structures formed. 
Cells were exposed to a final concentration of 0.5, 1, 2.5, 3.5, 4.5, 5, 10 or 25 
μM of Aβ, using a volume of DMSO:PBS in DMEM/F12 +GlutaMAX® +10% 
FCS (ratio the same as that in Aβ cultures) as a control. Immediately after, cells 
were exposed to a second set of five 3 minute IR1072 or Sham exposures and 
returned to the incubator. 24 hours after the addition of Aβ, the cells were again 
exposed to five sets of 3 minute IR1072 or Sham treatments, 30 minutes apart, 
and again returned to the incubator. 24 hours after the third set of IR1072 or 
Sham exposures a CytoTox 96® Non-radioactive assay, measuring LDH 
release, was performed on the cultures, as defined in 2.6.4. 
Data were analysed using a two-way ANOVA analysis of variance, narrative of 
the results is shown below. Data shown as mean ± SEM in figure 3.7. 
IR Treatment accounts for 2.49% of the total variance, ***p<0.0001. If IR 
treatment has no effect overall, there is a less than 0.1% chance of randomly 
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observing this effect in an experiment this size, or larger. The effect of IR 
treatment is considered extremely significant. 
Aβ concentration accounts for approximately 80.04% of the total variance, 
***p<0.0001. If Aβ concentration has no effect overall, there is a less that 0.1% 
chance of randomly observing an effect in an experiment of this size, or larger. 
The effect of concentration is considered extremely significant. 
Exposure to IR1072 had no significant effect, compared to sham treated 
controls, against cell death when cells were exposed to PBS, 0.5 μM or 1 μM 
Aβ42. However, there was a trend for a reduction in cell death in the IR1072 
treated condition, compared to sham treated controls (p<0.1) at 2.5 μM and 3.5 
μM Aβ42. 
At 4.5 μM Aβ, treatment of CAD cells with IR1072 elicited a statistically 
significant reduction in cell death of 23.13%, compared to sham treated 
controls. 
Concentrations of Aβ at 5 μM, 10 μM and 25 μM were exceedingly toxic to 
Sham treated cells. However, despite the high concentrations of Aβ treated of 
cells with IR1072 significantly reduced cell death by 23.94%, 24.13% and 
16.43%, respectively. 
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Figure 3.7. A column graph to compare the effect of IR1072 exposure against Sham-treatment 
on Aβ induced cell death. Cell death determined via measuring the concentration of LDH 
release into media and expressed a percentage of the number of total cells present in culture. 
Mean values ± SEM. *p<0.05, **p<0.01, ***p<0.001. 
  
 
151 
Neuronal CAD cell protection afforded by IR1072 preconditioning, compared 
to sham-treated controls when cell toxicity is induced through Aβ exposure 
Aβ (μM) n = P Value Increase or 
decrease in 
cell death 
Percentage 
change in 
cell death 
(%) 
Percentage 
of cell 
protection 
induced (%) 
PBS Only 18 - - - - 
0.5 6 - - - - 
1 6 - - - - 
2.5 6 NS ↓ 7.45 25.17 
3.5 6 NS ↓ 8.26 23.70 
4.5 6 *<0.05 ↓ 9.24 23.13 
5 6 ***<0.001 ↓ 10.64 23.94 
10 6 ***<0.001 ↓ 8.02 24.13 
25 6 ***<0.001 ↓ 11.93 16.43 
 
Table 3.1. Data with a trend toward significant differences are shaded blue (p<0.1). Data with 
statistically significant altered protection levels are shaded green. Data were analysed using a 
Two-way ANOVA analysis of variance. Arrows indicate direction of altered expression, (↑, 
increase; ↓, decrease), ‘-‘ indicates no significant change. Abbreviations: Aβ, β-amyloid(1-42); 
N/C, No Change; PBS, phosphate buffered saline. 
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3.3 Discussion 
The level of protection achieved through IR1072 preconditioning against 
hydrogen peroxide insults appeared to be dependent on the severity of the 
subsequent insult. The higher the concentration of hydrogen peroxide, the less 
IR1072 exposure was able to protect against insults. Previous work in our 
laboratory using glutamate as an excitotoxic insult also found IR1072 
preconditioning was neuroprotective in a severity-dependent manner in primary 
cultures (Burroughs, 2010). 
IR1072 conditioning of CAD cultures following the addition of hydrogen peroxide 
also elicited neuroprotective effects, in an insult dependent manner. It was also 
interesting to note that the level of neuroprotection observed was greater than 
that observed when cultures were preconditioned with IR1072 before addition of 
hydrogen peroxide, despite exposure to higher concentrations of hydrogen 
peroxide. These data suggest that IR1072 preconditioning may not be required 
for a profound level of neuroprotection. It also shows that IR1072 is still able to 
elicit biological effects despite severe toxic conditions. 
More research needs to be conducted to determine the concentrations of 
hydrogen peroxide that IR1072 can protect against and to what degree 
preconditioning can be protective against these concentrations, and whether 
protection observed through IR1072 exposure without preconditioning can be 
augmented. Research also needs to be conducted into the role of IR1072 
against a greater range of insults; such as serum deprivation, rotenone or 
cyanide exposure. LLLT has also been previously shown to be promote cell 
survival and protect against UVA (Bradford et al., 2005), methanol-derived 
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formate (Eells et al., 2003), MPP+ (1-methyl-4-phenylpyridium) and rotenone 
exposure (Liang et al., 2008), amongst other insults, in vitro. 
LLLT has previously been shown to be protective against potassium cyanide 
induced cell death in visual cortical neurons that had been preconditioned with 
NIR at 670 nm for 10 minutes, at a total energy density of 30 J/cm2. Liang 
(2006) also found that the degree of protection depended on the severity of the 
insult, with approximately 50% protection achieved at 100 μM potassium 
cyanide and 33% at 300 μM. The authors found that LLLT was protecting visual 
cortical neurons via increased Bcl-2 levels and decreased Caspase-3 and BAX 
levels, suggesting direct interaction of LLLT with apoptotic pathways (Liang et 
al., 2006). Preconditioning of striatal and cortical neurons with LLLT at 670 nm, 
twice a day for 80 seconds, protected against rotenone- (56% and 66%, 
respectively) and MPP+ induced apoptosis (37% and 47%, respectively). 
Inhibition of ATP production by MPP+ was also significantly reversed through 
LLLT preconditioning; rising from 48% to 70% of control levels (Ying et al., 
2008). 
Increased CAD cell viability in conditions where IR1072 exposure was the only 
variable was somewhat surprising. Cell proliferation following LLLT has been 
reported in multiple cell culture systems and cell types; including osteoblasts 
(Kreisler et al., 2003, Pires Oliveira et al., 2008, Ueda and Shimizu, 2003), 
fibroblasts (Hawkins and Abrahamse, 2006, Taniguchi et al., 2009, Vinck et al., 
2003), muscle cells and epithelial cells (Sommer et al., 2001, Whelan et al., 
2001). However, it had not been reported in neuronal cells, therefore it was 
important to determine whether IR1072 exposure was causing the CAD cultures 
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to actively proliferate or whether the increased viability was due to decreased 
cell-turnover which occurs naturally in any culture system. 
Following the discovery of significantly increased cell viability in IR1072 treated 
CAD cells, compared to sham treated cultures, Ki67 was used to stain cells. 
These data (Figure 3.4 and 3.5) clearly demonstrate no significant difference in 
proliferation between the IR1072 condition and the sham-treated condition. 
Further to this, ATP concentrations in sham and IR1072 treated cultures were 
also examined to determine whether this was a factor in the increased cell 
viability, as increased ATP levels and mitochondrial electron transport activity 
have been specifically reported following LLLT (see introduction 1.1.6). 
However, no significant change in ATP concentration was found when the two 
conditions were compared. This suggests that IR1072 doesn’t alter ATP 
production, or further IR1072 exposures are required to see a significant 
alteration in ATP levels. Repeated daily exposures may also be required to see 
long term changes in level. It would also be of interest to measure ADP levels, 
ATP production could be increased following IR1072 exposure but if 
consumption is also increased, no net change in ATP levels would be identified. 
It would also be difficult to identify changes in ATP if the alterations are only 
transient, the detection system used would not be sensitive enough to detect 
such alterations. Therefore, through concomitantly measuring ADP 
concentration a better profile of electron transport chain activity during/after 
LLLT could be obtained. 
There are a significant number of techniques which are in use to form Aβ 
structures from synthetic Aβ peptide. The advantage of ‘growing’ Aβ structures 
in vitro lies in the fact that conditions can be tightly controlled and manipulated 
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to create a particular structure or a mixture of structures. However, there is not 
a ‘standard’ method for the formation of Aβ oligomers or aggregates; this has 
resulted in the ability of aggregates formed in different conditions to have 
significantly different efficacies despite being formed from the same starting 
peptide (Benilova et al., 2012, Haass and Selkoe, 2007). Methodologies are 
available for generating Aβ structures from synthetic peptides, with a number of 
conditions manipulated to force the formation towards fibrillar or oligomeric 
structures (El-Agnaf et al., 2001, Isobe et al., 2000, Kayed et al., 2003, King et 
al., 2009, Kranenburg et al., 2005, Kudva et al., 1997, Lorenzo and Yankner, 
1994). An aim for this investigation was to create an Alzheimer’s disease model 
system in vitro, and to create a relatively simple method through which a range 
of Aβ-derived structures could be formed which perhaps more closely represent 
what is clinically present in the Alzheimer’s disease brain. Fibrils formed through 
the method described in 2.6.7, were approximately 10 nm in diameter, in same 
range as diameters previously reported in vitro (Hartley et al., 1999, Lorenzo 
and Yankner, 1994), with diffuse oligomeric-type structures forming alongside 
fibrils, visible in figure 2.3. 
 A secondary aim was to investigate whether this synthetic Aβ had any effect on 
cell death, and if IR1072 exposure altered the degree of Aβ-induced cell toxicity. 
IR1072 exposure was found to consistently and significantly reduce cell death 
caused by Aβ, by up to 25%, over the range of Aβ concentrations (0.5-25 μM) 
used. The lack of a significant level of cell death at low concentrations of Aβ 
(0.5-1 μM) demonstrates that it is not the mere presence of Aβ that is toxic to 
cells and that an insult threshold must be achieved before a significant level of 
cell death is observed, supporting data which have shown patients that despite 
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expressing low levels of Aβ, never develop clinically diagnosable Alzheimer’s 
disease (Haass and Selkoe, 2007). 
The lack of a significant neuroprotective effect of LLLT at low Aβ concentrations 
(0.5-2.5 μM) is interesting; it suggests that Aβ levels have to reach a damaging 
level before neuroprotective effects induced by IR1072 become activated. The 
range of Aβ concentrations used would not necessarily be found in vivo. 
However, the use of potentially unrealistic concentrations in vitro is a necessary 
experimental limitation, as synthetic Aβ peptides have been reported to be less 
neurotoxic than cell-derived Aβ (Benilova et al., 2012). Nevertheless, there is 
evidence to suggest cellular concentrations of Aβ can reach micromolar levels 
in vesicular compartments; therefore concentrations used in this investigation 
do have biological relevance (Hu et al., 2009). 
In conjunction with other results indicating a role for heat shock proteins in the 
neuroprotective effects observed following IR1072 exposure, the methodology 
for the production of toxic Aβ structures could be explored further through 
utilising the continuous culture system. Further characterisation of the CAD cell 
line is needed to determine which HSPs are lacking and which are expressed. 
Indeed, HSP27 has been shown to protect against hydrogen peroxide insults 
through regulation of glutathione levels (Preville et al., 1999), a potential 
mechanism occurring here. Our laboratory has determined that neither 
differentiated nor undifferentiated CAD cells express αB crystallin (Chazot et al., 
unpublished), but little is known regarding other HSPs. The ability to transfect 
cultures with extra copies of heat shock protein machinery, to investigate 
whether the neuroprotective effects can be potentiated, is an important starting 
point following further characterisation. 
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In vitro systems are important and useful investigative tools; they do however 
have disadvantages, particularly with the use of continuous cell lines, such as 
the CAD cell line. Continuous cell lines are typically poorly differentiated and 
have been shown to lose many of the original phenotypic characteristics of the 
original in vivo cell type. Immortalised cell lines are characteristically 
homogenous, compared to primary cultures, and the results from such cultures 
are much easier to standardise (Hartung et al., 2002). The CAD cell line used in 
this investigation was homogenous and CAD cell cultures have previously been 
shown to lack the expression of glia specific markers such as GFAP (Qi et al., 
1997). 
The brain is an intricate organ, comprised of a complex population of cells, with 
subpopulations possessing different characteristics whose expression is not 
usually limited to discrete locations. This adds extra layers of complexity to an 
organ which is relatively poorly understood. Therefore the use of cultured 
neurons, whether primary or continuous, has limitations in that these neuronal 
populations lack the diversity of the cell types found in the brain. An advantage 
of continuous culture is that many of the cell lines can be manipulated to 
differentiate into more favourable cell types, through the addition or removal of 
growth factors. Cath.a cells, from which the CAD cells are derived, are classed 
as a CNS catecholaminergic cell line despite lacking significant numbers of 
neurites. However, CAD cells do express neuron-specific proteins, synaptic 
vesicles and visible processes (Qi et al., 1997). 
In the studies conducted in this chapter, CAD cells were not fully differentiated – 
CAD cells show a unique ability to reversibly morphologically differentiate on the 
withdrawal of serum from the culture medium. All experiments in this chapter 
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were conducted in DMEM/F12 +GlutaMAX®, plus 10% foetal calf serum. In 
serum containing media the cell population will double over 18-22 hours, which 
dramatically drops upon serum removal (Qi et al., 1997). In the presence of 
serum, CAD cells only display short processes and lose some of the 
morphology associated with neurons, however they do still express neuronal 
markers such as tyrosine hydroxylase and synaptotagmin (Qi et al., 1997). 
Although processes were visible in the cultures used when viewed under the 
microscope, it may be beneficial to repeat the experiments detailed in this 
chapter with fully differentiated CAD cultures to determine if a mature neuron is 
still able to be sufficiently protected from Aβ an hydrogen peroxide toxicity by 
IR1072. 
Overall this investigation has established that acute IR1072 exposure is 
neuroprotective against both H2O2 and Aβ insults. The degree of 
neuroprotection appears to be dependent upon the severity of the insult. With 
IR1072 preconditioning, the in vitro system appears to be able to withstand 
more significant insults than when cultures are exposed to IR1072 after 
exposure to an insult. The apparent neuroprotective response from IR1072 
exposure to toxicity does not appear to occur as a result of increased cell 
proliferation, nor does it appear to be attributed to increased ATP production 
following IR1072 exposure. The ability for acute IR1072 exposure to 
significantly protect against cell toxicity caused by two molecules/species 
associated with propagation of the disease state in Alzheimer’s disease 
provides an exciting insight into the neuroprotective potential for IR1072 in 
disease management. 
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The remaining chapters focus on the use of IR1072 in vivo systems. It is 
important to investigate the effects of IR1072 in an in vivo system to provide 
insight into the mechanisms of action through which IR1072 has been shown to 
be neuroprotective when neurons are exposed to a number of insults. An 
important mechanism to investigate relates to mitochondria, as these organelles 
have been proposed to act as the primary photoacceptor for NIR. The principle 
aim of the following chapter is to determine whether acute IR1072 exposure 
alters activities of certain mitochondrial electron chain complexes, and whether 
these data correlate to the absence of increased ATP concentrations observed 
in the present chapter. 
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Chapter 4: Acute IR1072 Treatments - Effects in vivo on mitochondrial 
respiration rates 
 
4.1 Introduction 
4.1.1 In vivo model system- Mitochondria 
Mice were irradiated as described in 2.2.1, using the same methods used as 
described by Michalikova (2008) and Burroughs (2010). To further investigate 
the effects of acute of IR1072 on Complex I and II respiratory chain activity, 
oxidative phosphorylation was measured using the polarographic method in 
mitochondria isolated from both male and female CD-1 mouse liver and brain 
tissue, at 3 months of age, in sham and IR1072-preconditioned animals. 
Mitochondria were isolated in this investigation from both the liver and the brain. 
In order to obtain sufficient mitochondria for experimental repeats, a minimum of 
three mice were used for each preparation. A Clark-type electrode was used to 
measure oxygen consumption polarographically (Sweetman and Weetman, 
1969). The polarographic method of measuring respiratory rates in both cells 
and isolated organelles, such as mitochondria, was first reported in 1956 by 
Chance & Williams. This method enabled measurement of the rate of oxygen 
consumption in the presence of a range of substrates and in the absence and 
presence of phosphate. Work by Chance & Williams also resulted in the 
discovery of three energy conservation sites in the electron transport chain 
(Chance and Williams, 1956a, Ernster, 1993). 
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The ratio between the active state of respiration (state 3) and controlled 
respiration, after all ADP has been phosphorylated, (return to state 4) is known 
as the respiratory control coefficient or index (RCI). This ratio allows the 
experimenter to determine the strength of mitochondrial membrane coupling. 
The greater the RCI, the more tightly coupled the mitochondrial preparation. 
The mitochondria membrane needs to be tightly coupled in order for the 
electron transport chain to act efficiently and to phosphorylate ADP to ATP 
(Campello et al., 1964). 
Substrates, glutamate plus malate and succinate, measure the oxidative 
phosphorylation activity of Complex I and Complex II respectively (Chance and 
Williams, 1956b). Earlier work in our laboratory has demonstrated that daily, 
whole animal exposure, sessions of six minute IR1072 periods, over a 10 day 
period is sufficient to improve working memory in both male and female CD-1 
mice. IR exposed aged (12 months) CD-1 mice showed increased consideration 
in their decision making and demonstrated a significantly improved cognitive 
performance, comparable to that of young (4 month) CD-1 mice (Michalikova et 
al., 2008). Previously our laboratory has also reported that acute IR1072 treated 
7 month old male CD-1 mice displayed higher Complex II activity (at state 4, 
state 3 and return to state 4 respiration rates) in isolated brain mitochondria 
compared to sham treated controls (*p<0.05). However there was no difference 
in endogenous respiration (Burroughs, 2010). 
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4.2 Results: Acute IR1072-preconditioning in CD-1 mice: Mitochondrial 
respiratory studies 
4.2.1 Oxidative Phosphorylation Measurements of Three Month old CD-1 
Mice: Liver 
4.2.1.1 Complex I – Glutamate plus Malate 
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Figure 4.1. Effect of acute sham or IR exposure on glutamate plus malate respiratory rates in 3 
month old CD-1 mouse liver mitochondria (in vivo). Mean values ± SEM, n = 4, *p<0.05, 
***p<0.001. 
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Figure 4.2. Effect of acute sham or IR exposure on glutamate plus malate RCI in 3 month old 
CD-1 mouse liver mitochondria (in vivo). Mean values ± SEM, n = 4. 
 
Effect of acute IR1072 preconditioning on Complex I activities in mitochondria 
isolated from liver, compared to age-matched sham-treated controls, n=4 
Respiratory rate 
(ng O2 min
-1 mg protein-1) 
P Value Result: 
↑/↓ 
Percentage 
change (%) 
Figure 
Endogenous 0.084 ↓ 49.54 4.1 
State 4 <0.0001 ↓ 74.28 4.1 
State 3 0.022 ↓ 61.88 4.1 
Return to State 4 0.001 ↓ 73.44 4.1 
RCI 0.846 - - 4.2 
 
Table 4.1. Data with a trend in altered activity are shaded blue (p<0.1), data with statistically 
significant altered activity levels (p<0.05) are shaded green. Arrows indicate direction of altered 
expression, (↑, increase; ↓, decrease), ‘-‘ indicates no significant change. *p<0.05; **p<0.01. 
Abbreviations: RCI, respiratory control index. 
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4.2.1.2 Complex II – Succinate 
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Figure 4.3. Effect of acute sham or IR exposure on succinate respiratory rates in 3 month old 
CD-1 mouse liver mitochondria (in vivo). Mean values ± SEM, n = 4, **p<0.01, ***p<0.001. 
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Figure 4.4. Effect of acute sham or IR exposure on succinate RCI in 3 month old CD-1 mouse 
liver mitochondria (in vivo). Mean values ± SEM, n = 4. 
 
Effect of acute IR1072 preconditioning on Complex II activities in mitochondria 
isolated from liver, compared to age-matched sham-treated controls, n=4 
Respiratory rate 
(ng O2 min
-1 mg protein-1) 
P Value 
 
Result: 
↑/↓ 
Percentage 
change (%) 
Figure 
Endogenous **0.005 ↓ -58.50 4.3 
State 4 0.058 ↓ -42.34 4.3 
State 3 ***0.001 ↓ -52.57 4.3 
Return to State 4 0.058 ↓ -42.34 4.3 
RCI 0.528 - - 4.4 
 
Table 4.2. Data with a trend in altered activity are shaded blue (p<0.1), data with statistically 
significant altered activity levels (p<0.05) are shaded green. Arrows indicate direction of altered 
expression, (↑, increase; ↓, decrease), ‘-‘ indicates no significant change. *p<0.05; **p<0.01, 
***p<0.001. Abbreviations: RCI, respiratory control index.  
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4.2.2 Oxidative Phosphorylation Measurements of Three Month old CD-1 
Mice: Brain 
4.2.2.1 Complex I – Glutamate plus Malate 
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Figure 4.5. Effect of acute sham or IR exposure on glutamate plus malate respiratory rates in 3 
month old CD-1 mouse brain mitochondria (in vivo). Mean values ± SEM, n = 4. 
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Figure 4.6. Effect of acute sham or IR exposure on glutamate plus malate RCI in 3 month old 
CD-1 mouse brain mitochondria (in vivo). Mean values ± SEM, n = 4. 
 
Effect of acute IR1072 preconditioning on Complex I activities in mitochondria 
isolated from brain, compared to age-matched sham-treated controls, n=4 
Respiratory rate 
(ng O2 min
-1 mg protein-1) 
P Value Result: 
↑/↓ 
Percentage 
change (%) 
Figure 
Endogenous 0.811 - - 4.5 
State 4 0.734 - - 4.5 
State 3 0.150 - - 4.5 
Return to State 4 0.956 - - 4.5 
RCI 0.155 - - 4.6 
 
 Table 4.0.3. Abbreviations: RCI, respiratory control index, ‘-‘ indicates no significant change. 
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4.2.2.2 Complex II – Succinate 
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Figure 4.7. Effect of acute sham or IR exposure on succinate respiratory rates in 3 month old 
CD-1 mouse brain mitochondria (in vivo). Mean values ± SEM, n = 4. 
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Figure 4.8. Effect of acute sham or IR exposure on succinate RCI in 3 month old CD-1 mouse 
brain mitochondria (in vivo). Mean values ± SEM, n = 4. 
 
Effect of acute IR1072 preconditioning on Complex II activities in mitochondria 
isolated from brain, compared to age-matched sham-treated controls, n=4 
Respiratory rate 
(ng O2 min
-1 mg protein-1) 
P Value Result: 
↑/↓ 
Percentage 
change (%) 
Figure 
Endogenous 0.011 ↑ 137.93 4.7 
State 4 0.398 - - 4.7 
State 3 0.642 - - 4.7 
Return to State 4 0.217 - - 4.7 
RCI 0.024 ↑ 42.80 4.8 
 
Table 4.4. Data with statistically significant altered activity levels (p<0.05) are shaded green. 
Arrows indicate direction of altered expression, (↑, increase; ↓, decrease), ‘-‘ indicates no 
significant change. *p<0.05; **p<0.01. Abbreviations: RCI, respiratory control index.  
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4.3 Results: Absorption Spectra of Isolated Mitochondria 
4.3.1 Absorbance Profile of Isolated Irradiated Mitochondria 
Mitochondria were isolated as described in 2.5.1, and a Lowry assay performed 
(see 2.3.1). Each sample was then diluted to 1 mg/ml. Mitochondrial 
absorbance spectrum was measured on three occasions, from 1500 nm to 600 
nm, and mitochondria were irradiated at 1072 nm as detailed in 2.12.1. Average 
absorbances (after correction for baseline values) plotted in figure 4.9 and 4.10, 
n = 3. The shaded area in the figure refers to the bandwidth of light emitted by 
the IR1072 LEDs, which have a bandwidth of 25 nm. 
 
4.3.2 Absorbance Profile of Mitochondria Irradiated for 10 days in vivo 
Mice were irradiated as described in 2.2.1 and mitochondria were isolated from 
the brain and liver of 3 month old D-1 mice as described in 2.5.1, and a Lowry 
assay performed (see 2.3.1). Each sample was then diluted to 1 mg/ml. 
Mitochondrial absorbance spectrum was measured three times, from 1500 nm 
to 600 nm, and mitochondria were irradiated at 1072 nm as detailed in 2.12.1. 
Average absorbance (after correction for baseline values) is plotted in figure 
4.11, n = 4. The shaded area in the figure refers to the bandwidth of light 
emitted by the IR1072 LEDs, which have a bandwidth of 25 nm. 
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4.4 Discussion 
The aim of this line of research was to investigate whether acute IR1072 
exposure had any effect on the activity of Complex I and/or Complex II in the 
ETC, of isolated mitochondria from both male and female CD-1 mice at three 
months of age. 
A minimum of three mouse brains are required for each preparation in order to 
isolate a sufficient quantity of mitochondria for adequate experimental repeats. 
Therefore, it was only possible to complete two repeats for each sex for each 
substrate condition. These investigations were completed to further previous 
work in our laboratory which had investigated the effect of acute IR1072 
exposure on 7 month old male CD-1 mice (Burroughs, 2010). 
As it has been widely reported that mitochondria act as the primary absorption 
site for LLLT, with cytochrome c oxidase as the proposed principle 
photoacceptor for NIR (Gao and Xing, 2009, Karu, 1999, Karu et al., 2004, Karu 
et al., 2005), it was important to investigate mitochondrial respiratory activity 
following IR1072 exposure. It has previously been reported that up to 50% of 
NIR is able to be absorbed by mitochondrial chromophores (such as 
cytochrome c oxidase) in the liver (Beauvoit et al., 1995, Beauvoit et al., 1994), 
therefore it was of interest to investigate liver, as well as brain, mitochondria. As 
the IR treatment apparatus facilitated irradiation at every conceivable angle of 
the entire CD-1 mouse, investigation of oxidative phosphorylation of 
mitochondrial isolated from the liver and brain of animals was the principle 
target of these investigations. 
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In order to measure activity of particular components of the ETC, glutamate plus 
malate and succinate were used to measure the activity of complex I and 
complex II respectively (Burroughs, 2010, Chance and Williams, 1956b, 
Markham et al., 2004). Measuring different complexes using oxidative 
phosphorylation allows determination of both the degree of mitochondrial 
coupling and to investigate where any alterations in the ETC activity occur, if 
any, following acute IR1072 exposure. As mentioned previously, the RCI gives 
a measure of mitochondrial coupling. A high RCI value dictates tightly coupled 
mitochondria, values for adequately coupled mitochondria for Complex I and 
Complex II are given in table 4.9. 
 
IR Treatment 
Condition 
Glutamate + Malate 
(Complex I) 
Succinate 
(Complex II) 
Chance & Williams, 
1956a 
- >3 >2 
3 month old Male CD-1 
mice - Liver 
Sham 3.242 ± 0.228 2.908 ± 0.175 
IR 3.168 ± 0.300 2.790 ± 0.024 
3 month old Male CD-1 
mice - Brain 
Sham 2.590 ± 0.195 2.091 ± 0128 
IR 3.506 ± 0.654 2.986 ± 0.355 
 
Table 4.5. RCI values generated through respiratory studies in this investigation, compared to 
the values of Chance & Williams (1956a), which indicate tightly coupled mitochondria. Cells 
shaded green indicate loosely coupled mitochondria. 
For the respiratory studies performed with mitochondria isolated from CD-1 
mice, the value highlighted in table 4.5 indicates more loosely coupled 
mitochondria and thus oxidative phosphorylation results less reliable. However, 
there are reports in mice and nematodes that show reduced mitochondrial 
coupling to be protective, by having a more loosely coupled membrane, the 
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electron transport chain is less efficient but lower levels of ROS are produced, a 
normal by-product of respiration, and this in turn has been attributed to 
increased lifespan (Lemire et al., 2009). 
However, all other RCI values were all above 3 or 2 for glutamate plus malate 
and succinate, respectively, indicating tightly coupled mitochondria and 
therefore more reliable oxidative phosphorylation readings (Campello et al., 
1964, Chance and Williams, 1956b). Acute IR1072 exposure did not affect 
mitochondria coupling, except in Complex II in brain mitochondria. This 
suggests that IR1072 exposure may result in a more efficient ETC and therefore 
lead to the increased ATP levels commonly reported following IR exposure – 
although only preliminary experiments into ATP levels following IR1072 were 
conducted in this investigation (see Chapter 3). This could be supported 
through investigation of SDHC (succinate dehydrogenase Complex II) levels, a 
membrane coupled component of the electron transport chain. It is possible that 
the RCI for the sham-treated mice is low due to the length of time isolation 
requires. Long preparatory methods adversely effects mitochondrial coupling. 
Brain mitochondria are particularly predisposed to low coupling values, due to 
long Percoll® filtration steps to remove synaptosomes (Markham et al., 2004). 
These respiratory studies found that acute IR1072 showed significantly 
decreased endogenous respiratory rates in liver mitochondria for both Complex 
I and II, with significantly increased Complex II in brain mitochondria, perhaps 
as a result of a greater degree of mitochondrial membrane coupling. 
Interestingly, following acute IR1072 exposure both Complex I and II activity 
were significantly reduced in mitochondria isolated from the liver, however this 
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was more profound in Complex I than Complex II. These results were 
somewhat unexpected as previous work in our laboratory has found that neither 
Complex I or Complex II activity were altered in 7 month old  mouse liver 
mitochondria (Burroughs, 2010). 
Significantly, mice at 3 months of age also showed significantly increased 
Complex II activity in brain mitochondria, when exposed to acute IR1072. In 
conjunction with the results reported by Burroughs, 2010, the results from this 
study demonstrate consistent upregulation of Complex II following acute IR1072 
exposure, however results from 7 month old mice showed altered activity 
across all stages of oxidative phosphorylation. Supporting the suggestion that 
age affects the magnitude of effects of IR1072, as explored in Chapter 5. 
It would be particularly interesting to conduct further investigations using male 
mice to repeat work by Michalikova, et al., 2008, who found LLLT at 1072 nm 
significantly improved working memory in middle-aged female CD-1 mice. 
Female CD-1 mice have already been shown to have a significantly better 
working memory than age-matched male CD-1 mice at both 4 and 12 months 
(Ennaceur et al., 2008, Michalikova et al., 2008), therefore finding acute IR1072 
exposure has reduced ETC activity in age-matched mice (male and female), it 
would be of particular significance to determine whether IR1072 
potentiates/augments the working memory deficits these mice have already 
demonstrated through the altered Complex I and II activity reported here. 
Burroughs, 2010, chronically IR1072 treated CD-1 male mice and exposed the 
mice to a 3D radial maze. IR1072 treated mice showed improved working 
memory compared to sham-treated controls, but only in mice treated from 3 
months of age and not those who started IR1072 exposure at 7 months of age – 
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again suggesting that younger mice may be more susceptible to acute IR1072 
exposure (Burroughs, 2010). When mice reach a certain severity of learning 
deficit or state of amyloidosis, chronic IR1072 exposure may be required to 
have a significant impact. As detailed in chapter 5, more significant differences 
in a range of protein levels were found in older CD-1 mice exposed to chronic 
IR1072. In future it would be of interest to investigate the effects of chronic 
IR1072 exposure on mitochondrial complex activities. 
It is perhaps surprising that there were significant alterations in Complex I 
activity in liver mitochondria, as it has previously been reported that NADH-
dehydrogenase, a chromophore component of Complex I, which is believed to 
act as the principle photoacceptor in the blue-spectral region solely (Gao and 
Xing, 2009, Karu, 1988). Alterations in Complex I activity following NIR are not 
commonly reported, perhaps because investigations focus on the activity of 
cytochrome c oxidase (Complex IV) activity as this has been reported to act as 
the main photoacceptor in the red to near infrared light region (Gao and Xing, 
2009, Karu, 1999). However significant effects of NIR on Complex I have been 
reported by several groups. NIR at 633 nm, has been shown to reverse 
rotenone-induced inhibition of Complex I in retinal nerves of rats in a dose 
dependent fashion, preventing nerve damage (Rojas et al., 2008). 
Preconditioning of striatal and cortical neurons with NIR at 670 nm, has also 
been found to protect against apoptosis and inhibition of ATP synthesis; 
induced by MPP+ which act through inhibiting Complex I activity (Liang et al., 
2008, Ying et al., 2008). NIR, at 670 nm, has also been shown to reverse nitric 
oxide-mediated inhibition of oxygen consumption at Complex IV (NO competes 
with O2 for the active site in cytochrome c oxidase) and Complex I, and thus 
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protect cardiomyocytes against hypoxia and re-oxygenation injury (Zhang et al., 
2009). Altered Complex I and II activity may be due to IR1072 affecting ΔѰm, 
notably increased ΔѰm has been shown to alter NADH-linked dehydrogenase 
reactions (Karu, 2008, Passarella et al., 1984). This wealth of published data, 
as well as data found in this investigation, supports the principle that Complex I 
does not specifically act as a photoacceptor to the blue-spectral region, but also 
appears to be influenced by light in the red-near infrared region. 
LLLT at 904 nm has been shown to increase Complex IV, perceived as the 
principle NIR photoacceptor, and Complex II activity in mitochondria at wound 
sites in Wistar rats (Silveira et al., 2007). Indeed LLLT at 904 nm has since also 
been shown to increase the activity of Complex I, II, III and IV at sites of muscle 
damage in Wistar rats (Silveira et al., 2009), supporting evidence found in this 
investigation and respiratory studies performed by Burroughs, 2010, who found 
increased Complex II activity in brain mitochondria in 7 month old CD-1 mice 
(Burroughs, 2010). This study found significantly increased Complex II activity 
in female CD-1 brain mitochondria following acute IR1072 exposure. Taken 
together, these data suggest that Complex I and Complex II activity are able to 
be manipulated by LLLT and may therefore result in alterations in ETC activity. 
Influence of electron transport chain activity by IR1072 may alter ΔѰm, ATP and 
reactive oxygen species production, all of which can result in induction of 
signalling pathways and increased energy availability (Reviewed - Gao and 
Xing, 2009). It has been proposed that intracellular gradients of ADP, 
established at the synapse due to high ATP consumption, can slow down the 
motility of mitochondria resulting in concentration of mitochondria at sites of 
high ATP requirement. ADP concentration is tightly linked to mitochondrial 
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respiration rates; with more ADP available, the ETC can produce more ATP 
which is quickly consumed. This may explain why increased ETC complex 
activity has been observed in the brain tissue, which consumes significantly 
more energy than liver tissue (Mironov, 2007), following irradiation at 1072 nm. 
These data suggest that neurons may be able to function better following 
irradiation, and this data perhaps explains why no change in ATP levels were 
reported in Chapter 3, as ΔѰm gradients may only be apparent over small 
regions of high activity in neurons, occur in a transient manner and depend on 
ADP availability, but it does provide data to show longer term IR exposure has 
the potential to alter ETC activity. 
The magnitude of the secondary effects of NIR absorption appears to differ 
across a range of studies; this is most likely due to the choice of wavelength, 
protocol and biological system used, as well as knowledge that different 
wavelengths appear to have different capabilities regarding modulating 
alternate components of the ETC. As in this investigation, a great deal of 
primary research into the NIR photoacceptor has relied on oxidative 
phosphorylation studies. These investigations isolate mitochondria from their 
cellular environment which in turn may alter parameters of the ETC; the lack of 
direct in-situ experimental support of these assays limits extrapolation and 
application of the results to other biological systems. 
From the absorption spectra of mitochondria shown in figures 4.17 and 4.18, 
there appears to be a broad peak from 1150-1000 nm, which may relate to a 
particular protein/complex responsible for absorption of NIR at 1072 nm. This 
peak appears to be more prominent in liver mitochondria than brain 
mitochondria; as previously stated liver chromophores are thought to be 
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responsible for up to 50% of NIR absorption (Beauvoit et al., 1995, Beauvoit et 
al., 1994). The absorption profile of isolated mitochondria does not appear to be 
significantly different following irradiation, whether that occurs in vitro or in vivo. 
The absorption intensity does appear to significantly alter (see figures 4.17 and 
4.18) following irradiation, after the first few exposures it appears to increase 
before decreasing to below ‘control’ or ‘sham’ levels in liver mitochondria. 
However, the opposing effect seems to occur in brain mitochondria, where the 
final absorption profile (five sets of IR1072 exposures in vitro) is above that of 
the ‘control’ level. In the absorption profile of liver mitochondria irradiated or 
sham-treated in vivo, there is a significant peak at approximately 1200 nm 
which is not present in the mitochondria previously isolated (see figure 4.19). As 
the peak is present in both sham and IR exposed mitochondria, this may be due 
to a contaminant. A significant amount of further research needs to be carried 
out in order to identify the proteins/complexes responsible to the peaks in the 
mitochondrial profiles and to determine whether quantities/activities of these 
proteins/complexes alter following IR exposure, techniques utilising mass 
spectroscopy could aid in this investigation. 
As the predominant result from this chapter has been the discovery of reduced 
Complex I and II activity in the liver, with the observation of increased Complex 
II consistent with previous research, it would be beneficial to repeat these 
experiments and to directly measure ATP content of cells in order to establish 
whether IR1072 is altering ATP levels through altering Complex activity in both 
tissues. As the in vitro system used in Chapter 3 was a neuronal system, 
perhaps the result of no net change in ATP that was observed is only applicable 
to the activity of Complex I and II investigated in brain mitochondria – in this 
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chapter, only Complex II was reported to be increased. Therefore it would be of 
significant interest to determine both ATP and ADP levels in isolated 
mitochondria to investigate whether there is a change in the ATP:ADP ratio 
following IR1072 exposure. Further work could also be performed in situ 
through the use of fluorescent dyes, such as JC-1 (5,5’,6,6’-tetrachloro-1,1’,3,3’ 
tetraethylbenzimidazolylcarbocyanine iodide), to monitor the effects of NIR on 
the mitochondrial membrane potential during and following LLLT in living cells 
(Johnson et al., 1981, Mathur et al., 2000). Using biochemical techniques, as 
described by Silveira, 2009, investigation of the effect of IR1072 on other 
components of the ETC, not previously studied would be useful, namely 
Complex IV (Silveira et al., 2009). These experiments would provide a 
comprehensive overview of the effects of IR1072 on the ETC to examine 
whether these effects alter across age and sex of animals, as suggested from 
the findings reported in this chapter, as well as what effect longer term exposure 
protocols may induce. 
These data have provided important insights into the role of age in the biological 
effects of IR1072 exposure, with younger mice demonstrating more activity 
alterations than older counterparts investigated previously, suggesting different 
magnitudes of biological effects are conceivable in whole animal systems. 
These data provide support that IR1072 is able to alter mitochondrial activity, 
whether this is via direct absorption through proposed photoacceptors or via an 
alternate mechanism remains unknown. However, the absorption profiles of 
isolated mitochondria clearly demonstrate that there appears to be molecule(s) 
present which absorbs at 1072 nm. These in vivo data provided important 
insights into photomodulatory effects in one mouse model, CD-1; it was 
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important to also investigate the effects of gender on electron transport chain 
activity in TASTPM mice; this is explored in chapter 6. 
The next chapter centres on investigation of the effects of chronic IR1072 
exposure in the CD-1 mouse strain which has premature learning deficits. The 
aim of this chapter was to build on previously published data which established 
IR1072 exposure improved the memory performance of CD-1 mice. This 
chapter aims to probe putative proteins and pathways involved in the biological 
effects of IR1072 absorption which may be responsible for the improved 
behavioural performance of the CD-1 strain. 
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Chapter 5: Age-dependent changes in protein expression and the effect of 
in vivo chronic IR1072 exposure on protein expression in CD-1 mice 
 
5.1 Introduction 
It has been reported that 50% of CD-1 mice die before they reach two years of 
age, with 50% of females surviving to 18 months, while 50% of males only living 
until 16 months (Ennaceur et al., 2008, Homburger et al., 1975). Amyloidosis is 
the most common cause of death in both male and female CD-1 mice, with its 
presence observed in 50% of mice, of both sexes. However, it has been found 
to arise in males at 8 months of age, whereas females do not display amyloid 
deposition until 12 months of age (Engelhardt et al., 1993). Amyloidosis is the 
principle cause of death in the CD-1 strain. This systemic amyloidosis is 
postulated to be due to an underlying chronic inflammatory disorder (Engelhardt 
et al., 1993, Frith and Chandra, 1991). Amyloid deposition is systemic, 
beginning with the duodenum, jejunum and ileum, death commonly following 
infiltration of kidney glomeruli, although all internal organs can be affected. The 
amyloid is similar to that found in humans, it is composed of wide, non-
branching strands (Frith and Chandra, 1991). A significant number of CD-1 
mice have also been repeatedly shown to develop abscesses, tumours and 
septicaemia; with neoplastic lesions more common in male mice (Engelhardt et 
al., 1993). 
Cognitive deficits in the CD-1 strain have previously been reported by Mizumori 
(1982), who demonstrated a lack of working memory in male mice of this strain 
when mice were faced with an enclosed radial maze at three months of age 
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(Mizumori et al., 1982). This was further investigated using detailed behavioural 
analysis in both male and female CD-1 mice at 4 months and 12 months of age. 
These studies found that 4 month old female mice performed significantly better 
in the behavioural tests than age-matched males; with older mice consistently 
demonstrating a reduced capability to acquire a working memory when 
compared to their younger counterparts (Ennaceur et al., 2008, Michalikova et 
al., 2008). CD-1 mice were also shown to lack memory retention in ‘land-based’ 
maze tasks compared to other strains (Patil et al., 2009). The CD-1 strain also 
show an impaired response to shock, the authors hypothesise that this is due to 
motor characteristics of the strain rather than cognitive issues, as they have 
also shown small amounts of ‘freezing’ behaviour when exposed to fear 
conditioning (Adams et al., 2002). 
A potential reason for the limited cognitive function seen in the CD-1 strain 
could be attributed to a reduced brain size, relative to that of other mouse 
strains. For example CD-1 mice show significantly smaller brain volumes, 
compared to age matched C57 mice, despite the C57 having smaller body 
mass. The cerebral cortex has been reported to be 10% smaller, and ventricular 
compartments 13% smaller in the CD-1 mouse, but with an approximately 4% 
larger striatum than C57 mice (Chen et al., 2006). The smaller cortex of the CD-
1 mouse may explain why the C57 strain consistently out-performs the CD-1 
strain in memory-based tasks (Ennaceur et al., 2006, Michalikova et al., 2010, 
Patil et al., 2009). 
These data demonstrate that the CD-1 strain develops premature cognitive 
deficits, advocating the use of this strain in the study of ageing and in 
investigating the modulation of this process. 
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The aim of this chapter was to establish protein changes that occur during 
ageing of the CD-1 strain, which may contribute to their learning deficits which 
progress with age and premature death. Relatively little is known about protein 
expression in this mouse strain during ageing, additional research was required 
to further work previously undertaken in our laboratory, whereby male mice at 3, 
10 and 12 months were investigated (Burroughs, 2010). A second aim was to 
determine whether chronic IR1072 treatment of young and old CD-1 mice, 
would alter protein expression and whether the magnitude of alteration was 
age-dependent, through the use of immunoblotting and immunohistochemistry. 
Male mice were exposed to sham or IR1072 treatments as described in 2.2.2., 
from 2 months of age until 7 months of age (denoted as ‘Young’ mice) and from 
7 months to 13 months of age (denoted as ‘Old’ mice). 
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5.2 Results 
5.2.1 Immunoblotting Analysis 
Data were analysed using ImageJ, version 1.43, National Institutes of Health, 
USA, and processed using Microsoft Office Excel 2007 and statistical analyses 
were carried out using GraphPad Prism Version 5, GraphPad Software Inc. 
Data is summarised in table 5.1. 
Male CD-1 mice at 12 months of age displayed a 55.51% reduction in HSP105 
expression, compared to mice of 3 months of age. Mice of 10 months of age 
also demonstrated a 42.75% decrease in HSP105 expression when compared 
to mice of 3 months of age. However, there was no significant difference 
between the expression of HSP105 in 10 month old male CD-1 mice and mice 
of 12 months of age. Data shown in figure 5.1 and table 5.1. 
Male CD-1 mice at 12 months of age showed a 39.40% decrease in HSP70 
expression compared to mice of 3 months of age. Mice at 10 months of age 
also showed a 14.79% trend for a decrease in HSP70 expression compared to 
mice of 3 months of age. Mice at 12 months of age also showed a 28.89% 
decrease in HSP70 expression compared to mice of 10 months of age. Data 
shown in figure 5.2 and table 5.1. 
Male CD-1 mice at 12 months of age showed a 45.40% decrease in TARP γ2 
expression, compared to mice of 3 months of age. Mice of 10 months of age 
also showed a 40.61% reduction in TARP γ2 expression compared to mice at 3 
months of age. All other comparisons were non-significant. Data shown in figure 
5.3 and table 5.1. 
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All other proteins investigated were deemed not to alter with age. 
All data were analysed using a one-way ANOVA with a Bonferroni’s multiple 
comparison post test. 
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B)  
 
 
 
 
 
 
 
 
 
 
Figure 5.1. Age dependent alterations in HSP105 expression; shown in 3 month, 10 month and 
12 month old male CD-1 mouse brains. A) is an immunoblot, each lane represents an individual 
mouse and B) shows the quantitative analyses of immunoblot data. Mean values ± SEM, n=3 at 
each age point, 12 month mice had a significant (*p<0.05) decrease in HSP105 expression, 
compared to 3 month CD-1 mice. All other comparisons were non-significant. Abbreviations: 
HSP105, Heat shock protein 105; OD, optical density. 
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Figure 5.2. Age dependent alterations in HSP70 expression; shown in 3 month, 10 month and 
12 month old male CD-1 mouse brains. A) is an immunoblot, each lane represents an individual 
mouse and B) shows the quantitative analyses of immunoblot data. Mean values ± SEM, n=3 at 
each age point. A significant reduction in HSP70 expression was found when comparing 
expression in 3 month old CD-1 mice to that of 12 month (*p<0.05) and 10 month to 12 month 
old CD-1 mice (***p<0.001). All other comparisons are non-significant. Abbreviations: HSP70, 
heat shock protein 70; OD, optical density. 
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Figure 5.3. Age dependent alterations in TARP γ2 expression; shown in 3 month, 10 month and 
12 month old male CD-1 mouse brains. A) is an immunoblot, each lane represents an individual 
mouse and B) shows the quantitative analyses of immunoblot data. Mean values ± SEM, n=3 at 
each age point. A significant reduction in TARP γ2 expression was found when comparing 
expression in 3 month old CD-1 mice to that of 10 month and 12 month old CD-1 mice 
(*p<0.05). All other comparisons are non-significant. Abbreviations: TARP γ2, Transmembrane 
AMPA regulatory protein γ2; OD, optical density. 
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Effect of age on protein expression in male CD-1 mice at 3, 10 and 12 months of 
age, n=3 for each condition 
Antibody/Protein P Value 
3
 v
s
. 
1
0
 
3
 v
s
. 
1
2
 
1
0
 v
s
. 
1
2
 
Result: 
↑ or ↓ 
Figure 
GSK-3β 0.890 - - - - Not shown 
HSF1 Not determined 
HSP105 0.044 NS * - ↓ Figure 5.1 
HSP70 0.001 NS *** ** ↓ Figure 5.2 
P-HSP27 0.414 - - - - Not shown 
αB crystallin 0.977 - - - - Not shown 
TARP γ2 0.015 * * - ↓ Figure 5.3 
TARP γ8 0.293 - - - - Not shown 
MAPK 0.133 - - - - Not shown 
 
Table 5.1. Data with a trend in altered expression levels are shaded blue (p<0.1), data with 
statistically significant altered expression levels (p<0.05) are shaded green. Arrows indicate 
direction of altered expression, (↑, increase; ↓, decrease), ‘-‘ indicates no significant change. 
*p<0.05, **p<0.01, ***p<0.001. Abbreviations: GSK-3β, glycogen synthase kinase-3β; HSF, 
heat shock factor; HSP, heat shock protein; MAPK, mitogen associated protein kinase; P-HSP, 
phosphorylated heat shock protein; TARP, transmembrane AMPA regulatory protein. 
  
 
193 
5.3 Chronic IR1072 treatment of CD-1 Male Mice 
Male CD-1 mice were irradiated as outlined in 2.2.2, this chronic (five month) IR 
exposure was performed on mice from two months of age, designated as 
‘Young CD-1 mice’, and mice from seven months of age, designated ‘Old CD-1 
mice’. Both age groups were exposed to the same treatment protocol and 
equipment. Sham mice were exposed to replica equipment, for the same time 
period, in the absence of IR1072. During the treatment period the weight of 
mice and temperature of equipment was monitored. Equipment as outlined in 
2.2.2.  
 
5.3.1 Young CD-1 Mice 
5.3.1.1 Immunoblotting 
Data were analysed using ImageJ, version 1.43, National Institutes of Health, 
USA, and processed using Microsoft Office Excel 2007 and statistical analyses 
were carried out using GraphPad Prism Version 5, GraphPad Software Inc. 
Data were analysed using a two-tailed student’s T test. Data shown represent 
mean ± SEM, n= number of replicates. 
Data is summarised in table 5.2. 
IR1072 preconditioned male 7 month of age CD-1 mice showed a 92.68% 
increase in P-HSP27 expression, a 91.60% increase in TARP γ2 expression 
and a 458.26% increase in SDHC expression compared to age-matched sham 
treated controls.  
 
194 
A) 
 
 
 
 
 
 
 
 
B) 
 
 
 
 
 
 
 
 
 
 
Figure 5.4. P-HSP27
 
expression in chronic preconditioned (in vivo) 7 month CD-1 male mice 
and Sham age matched controls. Each lane in A) demonstrates an individual mouse (n=4 for 
each condition) and B) represents quantitative analysis of P-HSP27 expression, demonstrating 
a significant increase in P-HSP27 expression following chronic IR1072 treatment, compared to 
sham treated animals, **p<0.01, Mean ± SEM. Abbreviations: P-HSP27, Phosphorylated-Heat 
shock protein 27; OD, optical density. 
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Figure 5.5. TARP γ2
 
expression in chronic IR1072 preconditioned (in vivo) 7 month CD-1 male 
mice and Sham age matched controls. Each lane in A) demonstrates an individual mouse (n=4 
for each condition) and B) represents quantitative analysis of TARP γ2
 
expression, 
demonstrating a significant increase in TARP γ2
 
expression following chronic IR1072 treatment, 
compared to sham treated animals, **p<0.01, Mean ± SEM. Abbreviations: TARP γ2, 
Transmembrane AMPA receptor regulatory protein γ2; OD, optical density. 
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Figure 5.6. SDHC
 
expression in chronic IR1072 preconditioned (in vivo) 7 month CD-1 male 
mice and Sham age matched controls. Each lane in A) demonstrates an individual mouse (n=4 
for each condition) and B) represents quantitative analysis of SDHC expression, demonstrating 
a significant increase in SDHC
 
expression following chronic IR1072 treatment, compared to 
sham treated animals, ***p<0.001, Mean ± SEM. Abbreviations: SDHC, Succinate 
dehydrogenase complex subunit C; OD, optical density. 
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Effect of Chronic IR1072 Preconditioning on protein expression in male CD-1 7 
month old mice, compared to age matched sham-treated controls, n=4 for each 
condition 
Antibody/Protein P Value 
Result: increase or 
decrease 
Figure 
GSK-3β 0.520 - Not shown 
HSF1 0.502 - Not shown 
P-HSP27 **0.007 ↑ Figure 5.4 
αB crystallin 0.883 - Not shown 
TARP γ2 **0.009 ↑ Figure 5.5 
TARP γ8 0.350 - Not shown 
SDHC ***<0.001 ↑ Figure 5.6 
GluA2 Not determined 
 
Table 5.2. Data with a trend in altered expression levels are shaded blue (p<0.1), data with 
statistically significant altered expression levels (p<0.05) are shaded green. Arrows indicate 
direction of altered expression, (↑, increase; ↓, decrease), ‘-‘ indicates no significant change. 
*p<0.05, **p<0.01, ***p<0.001. Abbreviations: GluA2, glutamate receptor 2; GSK-3β, glycogen 
synthase kinase-3β; HSP, heat shock protein; P-HSP, phosphorylated heat shock protein; 
SDHC, succinate dehydrogenase Complex II; TARP, transmembrane AMPA regulatory protein. 
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5.3.2 Old CD-1 Mice 
5.3.2.1 Immunoblotting 
Data were analysed using ImageJ, version 1.43, National Institutes of Health, 
USA, and processed using Microsoft Office Excel 2007 and statistical analyses 
were carried out using GraphPad Prism Version 5, GraphPad Software Inc. 
Data were analysed using a two-tailed student’s T test. Data shown represent 
mean ± SEM, n= number of replicates. 
Data is summarised in table 5.3. 
IR1072 preconditioned male 13 month of age CD-1 mice displayed a 51% 
reduction in HSF1, a 36.43% decrease in HSP70, a 43.13% reduction in αB 
crystallin and a 42.25% reduction in GluA2 expression compared to age-
matched sham treated controls. 
IR1072 preconditioned male 13 month of age CD-1 mice displayed a 329.69% 
increase in P-HSP27, a 48.75% increase in TARP γ2 expression compared to 
age-matched sham treated controls. 
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Figure 5.7. HSF1 expression in chronic IR1072 preconditioned (in vivo) 13 month CD-1 male 
mice and Sham age matched controls. Each lane in A) demonstrates an individual mouse (n=4 
for each condition) and B) represents quantitative analysis of HSF1 expression, demonstrating 
a significant reduction in HSF1 expression following chronic IR1072 treatment, compared to 
sham treated animals, *p<0.05, Mean ± SEM. Abbreviations: HSF1, Heat shock factor 1; OD, 
optical density. 
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Figure 5.8. HSP70 expression in chronic IR1072 preconditioned (in vivo) 13 month CD-1 male 
mice and Sham age matched controls. Each lane in A) demonstrates an individual mouse (n=4 
for each condition) and B) represents quantitative analysis of HSP70 expression, demonstrating 
a significant reduction in HSP70 expression following chronic IR1072 treatment, compared to 
sham treated animals, *p<0.05, Mean ± SEM. Abbreviations: HSP70, Heat shock protein 70; 
OD, optical density. 
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Figure 5.9. P-HSP27 expression in chronic IR1072 preconditioned (in vivo) 13 month CD-1 
male mice and Sham age matched controls. Each lane in A) demonstrates an individual mouse 
(n=4 for each condition) and B) represents quantitative analysis of P-HSP27 expression, 
demonstrating a significant increase in P-HSP27 expression following chronic IR1072 
treatment, compared to sham treated animals, **p<0.01, Mean ± SEM. Abbreviations: P-
HSP27, Phosphorylated Heat shock protein 27; OD, optical density. 
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Figure 5.10. αB Crystallin expression in chronic IR1072 preconditioned (in vivo) 13 month CD-1 
male mice and Sham age matched controls. Each lane in A) demonstrates an individual mouse 
(n=4 for each condition) and B) represents quantitative analysis of αB Crystallin expression, 
demonstrating a significant reduction in αB Crystallin expression following chronic IR1072 
treatment, compared to sham treated animals, *p<0.05, Mean ± SEM. Abbreviations: OD, 
optical density. 
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Figure 5.11. TARP γ2 expression in chronic IR1072 preconditioned (in vivo) 13 month CD-1 
male mice and Sham age matched controls. Each lane in A) demonstrates an individual mouse 
(n=4 for each condition) and B) represents quantitative analysis of TARP γ2 expression, 
demonstrating a significant increase in TARP γ2 expression following chronic IR1072 treatment, 
compared to sham treated animals, **p<0.01, Mean ± SEM. Abbreviations: TARP γ2, 
Transmembrane AMPA regulatory protein; OD, optical density. 
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Figure 5.12. GluA2 expression in chronic IR1072 preconditioned (in vivo) 13 month CD-1 male 
mice and Sham age matched controls. Each lane in A) demonstrates an individual mouse (n=4 
for each condition) and B) represents quantitative analysis of GluA2 expression, demonstrating 
a significant reduction in GluA2 expression following chronic IR1072 treatment, compared to 
sham treated animals, ***p<0.001, Mean ± SEM. Abbreviations: GluA2, AMPA glutamate 
receptor subunit 2; OD, optical density. 
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Effect of Chronic IR1072 Preconditioning on protein expression in male CD-1 13 
month old mice, compared to age matched sham-treated controls, n=4 for each 
condition 
Antibody/Protein P Value 
Result: increase or 
decrease 
Figure 
GSK-3β 0.557 - Not shown 
HSF1 *0.026 ↓ Figure 5.7 
HSP105 0.131 - Not shown 
HSP70 *0.028 ↓ Figure 5.8 
P-HSP27 **0.007 ↑ Figure 5.9 
αB crystallin *0.014 ↓ Figure 5.10 
TARP γ2 **0.006 ↑ Figure 5.11 
TARP γ8 0.418 - Not shown 
GluA2 ***0.001 ↓ Figure 5.12 
SDHC 0.282 - Not shown 
 
Table 5.3. Data with a trend in altered expression levels are shaded blue (p<0.1), data with 
statistically significant altered expression levels (p<0.05) are shaded green. Arrows indicate 
direction of altered expression, (↑, increase; ↓, decrease), ‘-‘ indicates no significant change. 
*p<0.05; **p<0.01, ***p<0.001. Abbreviations: GluA2, glutamate receptor 2; GSK-3β, glycogen 
synthase kinase-3β; HSP, heat shock protein; P-HSP, phosphorylated heat shock protein; 
SDHC, succinate dehydrogenase Complex II; TARP, transmembrane AMPA regulatory protein. 
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5.4 Discussion 
The aim of this chapter was to further elucidate proteins that alter with age of 
the CD-1 mouse, and to determine whether these proteins are also altered 
following chronic IR1072 exposure. Another aim of this chapter was to 
investigate whether protein changes altered in their profile and magnitude when 
comparing mice that began chronic IR1072 exposure at 2 months of age to 
those treated from 7 months of age. 
P
a
th
w
a
y
  
 
Protein 
CD-1 Timeline 
(Age in months) 
Effect of chronic IR1072 
exposure 
3 vs. 10 3 vs. 12 10 vs. 12 Young Old 
 
GSK-3β - - - - - 
C
h
a
p
e
ro
n
e
s
 HSF1 Not determined - *↓ 
HSP105 ↓(NS) ↓ - - - 
HSP70 ↓(NS) ***↓ **↓ *↓ *↓ 
P-HSP27 - - - **↑ **↑ 
αB Crystallin - - - - *↓ 
AMPA/
TARP 
TARP γ2 *↓ *↓ ↓ (NS) **↑ **↑ 
TARP γ8 - - - - - 
GluA2 Not shown ↓  N/D ***↓ 
 SDHC Not determined ***↑ - 
MAPK - - - N/D N/D 
 
Table 5.4. Summary of all effects on ageing CD-1 mice and chronically IR treated mice, 
determined by western blotting. Abbreviations: AMPA, 2-amino-3-(3-hydroxy-5-methyl-isoxazol-
4-yl)propanoic acid; GluA2, glutamate receptor 2; GSK-3β, glycogen synthase kinase-3 beta; 
HSF, heat shock factor; HSP, heat shock protein; P-HSP, phosphorylated heat shock protein; 
MAPK, mitogen associated protein kinase; SDHC, succinate dehydrogenase Complex II; TARP, 
transmembrane AMPA regulatory protein; NS, not significant trend; N/D, not determined. Purple 
shaded cells refer to results obtained previously in the laboratory. *p<0.05; **p<0.01, 
***p<0.001, ‘-‘ indicates no significant change. 
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There were a number of changes that occurred in protein expression levels in 
ageing CD-1 mice; these included a decrease in HSP105, HSP70 and TARP 
γ2. These data further add to the profile of protein changes that occur during 
ageing of the CD-1 mouse, previously our laboratory has reported levels of 
HSP27, BDNF (brain derived neurotrophic factor) and GluA2 (Chazot et al, 
unpublished) also decrease with age and a range of other proteins, including P-
HSP27, αB crystallin, HSP40, HSP60, HSP70 and HSP90 have been found to 
remain unchanged with age (Burroughs, 2010). The reduction in HSP70 and 
HSP105 during ageing, support the hypothesis of a reduced ability to induce 
HSP expression (Calderwood et al., 2009, Soti and Csermely, 2003), whilst 
reduced GluA2 and TARP γ2 with age may explain the learning deficits 
observed in the CD-1 mice that become more apparent with age (Ennaceur et 
al., 2008). From these data it could be implied that levels of HSF1 do not 
significantly alter during ageing of the CD-1 mouse, however it was not possible 
to directly investigate this due to lack of tissue, but it would be an interesting 
factor to investigate in the future. 
However, chronic IR1072 exposure did appear to reduce HSF1 levels in old 
CD-1 mice, but there was no change in HSF1 levels in young mice that were 
irradiated. It is interesting to note that while a number of HSPs were reduced in 
expression in old CD-1 mice that were irradiated, including HSP70 and αB 
crystallin, levels of P-HSP27 were increased. In previous work HSP27, HSP40 
and HSP60 have also been shown to be significantly increased in old CD-1 
mice that were chronically irradiated (Burroughs, 2010). There remains work to 
be done regarding the role/function of HSF1 in the ‘normal’ state, definition of 
function has only been established using severe hypothermia and acute 
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stresses such as dietary restriction. This work has been done mainly in C. 
elegans, and the impact of HSF1 on mammalian longevity remains to be 
established (Anckar and Sistonen, 2011). These data suggest levels of HSF1 
may not be a sufficiently sensitive measure of the capability of HSP expression 
or that HSP expression may be influenced by other mechanisms such as the 
STAT3 pathway (Saito et al., 2009, Yamagishi et al., 2009). 
It is very interesting to note that an increased level of phosphorylated HSP27 
was observed in both young and old CD-1 mice exposed to chronic IR1072. 
Phosphorylated HSP27 forms tetramers, which are able to target proteins 
towards ubiquitination, initially stabilising the aggregates before removing them. 
Functionality of P-HSP27 in vivo is difficult to determine as the phosphorylation 
status can change rapidly and alternately phosphorylated isoforms can exist at 
any one time (Rogalla et al., 1999). As well as this, it is thought that the small 
oligomers of HSP27 that form following phosphorylation are the structures 
which interact with DAXX, preventing FAS-mediated cell death (see figure 1.12.; 
Beere, 2004, Garrido, 2002). Increased HSP27 is not only anti-apoptotic but is 
also able to activate and stabilise Akt to promote cell survival (Beere, 2004, 
2005, Gao and Xing, 2009). Previous data showing increased HSP27, in both 
young and old CD-1 mice (Burroughs, 2010), supports data found in 
investigations with both the CD-1 strain and TASTPM strain following IR1072 
exposure (see Chapter 6). HSP27 and the phosphorylated version have both 
been found to be consistently increased following chronic IR1072 exposure. 
Further work to investigate whether this is also the case for female CD-1 mice 
would be important to undertake. It was also interesting to find that the sHSP, 
αB crystallin, was decreased in old CD-1 mice that were chronically IR treated 
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but no change was found in young CD-1 mice that were irradiated, as well as no 
change in levels was found during ageing in the CD-1 line. The reduction in old 
CD-1 mice may be a result of decreased HSF1 levels that were also observed, 
however decreased αB crystallin has also been found in male and female 
TASTPM mice that have undergone chronic irradiation. It is therefore perhaps 
of more interest that young CD-1 mice showed no change in αB crystallin levels. 
The reduction in αB crystallin may be attributed to cell stress, the TASTPM 
strain already have a significant amyloid load at 7 months of age and the CD-1 
strain have been reported to display increased amyloidosis with age 
(Engelhardt et al., 1993), in the face of more stress, the response to IR1072 
appears to be greater. The role of αB crystallin is not clear; it has been shown to 
exacerbate Aβ oligomer formation (Narayanan et al., 2006, Stege et al., 1999) 
but also increase tau degradation and dephosphorylation (Bjorkdahl et al., 
2008), as well as suppressing caspase-3 activation in apoptosis (Beere, 2004, 
2005). However, more data suggest a negative role for the sHSP in disease 
progression (Mao et al., 2001), therefore reduced αB crystallin may be a 
protective mechanism elicited by the cell, preventing exacerbation of the 
disease state. 
This investigation found that chronic IR1072 exposure reduced HSP70 in old 
CD-1 mice, with previous reports showing reduction in young CD-1 mice also 
(Burroughs, 2010). Reduced HSP70 is particularly interesting in conjunction 
with reduced αB crystallin, as the two chaperones have been suggested to act 
synergistically in vivo to enable refolding of aggregates (Haslbeck et al., 2005). 
This data suggests that in some conditions, IR1072 exposure may not be 
beneficial. Reduced HSP70 may result in limited chaperone capabilities, 
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diminished direction of proteins toward the ubiquitin-proteasome system and a 
dampened ability to prevent apoptosis via the extrinsic pathway (Mayer and 
Bukau, 2005, Mosser et al., 1997, Ohtsuka and Suzuki, 2000, Turturici et al., 
2011). But no change was found in the levels of HSP105 following chronic 
irradiation, in young or old CD-1 mice, and HSP105 has been shown to 
compensate for HSP70 under certain cellular conditions and it has been shown 
to cause HSP70 to bind to substrates with a high affinity and in some conditions 
induce HSP70 expression. Therefore maintenance of HSP105 levels may aid in 
using the low levels of HSP70 in the best way for the cell (Saito et al., 2009, 
Yamagishi et al., 2004, Yamagishi et al., 2003, Yamagishi et al., 2000). 
As differential effects of chronic IR1072 irradiation were found in male and 
female TASTPM mice (discussed in Chapter 6), it would be useful to repeat the 
age points investigated here with female CD-1 mice that have undergone the 
same treatment protocol to investigate whether this reduction is specific to CD-1 
mice or whether it is a specific secondary effect to male CD-1 mice, as gender 
differences in HSP expression have been previously reported in a range of 
tissues (Voss et al., 2003). 
TARP γ2, also known as stargazin, is a transmembrane AMPA (α-amino-3-
hydroxy-5-methyl-4-isoxazolepropionic acid) regulatory protein, one of a family 
of TARP proteins which are amongst a larger group of AMPA receptor binding 
partners, responsible for the trafficking and synaptic localisation of the 
glutamate ion-gated channel proteins which mediate excitatory 
neurotransmission (Donoghue, 2009, Vandenberghe et al., 2005). Lack of 
TARP γ2 results in an absence of spontaneous AMPA receptor activity, 
demonstrating requirement of TARP γ2 in trafficking of AMPA receptors to the 
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cell surface although the precise mechanism of trafficking remains unknown. 
TARP γ2 is believed to be important in the correct folding of the AMPA receptor, 
(Vandenberghe et al., 2005) but the principal role of TARP γ2 is thought to be 
acting as an auxiliary AMPA subunit, enabling interaction with scaffold proteins 
of the PSD (postsynaptic density; Bats et al., 2007). Increased expression of 
TARP γ2, as observed in this investigation following chronic IR1072 exposure of 
CD-1 mice at both age points, has been shown to result in increased numbers 
of AMPA receptors, localising to the cell surface but the ratio of synaptic:non-
synaptic AMPA receptors does not change. This data suggest that the size of 
the PSD limits the number of synaptic AMPA receptors which can be at the cell 
surface, and therefore the effect of upregulation on long term potentiation (LTP) 
may be limited (Bats et al., 2007, Donoghue, 2009). The observed increase in 
TARP γ2 seen following chronic IR1072 exposure in CD-1 mice, suggests a 
potential for influence of LLLT over LTP. It is also interesting to note that levels 
of TARP γ2 and GluA2 decrease with age of the CD-1 mice, suggesting LTP 
becomes compromised with age, this could explain learning deficits which 
become apparent in behaviour tests with older CD-1 mice, compared to 
younger mice (Ennaceur et al., 2008), therefore higher TARP γ2 levels would 
cause AMPA receptors to return to the PSD, increasing receptor activity. These 
data provide support for work with CD-1 mice previously conducted in our 
laboratory where acute treatment with IR1072 was sufficient to improve working 
memory in both male and female CD-1 mice. IR exposed aged (12 months) 
mice showed increased consideration in their decision making and 
demonstrated a significantly improved cognitive performance, tantamount to 
that of young (4 month) CD-1 mice (Michalikova et al., 2008). This influence of 
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IR1072 over TARP γ2, and therefore potential LTP, is a very promising 
application. The reduction of GluA2 levels following IR1072 exposure in old CD-
1 mice is a particularly interesting response. GluA2 is a subunit of the AMPA 
receptor, its presence determine the receptors permeability to calcium, sodium 
and potassium and is important in receptor trafficking and long-term depression. 
AMPA receptors are believed to express GluA1 in the absence of GluA2, 
rendering receptors sensitive to calcium, a sensitivity which can be heightened 
through increased TARP γ2 levels. GluA2 redundant receptors have been found 
in GABA-ergic inhibitory neurons, increasing excitability of the neurons 
ultimately with the potential to increase synaptic plasticity and LTP. Therefore in 
the future it would be of significant interest to determine where reduced GluA2 
levels are compensated by amplified GluA1 levels (Bats et al., 2007, Man, 
2011).  
The significant increase in SDHC, succinate dehydrogenase Complex II, 
following chronic IR1072 exposure is of particular interest as it is only present in 
CD-1 mice that were treated from 2 months of age, and not in those treated 
from 7 months of age. This suggests that younger mice may be more 
susceptible to the effects of IR1072 of mitochondria. The profound increase in 
SDHC, part of Complex II that is mitochondrial membrane bound, suggested 
that there may be an increase in electron transport chain complexes and 
potentially, activity and efficiency via increased coupling to the membrane. 
SDHC is very unstable when not membrane bound, suggesting the detected 
levels are membrane bound, and the greater the levels of SDHC, the more 
resistant the cell is to oxidative damage. Perhaps the increase in SDHC is not 
surprising, as increased Complex II activity has been previously reported in rats 
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irradiated at 904 nm (Silveira et al., 2007). Work conducted in our laboratory 
has also found increased Complex II activity in IR1072-exposed CD-1 mice at 7 
months of age (Burroughs, 2010) and this investigation has reported increased 
Complex II activity in mice at 3 months of age following acute irradiation. 
However, oxidative phosphorylation has not been investigated in mice which 
have undergone chronic IR1072 exposure; this would be of significant interest 
to complete as it would enable determination of whether the increased SDHC 
results in a functional improvement of Complex II activity. Data in this 
investigation has shown decreased activity of Complex I in male and female, 
mice at 3 months of age following acute IR1072 exposure. It would be of 
significant interest to look into the effect of chronic irradiation on young and old, 
as well as male and female CD-1 mice. It may be the case that the ETC in 
younger mice is more susceptible to irradiation but it may also be that a degree 
of stress is required to evoke a profound protective response from NIR. The 
majority of work undertaken with LLLT has utilised wounding or sub-lethal toxic 
insults (as detailed in Introduction 1.1.7) in order to determine the protective 
mechanisms of NIR. There has been very little work undertaken whereby a 
‘normal’ system is exposed to LLLT and the effects examined, the work that has 
been performed has focussed on proliferation, namely in osteoblasts (Kreisler et 
al., 2003, Pires Oliveira et al., 2008, Ueda and Shimizu, 2003), fibroblasts 
(Taniguchi et al., 2009, Vinck et al., 2003), muscle cells and epithelial cells 
(Sommer et al., 2001). The study of the effects of LLLT on the ‘normal’ system 
is an area requiring further examination; data reported in this investigation 
suggests that it is plausible that the magnitude of secondary effects of LLLT are 
dependent on the severity of the stress that the system is under. With 
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potentially more arduous stresses, such as accumulation of Aβ and 
phosphorylated tau in TASTPM mice, compared to the onset of amyloidosis in 
the CD-1 mice, resulting in initiation of a greater stress response. The stress of 
ageing in the CD-1 mice does appear to have an effect on the secondary effects 
of IR1072 as a greater number of the proteins examined were altered in the old 
CD-1 mice, compared to young CD-1 mice. This may also be due to 
progressive amyloidosis which occurs with age in the CD-1 mice, resulting in 
more cellular stress in older mice than younger mice and the higher level of 
stress triggers greater biological effects, secondary to LLLT. 
These investigations have demonstrated that IR1072 exposure affects a 
number of proteins in the mammalian system that have been shown to have key 
roles in the maintenance of homeostasis within the cell; preventing the build up 
of toxic aggregates, encouraging cell survival or directing the cell towards 
apoptosis when deemed necessary. It was also interesting to find that the 
expression of a number of these proteins decrease with age in the CD-1 strain. 
Alterations were also observed in a regulatory protein, TARP γ2, required for 
LTP, which may explain improved learning and working-memory seen in the 
CD-1 strain following IR1072 exposure (Michalikova et al., 2008), a protein 
which was also found to decrease with the age of the animals. Molecular 
changes may occur as a direct result of some of the altered mitochondrial 
electron transport chain complexes that were observed following IR1072 
exposure, detailed in Chapter 4. 
The next chapter utilises the data obtained from Chapter 5 to investigate 
whether IR1072 also modifies the expression levels of a number of proteins 
important in cell survival and LTP in a mouse model of Alzheimer's disease 
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(TASTPM) as well as the premature learning deficit CD-1 strain. It is important 
to determine whether the effects observed with the CD-1 strain are applicable to 
another dementia mouse model, which would support of a general mechanistic 
basis for photobiomodulation in a range of neurodegenerative diseases. 
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Chapter 6: Age-dependant changes in protein expression and the effect of 
chronic in vivo IR1072 exposure on protein expression in TASTPM mice 
 
6.1 Introduction 
The development of transgenic animal models of disease has provided useful 
tools to investigate the role of Aβ in AD progression and to provide knowledge 
to limit disease progression. Overexpression of APP, amyloid precursor protein, 
containing mutations associated with familial AD has allowed the study of AD 
pathology, behaviour and processing of Aβ in transgenic lines. A limitation of 
the use of transgenic lines is that they typically display exaggerated Aβ 
pathology and perhaps unsurprisingly, the use of familial mutations results in 
phenotypes which are more closely associated with familial AD which is much 
less common that sporadic forms (Balducci and Forloni, 2011). However, the 
major limitation of transgenic APP/PS1 (amyloid precursor protein/presenilin 1) 
lines is the lack of neuronal death and intracellular/extracellular NFTs which are 
frequently observed to be in AD patient samples. These characteristics are 
difficult to reproduce in animal models, demonstrating that there is still a 
significant level of development required to produce pathologically accurate 
transgenic systems (Balducci and Forloni, 2011, O'Brien and Wong, 2011). 
The TASTPM transgenic line were created at GlaxoSmithKline (Harlow, UK) by 
crossing two transgenic lines, TAS10 and TPM, which expressed the Swedish 
double APP 695 and presenilin-1 M146V mutations, respectively but from the 
C57BL/6 background. Expression of both transgenes is driven by a THY-1 
promoter (Howlett et al., 2004). The TASTPM mouse line display a rapid age-
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dependent increase the total level of Aβ(1-40) and Aβ(1-42), which ultimately 
results in plaque formation. The mice display a higher proportion of soluble Aβ 
when young and as the mice age, the proportion of insoluble Aβ increases, this 
is concomitant with the onset of observable Aβ plaques in the TASTPM brain 
(Hussain et al., 2006). Intracellular and extracellular Aβ have been found in the 
TASTPM mouse (Howlett and Richardson, 2009). Plaque deposition is clear in 
the cortex of TASTPM mice from 3 months of age, with mature plaques evident 
from six months of age. At six months of age, plaques have established fibrillar 
cores surrounded by degenerating neurites and reactive glia and temporal lobe 
degeneration (Howlett et al., 2004). At six months of age, cognitive function has 
also been shown to decline (Ennaceur & Chazot, unpublished). Female 
TASTPM mice have been shown to have a higher Aβ load than male age-
matched mice, but this difference appears to have no bearing on differences in 
cognitive function between the sexes (Howlett et al., 2004). 
Many transgenic mouse models of Alzheimer’s disease exist, a high proportion 
with similar mutations to the TASTPM strain, nevertheless little neuronal loss is 
commonly observed. This raises questions regarding the validity of these 
strains as models of the human disease. However, some neuronal loss is 
observed in TASTPM mice, this neuronal loss has been shown to correlate with 
total Aβ (40 amino acid and 42 amino acid) levels (Howlett, 2006); as well as 
observation of ultrastructural increases in synaptic distances (Richardson et al., 
2003), both relationships increase with animal age. Neuronal loss has been 
identified in the hippocampus in TASTPM mice, appearing to occur in a similar 
manner in the human AD brain, but to a lesser degree. An immune response to 
Aβ also appears to be present in the TASTPM strain, with microglia and 
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astrocytes found to colocalise with Aβ plaques and their pathology correlating to 
Aβ deposition and dystrophic neurites (Howlett et al., 2008, Kurt et al., 2001, 
Richardson et al., 2003). Hyperphosphorylated tau is observable in small 
amounts from four months of age, closely associated with Aβ deposits; with the 
levels increasing with age, however, the formation of NFTs has not been 
observed (Howlett et al., 2008). Paired-helical-like filaments have been 
observed in hippocampal neurons of TASTPM mice (Kurt et al., 2003), but it is 
unclear whether the phosphorylation pattern is relatable to that observed in 
human AD. These data suggest that the TASTPM transgenic line are a suitable 
Aβ-model system to study the neurodegeneration that occurs in AD, albeit with 
a somewhat dampened inflammatory and tau tangle involvement. 
Non-cognitive behaviour has also been studied in the TASTPM mice, however 
not in great detail. Male TASTPM mice have been reported to be more 
aggressive, such that single housing is needed. TASTPM mice also show 
locomotor hyperactivity as they age, reduced body weight despite increased 
feeding frequency and duration, premature death, disinhibition and alterations in 
circadian rhythm (Pugh et al., 2007). The authors suggest some changes are a 
result of developmental problems rather than as a direct result of amyloid 
pathology, such as altered feeding patterns and weight loss. They do however; 
associate some changes with amyloid neuropathology, such as increased 
aggression and anxiety (Pugh et al., 2007). The TASTPM mouse has been 
suggested to reproduce some of the human behavioural alterations seen in AD, 
including altered sleep patterns and aggression. However, comparables 
between mouse and human behaviour are not easily establish due to their 
complex nature (Graham, 2011). 
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The aim of this chapter was to further investigate protein level alterations during 
ageing in male TASTPM mice, and following chronic IR1072 exposure in both 
male and female TASTPM mice, including HSPs, APP and Aβ. Mice were 
exposed to sham or IR1072 treatments as described in 2.2.2., from 2 months of 
age.  
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6.2 Results 
Data were analysed using ImageJ, version 1.43, National Institutes of Health, 
USA, and processed using Microsoft Office Excel 2007 and statistical analyses 
were carried out using GraphPad Prism Version 5, GraphPad Software Inc. 
 
6.2.1 Immunoblot Analysis 
Male TASTPM mice at 12 months of age demonstrated a 46.54% reduction in 
HSP105 expression compared to mice of 3 months of age. Mice of 7 months of 
age showed a 34.80% reduction compared to mice of 3 months of age. All other 
comparisons were non-significant. Data shown in figure 6.1 and table 6.1. 
Male TASTPM mice at 12 months of age displayed a 199.53% increase in 
expression of αB crystallin compared to mice of 3 months of age. Mice at 7 
months of age showed a 260.89% higher expression compared to mice of 3 
months of age. There was no significant difference in expression of αB crystallin 
when comparing male TASTPM mice of 7 and 12 months of age. Data shown in 
figure 6.2 and table 6.1. 
Male TASTPM mice at 7 months of age demonstrated a 40.35% reduction in 
TARP γ2 expression compared to mice of 3 months of age. Mice at 12 months 
of age showed a 20.10% decrease expression compared to mice at 3 months of 
age. There was no significant difference between TARP γ2 expression between 
mice of 7 and 12 months of age. Data show in figure 6.3 and table 6.1. 
All data were analysed using a one-way ANOVA with a Bonferroni’s multiple 
comparison post test and is summarised in table 6.1. 
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Figure 6.1. Age dependent alterations in HSP105 expression, shown in 3, 7 and 12 month old 
TASTPM male mouse brain. A) is an immunoblot where each lane represents an individual 
mouse and B) shows the quantitative analysis of immunoblot data. Mean values ± SEM, n=3 for 
each age point. A significant reduction was found between 3 month old mice to both 7 and 12 
months mice (*p<0.05, **p<0.01 respectively). All other comparisons were non-significant. 
Abbreviations: HSP, heat shock protein; OD, optical density. 
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Figure 6.2. Age dependent alterations in αB Crystallin expression, shown in 3 months, 7 
months and 12 months TASTPM mouse brains. A) is an immunoblot, each lane represents an 
individual mouse and B) shows the quantitative analyses of immunoblot data. Mean values ± 
SEM, n=3 at each age point. A significant increase in expression of αB crystallin is found when 
comparing 3 month old TASTPM mice to both 7 month and 12 month old TASTPM mice 
(**p<0.01). All other comparisons non-significant. Abbreviations: OD, optical density. 
  
3 7 12
0.0
0.4
0.8
1.2
1.6
**
**
Age (months)
A
lp
h
a
 B
 C
ry
st
a
ll
in
 E
xp
re
ss
io
n
 (
O
D
)
αB 
Crystallin 
β-actin 
         3 months               7 months             12 months 
 
223 
A) 
 
 
 
 
 
 
 
 
B) 
 
 
 
 
 
 
 
 
 
 
Figure 6.3. Age dependent alterations in TARP γ2
 
expression, shown in 3 months, 7 months 
and 12 months TASTPM mouse brains. A) is an immunoblot, each lane represents an individual 
mouse and B) shows the quantitative analyses of immunoblot data. Mean values ± SEM, n=3 at 
each age point. There is a trend for decreased expression at 7 months of age, compared to 
mice at 3 months (p<0.1), as well as a significantly decreased expression at 12 months of age 
compared to mice at 3 months of age (*p<0.05). All comparisons are non-significant. 
Abbreviations: TARP γ2, Transmembrane AMPA regulatory protein; OD, optical density. 
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Effect of age on protein expression in male TASTPM mice at 3, 7 and 12 months 
of age, n=3 for each condition 
Antibody/Protein P Value 
3
 v
s
. 
7
 
3
 v
s
. 
1
2
 
7
 v
s
. 
1
2
 
Result: 
↑ or ↓ 
Figure 
APP 0.242 - - - - Not shown 
Aβ (1-40) 0.166 - - - - Not shown 
Aβ (1-42) Not determined 
Presenilin 1 Not determined 
AT8 0.371 - - - - Not shown 
P-Tau (S519) 0.760 - - - - Not shown 
GSK-3β 0.217 - - - - Not shown 
HSF1 0.445 - - - - Not shown 
HSP105 0.008 * ** NS ↓ Figure 6.1 
HSP27 0.460 - - - - Not shown 
HSP70 0.479 - - - - Not shown 
P-HSP27 0.180 - - - - Not shown 
αB crystallin 0.002 ** ** NS ↑ Figure 6.2 
TARP γ2 0.072 NS * - ↓ Figure 6.3 
TARP γ8 0.109 - - - - Not shown 
THY-1 Not determined 
 
Table 6.1. Data with a trend in altered expression levels are shaded blue (p<0.1), data with 
statistically significant altered expression levels (p<0.05) are shaded green. Arrows indicate 
direction of altered expression, (↑, increase; ↓, decrease), ‘-‘ indicates no significant change. 
*p<0.05, **p<0.01, ***p<0.001. Abbreviations: APP, amyloid precursor protein; Aβ, β-amyloid; 
AT8, hyperphosphorylated tau; GSK-3β, glycogen synthase kinase-3β; HSF, heat shock factor; 
HSP, heat shock protein; P-HSP, phosphorylated heat shock protein; P-tau, phosphorylated 
tau; TARP, transmembrane AMPA regulatory protein; NS, not significant.  
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6.3 Chronic IR treatment of TASTPM 
There were difficulties in maintaining aged populations of TASTPM mice for 
longer than 7 months. Therefore chronic IR1072 treatment of mice was limited 
to when the mice reach 7 months of age. From 2 months of age, both male and 
female TASTPM mice were conditioned with IR1072 for six minute periods, for 
two consecutive days, twice a week for a total of five months. Sham mice were 
exposed to replica equipment, for the same time period, in the absence of 
IR1072. During the treatment period the weight of mice and temperature of 
equipment was monitored. Equipment is as detailed in 2.2.2. 
 
6.3.1 Female TASTPM Mice 
6.3.1.1 Immunoblotting 
Data were analysed using a two-tailed student’s T test. Data shown represent 
mean ± SEM, n= number of replicates. Data is summarised in table 6.2. 
IR1072 preconditioned female TASTPM mice displayed an 80.44% reduction in 
APP (amyloid precursor protein) expression, a 79.89% decrease in β-amyloid(1-
42) expression, a 78.41% lower αB crystallin expression and a 56.87% reduction 
in Presenilin-1 expression compared to age-matched sham treated controls. 
IR1072 preconditioned female TASTPM mice displayed a 58.42% trend for 
decreased P-tau (S519) expression compared to age-matched sham treated 
controls. 
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IR1072 preconditioned female TASTPM mice demonstrated a 54.20% higher 
HSP105 expression, a 74.90% increase in HSP70 expression, 67.01% higher 
HSP27 expression, a 62.87% increase in P-HSP27 expression and a 654.34% 
increase in TARP γ2 expression compared to age-matched sham treated 
controls. 
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Figure 6.4. APP expression in chronic IR1072 preconditioned (in vivo) 7 month TASTPM 
Female mice and Sham age matched controls. Each lane in A) demonstrates an individual 
mouse (n=3 for each condition) and B) represents quantitative analysis of APP expression, 
demonstrating that chronic IR1072 exposure significantly decreases APP expression (**p<0.01). 
Mean values ± SEM. Abbreviations: APP, Amyloid precursor protein; OD, optical density. 
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Figure 6.5. β-amyloid(1-42) expression in chronic IR1072 preconditioned (in vivo) 7 month 
TASTPM female mice and Sham age matched controls. Each lane in A) demonstrates an 
individual mouse (n=3 for each condition) and B) represents quantitative analysis of β-amyloid(1-
42) expression, indicating that IR1072 treatment significantly decreases β-amyloid(1-42) 
expression in preconditioned animals (**p<0.01) Mean ± SEM. Abbreviations: Aβ, β-amyloid; 
OD, optical density. 
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Figure 6.6. PS1 expression in chronic IR1072 preconditioned (in vivo) 7 month TASTPM female 
mice and Sham age matched controls. Each lane in A) demonstrates an individual mouse (n=3 
for each condition) and B) represents quantitative analysis of PS1 expression, indicating that 
IR1072 treatment significantly decreases PS1 expression in preconditioned animals (**p<0.01) 
Mean ± SEM. Abbreviations: PS1, Presenilin 1; OD, optical density. 
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Figure 6.7. P-Tau (S519) expression in chronic IR1072 preconditioned (in vivo) 7 month 
TASTPM Female mice and Sham age matched controls. Each lane in A) demonstrates an 
individual mouse (n=3 for each condition) and B) represents quantitative analysis of P-Tau 
(S519) expression. There is a trend for decreased P-Tau (S519) expression in chronic IR 
preconditioned animals (p<0.1). Mean ± SEM. Abbreviations: P-Tau (S519), phosphorylated 
tau; OD, optical density. 
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Figure 6.8. HSP105 expression in chronic IR1072 preconditioned (in vivo) 7 month TASTPM 
Female mice and Sham age matched controls. Each lane in A) demonstrates an individual 
mouse (n=3 for each condition) and B) represents quantitative analysis of HSP105 expression, 
indicating that IR1072 treatment significantly increases HSP105 expression in preconditioned 
animals (*p<0.05). Mean ± SEM. Abbreviations: HSP105, Heat shock protein 105; OD, optical 
density. 
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Figure 6.9. HSP70 expression in chronic IR1072 preconditioned (in vivo) 7 month TASTPM 
Female mice and Sham age matched controls. Each lane in A) demonstrates an individual 
mouse (n=3 for each condition) and B) represents quantitative analysis of HSP70 expression, 
indicating that IR1072 treatment significantly increased HSP70 expression in preconditioned 
animals (*p<0.05). Mean ± SEM. Abbreviations: HSP70, Heat shock protein 70; OD, optical 
density. 
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Figure 6.10. HSP27 expression in chronic IR1072 preconditioned (in vivo) 7 month TASTPM 
Female mice and Sham age matched controls. Each lane in A) demonstrates an individual 
mouse (n=3 for each condition) and B) represents quantitative analysis of HSP27 expression, 
IR1072 treated mice showed a significantly increased expression of sham treated age matched 
controls (*p<0.05) Mean ± SEM. Abbreviations: HSP27, Heat shock protein 27; OD, optical 
density. 
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Figure 6.11. P-HSP27 expression in chronic IR1072 preconditioned (in vivo) 7 month TASTPM 
Female mice and Sham age matched controls. Each lane in A) demonstrates an individual 
mouse (n=3 for each condition) and B) represents quantitative analysis of P-HSP27, 
demonstrating a significant increase in expression following chronic IR treatment (*p<0.05). 
Mean ± SEM. Abbreviations: P-HSP27, Phosphorylated Heat Shock Protein 27; OD, optical 
density. 
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Figure 6.12. αB Crystallin expression in chronic IR1072 preconditioned (in vivo) 7 month 
TASTPM female mice and Sham age matched controls. Each lane in A) demonstrates an 
individual mouse (n=3 for each condition) and B) represents quantitative analysis of αB 
Crystallin expression, indicating that IR1072 treatment significantly increases αB Crystallin 
expression in preconditioned animals (***p<0.001) Mean ± SEM. Abbreviations: OD, optical 
density. 
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Figure 6.13. TARP γ2 expression in chronic IR1072 preconditioned (in vivo) 7 month TASTPM 
female mice and Sham age matched controls. Each lane in A) demonstrates an individual 
mouse (n=3 for each condition) and B) represents quantitative analysis of TARP γ2, 
demonstrating a significant increase in expression following chronic IR treatment (***p<0.001). 
Mean ± SEM. Abbreviations: TARP, Transmembrane AMPA regulatory protein; OD, optical 
density.  
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Effect of Chronic IR1072 Preconditioning on protein expression in female 
TASTPM mice, compared to age matched sham-treated controls, n=3 for each 
condition 
Antibody/Protein P Value 
Result: increase or 
decrease 
Figure 
APP **0.009 ↓ Figure 6.4 
Aβ(1-40) 0.770 - Not shown 
Aβ(1-42) **0.006 ↓ Figure 6.5 
Presenilin 1 **0.003 ↓ Figure 6.6 
AT8 0.982 - Not shown 
P-Tau (S519) 0.052 ↓ Figure 6.7 
GSK-3β 0.818 - Not shown 
HSF1 Not determined 
HSP105 *0.016 ↑ Figure 6.8 
HSP70 *0.048 ↑ Figure 6.9 
HSP27 *0.017 ↑ Figure 6.10 
P-HSP27 *0.029 ↑ Figure 6.11 
αB crystallin ***<0.001 ↓ Figure 6.12 
TARP γ2 ***<0.001 ↑ Figure 6.13 
TARP γ8 0.188 - Not shown 
THY-1 0.767 - Not shown 
 
Table 6.2. Data with a trend in altered expression levels are shaded blue (p<0.1), data with 
statistically significant altered expression levels (p<0.05) are shaded green. Arrows indicate 
direction of altered expression, (↑, increase; ↓, decrease), ‘-‘ indicates no significant change. 
*p<0.05, **p<0.01, ***p<0.001. Abbreviations: APP, amyloid precursor protein; Aβ, β-amyloid; 
AT8, hyperphosphorylated tau; GSK-3β, glycogen synthase kinase-3β; HSF, heat shock factor; 
HSP, heat shock protein; P-HSP, phosphorylated heat shock protein; P-tau, phosphorylated 
tau; TARP, transmembrane AMPA regulatory protein; NS, not significant.  
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6.3.1.2 Immunohistochemistry 
Immunohistochemical analysis showed no qualitative differences between 
IR1072-treated 7 month TASTPM female mice, compared to sham-treated 
controls (n=3 for each condition). 
Effect of Chronic IR1072 Preconditioning on protein expression in female 
TASTPM mice, compared to age matched sham-treated controls, n=3 individual 
mice for each condition 
Antibody/Protein Result: increase (↑) or decrease (↓) Figure 
AT8 No detectable change Not shown 
GSK-3β No detectable change Not shown 
  
Table 6.3. Summary table of immunohistochemical analysis of protein expression. 
Abbreviations: AT8, hyperphosphorylated tau; GSK-3β, glycogen synthase kinase-3β. 
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6.3.2 Male TASTPM Mice 
6.3.2.1 Immunoblotting 
Data were analysed using a two-tailed student’s T test. Data shown represent 
mean ± SEM, n= number of replicates. Data is summarised in table 6.4. 
IR1072 preconditioned male TASTPM mice displayed a 45.48% reduction in 
APP expression, a 98.79% lower HSF1 level, a 76.36% decrease in HSP105 
expression, a 95.88% reduction in HSP70 levels and a 69.34% lower αB 
crystallin expression compared to age-matched sham treated controls. 
IR1072 preconditioned male TASTPM mice showed a 39.76% trend for reduced 
AT8 expression compared to age-matched sham treated controls. 
IR1072 preconditioned male TASTPM mice demonstrated a 92.54% higher 
HSP27 expression and a 92.11% increase in P-HSP27 levels compared to age-
matched sham treated controls.  
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Figure 6.14. APP expression in chronic IR1072 preconditioned (in vivo) 7 month TASTPM male 
mice and Sham age matched controls. Each lane in A) demonstrates an individual mouse (n=4 
for each condition) and B) represents quantitative analysis of APP expression, indicating that 
IR1072 treatment significantly decreases APP expression in preconditioned animals (*p<0.05), 
Mean values ± SEM. Abbreviations: APP, Amyloid precursor protein; OD, optical density. 
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Figure 6.15. AT8 (hyperphosphorylated tau) expression in chronic IR1072 preconditioned (in 
vivo) 7 month TASTPM male mice and Sham age matched controls. Each lane in A) 
demonstrated in individual mouse (Sham, n=4, IR, n=3 for each condition) and B) represents 
quantitative analysis of AT8 expression. A trend for reduced expression of AT8 is observed in 
chronic IR treated animals, in comparison to Sham treated animals (p<0.01). Mean ± SEM. 
Abbreviations: AT8, hyperphosphorylated tau; OD, optical density. 
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Figure 6.16. HSF1 expression in chronic IR1072 preconditioned (in vivo) 7 month TASTPM 
male mice and Sham age matched controls. Each lane in A) demonstrates an individual mouse 
(n=4 for each condition) and B) represents quantitative analysis of HSF1 expression, indicating 
that IR1072 treatment significantly decreases HSF1 expression in preconditioned animals 
(**p<0.01). Mean ± SEM. Abbreviations: HSF1, Heat Shock Factor 1; OD, optical density. 
  
Sham IR
0.0
0.2
0.4
0.6
0.8
1.0
1.2
1.4
1.6
1.8
2.0
**
IR Treatment
H
SP
1
0
5
 E
xp
re
ss
io
n
 (
O
D
)
HSF1 
β-actin 
Sham IR 
 
243 
A) 
 
 
 
 
 
 
 
 
B)  
 
 
 
 
 
 
 
 
 
 
Figure 6.17. HSP105 expression in chronic IR1072 preconditioned (in vivo) 7 month TASTPM 
male mice and Sham age matched controls. Each lane in A) demonstrates an individual mouse 
(n=4 for each condition) and B) represents quantitative analysis of HSP105 expression, 
indicating that IR1072 treatment significantly increases HSP105 expression in preconditioned 
animals (***p<0.001). Mean ± SEM. Abbreviations: HSP105, Heat shock protein 105; OD, 
optical density. 
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Figure 6.18. HSP70 expression in chronic IR1072 preconditioned (in vivo) 7 month TASTPM 
male mice and Sham age matched controls. Each lane in A) demonstrates an individual mouse 
(n=4 for each condition) and B) represents quantitative analysis of HSP70 expression, indicating 
that IR1072 treatment significantly increases HSP70 expression in preconditioned animals 
(**p<0.01). Mean ± SEM. Abbreviations: HSP70, Heat shock protein 70; OD, optical density. 
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Figure 6.19. HSP27 expression in chronic IR1072 preconditioned (in vivo) 7 month TASTPM 
male mice and Sham age matched controls. Each lane in A) demonstrates an individual mouse 
(n=4 for each condition) and B) represents quantitative analysis of HSP27 expression, indicating 
that IR1072 treatment significantly increases HSP27 expression in preconditioned animals 
(*p<0.05). Mean ± SEM. Abbreviations: HSP27, heat shock protein 27; OD, optical density. 
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Figure 6.20. P-HSP27 expression in chronic IR1072 preconditioned (in vivo) 7 month TASTPM 
male mice and Sham age matched controls. Each lane in A) demonstrates an individual mouse 
(Sham, n=4, IR, n=3 for each condition) and B) represents quantitative analysis of P-HSP27 
expression. Animals chronically treated with IR1072 showed a significantly increased 
expression of P-HSP27 compared to sham treated controls (*p<0.05). Mean ± SEM. 
Abbreviations: P-HSP27, phosphorylated heat shock protein 27; OD, optical density. 
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Figure 6.21. αB Crystallin expression in chronic IR1072 preconditioned (in vivo) 7 month 
TASTPM male mice and Sham age matched controls. Each lane in A) demonstrates an 
individual mouse (n=4 for each condition) and B) represents quantitative analysis of αB 
crystallin expression. Animals chronically treated with IR1072 showed a significantly decreased 
expression of αB Crystallin compared to sham treated controls (*p<0.05). Mean ± SEM. 
Abbreviations: OD, optical density. 
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Effect of Chronic IR1072 Preconditioning on protein expression in male TASTPM 
mice, compared to age matched sham-treated controls, n=3/4 for each condition 
Antibody/Protein P Value Result: increase or 
decrease 
Figure 
APP *0.048 ↓ Figure 6.14 
Aβ(1-40) 0.183 - Not shown 
Aβ(1-42) 0.934 - Not shown 
Presenilin 1 0.390 - Not shown 
AT8 0.055 ↓ Figure 6.15 
P-Tau (S519) 0.998 - Not shown 
GSK-3β 0.686 - Not shown 
HSF1 **0.001 ↓ Figure 6.16 
HSP105 ***<0.001 ↓ Figure 6.17 
HSP70 **0.005 ↓ Figure 6.18 
HSP27 *0.050 ↑ Figure 6.19 
P-HSP27 *0.034 ↑ Figure 6.20 
αB crystallin *0.041 ↓ Figure 6.21 
TARP γ2 0.497 - Not shown 
TARP γ8 0.968 - Not shown 
THY-1 0.203 - Not shown 
 
Table 6.4. Data with a trend in altered expression levels are shaded blue (p<0.1), data with 
statistically significant altered expression levels (p<0.05) are shaded green. Arrows indicate 
direction of altered expression, (↑, increase; ↓, decrease), ‘-‘ indicates no significant change. 
*p<0.05, **p<0.01, ***p<0.001. Abbreviations: APP, amyloid precursor protein; Aβ, β-amyloid; 
AT8, hyperphosphorylated tau; GSK-3β, glycogen synthase kinase-3β; HSF, heat shock factor; 
HSP, heat shock protein; P-HSP, phosphorylated heat shock protein; P-tau, phosphorylated 
tau; TARP, transmembrane AMPA regulatory protein; NS, not significant. 
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6.3.2.2 Immunohistochemistry 
Immunohistochemical analysis showed qualitative differences between IR1072-
treated 7 month TASTPM male mice, compared to sham-treated controls (n=3 
for each condition). Data shown in figure 6.22 is representative of all repeats. 
Effect of Chronic IR1072 Preconditioning on protein expression in male TASTPM 
mice, compared to age matched sham-treated controls, n=3 for each condition 
Antibody/Protein Result: increase (↑) or decrease (↓) Figure 
AT8 ↓ CA1 and CA2/3 Figure 6.22 
GSK-3β No detectable change Not shown 
  
Table 6.5. Summary table of immunohistochemical analysis of protein expression. 
Abbreviations: AT8, hyperphosphorylated tau; CA, cornu ammonis; GSK-3β, glycogen synthase 
kinase-3β. 
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 Figure 6.22. AT8 (hyperphosphorylated tau Ser202/Thr205) expression in chronically IR1072 
treated and sham-treated (in vivo) 7 month old male TASTPM mice, each image is 
representative of staining, n=3 for each condition. Abbreviations: Ctx, cerebral cortex; CPu, 
caudate putamen; CA (1/2/3), Cornu ammonis; DG, Dentate Gyrus; Cb, Cerebellum; IR, 
Infrared at 1072 nm wavelength. Scale bar represents 200 μm. 
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6.4 TASTPM Mice: Mitochondrial respiratory studies 
Mitochondria that were assayed in this part of the investigation were neither 
sham nor IR1072 exposed. The purpose of these assays was to determine 
whether endogenous levels of Complex I and II activity differ between male and 
female TASTPM mice of the same age, which was on average 6 months. 
 
6.4.1 TASTPM Male and Female Mice: Liver 
6.4.1.1 Complex I – Glutamate plus Malate 
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Figure 6.23. Differences between glutamate plus malate respiratory rates in age-matched male 
(n=6) and female (n=3) TASTPM mouse liver mitochondria (in vivo). Mean values ± SEM, 
*p<0.05, **p<0.01, ***p<0.001. 
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Figure 6.24. Difference between glutamate plus malate RCI in age-matched male (n=6) and 
female (n=3) TASTPM mouse liver mitochondria (in vivo). Mean values ± SEM. 
 
 
Differences between electron transport chain Complex I activities, when 
comparing mitochondria isolated from liver tissue of female (n=3) to male (n=6) 
TASTPM mice of 6 months of age 
Respiratory rate 
(ng O2 min
-1 mg protein-1) 
P Value Result: ↑/↓ Percentage 
change (%) 
Figure 
Endogenous 0.569 - - 6.23 
State 4 **0.003 ↑ 114.51 6.23 
State 3 *0.013 ↑ 89.64 6.23 
Return to State 4 ***<0.001 ↑ 235.94 6.23 
RCI 0.060 ↑ 72.01 6.24 
 
Table 6.6. Data with a trend in altered activity are shaded blue (p<0.1), data with statistically 
significant altered activity levels (p<0.05) are shaded green. Arrows indicate direction of altered 
expression, (↑, increase; ↓, decrease), ‘-‘ indicates no significant change. *p<0.05; **p<0.01, 
***p<0.001. Abbreviations: RCI, respiratory control index.  
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6.4.1.2 Complex II - Succinate 
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Figure 6.25. Differences between succinate respiratory rates in age-matched male (n=6) and 
female (n=3) TASTPM mouse liver mitochondria (in vivo). Mean values ± SEM, *p<0.05. 
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Figure 6.26. Difference between succinate RCI in age-matched male (n=6) and female (n=3) 
TASTPM mouse liver mitochondria (in vivo). Mean values ± SEM. 
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Differences between electron transport chain Complex II activities, when 
comparing mitochondria isolated from liver tissue of female (n=3) to male (n=6) 
TASTPM mice of 6 months of age 
Respiratory rate 
(ng O2 min
-1 mg protein-1) 
P Value Result: ↑/↓ Percentage 
change (%) 
Figure 
Endogenous 0.310 - - 6.25 
State 4 *0.028 ↑ 95.51 6.25 
State 3 0.158 - - 6.25 
Return to State 4 0.059 ↑ 90.05 6.25 
RCI 0.978 - - 6.26 
 
Table 6.7. Data with a trend in altered activity are shaded blue (p<0.1), data with statistically 
significant altered activity levels (p<0.05) are shaded green. Arrows indicate direction of altered 
expression, (↑, increase; ↓, decrease), ‘-‘ indicates no significant change. *p<0.05; **p<0.01, 
***p<0.001. Abbreviations: RCI, respiratory control index. 
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6.4.2 TASTPM Male and Female Mice: Brain 
6.4.2.1 Complex I – Glutamate plus Malate 
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Figure 6.27. Differences between glutamate plus malate respiratory rates in age-matched male 
(n=6) and female (n=3) TASTPM mouse brain mitochondria (in vivo). Mean values ± SEM, 
*p<0.05. 
 
 
 
 
 
Figure 6.28. Difference between glutamate plus malate RCI in age-matched male (n=6) and 
female (n=3) TASTPM mouse brain mitochondria (in vivo). Mean values ± SEM, *p<0.05. 
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Differences between electron transport chain Complex I activities, when 
comparing mitochondria isolated from brain tissue of female (n=3) to male (n=6) 
TASTPM mice of 6 months of age 
Respiratory rate  
(ng O2 min
-1 mg protein-1) 
P Value  Result: ↑/↓ Percentage 
change (%) 
Figure 
Endogenous 0.507 - - 6.27 
State 4 0.459 - - 6.27 
State 3 *0.044 ↑ 215.47 6.27 
Return to State 4 0.150 - - 6.27 
RCI *0.047 ↑ 62.47 6.28 
 
Table 6.8. Data with statistically significant altered activity levels are shaded green. Arrows 
indicate direction of altered expression, (↑, increase; ↓, decrease), ‘-‘ indicates no significant 
change. *p<0.05. Abbreviations: RCI, respiratory control index. 
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6.4.2.2 Complex II - Succinate 
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Figure 6.29. Differences between succinate respiratory rates in age-matched male (n=6) and 
female (n=3) TASTPM mouse brain mitochondria (in vivo). Mean values ± SEM, *p<0.05, 
**p<0.01. 
Male Female
0
1
2
3
4
R
C
I
 
Figure 6.30. Difference between succinate RCI in age-matched male (n=6) and female (n=3) 
TASTPM mouse brain mitochondria (in vivo). Mean values ± SEM. 
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Differences between electron transport chain Complex II activities, when 
comparing mitochondria isolated from brain tissue of female (n=3) to male (n=6) 
TASTPM mice of 6 months of age 
Respiratory rate 
(ng O2 min
-1 mg protein-1) 
P Value Result: ↑/↓ Percentage 
change (%) 
Figure 
Endogenous 0.236 - - 6.29 
State 4 *0.016 ↑ 249.93 6.29 
State 3 **0.001 ↑ 229.02 6.29 
Return to State 4 *0.026 ↑ 231.51 6.29 
RCI 0.946 - - 6.30 
 
Table 6.9. Data with statistically significant altered activity levels are shaded green. Arrows 
indicate direction of altered expression, (↑, increase; ↓, decrease), ‘-‘ indicates no significant 
change. *p<0.05; **p<0.01. Abbreviations: RCI, respiratory control index. 
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6.5 Discussion 
The aim of this chapter was to further establish protein changes that occur 
during ageing of the TASTPM mouse and to determine whether these proteins 
altered following chronic IR1072 exposure in age-matched male or female mice. 
P
a
th
w
a
y
  
 
Protein 
TASTPM Timeline 
(Age in months) 
Effect of chronic IR1072 
exposure 
3 vs. 7 3 vs. 12 7 vs. 12 ♀ ♂ 
A
m
y
lo
id
/t
a
u
 
APP - - - ↓** ↓* 
β-amyloid(1-40) - - - - - 
β-amyloid(1-42) Not determined ↓* - 
PS-1 Not determined ↓* - 
AT8 - - - - ↓ (NS) 
P-Tau (S519) - - - ↓ (NS) - 
GSK-3β - - - - - 
C
h
a
p
e
ro
n
e
s
 
HSF1 - - - N/D ↓** 
HSP105 ↓* ↓** ↓ (NS) ↑* ↓*** 
HSP70 - - - ↑* ↓** 
HSP27 - - - ↑* ↑* 
P-HSP27 - - - ↑* ↑* 
αB Crystallin ↑** ↑** ↑ (NS) ↓*** ↓* 
TARPs 
TARP γ2 - ↓ (NS) - ↑*** - 
TARP γ8 - - - - - 
 THY-1 Not determined - - 
 
Table 6.10. Summary of effects of ageing in TASTPM mice and chronically IR treated mice, 
determined by western blotting. Abbreviations: APP, amyloid precursor protein; AT8, 
hyperphosphorylated tau; P-Tau (S519), phosphorylated tau at serine 519; GSK-3β, glycogen 
synthase kinase-3 beta; PS-1, Presenilin-1; HSF, heat shock factor; HSP, heat shock protein; 
P-HSP, phosphorylated heat shock protein; NS, non significant trend; N/D, not determined; 
TARP, transmembrane AMPA regulatory protein. *p<0.05; **p<0.01, ***p<0.001, ‘-‘ indicates no 
significant change. 
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The TASTPM transgenic line expresses the mutant APP and PS1 genes under 
the THY-1 promoter, considered a neuron specific promoter with a degree of 
region specific expression. Highest levels of THY-1 expression have been found 
in the striatum, hippocampus, cortex, cerebellum, with low level expression in 
the spinal cord and retina (Graham, 2011, Seki et al., 2002). The areas 
associated with higher degrees of THY-1 expression are amongst the first areas 
that become progressively damaged in AD, and vice versa, with areas showing 
less expression reported to be affected later in disease progression or affected 
to a lesser extent. The expression of this promoter should not alter with age in 
the mouse, supported by the finding of no change in APP or Aβ(1-40) levels with 
increasing age via immunoblotting, with Aβ(1-40) data supported by previous 
immunohistochemical labelling data (Burroughs, 2010), however it was not 
possible to directly examine THY-1 levels in the TASTPM ageing timeline. It 
was not possible to investigate levels of Aβ(1-42), PS1 or THY-1 during ageing 
due to sample degradation; however it would be of significant interest to 
investigate these in ageing TASTPM mice. In future it would also be beneficial 
to directly investigate THY-1 expression, which could be examined using a 
luciferease promoter for the THY-1 gene for example, to determine whether it 
alters during ageing; as a neuron specific promoter some change in expression 
may be expected as a degree of neuronal death is a factor in disease 
progression in TASTPM mice, however only at a low level is neuronal loss 
observed. 
The lack of change observed in Aβ levels with age of the TASTPM mouse 
investigated here, is perhaps not surprising as established plaques have been 
reported by three months of age and deposits of Aβ in the cortex by 2 months of 
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age (Howlett and Richardson, 2009). Therefore, the age of the mice 
investigated here, may be too old for any significant changes in Aβ levels to be 
observed. It is also important to note that Aβ investigated by immunoblotting is a 
measure of both soluble and insoluble protein. The quantity of plaque-type 
structures has been found to be increased with age (Burroughs, 2010, Howlett 
and Richardson, 2009, Hussain et al., 2006) which may mean that the soluble 
proportion of Aβ is decreasing with age, however this cannot easily be 
determined via immunoblotting but could be further investigated with ELISA 
(enzyme-linked immunosorbant assay) based methodology (Wang et al., 1999). 
Investigation of this nature of the Aβ protein would be interesting to determine 
following IR1072 exposure to establish whether the disease state may be 
modified by LLLT, Burroughs, 2010 has already established chronic IR1072 
exposure reduces small Aβ plaques in the cortex and dentate gyrus (Burroughs, 
2010, Howlett and Richardson, 2009, Hussain et al., 2006). 
Microtubule associated protein (MAP) tau is abnormally hyperphosphorylated in 
AD and aggregates as PHFs in neurofibrillary tangles (NFTs). The pattern of tau 
phosphorylation correlates with the loss of neuronal integrity (Augustinack et al., 
2002). Tau phosphorylated at Ser202/Thr205 (AT8 Antibody) is associated with 
both intracellular and extracellular NFTs (Goedert et al., 1995), whereas tau 
phosphorylated at Ser199/Ser202 (P-tau S519 antibody; Hanger et al., 2009) is 
associated with filamentous tau as it forms pre-NFT structures (Augustinack et 
al., 2002). There was an increase in the level of tau phosphorylated at 
Ser202/Thr205 (Goedert et al., 1995) with age of the TASTPM mice, however 
this was borderline non significant. These data provide support for 
immunolabelling with the AT8 antibody, which has previously been shown to 
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increase with age in the TASTPM mouse, significantly but not profoundly 
(Howlett et al., 2008). However, the lack of significant change in levels of tau 
phosphorylated at Ser199/Ser202 and Ser202/Thr205 is perhaps not surprising 
as limited involvement of phosphorylated tau in the TASTPM disease 
progression has been reported. Phosphorylated tau has been shown to co-
localise with dystrophic neurites adjacent to Aβ plaques but to be absent 
intracellularly in the TASTPM mouse (Howlett et al., 2008). Concomitantly, no 
change was observed in GSK-3β levels (kinase responsible for phosphorylation 
of tau at these residues) in this investigation, whereas it has been reported to 
increase abnormally in the Alzheimer’s disease brain, supporting minimal tau 
involvement in the disease state. Increased GSK-3β can repress HSF1, and 
therefore the chaperone response to protein aggregation/misfolding (Bhat et al., 
2004, Calderwood et al., 2009). No change in levels of GSK-3β during 
increasing age of the TASTPM mouse may be due to an established disease 
state being present at an early age; therefore no notable increase is observed. 
However, it may also be due to the limited neuronal loss  and limited tau 
involvement in the disease state mentioned previously, as high GSK-3β activity 
levels have been shown to lead to increased neuronal death and neurite 
retraction which are not observed in TASTPM mice (Bhat et al., 2004). 
Phosphorylation of the Ser199/202 has been particularly implicated in 
neurofibrillary pathology of AD (Maurage et al., 2003), something not 
significantly observed in this model (Howlett et al., 2008, Kurt et al., 2003) and 
something which was not found to alter with age of the TASTPM mouse in this 
investigation.  
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A significant age-dependent decrease in HSP105 levels was found in the 
TASTPM mice, along with a significant increase in levels of αB crystallin. No 
changes were observed in the levels of other heat shock proteins investigated 
in this study including HSP70, HSP27 and P-HSP27. It is also worth noting that 
there was no change in levels of HSF1 during the ageing process of TASTPM 
mice, supported by previously reported data that show no change in HSF1 
levels during ageing but it is instead the activation of HSF1 that becomes 
compromised which ultimately results in the accumulation of aggregates 
(Calderwood et al., 2009, Soti and Csermely, 2000). 
If ageing cells become stressed due to high aggregate load there are fewer 
HSPs present to protect against damage, particularly those that are able to act 
at low concentrations of ATP which is the main function of HSP105. Reduced 
levels of HSP105 could suggest that the repression of HSC70 chaperone 
activity, by HSP105α via increased ATP hydrolysis (Yamagishi et al., 2003) is 
somewhat reversed; potentially increasing the refolding capabilities of HSP70. 
However, despite no change in HSP70 levels, reduced levels of the co-
chaperone HSP40 have previously been reported during ageing of TASTPM 
mice (Burroughs, 2010), a co-chaperone important for protein refolding. 
Therefore, despite reduced HSP105 inhibition of HSP70 chaperone activity, the 
concomitant lack of HSP40 suggests a persistent dampened ability for HSP70 
to renature damaged proteins during ageing (Sahara et al., 2007). Another 
factor to consider is the anti-apoptotic role of HSP105. HSP105 is able to inhibit 
the activation of JNK and therefore activation of a number of caspases (detailed 
in 1.3.2; Hatayama et al., 2001); ergo lower HSP105 levels may result in 
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increased activity of pro-apoptotic proteins and thus cells become more 
susceptible to stress and are more likely to undergo apoptosis. 
Increased levels of αB crystallin detected with increasing age of the TASTPM 
mice suggest that HSF1 is still able to be activated; indeed increased αB 
crystallin levels have been previously reported in patients with Alzheimer’s 
disease, particularly in regions associated with senile plaques and 
neurofibrillary tangles (Bjorkdahl et al., 2008, Mao et al., 2001, Renkawek et al., 
1994). The highly significant profound down-regulation of αB crystallin following 
chronic IR1072 exposure in TASTPM mice is particularly interesting as it is one 
of the effects that occur in both the male and female mice. αB crystallin also 
appears to interact with Aβ(1-40) and Aβ(1-42), preventing fibril maturation and 
elongation (Narayanan et al., 2006, Shammas et al., 2011, Stege et al., 1999, 
Yoo et al., 2001). However, this interaction appears to occur via encouragement 
of oligomeric Aβ structure formation (Narayanan et al., 2006) which is now 
widely believed to be the more toxic Aβ structure (Benilova et al., 2012, 
Fandrich et al., 2011, Haass and Selkoe, 2007), therefore increased αB 
crystallin during ageing could be causing increased Aβ toxicity. Conversely, αB 
crystallin has been shown to increase tau degradation as well as preventing 
phosphorylation and encouraging dephosphorylation of tau in N2a 
neuroblastoma cells (Bjorkdahl et al., 2008), but there was no reduction in 
levels of phosphorylated tau investigated in this study despite the concomitant 
increase in αB crystallin. As well as this, increased αB crystallin levels could be 
working with HSP70 to incapacitate and re-fold aggregates as they have been 
reported to work synergistically (Ecroyd and Carver, 2009, Haslbeck et al., 
2005). Further work with αB crystallin, to identify the type of structures that the 
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small chaperone is associating with, tau and Aβ, would be crucial in order to 
understand the role of αB crystallin in the latter stages of disease progression. 
There were a considerable number of differences in the effect of chronic IR1072 
exposure, when compared to sham-treated animals, between male and female 
TASTPM mice. A critical factor to consider initially was whether chronic IR1072 
had any effect on the expression of the THY-1 promoter itself. No change was 
observed in levels of THY-1 in female or male TASTPM mice that were 
chronically IR1072 treated, suggesting that any of the observed secondary 
changes in protein levels; particularly alterations in APP, APP-derived proteins 
and PS1, are not due to IR1072 affecting the transgene promoter. 
A highly profound reduction in APP was found in the female and male mice 
chronically exposed to IR1072. It has previously been reported that female 
TASTPM mice have a higher amyloid-load than their male counterparts, with 
cerebral concentrations higher at all age point investigated, suggesting gonadal 
hormones may play a role in the processing of APP (Howlett et al., 2004). 
Oestrogen loss at menopause had been associated with increased risk of 
Alzheimer’s disease (Paganini-Hill and Henderson, 1994, Simpkins et al., 
1997), however the increased amyloid-load in the female TASTPM mouse is 
unlikely to be due to reproductive senescence as amyloid deposits can be 
observed from three months of age; indeed IR exposure was started at two 
months of age.  
The unexpected finding of a significant reduction in APP in IR1072 exposed 
female and male mice may explain the concomitant significant reduction in 
levels of Aβ(1-42) in the female mice, however this is not present in male mice. 
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The absence of a reduction in Aβ, despite a reduction in APP, in male TASTPM 
mice may be due to a reduced production of the peptides in the first place. This 
may explain why there is no observable change in Aβ(1-42) levels in male 
TASTPM mice that have undergone chronic IR1072 exposure despite reduced 
APP, as it may be that the levels of non-toxic APP products are reduced but this 
was not investigated in this study. Androgens, strongly expressed in males, 
including testosterone and 5α-dihydrotestosterone, have been shown to reduce 
the secretion of Aβ peptides and enhance the secretion of non-amyloidogenic 
APP products, thus protecting against disease progression (Gouras et al., 2000, 
Ramsden et al., 2003). The APP gene contains a heat shock element, and it 
has been shown to become upregulated via a variety of stresses (ethanol, heat 
stress). Therefore the reduction in HSF1, which binds to the HSE to trigger 
transcription, may be a causal factor in the reduced levels of APP observed in 
male and female TASTPM mice (Dewji and Do, 1996, Dewji et al., 1995). These 
data may explain why the effects of IR1072 on Aβ products are more significant 
in female TASTPM mice compared to males, as male androgens are able to 
prevent some of the toxic effects from APP-derived products; therefore the cell 
may be considered less stressed and a lower protective response is initiated via 
by IR1072 exposure. It is notable that despite reduction in the Aβ(1-42) peptide, 
no change in the Aβ(1-40) peptide in female mice was observed following chronic 
IR exposure. Why there appears to be discrimination between which Aβ peptide 
is removed in chronically IR1072 exposed female mice is unknown, but perhaps 
this suggests that the cell can discriminate which of the peptides is more toxic 
and prioritise the removal of the more toxic structure. 
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There were trends for decreased phosphorylated tau in both sexes following 
chronic IR exposure; however the male mice saw a reduction in levels of tau 
phosphorylated at the Ser202/Thr205, whereas female mice saw a trend for 
decreased levels of tau phosphorylated at the Ser199/Ser202 site. These data 
were supported with immunohistochemical analysis, a reduction in AT8 labelling 
was observed in the CA1/2/3 regions of the hippocampus, whereas females 
saw no reduction in AT8 staining across the brain. This is particularly interesting 
as the hippocampus is one of the first areas to become severely affected in 
Alzheimer’s disease (Benilova et al., 2012). 
Treatment with IR1072 led to a reduced filamentous tau (Ser199/Ser202) 
expression indicating potential dual beneficial effects for IR1072 exposure upon 
amyloid and tau pathology, the former being more profound. However, the 
mechanism for this reduction in P-tau needs further investigation as levels of 
GSK-3β did not change, this is not to say that the activity of GSK-3β is not 
altered by IR1072 exposure. GSK-3β is known to phosphorylate tau on at least 
14 of the 19 sites associated with PHF formation, including Ser199, Ser202, 
(which were both phosphorylated in the P-tau investigated in this study) Ser235, 
Ser396 and Ser404 (Hernandez et al., 2009, Rankin et al., 2007, Rankin et al., 
2008, Sun et al., 2002, Voss and Gamblin, 2009). Immunohistochemical data 
supported these (immunoblotting) data, with no obvious change observed 
across the brain in GSK-3β levels in either sex following chronic IR1072 
exposure. Further experiments are required to determine whether IR1072 
irradiation may be reducing hyperphosphorylated tau levels via another kinase 
known to interact directly or indirectly with tau, such as cyclin-dependent 
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kinase-5 (cdk-5), cdc-2/cdk1 or MAP kinase and whether levels of tau which 
has been phosphorylated at other sites are also reduced (Sun et al., 2002). 
Despite no change in THY-1 expression, the level of PS1 was found to 
decrease in female TASTPM mice following chronic IR exposure, but this 
change was not observed in age-matched males. Mutations in PS1 are 
particularly associated with familial AD, and lead to increased deposition of Aβ. 
The mechanism of PS1 in Alzheimer’s disease progression is not fully 
understood; PS1 comprises the major component of the γ-secretase which is 
responsible for the cleavage of APP C-terminal to produce Aβ(1-40) and Aβ(1-42). 
Mutations in PS1, have been shown to lead to favoured production of the 42 aa 
length Aβ peptide, which has been reported to be up to 10-fold more toxic than 
the 40 aa peptide (Matsuzaki, 2011). This increased production of Aβ(1-42) 
explains how mutations in PS1 lead to accelerated disease pathology and 
exacerbation of neuronal loss (Berezovska et al., 2005, Hardy, 1997, Sudoh et 
al., 1998). The TASTPM strain express the PS1 gene with M146V mutation, a 
mutation not known to cause any overt phenotype, although alterations in 
intracellular calcium signalling, increased excitotoxicity and reduced basal 
synaptic transmission have all been observed (Reviewed - Graham, 2011). The 
reduction in PS1 levels in chronically IR1072 exposed females TASTPM mice 
could also explain the reduced levels of Aβ(1-42) found, as less cleavage of APP 
by the mutated PS1 can occur. Female TASTPM mice, show greater Aβ 
deposition, as mentioned previously (Howlett et al., 2004), and although they 
did not show a greater cognitive decline than their male counterparts, it may be 
that the disease state is more severe and subsequently the response to chronic 
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IR1072 exposure is greater with reduced Aβ(1-42) and PS1 leading to a reduced 
disease state.  
There were also a considerable number of differences in the effects of chronic 
IR1072 exposure on the expression of a range of chaperone proteins between 
male and female TASTPM mice. On the whole, IR-treated male TASTPM mice 
generally displayed reduced expression of HSP and sHSP, compared to sham-
treated controls. Significantly, this could be attributed to the notable reduction in 
HSF1 levels in male IR1072 exposed mice. HSF1, heat shock factor 1, is 
responsible for the induction of HSP expression, detailed in Chapter 1.3.1. The 
translocation of HSFs to the nucleus is required for chaperone expression; 
reduced HSF1 could mean that the cell is less able to initiate expression of 
proteins needed for refolding and in preventing initiation of apoptotic pathways 
needed for survival. Increased HSP27 levels may be responsible for reduced 
HSF1 levels by targeting HSF1 to sumoylation, a modification which blocks the 
transactivating capacity of HSF1, targeting it for removal. As well as this HSF1 
is also able to be modified by CHIP (Calderwood et al., 2009, Lanneau et al., 
2010). Of all of the chaperones investigated, HSP70, HSP105 and αB crystallin 
levels were significantly reduced, but expression of HSP27 and P-HSP27 were 
increased, HSP60 has also previously been reported to decrease following 
chronic IR exposure in male TASTPM mice (Burroughs, 2010). Unfortunately, 
immunoblotting data for HSF1 levels in female TASTPM mice was not obtained 
due to lack of material. 
It is particularly interesting that levels of HSP27 and P-HSP27 were significantly 
increased in both male and female TASTPM mice exposed to chronic IR1072; 
as HSP27 in large oligomeric forms is a capable chaperone, whilst able to also 
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stabilise the actin cytoskeleton and more importantly act as a potent anti-
apoptotic molecule via inhibiting a number of pathways including FAS-mediated 
cell death, see figure 1.12 (Samali et al., 2001). Due to its small sized tetramers 
phosphorylated HSP27 is able to shuttle between the nucleus and the 
cytoplasm, targeting cellular aggregates toward the ubiquitin removal system, 
aiding cellular defence against aggregate accumulation (Lanneau et al., 2010). 
HSP27 has also been shown to interact with hyperphosphorylated tau and 
target it for dephosphorylation by phosphatases (Koren et al., 2009, Shimura et 
al., 2004), a potential mechanism for the observed trend towards reduced 
phosphorylated tau in both male and female mice chronically exposed to 
IR1072. Interestingly, increased HSP27 expression has previously been 
reported in human fibroblasts following LLLT (400-2000 nm). This increase was 
accompanied by increased release of the anti-apoptotic proteins Bcl-2 and BCL-
XL (Frank et al., 2004). These data support a neuroprotective role for increased 
HSP27 levels found in TASTPM mice chronically exposed to IR1072. 
Chronic IR treatment of female TASTPM mice also resulted in the increase in 
levels of HSP70 and HSP105, with a reduction in αB crystallin levels. Previous 
work utilising LLLT at both 623.8 and 815 nm has also been shown to induce 
increased HSP70 expression. Investigations by Novoselova, (2006) found that 
even brief LLLT at 632.8 nm resulted in a pronounced increase in HSP70 
expression in macrophages and lymphocytes, modulating immune system 
function (Novoselova et al., 2006). Work by Souil, (2001) demonstrated that NIR 
at 815 nm significantly increased the expression of HSP70 in rat skin. In areas 
of wounding that were irradiated, increased HSP70 expression was found to 
persist for seven days following initial IR exposure, and the irradiated wounding 
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areas displayed improved tissue regeneration and healing (Souil et al., 2001). 
These data suggest that following the initial LLLT, resulting in chaperone 
upregulation, may in turn trigger into action the cell’s own mechanisms and 
alleviate stress in a long term manner. 
Therefore, it is perhaps not surprisingly that chronic IR1072 exposure resulted 
in increased HSP70 expression in female mice. Increased HSP70 has also 
been shown to protect against neuronal injury (Yenari et al., 1999, Yenari et al., 
2005). As well as the capacity to refold misfolded proteins, HSP70 has the 
ability to direct proteins toward the ubiquitin system via CHIP and BAG-1 that 
cannot be refolded, such as Aβ (Lanneau et al., 2010). Indeed, extracellular 
HSP70 has been reported to remove Aβ in senile plaques via microglial driven 
phagocytosis (Evans et al., 2006, Kakimura et al., 2002), as well as preventing 
the aggregation of Aβ in the cytosol (Koren et al., 2009, Magrane et al., 2004). 
Upregulation of HSP70 has previously been shown to reduce Aβ levels, 
deposition, and Aβ-induced neurotoxicity (Hoshino et al., 2011). The beneficial 
effects of HSP70 are not limited to Aβ, it has also been shown to bind 
hyperphosphorylated tau, prevent its oligomerisation and direct it towards 
degradation (Patterson et al., 2011, Voss et al., 2012). These roles for HSP70 
and its increased expression in female TASTPM mice chronically exposed to 
IR1072, provide another potential explanation for the simultaneous reduction in 
Aβ(1-42) and P-tau. 
Increased HSP105 levels were also found in female TASTPM mice chronically 
exposed to IR1072 compared to sham-treated controls. HSP105, as detailed in 
chapter 1.3.5, has been shown to negatively regulate the chaperone refolding 
capabilities of HSC70/HSP70 through hydrolysing ATP, forcing HSC70/HSP70 
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to act as a ‘holding’ chaperone with a much higher substrate affinity. By 
increasing binding time, the chance of the protein refolding correctly the first 
time of binding is increased (Yamagishi et al., 2004, Yamagishi et al., 2003, 
Yamagishi et al., 2000). HSP105 can also induce HSP70 expression via 
STAT3, independent of HSFs (Saito et al., 2009). As well as indirectly inducing 
neuroprotective mechanisms via HSP70, HSP105 has also been shown to 
suppress aggregate formation itself, to maintain tau in an unphosphorylated 
state, with HSP105 downregulation reported to increase Aβ(1-42) production and 
deposition (Eroglu et al., 2010, Yamagishi et al., 2010). 
During ageing of the TASTPM mice, levels of TARP γ2 were found to drop at 7 
months of age and at 12 months of age, compared to mice at 3 months of age. 
This may explain a number of the behavioural and developmental problems 
described in the TASTPM model (Pugh et al., 2007). It was also interesting to 
find that female TASTPM mice demonstrated a significant increase in levels of 
TARP γ2 following chronic IR1072 exposure, whereas male mice showed no 
significant change, again this data suggest influence of LLLT over LTP, as 
discussed in Chapter 5, a promising secondary effect of chronic irradiation. 
Increased levels of TARP γ2 may improve some of the behaviour alterations 
observed in the TASTPM strain. TARP γ2 has also been proposed to decrease 
the rate of AMPA receptor desensitisation and increase the recovery rate from 
desensitisation, as well as increase AMPA receptor trafficking to both the cell 
surface and importantly the synapse. This increase in TARP γ2 may act to 
compensate for neurodegeneration or reverse some of the downregulation of 
AMPA receptors found to occur in Alzheimer’s disease which is thought to 
contribute to cognitive decline which characterises the disease progression (Liu 
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et al., 2010). As mentioned in chapter 5, investigation of GluA1 and GluA2 
levels would be beneficial to comprehend the impact of IR1072 on LTP and 
LTD. 
Another factor to consider is whether gender differences in hormone levels 
affect heat shock protein levels, it has previously been established that basal 
levels of HSP expression differ between male and female rodents. Female rats 
have been shown to have decreased HSP27 and HSP90 levels in both muscle 
and heart tissue whilst increased levels of HSP60 and HSP70 in the kidney and 
heart respectively, compared to male rats (Voss et al., 2003). Despite little 
investigation of gender differences in protein expression in the brain, these data 
suggest that basal expression differences are possible, leading to differing 
effects on expression levels following IR1072 exposure. It is important to 
consider that hormones may have an important impact on the biological effects 
of NIR at IR1072 and this is an important factor to investigate in the future. 
Data shown in figures 6.23 - 6.30 are respiratory studies of mitochondria 
(Complex I and II) isolated from age-matched female and male TASTPM mice 
which have not been exposed to IR. It was somewhat surprising to find that 
female mice displayed consistently increased Complex I and Complex II activity 
in both liver and brain mitochondria, compared to male counterparts. The 
respiratory control index (RCI) for Complex I was significantly higher in both 
liver and brain mitochondria, although values for males were high enough for 
the mitochondria to be considered sufficiently coupled (see table 4.9; Campello 
et al., 1964). These data suggest that certain ETC components are more tightly 
coupled to the mitochondrial membrane in female mice and that their 
mitochondrial activity is significantly higher than males and potentially more 
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efficient. More tightly coupled membranes are less likely to produce a greater 
number of damaging free radicals, due to increased activity levels. As 
discussed previously, electron transport chain components are considered to be 
the primary site for absorption of NIR (Gao and Xing, 2009, Karu, 1999, Karu et 
al., 2004, Karu et al., 2005), therefore investigating the level of mitochondrial 
respiratory activity in TASTPM mice may provide an understanding as to the 
secondary effects of NIR absorption. Significantly higher respiratory rates in 
female over male TASTPM mice may mean that female mice are able to absorb 
a greater quantity of IR1072 and are more susceptible to the biological effects 
of NIR absorption. The redox state of cells has previously been shown to be 
important in magnitude of biological effects following NIR, more reduced cells 
are more susceptible to the effects of NIR (Gao and Xing, 2009, Karu, 1999, 
Karu, 2008). With a greater number of electrons available, Complex I and II are 
able to be more active. It can therefore be hypothesised that as female 
mitochondria have more active Complex I and II respiratory rates than males, 
their cells are in a more reduced state and therefore more susceptible to LLLT 
which is why the magnitude of effects, on the proteins investigated here, 
following chronic IR1072 irradiation in female TASTPM mice appear to be 
significantly greater than in chronically irradiated male TASTPM mice. 
These data suggest a plethora of mechanisms and proteins that could be 
involved in the reduction of APP, Aβ(1-42) and P-tau observed in this mouse 
model of Alzheimer’s disease following chronic IR1072 exposure, and 
endogenous mitochondrial ETC complex activity may play a key role in 
determining the magnitude of these effects. 
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The next chapter investigates the effects of IR1072 exposure on Caenorhabditis 
elegans, a well-characterised animal model of ageing. This chapter is designed 
to determine whether IR1072 exposure has an effect on C. elegans lifespan 
longevity, and whether these effects can be magnified with alternate IR1072 
exposure protocols. Most importantly, C. elegans is used to aid in the 
determination of proteins/pathways that underpin the observed beneficial 
biological effects reported in the mouse model systems previously investigated 
in this thesis.  
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Chapter 7: Using Caenorhabditis elegans to understand IR1072 
 
7.1 Introduction 
Work with the nematode Caenorhabditis elegans was adopted in order to aid in 
the elucidation of the molecular mechanism through which IR1072 elicits its 
biological effects and to determine signalling/molecular pathways that are 
critical for these effects. The nematode was also used in order to establish 
whether IR1072 could also modulate a further biological system than those 
previously investigated. 
 
7.1.1 Anatomy and Life cycle 
The nematode Caenorhabditis elegans was the first model system to show that 
a single gene mutation was able to extend lifespan. From the identification of 
this age-1 gene mutation in the 1980’s (Friedman and Johnson, 1988a), C. 
elegans has become a well used and thus well characterised, model for the 
study of ageing. The nematodes are comprised of only 959 somatic cells, 
enclosed by a sturdy but flexible external structure called the cuticle. 
Nematodes are able to move through striated muscle fibres attached to the 
cuticle, food is taken in through the mouth, compressed and pumped by the 
pharynx into the intestine, which runs the entirety of the nematode. C. elegans 
are typically grown on agar plates with a lawn of bacteria to act as a food 
source, but they can be grown axenically, in liquid culture media or on agar 
plates (Hobert, 2005, White et al., 1986). 
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Adult nematodes are either male of self-fertilising hermaphrodites, however 
hermaphrodites are unable to cross-fertilise with other hermaphrodites. Males 
typically comprise a very small fraction (~0.1%) of the offspring from 
hermaphrodites, and are different in appearance to hermaphrodite nematodes, 
see figure 7.1 (Johnson, 2003). 
 
 
Figure 7.1. Differences between hermaphrodite and male C. elegans (Zarkower, 2006) 
 
C. elegans have a very short life span, with a life cycle consisting of four larval 
stages, termed L1-L4 (see figure 7.2), on average, a nematode lifespan is 18-20 
days when grown at 20°C, reaching 25-30 days when grown at lower 
temperatures, such as 10-14°C on agar plates. At 25°C the average lifespan of 
nematodes drops to between 7-11 days (Johnson, 2003, Klass, 1977). 
Development occurs relatively quickly with eggs able to develop into 
reproductive adults after three days at 25°C. Reproduction is largely finished by 
the fifth day of adulthood, but is completely ceased by day 10 of adulthood; on 
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average each hermaphrodite can lay 300 eggs during their reproductive period 
(Johnson, 2003, Klass, 1977, Olsen et al., 2006b). 
 
 
Figure 7.2. Stages of C. elegans development (Wood, 1988). 
 
C. elegans are a particularly distinguished model in which to study ageing. Their 
lifespan is able to be easily modulated through the use of genetic manipulation; 
a significant number of mutations have already been identified in C. elegans 
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which alter the rate of ageing, some mutations have been shown to extend 
lifespan by three or four times that of wild-type nematodes. Lifespan can also be 
significantly extended via environmental influences such as temperature, diet, 
reproduction and oxygen levels (Riddle, 1997). The aims of using a relatively 
simple model, such as C. elegans, are to help understand human ageing and 
how this process increases risk of certain diseases such as neurodegenerative 
disorders. 
 
7.1.2 Advantages and Disadvantages in Investigating Neurodegenerative 
Disorders 
The nervous system of C. elegans has been extensively studied. It consists of 
302 neurons and 56 glial cells. There are 118 classes of neurons in the adult 
hermaphrodite, the position of which is reproducible from nematode to 
nematode (Hobert, 2005, White et al., 1986). This lack of variation has enabled 
the positions and connectivity of approximately 6000 synapses, 700 gap 
junctions and 2000 neuromuscular junctions to be established, with 
approximately 57,000 interconnections mapped in total (Chalfie and Jorgensen, 
1998, Schafer, 2005, White et al., 1986).  
In comparison to vertebrate system which contains billions of neurons, the 
nematode C. elegans possesses a relatively small, well characterised nervous 
system in which to study molecular and cellular processes. C. elegans have 
enabled the identification of a number of proteins involved in the development of 
nervous system function, pharmacological mechanisms of action of 
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psychotropic drugs and a significant amount of data about genes involved in 
ageing and longevity (Kenyon, 2010, Riddle, 1997, Schafer, 2005). 
The C. elegans nervous system shares a number of similarities with that of 
vertebrates including the neurotransmitters that are present. Glutamate acts in 
the nervous system, monoamines act as modulatory neurotransmitters, with 
acetylcholine acting as the major excitatory neurotransmitter at neuromuscular 
junctions and GABA as the major inhibitory neurotransmitter. However, there 
are a number of differences between the vertebrate and nematode nervous 
systems; neurons are more simple, with each usually only having one process 
and they lack postsynaptic specialisations seen in vertebrates. It also appears 
that the majority of cellular connections occur via gap junctions (Chalfie and 
Jorgensen, 1998). It is important to note that C. elegans lack genes encoding 
voltage-gated sodium channels, and therefore action potentials are thought to 
rely on voltage-gated calcium channels and graded potentials in order to initiate 
neuronal signalling, unlike the vertebrate system. However, C. elegans do 
express motor neurones, sensory neurones and interneurons (Chalfie and 
Jorgensen, 1998, Sawin et al., 2000) and 42% of human disease related genes 
have a nematode orthologue (Culetto and Sattelle, 2000). 
Synaptic connectivity is very different in C. elegans to the human brain, an 
example being behavioural alterations following the loss of dopamine neurons. 
In the nematode, the loss of dopaminergic neurons increase the motor activity 
so much that the nematodes are unable to slow down to eat, the opposite of 
which occurs in Parkinson’s disease (Jorgensen, 2004, Wolozin et al., 2011). 
Considerable understanding of neuronal connectivity has been gained through 
extensive mapping of connections in the nematode system. However, the 
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electron microscopy data does not give functionality, i.e. synaptic 
neurotransmitter specificity and whether these are excitatory or inhibitory. Work 
is underway to provide further detail to this extensive mapping; regarding 
behavioural, neurochemical and activity mapping. Therefore despite defining C. 
elegans as a ‘well characterised model of ageing’ a significant amount remains 
unknown (Riddle, 1997, Schafer, 2005). 
There are many advantages and disadvantages to using C. elegans in ageing 
research. The nematodes are essentially cheap and easy to propagate, they 
display no apparent ill-effects of inbreeding, their genome has been completely 
sequenced and the development of each individual worm is almost identical. 
Strains are also able to cryogenically stored for long periods of time, with no 
observable detrimental effects. Nematodes are short lived, making them an 
ideal model to investigate processes/genes involved in ageing. Their lifespan 
has been shown to be dramatically modified following the mutation of genes 
implicated in the ageing process such as daf-2 and daf-16 (nematode 
equivalents to the insulin receptor and FOXO (Forkhead Family Box O) 
transcription factor, respectively), both part of the first metabolic process 
discovered to regulate ageing. Signalling from the DAF-2 receptor to the DAF-
16 transcription factor has been shown to control longevity and metabolism, 
with mutations in daf-2 extending lifespan (Dorman et al., 1995, Lee et al., 
2003). The primary role of daf-2 is to negatively regulate DAF-16, which is 
important during normal development of the nematode but in the adult; 
reducing/removing daf-2 activity enables DAF-16 to increase longevity to up to 
three fold that of a wild-type nematode (Kenyon, 2011, Kenyon, 2010, Ogg et 
al., 1997). DAF-16 is the primary downstream effector of daf-2 signalling, with 
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DAF-16 able to enter the nucleus and effect the expression of a number of 
genes, including hsf-1. It has also been identified that HSF1 is required for daf-2 
mutations to extend lifespan, suggesting that DAF-16 and HSF1 act together to 
activate genes, including those for heat shock proteins, to result in this effect 
(Hsu et al., 2003). 
There are however, disadvantages in using C. elegans as a model system, 
particularly when using the nematode as an investigative tool to further 
understand human ageing. Major differences stem from the large evolutionary 
separation of nematodes from mammals. Nematodes are invertebrates; 
possess no circulatory system, nor immune system. However they do display 
declining physiological processes with age including reproductive senescence, 
reduced movement, defection frequency, pharyngeal pumping, sperm number 
and loss of tissue integrity (reviewed - Huang et al., 2004). Nematodes have 
four defined stages of ageing, Stage I – progeny production, from L4 stage to 
the end of the self-fertilisation period; Stage II – post-reproductive period, 
vigorous movement; Stage III – reduced motor activity; Stage IV – minimal 
motor activity, cessation of pharyngeal pumping until the end of lifespan (Huang 
et al., 2004). These features, along with lifespan analysis, enable 
comprehension of phenotype generation through manipulation of particular 
genes/proteins in the ageing process (Johnson, 2003, 2008, Klass, 1977). 
Gene expression can be readily modified in C. elegans, through generation of 
knock down strains, RNAi (RNA interference) or gene deletion. The use of RNAi 
in C. elegans is a powerful method to study the genome of the organism. RNAi 
functions to inactivate specific genes through propagating the nematode on E. 
coli lawns which express double stranded RNA, analogous to genes under 
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investigation, which are then able to post-transcriptionally silence expression of 
the target gene, it has however not been shown to be successful for every 
gene. Through this method, interaction of nematode chaperones with certain 
substrates has been investigated, including in several mutant nematode strains 
that express the β-amyloid peptide (Fonte et al., 2002, Kapulkin et al., 2005, 
Olsen et al., 2006b). 
Many studies have found that mutations attributed to human disease display 
similar types of dysfunction when induced in C. elegans. Despite approximately 
one third of genes in mammals having no homologues in nematodes, cross-
species translation of function is thought to derive from high levels of homology 
in functional domains which are often hidden through apparent low-level total 
protein homology (Johnson, 2003, Olsen et al., 2006b, Wolozin et al., 2011). 
Another difficulty is biochemical analysis of individual nematodes; due to their 
small size (adults are approximately 1 mm in length), individually they do not 
provide a great deal of material to assay and thus large quantities are required. 
The thick cuticle can also prove difficult to penetrate and bacterial colonisation 
of the gut can result in sample contamination. These factors make biochemical 
analysis of individual nematodes particularly difficult. But the transparent nature 
of the nematodes enables in vivo study of fluorescently tagged proteins in great 
depth. As well as this, C. elegans can be used in electrophysiological and 
pharmacological investigation. Patch-clamping is particularly difficult; again due 
to the tough nature of the cuticle, but via the use of embryonic C. elegans cells 
in culture, many obstacles faced with adult nematodes can be overcome 
(Bianchi and Driscoll, 2006, Johnson, 2003). 
 
284 
Nematodes represent a superb platform for preliminary screening of putative 
therapeutic medications before moving into transgenic mammals. C. elegans 
are a particularly useful model in identification of genes and molecular 
mechanisms involved in ageing, providing they are conserved. The simplicity of 
the nematode and the ability to genetically manipulate the organism makes it a 
valuable stepping stone, bridging the gap between the simplicity of in vitro 
studies and the complexity of the human brain (Wolozin et al., 2011). 
Providing IR1072 has an effect in C. elegans, the nematodes also provide a 
suitable system to aid in investigating the essential pathways for biological 
effects responsible for the absorbance of IR1072. Providing IR1072 had 
beneficial effects, another aim of this investigation was to begin to look at 
absorbance profiles of protein fractions from C. elegans to help identify where 
the primary photoacceptor may lie and to verify whether profiles obtained with 
nematodes had commonalities with mammalian absorbance profiles. 
 
7.1.3 C. elegans and Heat Shock Proteins 
Expression of specific proteins in C. elegans in response to heat stress was first 
reported by Snutch & Baillie in 1984. It was found that C. elegans express a 
range of heat shock proteins, spanning in molecular weights from 16-81 kDa, 
which have been defined to include HSP19, HSP25, HSP29, HSP38, HSP41, 
HSP81 and members of the HSP16, HSP60 and HSP70 families (Heschl and 
Baillie, 1989, Snutch and Baillie, 1984). 
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C. elegans have a highly conserved HSP70 family. This family is made up of 
constitutively expressed, inducible and pseudogenes with a minimum of nine 
proteins transcribed across at least three subfamilies (Heschl and Baillie, 1989). 
The molecular structure of HSP70 in C. elegans has high homology with the 
Dnak equivalent in E. coli, both molecules have a C-terminal substrate binding 
domains and a highly conserved ATP binding domain at the N-terminus, much 
the same as mammalian HSP70, and are expressed in the mitochondrion, 
endoplasmic reticulum lumen and cytoplasm (Heschl and Baillie, 1989, Yenari 
et al., 1999). 
Another extensively studied HSP family is the non constitutively expressed 
HSP16. The proteins within this family are related to the mammalian α-crystallin 
small heat shock protein family, so far four different genes which encode 
HSP16 family members have been identified, HSP16 expression is thought to 
be dependent upon exposure to heat stress (Dawe et al., 2006, Stringham et 
al., 1992). It is also interesting that accumulation of HSP16 has been observed 
with age of the nematode, and at particularly high concentrations in long-lived 
age-1 mutant strains. Mutations in age-1 render nematodes resistant to heat 
shock and have reported to cause up to a 65% increase in mean lifespan. The 
age-1 gene acts downstream of daf-2 in the insulin-like signalling pathway and 
encodes the nematode equivalent of mammalian catalytic subunit of PI3K 
(Friedman and Johnson, 1988a, b, Morris et al., 1996), emphasising the 
possibility for molecular chaperones to act as promoters of longevity (Walker 
and Lithgow, 2003).  
C. elegans provide a useful model to investigate function of chaperone 
inscribed genes, as knockout mouse models of chaperone genes have been 
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shown to produce models with minimal phenotypes considering the broad role 
of chaperones in cellular processes and maintenance. This leads to the idea 
that the mammalian system has compensatory mechanisms in place to cope 
with a degree of chaperone deficiency, although these are yet to be defined.  
Heat shock proteins have been shown to be important in longevity in C. elegans 
as well as mammals. Over expression of chaperones, including HSP70 and 
HSP16 family members, result in increased lifespan. Indeed early stress to 
induce higher endogenous levels of HSPs, results in the improved ability of the 
nematode to withstand stress in later life and therefore increase survival rates 
(Leitz et al., 2002, Lithgow et al., 1995, Olsen et al., 2006a, Wu et al., 2009). 
Silencing of hsf-1 expression, which is required to bind to the HSE in order to 
induce HSP production (see figure 1.11), results in decreased longevity 
(Garigan et al., 2002, Morley and Morimoto, 2004, Olsen et al., 2006a, b). 
Lifespan extension by HSF1 over-expression has also been reported to function 
together with the transcription factor DAF-16 to activate a subset of genes, 
including those that express for sHSPs, which are ultimately responsible for 
longevity (Hsu et al., 2003). 
These data show C. elegans to be an appropriate translational model to 
investigate disease and could provide important insights into chaperone 
function in ageing with the ability to use such technologies as RNAi to deftly 
target specific genes and thus potential compensatory mechanisms. 
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7.2 Results  
7.2.1 Initial Exposure Protocol 
All strains used in this investigation and their associated mutations are defined 
in table 2.2. 
Prior to the use of C. elegans to investigate the molecular mechanism of IR1072 
action, it needed to be established whether IR1072 has a clear effect on the 
nematode. Lifespan analysis was used as a measure of animal wellbeing. All 
lifespans were analysed as described in 2.9.5., utilising the Kaplan-Meier 
survival model, with statistical significance determined using Log-Rank and 
Wilcoxon analysis.  
Initial experiments were conducted using SS104, glp-4 (bn2)I, strain. 
Nematodes were shifted from 15°C to 25°C, to induce sterility, when nematodes 
reached L3/L4 stage (see figure 7.2) and lifespan experiments were started 24 
hours after this shift, when nematodes were young adults. Equipment was as 
described in figure 2.4, and 2.9.1, with the treatment protocol as described in 
2.9.2. 
Preliminary experiments using 35 mm plates are shown in figure 7.3 and 7.4. 
Figure 7.3 identified non-significant change in lifespan for SS104, glp-4 (bn2)I, 
when exposed to IR1072 for three minutes or six minutes, compared to sham 
treated controls. However, 12 minute exposure protocol resulted in an 11% 
increase in lifespan, significantly extending lifespan of the nematodes exposed 
to IR1072 compared to sham treated controls, detailed in figure 7.4 and table 
7.1. 
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The experimental protocol 2.9.3, was conducted using 60 mm agar plates (to 
avoid drying) and to identify whether the effect would be maintained using an 
alternate treatment protocol, still utilising the SS104, glp-4 (bn2)I, strain. These 
data showed a significant increase in mean lifespan, 16%, for the nematodes 
exposed to IR1072 for 12 minutes, compared to sham treated controls. Figure 
7.5 combines data from two individual experimental repeats, see table 7.12 for 
individual repeat data. 
Protocol 2.9.3 was conducted using the N2, C. elegans wild isolate. These data 
show a significant increase in mean lifespan, 13%, for the nematodes exposed 
to IR1072 for 12 minutes, compared to sham treated controls. Figure 7.6 
combines data from two individual experimental repeats, see table 7.12 for 
individual repeat data. 
Following the discovery of a consistent increase in lifespan in SS104, glp-4 
(bn2)I, nematodes exposed to IR1072, it was important to determine whether 
this longevity was due to a direct effect of IR1072 on the nematode or longevity 
was indirectly induced through affecting the bacterial lawn. It has previously 
been determined that proliferating bacteria accumulate in the gut and pharynx 
of nematodes as they age, having an adverse effect on lifespan. Exposure of 
nematodes to aminoglycosides, such as kanamycin, which limit bacterial 
proliferation, have previously been shown to extend nematode lifespan (Garigan 
et al., 2002). However the role of bacterial proliferation in the limitation of 
nematode lifespan is debated. Other researchers demonstrate increased 
lifespan of C. elegans via manipulation of E. coli independently of proliferation 
(Virk et al., 2012). Therefore it was important to determine whether IR1072 was 
reducing bacterial proliferation and thus increasing lifespan. In order to 
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investigate whether the lifespan extension was maintained in the presence of 
kanamycin, as described by Garigan et al (2002), protocol 2.9.3 was repeated 
using SS104, glp-4 (bn2)I, with kanamycin treated-OP50, as described in 2.9.6. 
12 minute IR1072 exposure of nematodes in the presence of a kanamycin-
treated OP50 food source resulted in a 10% extension of the mean lifespan, 
compared to sham treated controls, which were also exposed to kanamycin 
treated-OP50. Data shown in Figure 7.7, combines two lifespans analyses, for 
individual lifespan data, see table 7.12 (Garigan et al., 2002). 
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Figure 7.3. Lifespans of SS104, glp-4 (bn2)I, nematodes exposed to 12 minute, 6 minute or 3 
minute IR1072 exposures and sham-treated controls. 
 IR1072 Treatment Condition 
 3 Minute 6 Minute 12 Minute 
 Sham IR Sham IR Sham IR 
Total number 
of worms 
81 109 90 78 93 85 
Total died 66 102 86 72 92 73 
Total censored 15 7 4 6 1 12 
Mean 13.224 11.714 12.735 12.567 11.717 12.949 
Standard Error 0.620 0.262 0.326 0.418 0.293 0.458 
Log-rank *0.035 0.989 *0.026 
Wilcoxon 0.194 0.340 0.088 
 
Table 7.1. All data refers to figure 7.3, all lifespans were carried out at 25°C. 
0 
0.1 
0.2 
0.3 
0.4 
0.5 
0.6 
0.7 
0.8 
0.9 
1 
0 2 4 6 8 10 12 14 16 18 20 22 24 26 
S
u
rv
iv
a
l 
Day 
3 Minute Sham 
3 Minute IR 
6 Minute Sham 
6 Minute IR 
12 Minute Sham 
12 Minute IR 
 
291 
 
Figure 7.4. Lifespans of SS104, glp-4 (bn2)I, nematodes exposed to IR1072 for 12 minutes and 
sham-treated controls, from figure 7.3. 
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Figure 7.5. Lifespans of SS104, glp-4 (bn2)I, nematodes exposed to IR1072 as described in 
2.9.3, and sham treated controls, n=2 repeat lifespans. 
 
 IR1072 Treatment Condition 
 Sham IR Exposed 
Total number of worms 405 342 
Total died 394 316 
Total censored 11 26 
Mean 14.789 17.165 
Standard Error 0.234 0.311 
Log-rank *<0.001 
Wilcoxon *<0.001 
 
Table 7.2. All data refers to figure 7.5, all lifespans were carried out at 25°C. 
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Figure 7.6. Lifespans of N2, C. elegans wild isolate nematodes exposed to IR1072 as 
described in 2.9.3, and sham treated controls. 
 
 IR1072 Treatment Condition 
 Sham IR Exposed 
Total number of worms 90 70 
Total died 51 48 
Total censored 39 22 
Mean 15.034 16.975 
Standard Error 0.665 0.820 
Log-rank 0.071 
Wilcoxon 0.176 
 
Table 7.3. All data refers to figure 7.6, all lifespans were carried out at 25°C. 
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Figure 7.7. Lifespans of SS104, glp-4 (bn2)I, nematodes exposed to IR1072 as described in 
2.9.3, and sham treated controls, conducted on kanamycin-treated OP50, n=2 repeat lifespans. 
 
 IR1072 Treatment Condition 
 Sham IR Exposed 
Total number of worms 431 373 
Total died 407 365 
Total censored 24 8 
Mean 19.981 21.964 
Standard Error 0.228 0.256 
Log-rank *<0.001 
Wilcoxon *<0.001 
 
Table 7.4. All data refers to figure 7.7, all lifespans were carried out at 25°C. 
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7.2.2 Bacterial Viability 
Bacterial proliferation in the intestine of C. elegans has been suggested to be a 
cause of death in the nematode although this is debated, as detailed previously 
(Garigan et al., 2002, Virk et al., 2012). Therefore, in order to determine 
whether IR1072 was effecting bacterial proliferation and resulting in increased 
longevity, the viability of OP50 was determined following IR1072 exposure, with 
kanamycin acting as a positive control. The method followed was described as 
in 2.9.1 and 2.9.2. 
Control plates showed no significant difference in quantity of colony forming 
units (CFUs) (x108) (n=12, 19.730 ± 0.775) compared to IR-treated plates 
(n=12, 19.650 ± 0.425). However, kanamycin-treated plates showed a 
significant reduction in the quantity of CFUs (n=12, 15.330 ± 0.609, ***p<0.001) 
compared to both control and IR treated plates. 
CFUs were analysed using a one-way ANOVA with a Bonferroni’s multiple 
comparison post test. Data shown represents mean ± SEM.  
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Figure 7.8. A column graph to show IR1072 exposure has no significant effect on bacterial 
viability. Mean values ± SEM. A significant reduction in viability was found for kanamycin –
treated bacteria (***p<0.001) compared to control and IR1072 treated bacteria. All other 
comparisons were non-significant. 
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7.2.3 Alternate Exposure Protocol 
An important potential theory for lifespan extension for C. elegans, which 
warranted further investigation, was the concept that repeated mild heat 
treatments may be the cause of increased longevity. Despite lifespans being 
conducted in temperature controlled incubators, it was possible that the heating 
of the LED array during 12 minute exposures would cause mild heating of the 
nematodes. Repeated mild heat stress in has been reported to result in a 
significant extension of lifespan in C. elegans (Leitz et al., 2002, Lithgow et al., 
1995, Wu et al., 2009), with particular extension when exposed at L4 stage 
(Olsen et al., 2006a). Work by Olsen, 2006, identified that temperature shifting 
nematodes for several hours on consecutive days significantly increased their 
lifespan, utilising two strains with GFP-tagged promoters of heat shock proteins 
heat stress was shown to increase the activity of these promoters (Olsen et al., 
2006a). Small temperature rises, as little as 2.5 °C, using microwaves, have 
also been reported to induce expression of heat shock proteins. Rises from 25 
to 27.5°C have been shown to directly result in induction of HSP16 expression, 
although the mechanism of this action has been shown to be complex (Dawe et 
al., 2006) and the power ratings the nematodes were exposed to are up to fifty 
times greater (Leitz et al., 2002) than the beneficial range established for 
infrared light (Hamblin and Demidova, 2006). 
In order to investigate this theory, a thermocouple (copper/copper-nickel, type 
T. Detailed within appendix II) was used to measure temperature change in 
agar plates before, during and after the 12 minute exposure period. It was found 
that a 3°C change in temperature occurred during this time, as shown in figure 
7.9. The standard fitted cooling fans were sufficient to maintain temperature for 
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approximately six minutes, but after this time the temperature of the equipment 
was not able to be sufficiently counteracted by the fans. Therefore a third 
treatment protocol was started. 
It was decided that in order to remove any potential for the increased lifespan to 
be due to temperature, the exposure timings required changing. Via the use of 
the thermocouple, several short treatment times were investigated which would 
reduce the time the equipment was on, eliminating heating. In order to perform 
this change in protocol, more sophisticated methods of altering the timings of 
the LED array were required. Previous work had utilised timer plugs, however at 
this point a computer programme was written using LabVIEW™ (National 
Instruments, Texas, USA) which enabled control of on/off cycle of the array 
using a USB-controlled relay interface (Phidgets, Inc. USA) in conjunction with 
the set-up of a permanent thermocouple within the temperature controlled 
incubator. The LabVIEW™ programme was also configured to measure the 
electrical current across the thermocouple every second. This enabled the 
internal temperature of the agar plates to be continually monitored. Utilising this 
technology, multiple short cycle timings could be easily investigated and 
manipulated. Many timing ratios were investigated to identify timings which did 
not result in a measurable change in temperature during the ‘on’ period of the 
LED array, a number of these timings are shown in figures 7.9 – 7.13. However 
as is evident in the figures, many of these resulted in considerable rises in 
temperature. Shorter timing periods were investigated that did not cause a 
recordable rise in temperature. However, when a number of these were carried 
forward to lifespan protocol; the longevity effect was not always maintained, an 
example shown in figure 7.12, with the lifespan data from this protocol shown in 
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figure 7.14 and summarised in table 7.5. Ultimately, the protocol outlined in 
2.9.4 was established, the thermocouple recording from which is shown in 
figure 7.13. 
The treatment protocol was followed as described in 2.9.4 and conducted at 
25°C.  
All lifespans were analysed as described in 2.9.5. Utilising the Kaplan-Meier 
survival model, with statistical significance determined using Log-Rank and 
Wilcoxon analysis. 
Chronic IR1072 exposure on SS104, glp-4 (bn2)I, resulted in a 12% increase in 
lifespan, compared to sham-treated controls, n=3 individual lifespan 
experiments, figure 7.15 shows pooled data. Statistical analysis is shown in 
table 7.6, data is summarised in table 7.12. Therefore it was established that 
the new exposure protocol maintained the increased longevity previously 
observed, however in a moderately weaker form. 
In order to understand the pathways through which the lifespan effect was 
occurring several mutants were investigated. As previously mentioned, 
mutations in the insulin/insulin-like growth factor pathway extend lifespan but 
functional DAF-16 is required for that effect (Lee et al., 2003). Therefore to 
determine whether the IR1072-induce longevity occurred via a DAF-16 
dependent pathway, lifespans were conducted with a daf-16 mutant nematode. 
Chronic IR1072 exposure on GR1307, daf-16 (mgDf50) I, had no significant 
effect on lifespan compared to sham-treated controls, n=2 individual lifespan 
experiments, figure 7.16 shows pooled data. Statistical analysis is shown in 
table 7.7., data is summarised in table 7.12. 
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As the lifespan effect appeared to be dependent on functional DAF-16, it was 
decided to investigate one of the major downstream effectors of DAF-16, HSF1. 
This enabled investigation of more specific proteins required for the IR1072-
induced increase in longevity. Lifespan studies were conducted using a strain 
with mutated hsf-1. Chronic IR1072 exposure on PS3551, hsf-1(sy441) I, had 
no significant effect on lifespan compared to sham-treated controls, data shown 
in figure 7.17. Statistical analysis is shown in table 7.8 and table 7.12. 
Despite the C. elegans expressing a number of homologues to mammalian 
chaperones, it is not possible to investigate the specific roles of a number of 
these proteins as knockout of the genes proves lethal. The nematode 
equivalent to mammalian HSP70, HSP3, however was able to be investigated 
and is a protein of interest considering its significant role in a number of 
important homeostasis processes and the identification of it’s consistent 
upregulation following IR1072 exposure in murine studies. Chronic IR1072 
exposure on RB1104, hsp-3 (ok1083) X, had no significant effect on lifespan 
compared to sham-treated controls, n=3 individual lifespan experiments, figure 
7.18 shows pooled data. Statistical analysis is shown in table 7.9., data is 
summarised in table 7.12. 
Chronic IR1072 exposure on N2, C. elegans wild isolate, resulted in a 10% 
increase in lifespan compared to sham-treated controls, n=2 individual lifespan 
experiments, figure 7.19 shows pooled data. Statistical analysis is shown in 
table 7.10., data is summarised in table 7.12. 
Previously it has been discussed that the primary photoacceptor for infrared 
light lies within the mitochondria. Therefore it was decided to investigate 
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whether IR1072 exposure was damaging to the nematode mitochondria. A 
mutant strain was investigated which expressed HSP6 under a GFP promoter. 
HSP6 is a mitochondrial specific heat shock protein expressed at the onset 
damaging mitochondrial stress (Benedetti et al., 2006). Chronic IR1072 
exposure on SJ4100 [zcIs13 hsp-6::gfp], resulted in an 8% increase in lifespan 
compared to sham-treated controls, but no change in GFP expression (data not 
shown). Lifespan shown in figure 7.20 shows, statistical analysis is shown in 
table 7.11., data is summarised in table 7.12.  
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Figure 7.10. Data shown to represent the temperature change found when investigating a novel 
IR1072 protocol. Data shown is three minutes on, followed by three minutes off. This resulted in 
a 2°C change in temperature. 
 
Figure 7.11. Data shown to represent the temperature change found when investigating a novel 
IR1072 protocol. Data shown is one minute on, followed by one minute off. This resulted in a 
change in temperature of approximately 0.5°C. 
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Figure 7.12. Data shown is fifty seconds on, followed by 750 seconds off. This resulted in no 
change in temperature and the lifespan extension effect previously observed was eliminated, as 
shown in figure 7.14 and table 7.5. 
 
Figure 7.13. Data shown represents measurements taken during a protocol whereby infrared 
1072 nm was on for 50 seconds and off for 100 seconds. This was carried through to become 
treatment protocol 2.9.4. 
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Figure 7.14. Lifespan conducted using SS104, glp-4 (bn2)I nematodes. Treatment protocol 
used: 50 seconds IR1072 on, followed by 750 seconds off. This was repeated over 24 hours, 
every three days. 
 IR1072 Treatment Condition 
 Sham IR Exposed 
Total number of worms 162 141 
Total died 146 137 
Total censored 16 4 
Mean 15.865 16.557 
Standard Error 0.393 0.423 
Log-rank 0.239 
Wilcoxon 0.237 
 
Table 7.5. All Data refers to figure 7.14, all lifespans were carried out at 25°C. 
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Figure 7.15. A graph to show the effect of treatment protocol 2.9.4 on SS104, glp-4 (bn2)I, 
nematode lifespan compared to sham-treated controls, n=3 repeat lifespans. 
 
 IR1072 Treatment Condition 
 Sham IR Exposed 
Total number of worms 710 730 
Total died 645 665 
Total censored 65 64 
Mean 16.818 18.752 
Standard Error 0.248 0.282 
Log-rank *<0.001 
Wilcoxon *<0.001 
 
Table 7.6. All data refers to figure 7.15, all lifespans were carried out at 25°C. 
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Figure 7.16. A graph to show the effect of treatment protocol 2.9.4 on GR1307, daf-16 
(mgDf50) I, nematode lifespan compared to sham-treated controls, n=2 repeat lifespans. 
 
 IR1072 Treatment Condition 
 Sham IR Exposed 
Total number of worms 510 431 
Total died 447 365 
Total censored 63 66 
Mean 10.829 10.848 
Standard Error 0.183 0.215 
Log-rank 0.833 
Wilcoxon 0.644 
 
Table 7.7. All data refers to figure 7.16, all lifespans were carried out at 25°C. 
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Figure 7.17. A graph to show the effect of treatment protocol 2.9.4 on PS3551, hsf-1(sy441) I, 
nematode lifespan compared to sham-treated controls. 
 
 IR1072 Treatment Condition 
 Sham IR Exposed 
Total number of worms 110 77 
Total died 107 76 
Total censored 3 1 
Mean 11.830 12.370 
Standard Error 0.350 0.430 
Log-rank 0.366 
Wilcoxon 0.304 
 
Table 7.8. All data refers to figure 7.17, all lifespans were carried out at 25°C. 
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Figure 7.18. A graph to show the effect of treatment protocol 2.9.4 on RB1104, hsp-3 (ok1083) 
X, nematode lifespan compared to sham-treated controls, n=3 repeat lifespans. 
 
 IR1072 Treatment Condition 
 Sham IR Exposed 
Total number of worms 599 441 
Total died 364 279 
Total censored 235 162 
Mean 17.066 16.681 
Standard Error 0.229 0.267 
Log-rank 0.242 
Wilcoxon 0.206 
 
Table 7.9. All data refers to figure 7.18, all lifespans were carried out at 25°C. 
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Figure 7.19. A graph to show the effect of treatment protocol 2.9.4 on N2, C. elegans wild 
isolate nematode, lifespan compared to sham-treated controls, n=2 repeat lifespans. 
 
 IR1072 Treatment Condition 
 Sham IR Exposed 
Total number of worms 462 382 
Total died 335 271 
Total censored 137 111 
Mean 20.136 22.167 
Standard Error 0.541 0.610 
Log-rank *0.012 
Wilcoxon *0.010 
 
Table 7.10. All data refers to figure 7.19, all lifespans were carried out at 25°C. 
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Figure 7.20. A graph to show the effect of treatment protocol 2.9.3 on SJ4100, [zcIs13 hsp-
6::gfp], nematode lifespan compared to sham-treated controls. 
 
 IR1072 Treatment Condition 
 Sham IR Exposed 
Total number of worms 164 161 
Total died 145 136 
Total censored 19 25 
Mean 12.753 13.727 
Standard Error 0.365 0.395 
Log-rank 0.056 
Wilcoxon *0.033 
 
Table 7.11. All data refers to figure 7.20, all lifespans were carried out at 25°C. 
  
0 
0.1 
0.2 
0.3 
0.4 
0.5 
0.6 
0.7 
0.8 
0.9 
1 
0 2 4 6 8 10 12 14 16 18 20 22 24 26 28 
S
u
rv
iv
a
l 
Day 
Sham 
IR 
 31
2
 
Table 7.12. A summary table of individual nematode lifespans with are combined in the figures included in Chapter 7: Using Caenorhabditis elegans to 
Understand IR1072. Abbreviations: KAN, kanamycin. 
Strain IR1072 
Protocol 
IR1072 or 
Sham 
Mean 
Lifespan 
(days) 
Total (n=) Dead 
(n=) 
Censor 
(n=) 
% 
Lifespan 
Increase 
Statistical Analysis Figure 
Log-Rank Wilcoxon 
SS104, glp-4 
(bn2)I 
3 mins Sham 13.224 81 66 15 - *0.035 0.194 7.4 
IR 11.714 109 102 7 
6 mins Sham 12.735 90 86 4 - 0.989 0.340 7.3 
IR 12.567 78 72 6 
12 mins Sham 11.717 93 92 1 11 *0.026 0.088 
IR 12.949 85 73 12 
2.9.3 (12 
mins) 
Sham 14.319 211 206 5 11 *<0.001 *0.002 7.5 
IR 15.865 190 188 2 
Sham 15.297 194 188 6 24 *<0.001 *<0.001 
IR 18.888 152 128 24 
2.9.3 + KAN Sham 19.346 205 195 10 11 *<0.001 *<0.001 7.7 
IR 21.386 161 155 6 
Sham 20.558 226 209 17 9 *<0.001 *<0.001 
IR 22.395 212 210 2 
N2, wild type 
isolate 
2.9.3 Sham 15.034 90 51 39 13 0.072 0.176 7.6 
IR 16.975 70 48 32 
  
 31
3
 
SS104, glp-4 
(bn2)I 
2.9.4 (50 
seconds on, 
100 off) 
Sham 16.464 155 147 8 13 *<0.001 *0.003 7.15 
IR 18.671 200 162 38 
Sham 17.937 318 277 41 8 *0.008 *0.020 
IR 19.446 281 270 11 
Sham 16.119 237 233 4 12 *<0.001 *0.004 
IR 18.081 252 217 35 
GR1307, daf-
16 (mgDf50) 
2.9.4 Sham 8.559 262 237 25 - 0.323 0.692 7.16 
IR 8.705 257 214 43 
Sham 13.322 248 210 38 - 0.247 0.654 
IR 13.658 174 151 23 
PS3551, hsf-
1(sy441) I 
2.9.4 Sham 11.830 110 107 3 - 0.366 0.304 7.17 
IR 12.370 77 76 1 
RB1104, hsp-
3 (ok1083) X 
2.9.4 Sham 14.667 157 119 38 - 0.531 0.812 7.18 
IR 14.931 156 116 40 
Sham 17.057 238 141 97 - 0.776 0.937 
IR 17.056 173 106 67 
Sham 19.342 204 104 100 - 0.884 0.272 
IR 19.029 112 57 55 
N2, wild type 
isolate 
2.9.4 Sham 20.136 213 133 80 10 *0.012 *0.010 7.19 
IR 22.167 178 121 57 
Sham 19.684 259 202 57 10 *0.012 *0.010 
IR 21.588 204 150 54 
SJ4100, [zcIs 
13 hsp-6::gfp], 
2.9.4 Sham 12.753 164 145 19 8 0.056 *0.033 7.20 
IR 13.727 161 136 25 
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7.2.4 Absorption Spectra of Nematode Protein Extracts 
Nematode extracts were prepared as described in 2.11, and a Lowry assay 
performed (see 2.3.1). Each sample was then diluted to 1 mg/ml. The 
absorbance spectrum of both soluble protein (supernatant) and insoluble 
protein (pellet) was measured using a Shimadzu spectrophotometer from 1500 
nm to 600 nm. 
Each sample was measured three times and the average absorbance (after 
correction for baseline values) is plotted in figure 7.21. The shaded area in the 
figure refers to the wavelength of light emitted by the 1072 nm LEDs, which 
have a bandwidth of 25 nm. 
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7.3 Discussion 
The aim of this chapter was to determine whether IR1072 has an effect on the 
lifespan on C. elegans and if this occurred, to utilise this model system to 
identify proteins/pathways involved in any lifespan effect. 
These experiments have established that IR1072 exposure of C. elegans is 
able to extend lifespan significantly utilising a range of exposure times. Initial 
experiments, where nematodes were treated every day for 12 minutes over the 
duration of their adult lifespan, was altered to exposure every four hours for 24 
hours, repeated every three days for their adult lifespan; in order to determine 
whether the observed increase in lifespan could be augmented by more 
frequent exposures, which was found to be the case with mean lifespan 
increasing from 11% to 16%. Due to limited equipment availability, repeating 
exposures every three days also allowed for additional lifespans to be 
conducted alongside each other. 
It is important to note that lifespan analyses utilising the Kaplan-Meier survival 
model employ two statistical tests; Log-rank and Wilcoxon. These tests bias 
differences that occur during the survival curve in different manners. The Log-
rank analysis weights differences that occur at the start and end of the survival 
curve equally. However, the Wilcoxon analysis, concentrates on the number of 
nematodes at risk and weights changes that occur at the start of the survival 
curve higher than those that occur later on in the survival curve (Allison, 2010). 
Therefore upon analysis of survival data, it is interesting to note that the degree 
of significance for some lifespans alters when the Log-rank and Wilcoxon 
statistics are compared. The lifespans, initial 12 minute and three minute IR 
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exposures, figure 7.3 and 7.4, are both significant (p<0.05) for Log-rank 
analysis but show trends toward or no significant difference between sham and 
IR exposed groups when subject to Wilcoxon analysis. Therefore, this suggests 
that the initial few exposures of IR1072 are not sufficient to significantly reduce 
the number of individuals which die at the start of the lifespan but when 
accounting for the entire lifespan, the number of individuals surviving throughout 
is significantly greater in the IR exposed condition. In the lifespans that were 
conducted following these initial exposures, the Log-rank and Wilcoxon 
analyses were both significant, this suggest that the repeated nature of protocol 
2.9.4 (50 seconds on, 100 seconds off over 24 hours, repeated every three 
days) is now sufficient to start increasing the lifespan of the nematodes at risk 
after the first sets of exposures. 
It would of interest to investigate whether a single 24 hour exposure set had any 
impact on total lifespan and whether this single set is sufficient to induce a 
steady shift toward increased longevity in C. elegans. The fact that the majority 
of lifespan data displayed highly significant increases in longevity in the IR1072 
exposed condition, when examining both the Log-rank and Wilcoxon statistics, 
repeated, frequent exposures are more effective at increasing lifespan.  
Investigations using kanamycin-treated OP50 bacteria in conjunction with 
exposure to IR1072 have shown that the lifespan extension effect of IR1072 is 
maintained in the presence of kanamycin and IR1072 exposure had no effect 
on bacterial proliferation, shown in figure 7.7 and 7.8 respectively. It was 
therefore determined that the mechanism of action is most likely to occur 
directly via NIR interaction with the nematode directly, rather than extend the 
nematode lifespan via its food source. Verification of this could be achieved 
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through recording pharyngeal pumping rates of sham and IR exposed animals 
as stresses have been shown to reduce pumping rates, causing dietary 
restriction and then increased longevity (Jones and Candido, 1999). 
As detailed in figure 7.9, 12 minute exposure to IR1072 resulted in a 3°C rise in 
temperature in the incubator during this period. As mentioned previously, 
repeated mild heat stress has been reported to extend the lifespan of the 
nematode C. elegans (Leitz et al., 2002, Olsen et al., 2006a). Therefore to 
investigate whether this rise in temperature was sufficient to induce expression 
of chaperone proteins, namely HSP16.2 (αB crystallin homologue), a mutant 
nematode strain with this protein GFP-tagged was used. HSP16 family 
members have been reported to be expressed following temperatures rises of 
2.5°C from 25°C (Dawe et al., 2006) and as HSPs have been shown to be 
manipulated by IR1072 in murine model systems that have been irradiated in 
this investigation, it was of interest to examine whether heating may be 
responsible for the induced lifespan extension effect. 
Strains utilised in the Olsen, 2006, study, CL2070, dvIs70 [hsp-16.2::gfp; rol-
6(su1006)], which expresses HSP16.2 via a GFP-tagged promoter, and 
SJ4005, zcIs4 (hsp-4::GFP), which expresses HSP4, also via a GFP-tagged 
promoter, were exposed to IR1072 using the same protocol as describe in 2.9.4 
for 12 days and GFP-levels regularly monitored by eye, utilising a Leica Model 
MZ9.5 with the appropriate filter, no increase in GFP expression was observed 
in either strain following IR1072 (data not shown). This strain was chosen 
because HSP4 is a homologue to GRP78; a member of the HSP70 family which 
is localised to the endoplasmic reticulum, its expression would be expected 
following the onset of the unfolded protein response. The lack of GFP-HSP4 
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expression following IR1072 exposure suggests that exposure is not stress 
inducing. The SJ4100, [zcIs13 hsp-6::gfp], strain were used in lifespan 
experiments, HSP6 is expressed specially following mitochondrial stress and 
governs the mitochondrial-specific unfolded protein response. The lack of 
observable GFP-HSP6 expression in this strain suggests that IR1072 is not 
causing stress to the mitochondria and a lifespan extension effect is still 
observed.  
However, it was also determined that strains expressing proteins under GFP-
tagged promoters are not particularly sensitive to mild heat stress, as the strains 
required exposure to 30°C for over one hour and 37°C for a minimum of 36 
minutes to observe any increase in GFP levels. Significant chemical 
intervention was required to achieve an observable increase in GFP levels, 
using tunicamycin (1-5 μg/ml, HSP4; Calfon et al., 2002, Yoneda et al., 2004) 
and ethidium bromide (25-125 μg/ml, HSP6; Yoneda et al., 2004), or significant 
heat exposure (one hour at 37°C, HSP16.2 this study; four hours at 27.5°C, 
HSP16.2; Dawe et al., 2006), data not shown. These suggest that GFP based 
biomarkers may not be sensitive markers of moderate stress (Dawe et al., 
2006). 
The development of protocol 2.9.4 resulted in significant extension of SS104, 
glp-4 (bn2)I, lifespan, without the possibility of the effect being due to heating. 
Further work with a range of strains of C. elegans was performed in order to 
further elucidate a potential mechanism of action. Through using the GR1307, 
daf-16 (mgDf50) I, strain the lifespan effect was eliminated. This strain is a 
homozygous knock out for DAF-16, a FOXO-family transcription factor. DAF-16 
is a forkhead transcription factor which is able to regulate a range of genes 
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involved in development, metabolism, stress responses and longevity via 
insulin/insulin-like growth factor signalling including Akt kinases and the DAF-12 
nuclear hormone receptor (Lee et al., 2003, Murphy et al., 2003, Singh and 
Aballay, 2006). The removal of any lifespan effect suggests that a DAF-16 
pathway is required for IR1072-induced longevity. Knockdown of hsf-1 
expression in the PS3551, hsf-1(sy441) I, strain also resulted in the eradication 
of the lifespan effect found with SS104, glp-4 (bn2)I, strain. This gives further 
evidence to support that the longevity induced by IR1072 is a product of a DAF-
16 derived pathway as HSF1 regulated proteins, such as chaperones, are one 
of the main downstream effectors of this pathway, see figure 7.22 (Singh and 
Aballay, 2006), DAF16 and HSF1 are both required to activate HSP expression. 
Loss of HSF1 function has been previously reported to result in decreased 
longevity (Garigan et al., 2002) and increased copies result in increased 
lifespan (Hsu et al., 2003, Morley and Morimoto, 2004), as outlined in the 
Introduction 7.1.3. 
Further lifespan studies utilising the RB1104 strain, a nematode with a deletion 
affecting HSP3, found that the loss of this chaperone also resulted in the loss of 
the longevity effect. This was particularly interesting as it provided an insight 
into particular heat shock proteins that are required for longevity effect observed 
following chronic IR1072 exposure. HSP3, a homologue to GRP78, an ER 
based member of the HSP70 family, has previously been shown to interact with 
Aβ, suggesting a protective action to direct Aβ toward refolding or degradation 
rather than secretion (Fonte et al., 2002). These lifespans were conducted 
alongside SS104 and N2 lifespans to act as positive controls. 
 
 
321 
 
Figure 7.22. HSF1 activated by Heat shock (HS) and the DAF-2/DAF-16 pathway enhances 
protection against protein aggregation based disease. Abbreviations: HSF1, Heat Shock Factor 
1; HSP, Heat Shock Protein; sHSP, small Heat Shock Protein. 
It is also interesting to note that previous work investigating whether 
compensatory mechanisms of chaperones in nematodes occur, as in 
mammalian systems, RNAi knock down of HSP3 resulted in HSP4 (a second 
GRP78 homologue in nematodes) upregulation (which is also upregulated when 
other ER based chaperones are compromised). This is a very clear example of 
a chaperone compensatory mechanism, as both HSP3 and HSP4 encode 
members of the HSP70 family and presumably have similar function. This 
compensatory mechanism was also significant enough to prevent an increase in 
toxicity following the onset of Aβ expression (Kapulkin et al., 2005). However, it 
appears that the detrimental effect of HSP3 knock down in the strain used in the 
lifespans within this investigation was not able to be compensated for by HSP4 
upregulation. Assuming HSP3 would be able to be act in a similar protective 
manner as HSP4 in lifespan extension, as is suggested in the literature, no 
compensatory lifespan extension effect was observed in the RB1104 strain 
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when exposed to IR1072 (see table 7.12 and figure 7.18). This suggests that 
significant stresses, such as aggregates, are required to be present in order for 
sufficient compensation mechanisms to be initiated and these are not found 
during ‘normal’ nematode ageing, or that HSP4 does not function in the same 
manner as HSP3 in the ageing of C. elegans. Downregulation of individual 
chaperones has been shown to reduce longevity, but not as significantly as 
reduction in HSF1 itself, suggests that networks of chaperones function 
together in longevity (Morley and Morimoto, 2004). 
It would be of significant interest to conduct lifespan studies with further strains 
of C. elegans with other heat shock proteins knocked out/removed to identify 
whether any other chaperones are essential in the longevity response seen with 
chronic IR1072 treatment. However, it is not possible to generate knock out 
strains for the majority of the chaperones identified in C. elegans as they are 
detailed as lethal (see wormbase.org), thus limiting the investigation of roles of 
other chaperone proteins found to be altered in the mouse models which have 
been investigated in this research, and their role in NIR lifespan extension. This 
limitation could be tackled by attempting RNAi of proteins of interest in adult 
nematodes. 
The absorption spectra generated from both soluble and insoluble protein 
fractions of C. elegans homogenates provides some interesting data. These 
were preliminary experiments and only investigated C. elegans which had not 
been IR1072 exposed as a great quantity of nematodes were required in order 
to isolate sufficient quantities of protein in order to read the spectrum. In future it 
would be of interest to also investigate the absorption spectra of nematodes 
exposed to IR1072 in order to identify whether the peaks in absorption alter. 
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There do not appear to be any significant peaks in absorbance in the soluble 
fraction of protein at the range of wavelengths emitted by the LED IR1072 array. 
However, there is a broad peak in absorbance in the insoluble fraction, 
containing  membrane bound/associated proteins, ranging from 1150 – 1000 
nm, which appears to peak in the shaded section that identifies the range of 
wavelength emitted by the LEDs. These data also provide information that 
identifies that there is a peak in absorbance at the wavelength of IR of interest, 
suggesting that there is indeed a primary photoacceptor present in the 
nematode. These data also give a valuable insight into where (protein fraction) 
to search for the photoacceptor which is responsible for the absorption of 
IR1072 in the nematode. There remains a great deal of research to be done 
with this data however, as the structure responsible for the absorption of IR1072 
remains unknown. Preliminary work with absorption spectra for bacterial 
cultures has not identified a peak in absorbance in the infrared region of 
interest. Work using mass spectroscopy would begin to unravel what biological 
material is responsible for the broad absorption peak seen from 1150 - 1000 nm 
in figure 7.21. 
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7.4 Future work 
To further explore the role of HSP3 in the longevity effect observed following 
chronic IR1072, it would be beneficial to utilise RNAi against hsp3 to verify that 
this is not a strain specific loss of effect – RNAi could be used to knock out 
expression in the N2 or SS104 strain, strains where lifespan increases has 
been repeatedly verified in this investigation. Concurrently a HSP3 transgene 
could be introduced back into the RB1104 strain. Through adding HSP3 back 
into the strain, it would be of great interest to investigate whether the lifespan 
effect could be reinstated and to establish that the loss of effect is not a product 
of the strain mutation process. 
Investigation of other available chaperone knock out strains or via RNAi in adult 
nematodes, particularly those which have been shown to compensate for other 
chaperones, such as HSP4, and nematode orthologues to chaperone proteins 
which have been shown to be altered in mice that have been chronically 
exposed to IR1072, including HSP16.2 (nematode equivalent to mammalian αB 
crystallin), would be of great interest to investigate. 
Microarray screens to identify genes whose expression is altered following 
IR1072 exposure is another possible set of experiments to conduct. However, 
even when genes are identified that are altered, further lifespans with the genes 
of interest removed or RNAi-targeted may not provide definitive answers as to 
the role of these genes in the biological effects of IR1072 because the 
phenotype of IR1072 exposure is not particularly strong. If the lifespan 
extension was of greater magnitude, it would be easier to identify genes of 
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interest in the biological effect of LLLT at this wavelength in C. elegans. 
However, initial microarray work would be significantly informative. 
Future work with C. elegans and IR1072 would be to investigate the effects on 
models of disease, particularly focussing on models of Alzheimer’s disease; 
there are several models of Alzheimer’s disease which express the toxic β-
amyloid(1-42) peptide. Nematodes that express the peptide in their muscle wall 
display progressive paralysis, but nematodes that express the β-amyloid 
peptide pan-neuronally display no apparent phenotype despite having neuronal 
deposits of Aβ (Link, 2006, Link et al., 2003, Wolozin et al., 2011). This raises 
questions of the validity of such models, as expression driven by different 
promoters and in different cell types has profound effects on the end phenotype. 
Another issue is that C. elegans do not express APP, or the β-secretase that 
cleaves APP prior to γ-secretase creating the Aβ(1-42) toxic fragment, so the 
processing of APP cannot be examined. Cellular response to neuronal damage 
appears to depend on the location of the cell damage, different responses 
depending on the closeness to the soma, an added complication when utilising 
this model to investigate a human disease (Link, 2006, Link et al., 2003, 
Wolozin et al., 2011), therefore choice of strain and the obtained results must 
be carefully considered. 
Nematode models of AD do show oxidative stress, as in human cases and 
some strains have been shown to have tau-based toxicity, loss of GABA-ergic 
neurons, motor dysfunction and premature death. A lack of immune system also 
means the effects of microglial activation in AD cannot be investigated in the 
nematode models, as although nematodes have glia they function as sensory 
receptive sites, acting like neuronal sheaths not dissimilar to the role of 
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Schwann cells to muscle fibres. Nevertheless, nematode models have proved 
useful for examining the oxidation processes that occur immediately prior to Aβ 
deposition and for identifying genes that are activated when Aβ is expressed, as 
some models only begin to express Aβ upon temperature shift of the 
nematodes (Dimitriadi and Hart, 2010, Leung et al., 2008, Link, 2006, Link et 
al., 2003, Wolozin et al., 2011). 
Investigations by Fonte, 2002, found that much like in the human system, a 
range of intracellular chaperone proteins interacted with β-amyloid, in a C. 
elegans strain expressing the human sequence of the peptide. Utilising co-
immunoprecipitation, the investigators found that six chaperone proteins bound 
to Aβ; including two HSP70 family members, three HSP16 family members and 
another protein that is believed to regulate HSP70 function. These data suggest 
that even in C. elegans Aβ is aptly recognised as an abnormal protein and is 
targeted for removal, via chaperones much like as has been reported in AD 
(Fonte et al., 2002). This mechanism is not specific to Aβ, protein aggregation 
increases with nematode age and it is believed that increased copies of hsf-1 or 
specific heat shock protein genes counteract protein aggregation resulting in 
longevity, a mechanism by which may be utilised by IR1072 (Fonte et al., 2002, 
Walker and Lithgow, 2003, Wolozin et al., 2011). Lifespan experiments with 
IR1072 and this model would be of significant interest to conduct. 
In the future, it would be of significant interest to explore the effects of alternate 
IR1072 exposure protocols; and to conduct lifespan studies with daf-2 mutant 
strains to identify whether IR1072 can further extend nematodes with long 
lifespans. It would also be important to assess metabolic ageing of IR1072 
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exposed nematode. This could be conducted through examining mobility, 
pharyngeal pumping, lucigenin and ADP/ATP levels (Huang et al., 2004).  
Caenorhabditis elegans are a very valuable model system to begin research 
into the mechanism through which IR1072 elicits its biological effects, but as a 
system it has a number of limitations many of which restrict the translation of 
results to the understanding of human disease. However, in this investigation 
the nematode has provided a significant insight into the proteins/processes 
responsible for the biological effects of IR1072 observed in a number of murine 
models, aiding in the direction of further research and comprehension of the 
purported NIR mechanism of action. 
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Chapter 8: Overall Discussion and Future Work 
 
The aim of this project was to elucidate the photobiological effects of LLLT at 
IR1072 through the use of in vivo and in vitro systems, encompassing the use 
of two mouse strains, CD-1 and TASTPM; murine neuronal culture cell line 
CAD, and the well-characterised model of ageing, Caenorhabditis elegans. 
Previous investigations using IR1072 have established a number of significant 
effects of LLLT on several biological systems. Work by Bradford, 2005, 
established a cytoprotective effect of IR1072 against UVA toxicity on human 
lymphocytes and Burroughs, 2010, found IR1072 exposure provided a 
concentration-dependent protection of rat primary cultures against glutamate-
induced excitotoxicity (Bradford et al., 2005, Burroughs, 2010).  
Therefore, an aim for this investigation was to determine whether IR1072 could 
protect against other insults; Aβ, a causal factor in AD, and hydrogen peroxide, 
a by-product of cellular damage commonly detected alongside the degeneration 
of AD. This investigation has shown the beneficial effects of IR1072 exposure in 
a clonal CAD neuronal cell line, where IR1072 exposure is able to protect 
against both hydrogen peroxide insults and Aβ insults to a significant degree. 
As with excitotoxic insults utilising glutamate (Burroughs, 2010), IR1072 
exposure provided an insult-severity-dependent level of protection against cell 
death. Interestingly, a significant level of protection was consistently observed 
following Aβ insults despite the use of high concentrations which may only be 
on the limits of realistic in vivo concentrations (Benilova et al., 2012, Hu et al., 
2009). 
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However, a significant number of studies, utilising a range of NIR wavelengths 
have consistently demonstrated that LLLT can cause proliferation in a number 
of cell types; fibroblasts (Hawkins and Abrahamse, 2006, Taniguchi et al., 2009, 
Vinck et al., 2003), osteoblasts (Kreisler et al., 2003, Pires Oliveira et al., 2008, 
Ueda and Shimizu, 2003), muscle cells and epithelial cells (Sommer et al., 
2001, Whelan et al., 2001). Therefore, absence of increased proliferation in this 
investigation suggests that this wavelength is indeed protecting against cell 
death rather than causing proliferation of the cells, to mask the level of cell 
death that occurs as a result of toxic insults. 
The mechanism of this neuroprotection requires further investigation. The use 
of the CAD system provides a suitable model system in which to determine 
protein changes underlying neuroprotection. The levels of a number of proteins, 
particularly chaperones, are increased following IR1072 exposure in vivo. A 
number of chaperones have been reported to interact with Aβ in vivo and in 
vitro, therefore further characterisation of the CAD cell line is required to 
determine if these proteins are involved in the neuroprotective response 
mounted against the toxicity of Aβ. Work in our laboratory has already 
established that CAD cells do not express αB crystallin, a sHSP reported to 
exacerbate Aβ toxicity (Mao et al., 2001, Narayanan et al., 2006, Shammas et 
al., 2011, Stege et al., 1999, Yoo et al., 2001) and consistently shown to be 
modulated by IR1072 in murine tissue in this investigation. 
As discussed in introduction 1.1.3, the primary site of the absorption of NIR is 
believed to occur through photoacceptors located in the mitochondria, 
particularly cytochrome c oxidase. Previous work with IR1072 found acute 
exposure increased ETC activity, via complex II in the brain 7 month old CD-1 
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mice (Burroughs, 2010). The finding that female TASTPM mice have higher 
levels of Complex I and Complex II activity than their male counterparts, in 
control conditions is particularly interesting. This finding may provide an 
explanation for the considerable differences in the effects of chronic IR1072 
exposure on protein levels in female TASTPM mice compared to males. This 
higher endogenous ETC activity in female mice may be a result of a naturally 
reduced mitochondrial state, with more electrons available to increase the 
activity of the ETC, as cells with a more reduced oxidation state are reported to 
be more susceptible to the biological effects of NIR (Gao and Xing, 2009, 
Hamblin and Demidova, 2006, Karu, 1999, Karu, 2008, Karu et al., 2005). It is 
also interesting to note that following acute IR1072 exposure, 3 month old CD-1 
mice saw reduced Complex I and II activity in liver mitochondria, but increased 
Complex II activity in brain mitochondria, whereas there was no change in 
Complex I activity. Altered liver complex activity is perhaps not surprising, as 
liver chromophores are reported to accept up to 50% of NIR (Beauvoit et al., 
1995, Beauvoit et al., 1994). Thus the Complex I activity may appear reduced 
because there are not sufficient electrons available to generate an adequate 
proton gradient as the cells are overloaded with ATP. The cell’s pool of 
ADP/ATP is finite to the availability of Pi, limiting the production of further ATP if 
there is little ADP available. 
Altered Complex I and Complex II activity in CD-1 mitochondria following acute 
IR1072 exposure, supports data previously obtained demonstrating effects on 
LLLT, at a range of wavelengths, on both Complex I (Liang et al., 2008, Rojas 
et al., 2008, Ying et al., 2008, Zhang et al., 2009) and Complex II (Burroughs, 
2010, Silveira et al., 2009, Silveira et al., 2007) activity levels. This range of 
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data suggests that ETC components, which were previously purported to be 
strict absorbers of light in the blue spectral region, such as Complex I, cannot 
be categorised as simply, as modulation of their activity levels have been 
reported in a number of systems, at a number of wavelengths within the NIR 
range and following a number of different exposure protocols. 
A commonly reported secondary effect of LLLT is increased calcium levels, 
potentially as a result of increased ATP receptor binding due to increased ATP 
turnover following increased ETC activity. Calcium is a universal signalling 
molecule with the ability to modulate a significant number of mechanisms, 
including synaptic plasticity (see Introduction 1.8). Modulation of synaptic 
plasticity by LLLT could provide an explanation for the improved working 
memory observed in CD-1 mice following acute IR1072 exposure in a 3D maze 
(Michalikova et al., 2008). However, calcium signalling was not investigated in 
this study, but it is of significant interest to research in the future. 
It is interesting to note that following acute IR1072 exposure, there was no 
significant change in ATP levels reported in CAD neuroblastoma cells. 
However, ATP levels were only measured immediately following IR exposure 
and at four hours following IR exposure. It may be the case therefore that there 
is no change in ATP levels following IR exposure or that the change was 
transient and occurred at a time point between the times investigated. It may be 
that four hours after exposure, the excess ATP generated has been utilised for 
the initiation of other signalling processes and cannot therefore be detected. To 
further investigate the effect of IR1072 on ATP levels it would be useful to look 
at levels of both ATP and ADP and to determine whether the ATP:ADP ratio 
alters following IR1072 at a greater number of time points following exposure 
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and at a greater range of IR1072 exposure periods. It would also be of 
significant interest to investigate ATP levels in mouse tissue that had been 
irradiated, however this would require a significant number of additional 
methodological considerations to achieve a required level of sensitivity in 
detection (Khan, 2003). 
Several reactions are reported to occur following absorption of NIR, including 
alteration of the redox state and increased electron transfer (Karu et al., 1995). 
As previously mentioned, the oxidation state of the system being irradiated can 
determine the magnitude of the secondary effects elicited through LLLT (Karu, 
1999, Karu, 2008, Karu et al., 2005). As well as this, a reaction called ‘thermal 
relaxation’ is postulated to occur. This process occurs from a small amount of 
local transient heating of photoacceptors during the absorption of NIR (not 
heating the entire cell), resulting in alterations in biochemical activity (Karu et 
al., 1995, Karu et al., 1994). This mechanism may explain the robust nature in 
which alterations in heat shock protein expression are observed in all tissue 
investigated in this study, without any apparent negative results reported 
relating to local heating. 
The effects of IR1072 on the proteins investigated here were not all the same 
when comparing between CD-1 and TASTPM mice, although several 
similarities were present, particularly between male TASTPM and CD-1 young 
mice. However, there were a number of variations, this is most likely to be due 
to strain differences as both lines have different genetic backgrounds and the 
levels of cellular stress are believed to be considerably different between the 
two strains, as by 7 months of age TASTPM mice have a significant amyloid 
load and display some neuronal loss (Howlett et al., 2008), whereas 
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amyloidosis in CD-1 mice only becomes detectable at 8 months and 12 months 
of age for female and male mice respectively, and occurs in a systemic manner, 
rather than specific deposition in the brain (Engelhardt et al., 1993). This may 
also account for the differences observed when identifying proteins that alter 
with age in both the TASTPM and CD-1 strains. Another important factor to take 
into account when considering the results in this investigation is that the 
majority of samples analysed are taken from male mice, CD-1 and TASTPM 
timelines and all CD-1 Young and Old homogenates are from males only. A 
considerable number of proteins that were investigated following chronic 
IR1072 exposure were found to be differentially affected when comparing male 
to female in the TASTPM strain. This raises the question of whether gender 
differences, such as hormonal levels, are responsible for the differing 
magnitudes of secondary effects of IR1072 observed between male and female 
TASTPM mice. 
A limitation of this study is the volume of data obtained through western blotting. 
Western blotting is a particularly useful technique to determine the presence (or 
absence) of a particular protein within a tissue sample, it has a significant 
degree of sensitivity, it can detect nanogram quantities of protein and it has a 
high degree of specificity, due to its ability to separate proteins by molecular 
weight, charge and conformation. The major advantage of western blotting is 
the availability of specific antibodies against proteins and the ease of 
visualisation of protein bands via fluorescence. However analysis of western 
blotting is only semi-quantitative, comparisons of bands is relative to band 
density across the membrane used and advanced techniques, such as mass 
spectrometry, would be required to verify proteins following western blotting. 
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Mass spectrometry of a sample can be used to not only determine the quantity 
of the protein of interest that is present but it can also give information regarding 
modification of the protein, modification which can only be estimated by protein 
size from western blotting. In conjunction with the obtained western blotting 
data, ELISAs could be performed on samples. The ELISA methodology would 
enable greater detail to be obtained regarding the nature of the proteins in 
question, such as Aβ. An ELISA would enable the quantity of soluble and 
insoluble Aβ present; however western blotting would only detect the quantity of 
total Aβ. As mentioned previously, now that proteins of interest have been 
determined it would also be of significant interest to conduct microarrays to 
identify activity of genes of interest. However, western blotting provides a 
superb, replicable, semi-quantitative technique to begin investigating proteins of 
interest (Bolt and Mahoney, 1997, Chery et al., 2006, Cox and Mann, 2007, 
Mann, 2008, Wang et al., 1999). 
Work with C. elegans has provided important insights into mechanisms of LLLT 
as well as secondary effects of absorbance. This investigation has found that 
IR1072 has beneficial effects on more systems than previously established. 
Through a variety of protocols, this investigation has established that IR1072 
can extend lifespan of a number of C. elegans strains. More significantly than 
this, the use of C. elegans has provided important insight into mechanisms of 
increased longevity and has determined that the longevity effect depends on the 
insulin/insulin-like growth factor pathway in the nematode. The nematode 
orthologue of HSP70 (HSP3) was found to be essential for the longevity effect 
induced via IR1072 exposure. This result emphasises the importance of heat 
shock proteins in the beneficial effects of IR1072, as HSP70 is one heat shock 
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protein which has been consistently altered in both TASTPM and CD-1 mice 
following IR1072 exposure. The use of C. elegans as a model system has 
enabled important investigation into signalling processes involved in beneficial 
secondary effects of LLLT. As mentioned in chapter 7, there are several further 
experiments to conduct in order to verify the role of HSP3 in the observed 
increase in nematode longevity following IR1072 exposure. Despite important 
insights gained through the use of C. elegans, they are not an entirely suitable 
model to investigate many of the other heat shock proteins which have been 
found to be significantly altered in mammalian tissue reported in this thesis, as 
knock-out strains of many HSPs have been found to be lethal. The CAD 
neuroblastoma cell line could act to provide more information in this respect, as 
the cell line is further characterised by our laboratory, a range of important 
chaperones could be transfected into the cell line, if they are not already 
present, or overexpressed to determine whether the already beneficial and 
neuroprotective effects of IR1072 can be augmented through upregulation of 
the cell lines own protective mechanisms. 
 
8.1 Further work 
Investigations into IR1072 treatment protocols - Very few permutations of 
the IR exposure protocol have been investigated in mammalian experiments, 
largely due to time constraints and costs. Work with C. elegans enabled 
investigation of a number of exposure protocols, some of which showed no 
beneficial effects whilst others improved on already extended longevity. 
However, the repetitive nature of a number of the protocols conducted with 
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nematodes are not suitable for work with mammals, therefore careful 
consideration of appropriate procedures is required. This demonstrates that 
different protocols may have differing degrees of magnitude in achievable 
biological effects. Future work with alternate exposure protocols in mammalian 
tissues would be interesting to conduct to determine if the proteins altered in 
this investigation are able to be further modified. 
Investigations into ageing in female mice - The timeline samples 
investigated in this research used only male samples of both CD-1 and 
TASTPM mice. Work to investigate whether the same proteins found to be 
altered in age in male mice are modified in female mice, and whether they are 
varied to the same degree would be important to undertake. These data would 
also aid in the understanding of differential effects observed between male and 
female TASTPM mice exposed to chronic IR1072. 
Investigations into the effects of chronic IR1072 exposure on female CD-1 
mice - This investigation focussed on ‘young’ and ‘old’ male CD-1 mice that 
were chronically irradiated. As observed with TASTPM mice, effects of chronic 
IR1072 exposure differ significantly between sexes. Studies paralleled in female 
CD-1 mice would aid in determining whether differences found between male 
and female TASTPM mice are limited to one strain or are consistent across 
strains.  
Investigations into the effects of chronic IR1072 exposure on further age 
points of TASTPM mice - Following the observation that the effects of chronic 
IR1072 differ between CD-1 mice treated from 2 months of age to those treated 
from 7 months of age, similar investigations with TASTPM mice chronically 
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irradiated from later age points would be of significant interest. This may pose 
difficulties due to the high degree of early mortality that has been found in the 
TASTPM mice maintained at the University of Durham LSSU facility. It would 
also be of interest to investigate mice exposed from birth due to the fact that 
amyloid deposition is apparent from two months of age in the TASTPM strain. 
Investigations into calcium, ATP and other signalling molecules - 
Recording levels of these molecules, which are frequently reported to be altered 
following LLLT, would be worthwhile to establish in mammalian systems before 
and after IR1072 exposure. Electrophysiology and the CAD cell line could be 
used to investigate some of these components in vitro. Investigation of such 
signalling molecules would be important in understanding how large scale 
protein changes are initiated. 
Investigations into other proteins of interest in IR1072 exposed mice - As 
previously stated, to aid in understanding of HSPs and reduced Aβ levels, it 
would be advantageous to investigate CHIP, Akt, phosphorylated-αB crystallin 
and GluA1 and to build on GluA2 data obtained. It would also be of interest to 
investigate levels of APP immunohistochemically and levels of non-
amyloidogenic APP products. Significant reduction in male and female TASTPM 
mice of APP was found through immunoblotting, the area/s of the brain have 
reduced levels. 
Investigations with the CAD cells line - Characterisation of the CAD cell line 
is required and following this, the cell line could be manipulated to examine 
certain protein roles, including overexpression of HSPs, pharmacological 
induction of HSPs, in the absence and presence of Aβ. Work with the CAD cell 
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line could also aid in the determination of how IR1072 alters ΔѰm potential, 
ROS levels and mitochondrial motility. The work with cell lines could be 
continued to examine the effect of IR1072 on variants with excess or reduced 
numbers of mitochondria, and in conjunction with Aβ. 
Investigations to determine mechanism of action - Insights from C. elegans, 
determined HSP3, nematode HSP70 equivalent, appeared to be crucial for IR-
induced longevity. Therefore utilising RNAi of HSP3 in wild-type strains would 
help determine whether the knockout of IR1072 induced longevity in HSP3 
deficient nematodes is merely due to an unwanted effect of generating the 
mutant strain. As well as RNAi, outcrossing of the HSP3 knockout strain would 
be important to undertake to identify that the lack of IR1072 induced longevity in 
this strain is dependent on HSP3 alone and not due to an unknown confounding 
factor affecting the mutant strain. 
Investigations into primary photoacceptors of IR1072 - The bulk of data 
published regarding photoacceptors for the infra-red region focuses on 
wavelengths from 600-800 nm. There has been very little research into 
establishing photoacceptors that are responsible for the biological effects 
observed with wavelengths longer than 800 nm. Determination of the 
photoacceptor for 1072 nm would significantly enhance the understanding of 
mechanism of action. Work in this investigation has looked at absorbance 
profile for a selection of isolated cellular components, including mammalian 
mitochondria and soluble and insoluble protein fractions from nematodes. 
These data have shown peaks in absorbance which encompass 1072 nm, 
however further work needs to be carried out to determine precisely which 
proteins are responsible for this absorbance band. Mass spectrometry could aid 
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in this investigation. Determination of the primary photoacceptor would also aid 
in the acceptance of IR1072 as a beneficial treatment for neurodegenerative 
disorders. 
 
8.2 Future Applications 
Based on this research, a double blind, placebo controlled Phase II pilot clinical 
trial was recently completed in the USA to assess the effect of IR1072 exposure 
on the behavioural and cognitive symptoms associated with the early and mid 
stages of dementia in Alzheimer's disease patients. The outcome of which is 
currently under analysis. (www.clinicaltrials.gov) 
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Appendix I - Source of Materials 
 
1.0 Sigma Aldrich, Dorset, UK 
‘Luminol’ 5-Amino-1,4-pthalazinedione free acid 
10X PBS 
ADP (Adenosine 5’-diphosphate sodium salt) 
Agar 
Anti-β actin (ascites fluid) 
Bovine Serum Albumin, essentially fatty acid free 
Calcium Chloride 
Cholesterol 
Copper (II) Sulfate, min 99% 
Developing cassettes 
D-Mannitol 
DPX Mountant 
Ethidium bromide 
Ethyleneglycotetraacetic Acid (EGTA) 
Ethylenediaminetetraacetic Acid (EDTA) 
Folin-Ciolcalteau phenol reagent 
Kodak D-19 Developer 
Kodak Fixative 
L(-) Glutamic acid (non-animal salt) 
L(-) Malic acid disodium salt 
Magnesium sulphate 
p-coumaric Acid 
Peptone N-Z Soy BL7, Enzymatic hydrolysate 
Percoll® (pH 8.5-9.5 at 25°C) 
Potassium Phosphate 
Potassium phosphate monobasic (KH2PO4) 
Pre-Stained Standard Molecular Weight Markers 
Sodium Azide 
Sodium Dodecyl Sulphate (SDS) 
Sodium succinate dibasic hexahydrate, min 99% 
Triton-X100 
Poly-d Lysine 
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1.1 VWR/BDH Laboratory Supplies, Leicestershire, UK 
Acrylogel 3 Solution 40% (v/v) 
Ammonium persulphate 
Bromophenol Blue 
Dimethyl sulphoxide (DMSO) 
Disodium Phosphate (Na2PO4) 
Glycerol 
Isopropanol 
N,N,N’,N’-teranethylethylenediamine (TEMED) 
Potassium chloride 
Potassium phosphate 
Sodium Carbonate 
Sodium Chloride 
Sodium Dihydrogen Phosphate (NaH2PO4) 
Sodium hydrogen carbonate 
Sodium hydroxide 
Sodium potassium tartrate 
Sucrose 
Wheaton Glass dounce homogeniser 
 
1.2 Durham University 
Ethanol 
Marvel 
 
1.3 Fisher Scientific, Leicestershire, UK 
Cling film 
Dithiothreitol (DTT) 
DMEM/F12 plus glutamax 
Glycerol 
Glycine 
Hamilton Microliter 700 Series Syringe Model 705 
Horseradish peroxidase linked anti-mouse antibody 
Horseradish peroxidase linked anti-rabbit antibody 
Hydrochloric acid 1M 
Hyperfilm™ 
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Methanol 
Nitrocellulose Pore size 0.45 μm 
Paraformaldehyde 
Sodium Chloride 
Tris-base 
 
1.4 Invitrogen 
Alexa fluor 488 
ATP Determination Assay 
DAPI (4',6-diamidino-2-phenylindole) 
 
1.5 Cambrex Bio Science, Verviers, Belgium 
Foetal Calf Serum 
 
1.6 Promega Limited, Southampton, UK 
CytoTox96® Non-radioactive Cytotoxicity Assay 
 
1.7 Vector Laboratories, Peterborough, UK 
Biotinylated antibodies, rabbit and mouse 
M.O.M.™ Immunodetection Kit 
Vectastain® ABC Kit 
 
1.8 Calbiochem, Nottingham, UK 
Protease inhibitor cocktail set III 
Mowiol 
 
1.9 Ascent scientific - Now part of AbCam Biochemicals, Cambridge, UK 
β-amyloid(1-42) human peptide 
Tunicamycin 
 
1.10 Pierce 
Pierce SuperSignal West Pico Chemiluminescent Substrate 
Horseradish peroxidise linked anti-goat antibody 
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Appendix II – Thermocouple Reference Table 
 
Figure II.1. Thermocouple reference table 
Obtained from http://www.omega.com/thermocouples.html
 
 
344 
References 
ABISAMBRA, J. F., BLAIR, L. J., HILL, S. E., JONES, J. R., KRAFT, C., 
ROGERS, J., KOREN, J., 3RD, JINWAL, U. K., LAWSON, L., 
JOHNSON, A. G., WILCOCK, D., O'LEARY, J. C., JANSEN-WEST, K., 
MUSCHOL, M., GOLDE, T. E., WEEBER, E. J., BANKO, J. & DICKEY, 
C. A. 2010. Phosphorylation dynamics regulate Hsp27-mediated rescue 
of neuronal plasticity deficits in tau transgenic mice. J Neurosci, 30, 
15374-82. 
ABRAMOV, E., DOLEV, I., FOGEL, H., CICCOTOSTO, G. D., RUFF, E. & 
SLUTSKY, I. 2009. Amyloid-beta as a positive endogenous regulator of 
release probability at hippocampal synapses. Nat Neurosci, 12, 1567-76. 
ADAMS, B., FITCH, T., CHANEY, S. & GERLAI, R. 2002. Altered performance 
characteristics in cognitive tasks: comparison of the albino ICR and CD1 
mouse strains. Behav Brain Res, 133, 351-61. 
ALLISON, P. D. 2010. Survival Analysis Using SAS: A Practical Guide, Second 
Edition, SAS Institute. 
ANCKAR, J. & SISTONEN, L. 2011. Regulation of HSF1 function in the heat 
stress response: implications in aging and disease. Annu Rev Biochem, 
80, 1089-115. 
ARRIGO, A. P., SIMON, S., GIBERT, B., KRETZ-REMY, C., NIVON, M., 
CZEKALLA, A., GUILLET, D., MOULIN, M., DIAZ-LATOUD, C. & 
VICART, P. 2007. Hsp27 (HspB1) and alphaB-crystallin (HspB5) as 
therapeutic targets. FEBS Lett, 581, 3665-74. 
AUGUSTINACK, J. C., SCHNEIDER, A., MANDELKOW, E. M. & HYMAN, B. T. 
2002. Specific tau phosphorylation sites correlate with severity of 
neuronal cytopathology in Alzheimer's disease. Acta Neuropathol, 103, 
26-35. 
AVRAMOPOULOS, D. 2009. Genetics of Alzheimer's disease: recent 
advances. Genome Med, 1, 34. 
BALDUCCI, C. & FORLONI, G. 2011. APP transgenic mice: their use and 
limitations. Neuromolecular Med, 13, 117-37. 
BATS, C., GROC, L. & CHOQUET, D. 2007. The interaction between Stargazin 
and PSD-95 regulates AMPA receptor surface trafficking. Neuron, 53, 
719-34. 
BEAUVOIT, B., EVANS, S. M., JENKINS, T. W., MILLER, E. E. & CHANCE, B. 
1995. Correlation between the light scattering and the mitochondrial 
content of normal tissues and transplantable rodent tumors. Anal 
Biochem, 226, 167-74. 
BEAUVOIT, B., KITAI, T. & CHANCE, B. 1994. Contribution of the 
mitochondrial compartment to the optical properties of the rat liver: a 
theoretical and practical approach. Biophys J, 67, 2501-10. 
BEERE, H. M. 2004. "The stress of dying": the role of heat shock proteins in the 
regulation of apoptosis. J Cell Sci, 117, 2641-51. 
BEERE, H. M. 2005. Death versus survival: functional interaction between the 
apoptotic and stress-inducible heat shock protein pathways. J Clin 
Invest, 115, 2633-9. 
 
 
345 
BENEDETTI, C., HAYNES, C. M., YANG, Y., HARDING, H. P. & RON, D. 2006. 
Ubiquitin-like protein 5 positively regulates chaperone gene expression in 
the mitochondrial unfolded protein response. Genetics, 174, 229-39. 
BENILOVA, I., KARRAN, E. & DE STROOPER, B. 2012. The toxic Abeta 
oligomer and Alzheimer's disease: an emperor in need of clothes. Nat 
Neurosci, 15, 349-57. 
BENN, S. C. & WOOLF, C. J. 2004. Adult neuron survival strategies--slamming 
on the brakes. Nat Rev Neurosci, 5, 686-700. 
BEREZOVSKA, O., LLEO, A., HERL, L. D., FROSCH, M. P., STERN, E. A., 
BACSKAI, B. J. & HYMAN, B. T. 2005. Familial Alzheimer's disease 
presenilin 1 mutations cause alterations in the conformation of presenilin 
and interactions with amyloid precursor protein. J Neurosci, 25, 3009-17. 
BERGMANS, B. A. & DE STROOPER, B. 2010. gamma-secretases: from cell 
biology to therapeutic strategies. Lancet Neurol, 9, 215-26. 
BHAT, R. V., BUDD HAEBERLEIN, S. L. & AVILA, J. 2004. Glycogen synthase 
kinase 3: a drug target for CNS therapies. J Neurochem, 89, 1313-7. 
BIANCHI, L. & DRISCOLL, M. 2006. Culture of embryonic C. elegans cells for 
electrophysiological and pharmacological analyses. WormBook, 1-15. 
BJORKDAHL, C., SJOGREN, M. J., ZHOU, X., CONCHA, H., AVILA, J., 
WINBLAD, B. & PEI, J. J. 2008. Small heat shock proteins Hsp27 or 
alphaB-crystallin and the protein components of neurofibrillary tangles: 
tau and neurofilaments. J Neurosci Res, 86, 1343-52. 
BOLT, M. W. & MAHONEY, P. A. 1997. High-efficiency blotting of proteins of 
diverse sizes following sodium dodecyl sulfate-polyacrylamide gel 
electrophoresis. Anal Biochem, 247, 185-92. 
BRAAK, H. & BRAAK, E. 1991. Neuropathological stageing of Alzheimer-
related changes. Acta Neuropathol, 82, 239-59. 
BRAAK, H. & BRAAK, E. 1995. Staging of Alzheimer's disease-related 
neurofibrillary changes. Neurobiol Aging, 16, 271-8; discussion 278-84. 
BRAAK, H. & BRAAK, E. 1997. Frequency of stages of Alzheimer-related 
lesions in different age categories. Neurobiol Aging, 18, 351-7. 
BRADFORD, A., BARLOW, A. & CHAZOT, P. L. 2005. Probing the differential 
effects of infrared light sources IR1072 and IR880 on human 
lymphocytes: evidence of selective cytoprotection by IR1072. J 
Photochem Photobiol B, 81, 9-14. 
BROOKES, P. S., LEVONEN, A. L., SHIVA, S., SARTI, P. & DARLEY-USMAR, 
V. M. 2002. Mitochondria: regulators of signal transduction by reactive 
oxygen and nitrogen species. Free Radic Biol Med, 33, 755-64. 
BURROUGHS, S. L. 2010. Photobiomodulation with IR1072nm in the murine 
CNS:in vitro and in vivo studies. Ph.D Philosophy, University of Durham. 
BUTOW, R. A. & AVADHANI, N. G. 2004. Mitochondrial signaling: the 
retrograde response. Mol Cell, 14, 1-15. 
CALABRESE, V., SCAPAGNINI, G., RAVAGNA, A., GIUFFRIDA STELLA, A. 
M. & BUTTERFIELD, D. A. 2002. Molecular chaperones and their roles 
in neural cell differentiation. Dev Neurosci, 24, 1-13. 
CALDERWOOD, S. K., MAMBULA, S. S., GRAY, P. J., JR. & THERIAULT, J. 
R. 2007. Extracellular heat shock proteins in cell signaling. FEBS Lett, 
581, 3689-94. 
 
 
346 
CALDERWOOD, S. K., MURSHID, A. & PRINCE, T. 2009. The shock of aging: 
molecular chaperones and the heat shock response in longevity and 
aging--a mini-review. Gerontology, 55, 550-8. 
CALFON, M., ZENG, H., URANO, F., TILL, J. H., HUBBARD, S. R., HARDING, 
H. P., CLARK, S. G. & RON, D. 2002. IRE1 couples endoplasmic 
reticulum load to secretory capacity by processing the XBP-1 mRNA. 
Nature, 415, 92-6. 
CAMPELLO, A. P., VOSS, D. O., FREIRE, S. A. & BACILA, M. 1964. The Role 
of Citrate on the Respiratory Control of Isolated Rat Heart Sarcosomes. J 
Biol Chem, 239, 3842-6. 
CHALFIE, M. & JORGENSEN, E. M. 1998. C. elegans neuroscience: genetics 
to genome. Trends Genet, 14, 506-12. 
CHANCE, B. & WILLIAMS, G. R. 1956a. The respiratory chain and oxidative 
phosphorylation. Adv Enzymol Relat Subj Biochem, 17, 65-134. 
CHANCE, B. & WILLIAMS, G. R. 1956b. Respiratory enzymes in oxidative 
phosphorylation. VI. The effects of adenosine diphosphate on azide-
treated mitochondria. J Biol Chem, 221, 477-89. 
CHEN, S. & BROWN, I. R. 2007. Neuronal expression of constitutive heat 
shock proteins: implications for neurodegenerative diseases. Cell Stress 
Chaperones, 12, 51-8. 
CHEN, X. J., KOVACEVIC, N., LOBAUGH, N. J., SLED, J. G., HENKELMAN, 
R. M. & HENDERSON, J. T. 2006. Neuroanatomical differences between 
mouse strains as shown by high-resolution 3D MRI. Neuroimage, 29, 99-
105. 
CHERY, C., MOENS, L., CORNELIS, R. & VANCHAECKE, F. 2006. 
Capabilities and limitations of gel electrophoresis for elemental 
speciation: A laboratory experience. Pure Appl. Chem., 78, 91-103. 
CHINNERY, P. F. & SCHON, E. A. 2003. Mitochondria. J Neurol Neurosurg 
Psychiatry, 74, 1188-99. 
CONNELL, P., BALLINGER, C. A., JIANG, J., WU, Y., THOMPSON, L. J., 
HOHFELD, J. & PATTERSON, C. 2001. The co-chaperone CHIP 
regulates protein triage decisions mediated by heat-shock proteins. Nat 
Cell Biol, 3, 93-6. 
COX, J. & MANN, M. 2007. Is proteomics the new genomics? Cell, 130, 395-8. 
CULETTO, E. & SATTELLE, D. B. 2000. A role for Caenorhabditis elegans in 
understanding the function and interactions of human disease genes. 
Hum Mol Genet, 9, 869-77. 
DAWE, A. S., SMITH, B., THOMAS, D. W., GREEDY, S., VASIC, N., 
GREGORY, A., LOADER, B. & DE POMERAI, D. I. 2006. A small 
temperature rise may contribute towards the apparent induction by 
microwaves of heat-shock gene expression in the nematode 
Caenorhabditis Elegans. Bioelectromagnetics, 27, 88-97. 
DE VOS, K. J., GRIERSON, A. J., ACKERLEY, S. & MILLER, C. C. 2008. Role 
of axonal transport in neurodegenerative diseases. Annu Rev Neurosci, 
31, 151-73. 
DEHLE, F. C., ECROYD, H., MUSGRAVE, I. F. & CARVER, J. A. 2010. 
alphaB-Crystallin inhibits the cell toxicity associated with amyloid fibril 
formation by kappa-casein and the amyloid-beta peptide. Cell Stress 
Chaperones, 15, 1013-26. 
 
 
347 
DESMET, K. D., PAZ, D. A., CORRY, J. J., EELLS, J. T., WONG-RILEY, M. T., 
HENRY, M. M., BUCHMANN, E. V., CONNELLY, M. P., DOVI, J. V., 
LIANG, H. L., HENSHEL, D. S., YEAGER, R. L., MILLSAP, D. S., LIM, 
J., GOULD, L. J., DAS, R., JETT, M., HODGSON, B. D., MARGOLIS, D. 
& WHELAN, H. T. 2006. Clinical and experimental applications of NIR-
LED photobiomodulation. Photomed Laser Surg, 24, 121-8. 
DEWJI, N. N. & DO, C. 1996. Heat shock factor-1 mediates the transcriptional 
activation of Alzheimer's beta-amyloid precursor protein gene in 
response to stress. Brain Res Mol Brain Res, 35, 325-8. 
DEWJI, N. N., DO, C. & BAYNEY, R. M. 1995. Transcriptional activation of 
Alzheimer's beta-amyloid precursor protein gene by stress. Brain Res 
Mol Brain Res, 33, 245-53. 
DIMITRIADI, M. & HART, A. C. 2010. Neurodegenerative disorders: insights 
from the nematode Caenorhabditis elegans. Neurobiol Dis, 40, 4-11. 
DONOGHUE, P. 2009. Molecular Pharmacology of AMPA Receptor Trafficking 
Proteins - TARPs - Evidence for an Association with 5HT2c Receptors. 
Ph.D Philosophy, University of Durham. 
DORMAN, J. B., ALBINDER, B., SHROYER, T. & KENYON, C. 1995. The age-
1 and daf-2 genes function in a common pathway to control the lifespan 
of Caenorhabditis elegans. Genetics, 141, 1399-406. 
DOU, F., NETZER, W. J., TANEMURA, K., LI, F., HARTL, F. U., TAKASHIMA, 
A., GOURAS, G. K., GREENGARD, P. & XU, H. 2003. Chaperones 
increase association of tau protein with microtubules. Proc Natl Acad Sci 
U S A, 100, 721-6. 
DOUGAL, G. & KELLY, P. 2001. A pilot study of treatment of herpes labialis 
with 1072 nm narrow waveband light. Clin Exp Dermatol, 26, 149-54. 
DUCHEN, M. R. 2004. Roles of mitochondria in health and disease. Diabetes, 
53 Suppl 1, S96-102. 
ECKERT, A., SCHMITT, K. & GOTZ, J. 2011. Mitochondrial dysfunction - the 
beginning of the end in Alzheimer's disease? Separate and synergistic 
modes of tau and amyloid-beta toxicity. Alzheimers Res Ther, 3, 15. 
ECROYD, H. & CARVER, J. A. 2009. Crystallin proteins and amyloid fibrils. Cell 
Mol Life Sci, 66, 62-81. 
EELLS, J. T., HENRY, M. M., SUMMERFELT, P., WONG-RILEY, M. T., 
BUCHMANN, E. V., KANE, M., WHELAN, N. T. & WHELAN, H. T. 2003. 
Therapeutic photobiomodulation for methanol-induced retinal toxicity. 
Proc Natl Acad Sci U S A, 100, 3439-44. 
EELLS, J. T., WONG-RILEY, M. T., VERHOEVE, J., HENRY, M., BUCHMAN, 
E. V., KANE, M. P., GOULD, L. J., DAS, R., JETT, M., HODGSON, B. 
D., MARGOLIS, D. & WHELAN, H. T. 2004. Mitochondrial signal 
transduction in accelerated wound and retinal healing by near-infrared 
light therapy. Mitochondrion, 4, 559-67. 
EL-AGNAF, O. M., NAGALA, S., PATEL, B. P. & AUSTEN, B. M. 2001. Non-
fibrillar oligomeric species of the amyloid ABri peptide, implicated in 
familial British dementia, are more potent at inducing apoptotic cell death 
than protofibrils or mature fibrils. J Mol Biol, 310, 157-68. 
ELLIS, R. J. & VAN DER VIES, S. M. 1991. Molecular chaperones. Annu Rev 
Biochem, 60, 321-47. 
 
 
348 
ENGELHARDT, J. A., GRIES, C. L. & LONG, G. G. 1993. Incidence of 
spontaneous neoplastic and nonneoplastic lesions in Charles River CD-1 
mice varies with breeding origin. Toxicol Pathol, 21, 538-41. 
ENNACEUR, A., MICHALIKOVA, S., VAN RENSBURG, R. & CHAZOT, P. L. 
2006. Models of anxiety: responses of mice to novelty and open spaces 
in a 3D maze. Behav Brain Res, 174, 9-38. 
ENNACEUR, A., MICHALIKOVA, S., VAN RENSBURG, R. & CHAZOT, P. L. 
2008. Detailed analysis of the behavior and memory performance of 
middle-aged male and female CD-1 mice in a 3D maze. Behav Brain 
Res, 187, 312-26. 
ENWEMEKA, C. S. 2004. Therapeutic Light. Rehab Management, 17, 20-5, 56-
7. 
ERNSTER, L. 1993. P/O ratios--the first fifty years. Faseb J, 7, 1520-4. 
EROGLU, B., MOSKOPHIDIS, D. & MIVECHI, N. F. 2010. Loss of Hsp110 
leads to age-dependent tau hyperphosphorylation and early 
accumulation of insoluble amyloid beta. Mol Cell Biol, 30, 4626-43. 
EVANS, C. G., WISEN, S. & GESTWICKI, J. E. 2006. Heat shock proteins 70 
and 90 inhibit early stages of amyloid beta-(1-42) aggregation in vitro. J 
Biol Chem, 281, 33182-91. 
EYLES, S. J. & GIERASCH, L. M. 2010. Nature's molecular sponges: small 
heat shock proteins grow into their chaperone roles. Proc Natl Acad Sci 
U S A, 107, 2727-8. 
FANDRICH, M., SCHMIDT, M. & GRIGORIEFF, N. 2011. Recent progress in 
understanding Alzheimer's beta-amyloid structures. Trends Biochem Sci, 
36, 338-45. 
FONTE, V., KAPULKIN, V., TAFT, A., FLUET, A., FRIEDMAN, D. & LINK, C. D. 
2002. Interaction of intracellular beta amyloid peptide with chaperone 
proteins. Proc Natl Acad Sci U S A, 99, 9439-44. 
FORSTL, H. & KURZ, A. 1999. Clinical features of Alzheimer's disease. Eur 
Arch Psychiatry Clin Neurosci, 249, 288-90. 
FRANK, S., OLIVER, L., LEBRETON-DE COSTER, C., MOREAU, C., 
LECABELLEC, M. T., MICHEL, L., VALLETTE, F. M., DUBERTRET, L. & 
COULOMB, B. 2004. Infrared radiation affects the mitochondrial pathway 
of apoptosis in human fibroblasts. J Invest Dermatol, 123, 823-31. 
FRIEDMAN, D. B. & JOHNSON, T. E. 1988a. A mutation in the age-1 gene in 
Caenorhabditis elegans lengthens life and reduces hermaphrodite 
fertility. Genetics, 118, 75-86. 
FRIEDMAN, D. B. & JOHNSON, T. E. 1988b. Three mutants that extend both 
mean and maximum life span of the nematode, Caenorhabditis elegans, 
define the age-1 gene. J Gerontol, 43, B102-9. 
FRITH, C. H. & CHANDRA, M. 1991. Incidence, distribution, and morphology of 
amyloidosis in Charles Rivers CD-1 mice. Toxicol Pathol, 19, 123-7. 
GANDY, S. 2005. The role of cerebral amyloid beta accumulation in common 
forms of Alzheimer disease. J Clin Invest, 115, 1121-9. 
GAO, X. & XING, D. 2009. Molecular mechanisms of cell proliferation induced 
by low power laser irradiation. J Biomed Sci, 16, 4. 
GARIGAN, D., HSU, A. L., FRASER, A. G., KAMATH, R. S., AHRINGER, J. & 
KENYON, C. 2002. Genetic analysis of tissue aging in Caenorhabditis 
elegans: a role for heat-shock factor and bacterial proliferation. Genetics, 
161, 1101-12. 
 
 
349 
GARRIDO, C. 2002. Size matters: of the small HSP27 and its large oligomers. 
Cell Death Differ, 9, 483-5. 
GARRIDO, C., PAUL, C., SEIGNEURIC, R. & KAMPINGA, H. H. 2012. The 
small heat shock proteins family: The long forgotten chaperones. Int J 
Biochem Cell Biol. 
GIULIANI, A., LORENZINI, L., GALLAMINI, M., MASSELLA, A., GIARDINO, L. 
& CALZA, L. 2009. Low infra red laser light irradiation on cultured neural 
cells: effects on mitochondria and cell viability after oxidative stress. BMC 
Complement Altern Med, 9, 8. 
GLENNER, G. G. & WONG, C. W. 1984. Alzheimer's disease: initial report of 
the purification and characterization of a novel cerebrovascular amyloid 
protein. Biochem Biophys Res Commun, 120, 885-90. 
GOEDERT, M., JAKES, R. & VANMECHELEN, E. 1995. Monoclonal antibody 
AT8 recognises tau protein phosphorylated at both serine 202 and 
threonine 205. Neurosci Lett, 189, 167-9. 
GORDON, S. A. & SURREY, K. 1960. Red and far-red action on oxidative 
phosphorylation. Radiat Res, 12, 325-39. 
GOURAS, G. K., XU, H., GROSS, R. S., GREENFIELD, J. P., HAI, B., WANG, 
R. & GREENGARD, P. 2000. Testosterone reduces neuronal secretion 
of Alzheimer's beta-amyloid peptides. Proc Natl Acad Sci U S A, 97, 
1202-5. 
GRAHAM, L. 2011. Characterisation of transgenic mouse models of Alzheimer's 
disease. University of Dundee. 
GRILLO, S. L., DUGGETT, N. A., ENNACEUR, A. & CHAZOT, P. L. 2013. Non-
invasive infra-red therapy (1072 nm) reduces β-amyloid protein levels in 
the brain of an Alzheimer’s Disease mouse model, TASTPM. Journal of 
Photochemistry and Photobiology B: Biology, 
http://dx.doi.org/10.1016/j.jphotobiol.2013.02.015. 
GUO, J. L. & LEE, V. M. 2011. Seeding of normal Tau by pathological Tau 
conformers drives pathogenesis of Alzheimer-like tangles. J Biol Chem, 
286, 15317-31. 
GUZHOVA, I., KISLYAKOVA, K., MOSKALIOVA, O., FRIDLANSKAYA, I., 
TYTELL, M., CHEETHAM, M. & MARGULIS, B. 2001. In vitro studies 
show that Hsp70 can be released by glia and that exogenous Hsp70 can 
enhance neuronal stress tolerance. Brain Res, 914, 66-73. 
HAASS, C. & SELKOE, D. J. 2007. Soluble protein oligomers in 
neurodegeneration: lessons from the Alzheimer's amyloid beta-peptide. 
Nat Rev Mol Cell Biol, 8, 101-12. 
HAMBLIN, M. R. & DEMIDOVA, T. N. 2006. Mechanisms of low level light 
therapy. Proc. of SPIE, 6140, 614001-12. 
HANGER, D. P., ANDERTON, B. H. & NOBLE, W. 2009. Tau phosphorylation: 
the therapeutic challenge for neurodegenerative disease. Trends Mol 
Med, 15, 112-9. 
HARDY, J. 1997. Amyloid, the presenilins and Alzheimer's disease. Trends 
Neurosci, 20, 154-9. 
HARDY, J. & ALLSOP, D. 1991. Amyloid deposition as the central event in the 
aetiology of Alzheimer's disease. Trends Pharmacol Sci, 12, 383-8. 
HARTLEY, D. M., WALSH, D. M., YE, C. P., DIEHL, T., VASQUEZ, S., 
VASSILEV, P. M., TEPLOW, D. B. & SELKOE, D. J. 1999. Protofibrillar 
intermediates of amyloid beta-protein induce acute electrophysiological 
 
 
350 
changes and progressive neurotoxicity in cortical neurons. J Neurosci, 
19, 8876-84. 
HARTUNG, T., BALLS, M., BARDOUILLE, C., BLANCK, O., COECKE, S., 
GSTRAUNTHALER, G. & LEWIS, D. 2002. Good Cell Culture Practice. 
ECVAM Good Cell Culture Practice Task Force Report 1. Altern Lab 
Anim, 30, 407-14. 
HASLBECK, M., FRANZMANN, T., WEINFURTNER, D. & BUCHNER, J. 2005. 
Some like it hot: the structure and function of small heat-shock proteins. 
Nat Struct Mol Biol, 12, 842-6. 
HATAYAMA, T., HONDA, K. & YUKIOKA, M. 1986. HeLa cells synthesize a 
specific heat shock protein upon exposure to heat shock at 42 degrees C 
but not at 45 degrees C. Biochem Biophys Res Commun, 137, 957-63. 
HATAYAMA, T., YAMAGISHI, N., MINOBE, E. & SAKAI, K. 2001. Role of 
hsp105 in protection against stress-induced apoptosis in neuronal PC12 
cells. Biochem Biophys Res Commun, 288, 528-34. 
HATAYAMA, T. & YASUDA, K. 1998. Association of HSP105 with HSC70 in 
high molecular mass complexes in mouse FM3A cells. Biochem Biophys 
Res Commun, 248, 395-401. 
HAWKINS, D. H. & ABRAHAMSE, H. 2006. The role of laser fluence in cell 
viability, proliferation, and membrane integrity of wounded human skin 
fibroblasts following helium-neon laser irradiation. Lasers Surg Med, 38, 
74-83. 
HENDRICK, J. P. & HARTL, F. U. 1993. Molecular chaperone functions of heat-
shock proteins. Annu Rev Biochem, 62, 349-84. 
HENSHEL, D., LIM, J., SANDERS, R., ALI, Z., PATEL, A., 
GOPALAKRISHNAN, S., LARK, D., SNYDER, A. C., EELLS, J. T. & 
WATKINS, J. 2009. 57. Photobiomodulation reduces cellular oxidative 
stress in an animal model of diabetes. Mitochondrion, 9, 1-1. 
HERNANDEZ, F., DE BARREDA, E. G., FUSTER-MATANZO, A., GONI-
OLIVER, P., LUCAS, J. J. & AVILA, J. 2009. The role of GSK3 in 
Alzheimer disease. Brain Res Bull, 80, 248-50. 
HESCHL, M. F. & BAILLIE, D. L. 1989. Characterization of the hsp70 multigene 
family of Caenorhabditis elegans. DNA, 8, 233-43. 
HOBERT, O. 2005. Specification of the nervous system. WormBook, 1-19. 
HOMBURGER, F., RUSSFIELD, A. B., WEISBURGER, J. H., LIM, S., CHAK, 
S. P. & WEISBURGER, E. K. 1975. Aging changes in CD-1 HaM/ICR 
mice reared under standard laboratory conditions. J Natl Cancer Inst, 55, 
37-45. 
HOSHINO, T., MURAO, N., NAMBA, T., TAKEHARA, M., ADACHI, H., 
KATSUNO, M., SOBUE, G., MATSUSHIMA, T., SUZUKI, T. & 
MIZUSHIMA, T. 2011. Suppression of Alzheimer's disease-related 
phenotypes by expression of heat shock protein 70 in mice. J Neurosci, 
31, 5225-34. 
HOWLETT, D. R. 2006. P1-034: Quantification of cortical neurodegeneration in 
APP X PS1 transgenic mice. Alzheimer's & dementia : the journal of the 
Alzheimer's Association, 2, S104. 
HOWLETT, D. R., BOWLER, K., SODEN, P. E., RIDDELL, D., DAVIS, J. B., 
RICHARDSON, J. C., BURBIDGE, S. A., GONZALEZ, M. I., IRVING, E. 
A., LAWMAN, A., MIGLIO, G., DAWSON, E. L., HOWLETT, E. R. & 
HUSSAIN, I. 2008. Abeta deposition and related pathology in an APP x 
 
 
351 
PS1 transgenic mouse model of Alzheimer's disease. Histol Histopathol, 
23, 67-76. 
HOWLETT, D. R. & RICHARDSON, J. C. 2009. The pathology of APP 
transgenic mice: a model of Alzheimer's disease or simply 
overexpression of APP? Histol Histopathol, 24, 83-100. 
HOWLETT, D. R., RICHARDSON, J. C., AUSTIN, A., PARSONS, A. A., BATE, 
S. T., DAVIES, D. C. & GONZALEZ, M. I. 2004. Cognitive correlates of 
Abeta deposition in male and female mice bearing amyloid precursor 
protein and presenilin-1 mutant transgenes. Brain Res, 1017, 130-6. 
HSU, A. L., MURPHY, C. T. & KENYON, C. 2003. Regulation of aging and age-
related disease by DAF-16 and heat-shock factor. Science, 300, 1142-5. 
HU, X., CRICK, S. L., BU, G., FRIEDEN, C., PAPPU, R. V. & LEE, J. M. 2009. 
Amyloid seeds formed by cellular uptake, concentration, and aggregation 
of the amyloid-beta peptide. Proc Natl Acad Sci U S A, 106, 20324-9. 
HUANG, C., XIONG, C. & KORNFELD, K. 2004. Measurements of age-related 
changes of physiological processes that predict lifespan of 
Caenorhabditis elegans. Proc Natl Acad Sci U S A, 101, 8084-9. 
HUANG, Y. & MUCKE, L. 2012. Alzheimer mechanisms and therapeutic 
strategies. Cell, 148, 1204-22. 
HUANG, Y. Y., CHEN, A. C., CARROLL, J. D. & HAMBLIN, M. R. 2009. 
Biphasic dose response in low level light therapy. Dose Response, 7, 
358-83. 
HURTADO, O., DE CRISTOBAL, J., SANCHEZ, V., LIZASOAIN, I., 
CARDENAS, A., PEREIRA, M. P., COLADO, M. I., LEZA, J. C., 
LORENZO, P. & MORO, M. A. 2003. Inhibition of glutamate release by 
delaying ATP fall accounts for neuroprotective effects of antioxidants in 
experimental stroke. Faseb J, 17, 2082-4. 
HUSSAIN, I., HAWKINS, J., HARRISON, D., COLLIER, S., VINSON, M., 
BURBIDGE, S. A. & DAVIS, J. B. 2006. P1-033: The identification of 
distinct pools of Aβ in the brains of TASTPM mice. Alzheimer's & 
dementia : the journal of the Alzheimer's Association, 2, S104. 
HYLANDER, B. L., CHEN, X., GRAF, P. C. & SUBJECK, J. R. 2000. The 
distribution and localization of hsp110 in brain. Brain Res, 869, 49-55. 
ISHIHARA, K., YASUDA, K. & HATAYAMA, T. 1999. Molecular cloning, 
expression and localization of human 105 kDa heat shock protein, 
hsp105. Biochim Biophys Acta, 1444, 138-42. 
ISOBE, I., YANAGISAWA, K. & MICHIKAWA, M. 2000. A possible model of 
senile plaques using synthetic amyloid beta-protein and rat glial culture. 
Exp Neurol, 162, 51-60. 
ITTNER, L. M. & GOTZ, J. 2011. Amyloid-beta and tau--a toxic pas de deux in 
Alzheimer's disease. Nat Rev Neurosci, 12, 65-72. 
JAYA, N., GARCIA, V. & VIERLING, E. 2009. Substrate binding site flexibility of 
the small heat shock protein molecular chaperones. Proc Natl Acad Sci 
U S A, 106, 15604-9. 
JOHNSON, L. V., WALSH, M. L., BOCKUS, B. J. & CHEN, L. B. 1981. 
Monitoring of relative mitochondrial membrane potential in living cells by 
fluorescence microscopy. J Cell Biol, 88, 526-35. 
JOHNSON, T. E. 2003. Advantages and disadvantages of Caenorhabditis 
elegans for aging research. Exp Gerontol, 38, 1329-32. 
 
 
352 
JOHNSON, T. E. 2008. Caenorhabditis elegans 2007: the premier model for the 
study of aging. Exp Gerontol, 43, 1-4. 
JONES, D. & CANDIDO, E. P. 1999. Feeding is inhibited by sublethal 
concentrations of toxicants and by heat stress in the nematode 
Caenorhabditis elegans: relationship to the cellular stress response. J 
Exp Zool, 284, 147-57. 
JORGENSEN, E. M. 2004. Dopamine: should I stay or should I go now? Nat 
Neurosci, 7, 1019-21. 
KAKIMURA, J., KITAMURA, Y., TAKATA, K., UMEKI, M., SUZUKI, S., 
SHIBAGAKI, K., TANIGUCHI, T., NOMURA, Y., GEBICKE-HAERTER, 
P. J., SMITH, M. A., PERRY, G. & SHIMOHAMA, S. 2002. Microglial 
activation and amyloid-beta clearance induced by exogenous heat-shock 
proteins. Faseb J, 16, 601-3. 
KAMENETZ, F., TOMITA, T., HSIEH, H., SEABROOK, G., BORCHELT, D., 
IWATSUBO, T., SISODIA, S. & MALINOW, R. 2003. APP processing 
and synaptic function. Neuron, 37, 925-37. 
KANG, J., LEMAIRE, H. G., UNTERBECK, A., SALBAUM, J. M., MASTERS, C. 
L., GRZESCHIK, K. H., MULTHAUP, G., BEYREUTHER, K. & MULLER-
HILL, B. 1987. The precursor of Alzheimer's disease amyloid A4 protein 
resembles a cell-surface receptor. Nature, 325, 733-6. 
KANSKI, J., VARADARAJAN, S., AKSENOVA, M. & BUTTERFIELD, D. A. 
2002. Role of glycine-33 and methionine-35 in Alzheimer's amyloid beta-
peptide 1-42-associated oxidative stress and neurotoxicity. Biochim 
Biophys Acta, 1586, 190-8. 
KAPULKIN, W. J., HIESTER, B. G. & LINK, C. D. 2005. Compensatory 
regulation among ER chaperones in C. elegans. FEBS Lett, 579, 3063-8. 
KARU, T. 1999. Primary and secondary mechanisms of action of visible to near-
IR radiation on cells. J Photochem Photobiol B, 49, 1-17. 
KARU, T. 2010a. Mitochondrial mechanisms of photobiomodulation in context 
of new data about multiple roles of ATP. Photomed Laser Surg, 28, 159-
60. 
KARU, T., PYATIBRAT, L. & KALENDO, G. 1995. Irradiation with He-Ne laser 
increases ATP level in cells cultivated in vitro. J Photochem Photobiol B, 
27, 219-23. 
KARU, T., TIPHLOVA, O., ESENALIEV, R. & LETOKHOV, V. 1994. Two 
different mechanisms of low-intensity laser photobiological effects on 
Escherichia coli. J Photochem Photobiol B, 24, 155-61. 
KARU, T. I. 1988. Molecular Mechanism of the Therapeutic Effect of Low-
Intensity Laser Radiation. Lasers in the Life Sciences, 2, 53-74. 
KARU, T. I. 2008. Mitochondrial signaling in mammalian cells activated by red 
and near-IR radiation. Photochem Photobiol, 84, 1091-9. 
KARU, T. I. 2010b. Multiple roles of cytochrome c oxidase in mammalian cells 
under action of red and IR-A radiation. IUBMB Life, 62, 607-10. 
KARU, T. I. & KOLYAKOV, S. F. 2005. Exact action spectra for cellular 
responses relevant to phototherapy. Photomed Laser Surg, 23, 355-61. 
KARU, T. I., PYATIBRAT, L. V. & AFANASYEVA, N. I. 2004. A novel 
mitochondrial signaling pathway activated by visible-to-near infrared 
radiation. Photochem Photobiol, 80, 366-72. 
KARU, T. I., PYATIBRAT, L. V., KOLYAKOV, S. F. & AFANASYEVA, N. I. 
2005. Absorption measurements of a cell monolayer relevant to 
 
 
353 
phototherapy: reduction of cytochrome c oxidase under near IR radiation. 
J Photochem Photobiol B, 81, 98-106. 
KAYED, R., HEAD, E., THOMPSON, J. L., MCINTIRE, T. M., MILTON, S. C., 
COTMAN, C. W. & GLABE, C. G. 2003. Common structure of soluble 
amyloid oligomers implies common mechanism of pathogenesis. 
Science, 300, 486-9. 
KENYON, C. 2011. The first long-lived mutants: discovery of the insulin/IGF-1 
pathway for ageing. Philos Trans R Soc Lond B Biol Sci, 366, 9-16. 
KENYON, C. J. 2010. The genetics of ageing. Nature, 464, 504-12. 
KHAKH, B. S. & BURNSTOCK, G. 2009. The double life of ATP. Sci Am, 301, 
84-90, 92. 
KHAN, H. A. 2003. Bioluminometric assay of ATP in mouse brain: Determinant 
factors for enhanced test sensitivity. J Biosci, 28, 379-82. 
KING, M., NAFAR, F., CLARKE, J. & MEAROW, K. 2009. The small heat shock 
protein Hsp27 protects cortical neurons against the toxic effects of beta-
amyloid peptide. J Neurosci Res, 87, 3161-75. 
KLASS, M. R. 1977. Aging in the nematode Caenorhabditis elegans: major 
biological and environmental factors influencing life span. Mech Ageing 
Dev, 6, 413-29. 
KOREN, J., 3RD, JINWAL, U. K., LEE, D. C., JONES, J. R., SHULTS, C. L., 
JOHNSON, A. G., ANDERSON, L. J. & DICKEY, C. A. 2009. Chaperone 
signalling complexes in Alzheimer's disease. J Cell Mol Med, 13, 619-30. 
KRANENBURG, O., BOUMA, B., GENT, Y. Y., AARSMAN, C. J., KAYED, R., 
POSTHUMA, G., SCHIKS, B., VOEST, E. E. & GEBBINK, M. F. 2005. 
Beta-amyloid (Abeta) causes detachment of N1E-115 neuroblastoma 
cells by acting as a scaffold for cell-associated plasminogen activation. 
Mol Cell Neurosci, 28, 496-508. 
KREISLER, M., CHRISTOFFERS, A. B., WILLERSHAUSEN, B. & D'HOEDT, B. 
2003. Effect of low-level GaAlAs laser irradiation on the proliferation rate 
of human periodontal ligament fibroblasts: an in vitro study. J Clin 
Periodontol, 30, 353-8. 
KUDVA, Y. C., HIDDINGA, H. J., BUTLER, P. C., MUESKE, C. S. & 
EBERHARDT, N. L. 1997. Small heat shock proteins inhibit in vitro A 
beta(1-42) amyloidogenesis. FEBS Lett, 416, 117-21. 
KURT, M. A., DAVIES, D. C., KIDD, M., DUFF, K. & HOWLETT, D. R. 2003. 
Hyperphosphorylated tau and paired helical filament-like structures in the 
brains of mice carrying mutant amyloid precursor protein and mutant 
presenilin-1 transgenes. Neurobiol Dis, 14, 89-97. 
KURT, M. A., DAVIES, D. C., KIDD, M., DUFF, K., ROLPH, S. C., JENNINGS, 
K. H. & HOWLETT, D. R. 2001. Neurodegenerative changes associated 
with beta-amyloid deposition in the brains of mice carrying mutant 
amyloid precursor protein and mutant presenilin-1 transgenes. Exp 
Neurol, 171, 59-71. 
LAFERLA, F. M. 2010. Pathways linking Abeta and tau pathologies. Biochem 
Soc Trans, 38, 993-5. 
LANNEAU, D., WETTSTEIN, G., BONNIAUD, P. & GARRIDO, C. 2010. Heat 
shock proteins: cell protection through protein triage. 
ScientificWorldJournal, 10, 1543-52. 
 
 
354 
LEE, S. S., KENNEDY, S., TOLONEN, A. C. & RUVKUN, G. 2003. DAF-16 
target genes that control C. elegans life-span and metabolism. Science, 
300, 644-7. 
LEITZ, G., FALLMAN, E., TUCK, S. & AXNER, O. 2002. Stress response in 
Caenorhabditis elegans caused by optical tweezers: wavelength, power, 
and time dependence. Biophys J, 82, 2224-31. 
LEMIRE, B. D., BEHRENDT, M., DECORBY, A. & GASKOVA, D. 2009. C. 
elegans longevity pathways converge to decrease mitochondrial 
membrane potential. Mech Ageing Dev, 130, 461-5. 
LEUNG, M. C., WILLIAMS, P. L., BENEDETTO, A., AU, C., HELMCKE, K. J., 
ASCHNER, M. & MEYER, J. N. 2008. Caenorhabditis elegans: an 
emerging model in biomedical and environmental toxicology. Toxicol Sci, 
106, 5-28. 
LIANG, H. L., WHELAN, H. T., EELLS, J. T., MENG, H., BUCHMANN, E., 
LERCH-GAGGL, A. & WONG-RILEY, M. 2006. Photobiomodulation 
partially rescues visual cortical neurons from cyanide-induced apoptosis. 
Neuroscience, 139, 639-49. 
LIANG, H. L., WHELAN, H. T., EELLS, J. T. & WONG-RILEY, M. T. 2008. 
Near-infrared light via light-emitting diode treatment is therapeutic 
against rotenone- and 1-methyl-4-phenylpyridinium ion-induced 
neurotoxicity. Neuroscience, 153, 963-74. 
LIANG, J. J. 2000. Interaction between beta-amyloid and lens alphaB-crystallin. 
FEBS Lett, 484, 98-101. 
LINK, C. D. 2006. C. elegans models of age-associated neurodegenerative 
diseases: lessons from transgenic worm models of Alzheimer's disease. 
Exp Gerontol, 41, 1007-13. 
LINK, C. D., TAFT, A., KAPULKIN, V., DUKE, K., KIM, S., FEI, Q., WOOD, D. 
E. & SAHAGAN, B. G. 2003. Gene expression analysis in a transgenic 
Caenorhabditis elegans Alzheimer's disease model. Neurobiol Aging, 24, 
397-413. 
LITHGOW, G. J., WHITE, T. M., MELOV, S. & JOHNSON, T. E. 1995. 
Thermotolerance and extended life-span conferred by single-gene 
mutations and induced by thermal stress. Proc Natl Acad Sci U S A, 92, 
7540-4. 
LIU, S. J., GASPERINI, R., FOA, L. & SMALL, D. H. 2010. Amyloid-beta 
decreases cell-surface AMPA receptors by increasing intracellular 
calcium and phosphorylation of GluR2. J Alzheimers Dis, 21, 655-66. 
LORENZO, A. & YANKNER, B. A. 1994. Beta-amyloid neurotoxicity requires 
fibril formation and is inhibited by congo red. Proc Natl Acad Sci U S A, 
91, 12243-7. 
LOWRY, O. H., ROSEBROUGH, N. J., FARR, A. L. & RANDALL, R. J. 1951. 
Protein measurement with the Folin phenol reagent. J Biol Chem, 193, 
265-75. 
MACARIO, A. J. & CONWAY DE MACARIO, E. 2005. Sick chaperones, cellular 
stress, and disease. N Engl J Med, 353, 1489-501. 
MACARIO, A. J. & CONWAY DE MACARIO, E. 2007. Chaperonopathies by 
defect, excess, or mistake. Ann N Y Acad Sci, 1113, 178-91. 
MAGRANE, J., SMITH, R. C., WALSH, K. & QUERFURTH, H. W. 2004. Heat 
shock protein 70 participates in the neuroprotective response to 
 
 
355 
intracellularly expressed beta-amyloid in neurons. J Neurosci, 24, 1700-
6. 
MAN, H. Y. 2011. GluA2-lacking, calcium-permeable AMPA receptors--inducers 
of plasticity? Curr Opin Neurobiol, 21, 291-8. 
MANN, M. 2008. Can proteomics retire the western blot? J Proteome Res, 7, 
3065. 
MAO, J. J., KATAYAMA, S., WATANABE, C., HARADA, Y., NODA, K., 
YAMAMURA, Y. & NAKAMURA, S. 2001. The relationship between 
alphaB-crystallin and neurofibrillary tangles in Alzheimer's disease. 
Neuropathol Appl Neurobiol, 27, 180-8. 
MARKHAM, A., CAMERON, I., FRANKLIN, P. & SPEDDING, M. 2004. BDNF 
increases rat brain mitochondrial respiratory coupling at complex I, but 
not complex II. Eur J Neurosci, 20, 1189-96. 
MATHUR, A., HONG, Y., KEMP, B. K., BARRIENTOS, A. A. & ERUSALIMSKY, 
J. D. 2000. Evaluation of fluorescent dyes for the detection of 
mitochondrial membrane potential changes in cultured cardiomyocytes. 
Cardiovasc Res, 46, 126-38. 
MATSUZAKI, K. 2011. Formation of Toxic Amyloid Fibrils by Amyloid beta-
Protein on Ganglioside Clusters. Int J Alzheimers Dis, 2011, 956104. 
MATTSON, M. P. & LIU, D. 2003. Mitochondrial potassium channels and 
uncoupling proteins in synaptic plasticity and neuronal cell death. 
Biochem Biophys Res Commun, 304, 539-49. 
MAURAGE, C. A., SERGEANT, N., RUCHOUX, M. M., HAUW, J. J. & 
DELACOURTE, A. 2003. Phosphorylated serine 199 of microtubule-
associated protein tau is a neuronal epitope abundantly expressed in 
youth and an early marker of tau pathology. Acta Neuropathol, 105, 89-
97. 
MAYER, M. P. & BUKAU, B. 2005. Hsp70 chaperones: cellular functions and 
molecular mechanism. Cell Mol Life Sci, 62, 670-84. 
MEARES, G. P., ZMIJEWSKA, A. A. & JOPE, R. S. 2008. HSP105 interacts 
with GRP78 and GSK3 and promotes ER stress-induced caspase-3 
activation. Cell Signal, 20, 347-58. 
MEDRADO, A. P., SOARES, A. P., SANTOS, E. T., REIS, S. R. & ANDRADE, 
Z. A. 2008. Influence of laser photobiomodulation upon connective tissue 
remodeling during wound healing. J Photochem Photobiol B, 92, 144-52. 
MICHALIKOVA, S., ENNACEUR, A., VAN RENSBURG, R. & CHAZOT, P. L. 
2008. Emotional responses and memory performance of middle-aged 
CD1 mice in a 3D maze: effects of low infrared light. Neurobiol Learn 
Mem, 89, 480-8. 
MICHALIKOVA, S., VAN RENSBURG, R., CHAZOT, P. L. & ENNACEUR, A. 
2010. Anxiety responses in Balb/c, c57 and CD-1 mice exposed to a 
novel open space test. Behav Brain Res, 207, 402-17. 
MIRONOV, S. L. 2007. ADP regulates movements of mitochondria in neurons. 
Biophys J, 92, 2944-52. 
MIZUMORI, S. J., ROSENZWEIG, M. R. & KERMISCH, M. G. 1982. Failure of 
mice to demonstrate spatial memory in the radial maze. Behav Neural 
Biol, 35, 33-45. 
MOCHIZUKI-ODA, N., KATAOKA, Y., CUI, Y., YAMADA, H., HEYA, M. & 
AWAZU, K. 2002. Effects of near-infra-red laser irradiation on adenosine 
 
 
356 
triphosphate and adenosine diphosphate contents of rat brain tissue. 
Neurosci Lett, 323, 207-10. 
MORLEY, J. F. & MORIMOTO, R. I. 2004. Regulation of longevity in 
Caenorhabditis elegans by heat shock factor and molecular chaperones. 
Mol Biol Cell, 15, 657-64. 
MORRIS, J. Z., TISSENBAUM, H. A. & RUVKUN, G. 1996. A 
phosphatidylinositol-3-OH kinase family member regulating longevity and 
diapause in Caenorhabditis elegans. Nature, 382, 536-9. 
MOSSER, D. D., CARON, A. W., BOURGET, L., DENIS-LAROSE, C. & 
MASSIE, B. 1997. Role of the human heat shock protein hsp70 in 
protection against stress-induced apoptosis. Mol Cell Biol, 17, 5317-27. 
MOSSER, D. D., CARON, A. W., BOURGET, L., MERIIN, A. B., SHERMAN, M. 
Y., MORIMOTO, R. I. & MASSIE, B. 2000. The chaperone function of 
hsp70 is required for protection against stress-induced apoptosis. Mol 
Cell Biol, 20, 7146-59. 
MUCHOWSKI, P. J. & WACKER, J. L. 2005. Modulation of neurodegeneration 
by molecular chaperones. Nat Rev Neurosci, 6, 11-22. 
MURPHY, C. T., MCCARROLL, S. A., BARGMANN, C. I., FRASER, A., 
KAMATH, R. S., AHRINGER, J., LI, H. & KENYON, C. 2003. Genes that 
act downstream of DAF-16 to influence the lifespan of Caenorhabditis 
elegans. Nature, 424, 277-83. 
NARAYANAN, S., KAMPS, B., BOELENS, W. C. & REIF, B. 2006. alphaB-
crystallin competes with Alzheimer's disease beta-amyloid peptide for 
peptide-peptide interactions and induces oxidation of Abeta-Met35. 
FEBS Lett, 580, 5941-6. 
NICHOLL, I. D. & QUINLAN, R. A. 1994. Chaperone activity of alpha-crystallins 
modulates intermediate filament assembly. EMBO J, 13, 945-53. 
NICHOLLS, D. G. & BUDD, S. L. 2000. Mitochondria and neuronal survival. 
Physiol Rev, 80, 315-60. 
NOVOSELOVA, E. G., GLUSHKOVA, O. V., CHERENKOV, D. A., 
CHUDNOVSKY, V. M. & FESENKO, E. E. 2006. Effects of low-power 
laser radiation on mice immunity. Photodermatol Photoimmunol 
Photomed, 22, 33-8. 
O'BRIEN, R. J. & WONG, P. C. 2011. Amyloid precursor protein processing and 
Alzheimer's disease. Annu Rev Neurosci, 34, 185-204. 
OGG, S., PARADIS, S., GOTTLIEB, S., PATTERSON, G. I., LEE, L., 
TISSENBAUM, H. A. & RUVKUN, G. 1997. The Fork head transcription 
factor DAF-16 transduces insulin-like metabolic and longevity signals in 
C. elegans. Nature, 389, 994-9. 
OH, H. J., EASTON, D., MURAWSKI, M., KANEKO, Y. & SUBJECK, J. R. 
1999. The chaperoning activity of hsp110. Identification of functional 
domains by use of targeted deletions. J Biol Chem, 274, 15712-8. 
OHTSUKA, K. & SUZUKI, T. 2000. Roles of molecular chaperones in the 
nervous system. Brain Res Bull, 53, 141-6. 
OJHA, J., KARMEGAM, R. V., MASILAMONI, J. G., TERRY, A. V. & 
CASHIKAR, A. G. 2011. Behavioral defects in chaperone-deficient 
Alzheimer's disease model mice. PLoS One, 6, e16550. 
OKADA, E., FIRBANK, M., SCHWEIGER, M., ARRIDGE, S. R., COPE, M. & 
DELPY, D. T. 1997. Theoretical and experimental investigation of near-
 
 
357 
infrared light propagation in a model of the adult head. Appl Opt, 36, 21-
31. 
OLSEN, A., VANTIPALLI, M. C. & LITHGOW, G. J. 2006a. Lifespan extension 
of Caenorhabditis elegans following repeated mild hormetic heat 
treatments. Biogerontology, 7, 221-30. 
OLSEN, A., VANTIPALLI, M. C. & LITHGOW, G. J. 2006b. Using 
Caenorhabditis elegans as a model for aging and age-related diseases. 
Ann N Y Acad Sci, 1067, 120-8. 
OLSSON, T., HANSSON, O., NYLANDSTED, J., JAATTELA, M., SMITH, M. L. 
& WIELOCH, T. 2004. Lack of neuroprotection by heat shock protein 70 
overexpression in a mouse model of global cerebral ischemia. Exp Brain 
Res, 154, 442-9. 
OW, Y. P., GREEN, D. R., HAO, Z. & MAK, T. W. 2008. Cytochrome c: 
functions beyond respiration. Nat Rev Mol Cell Biol, 9, 532-42. 
OWEN-REECE, H., ELWELL, C. E., HARKNESS, W., GOLDSTONE, J., 
DELPY, D. T., WYATT, J. S. & SMITH, M. 1996. Use of near infrared 
spectroscopy to estimate cerebral blood flow in conscious and 
anaesthetized adult subjects. Br J Anaesth, 76, 43-8. 
PAGANINI-HILL, A. & HENDERSON, V. W. 1994. Estrogen deficiency and risk 
of Alzheimer's disease in women. Am J Epidemiol, 140, 256-61. 
PARCELLIER, A., SCHMITT, E., BRUNET, M., HAMMANN, A., SOLARY, E. & 
GARRIDO, C. 2005. Small heat shock proteins HSP27 and alphaB-
crystallin: cytoprotective and oncogenic functions. Antioxid Redox Signal, 
7, 404-13. 
PASSARELLA, S., CASAMASSIMA, E., MOLINARI, S., PASTORE, D., 
QUAGLIARIELLO, E., CATALANO, I. M. & CINGOLANI, A. 1984. 
Increase of proton electrochemical potential and ATP synthesis in rat 
liver mitochondria irradiated in vitro by helium-neon laser. FEBS Lett, 
175, 95-9. 
PATIL, S. S., SUNYER, B., HOGER, H. & LUBEC, G. 2009. Evaluation of 
spatial memory of C57BL/6J and CD1 mice in the Barnes maze, the 
Multiple T-maze and in the Morris water maze. Behav Brain Res, 198, 
58-68. 
PATTERSON, K. R., WARD, S. M., COMBS, B., VOSS, K., KANAAN, N. M., 
MORFINI, G., BRADY, S. T., GAMBLIN, T. C. & BINDER, L. I. 2011. 
Heat shock protein 70 prevents both tau aggregation and the inhibitory 
effects of preexisting tau aggregates on fast axonal transport. 
Biochemistry, 50, 10300-10. 
PEARSON, R. C. & POWELL, T. P. 1989. The neuroanatomy of Alzheimer's 
disease. Rev Neurosci, 2, 101-22. 
PEREZ, N., SUGAR, J., CHARYA, S., JOHNSON, G., MERRIL, C., BIERER, 
L., PERL, D., HAROUTUNIAN, V. & WALLACE, W. 1991. Increased 
synthesis and accumulation of heat shock 70 proteins in Alzheimer's 
disease. Brain Res Mol Brain Res, 11, 249-54. 
PIRES OLIVEIRA, D. A., DE OLIVEIRA, R. F., ZANGARO, R. A. & SOARES, 
C. P. 2008. Evaluation of low-level laser therapy of osteoblastic cells. 
Photomed Laser Surg, 26, 401-4. 
PREVILLE, X., SALVEMINI, F., GIRAUD, S., CHAUFOUR, S., PAUL, C., 
STEPIEN, G., URSINI, M. V. & ARRIGO, A. P. 1999. Mammalian small 
stress proteins protect against oxidative stress through their ability to 
 
 
358 
increase glucose-6-phosphate dehydrogenase activity and by 
maintaining optimal cellular detoxifying machinery. Exp Cell Res, 247, 
61-78. 
PUGH, P. L., RICHARDSON, J. C., BATE, S. T., UPTON, N. & SUNTER, D. 
2007. Non-cognitive behaviours in an APP/PS1 transgenic model of 
Alzheimer's disease. Behav Brain Res, 178, 18-28. 
QI, Y., WANG, J. K., MCMILLIAN, M. & CHIKARAISHI, D. M. 1997. 
Characterization of a CNS cell line, CAD, in which morphological 
differentiation is initiated by serum deprivation. J Neurosci, 17, 1217-25. 
RAMSDEN, M., NYBORG, A. C., MURPHY, M. P., CHANG, L., STANCZYK, F. 
Z., GOLDE, T. E. & PIKE, C. J. 2003. Androgens modulate beta-amyloid 
levels in male rat brain. J Neurochem, 87, 1052-5. 
RANKIN, C. A., SUN, Q. & GAMBLIN, T. C. 2007. Tau phosphorylation by 
GSK-3beta promotes tangle-like filament morphology. Mol 
Neurodegener, 2, 12. 
RANKIN, C. A., SUN, Q. & GAMBLIN, T. C. 2008. Pre-assembled tau filaments 
phosphorylated by GSK-3b form large tangle-like structures. Neurobiol 
Dis, 31, 368-377. 
READ, D. E. & GORMAN, A. M. 2009. Heat shock protein 27 in neuronal 
survival and neurite outgrowth. Biochem Biophys Res Commun, 382, 6-
8. 
REDDY, P. H. 2011. Abnormal tau, mitochondrial dysfunction, impaired axonal 
transport of mitochondria, and synaptic deprivation in Alzheimer's 
disease. Brain Res, 1415, 136-48. 
RENKAWEK, K., VOORTER, C. E., BOSMAN, G. J., VAN WORKUM, F. P. & 
DE JONG, W. W. 1994. Expression of alpha B-crystallin in Alzheimer's 
disease. Acta Neuropathol, 87, 155-60. 
RICHARDSON, J. C., KENDAL, C. E., ANDERSON, R., PRIEST, F., GOWER, 
E., SODEN, P., GRAY, R., TOPPS, S., HOWLETT, D. R., LAVENDER, 
D., CLARKE, N. J., BARNES, J. C., HAWORTH, R., STEWART, M. G. & 
RUPNIAK, H. T. 2003. Ultrastructural and behavioural changes precede 
amyloid deposition in a transgenic model of Alzheimer's disease. 
Neuroscience, 122, 213-28. 
RIDDLE, D. L. 1997. C. elegans II, Plainview, N.Y., Cold Spring Harbor 
Laboratory Press. 
ROGALLA, T., EHRNSPERGER, M., PREVILLE, X., KOTLYAROV, A., 
LUTSCH, G., DUCASSE, C., PAUL, C., WIESKE, M., ARRIGO, A. P., 
BUCHNER, J. & GAESTEL, M. 1999. Regulation of Hsp27 
oligomerization, chaperone function, and protective activity against 
oxidative stress/tumor necrosis factor alpha by phosphorylation. J Biol 
Chem, 274, 18947-56. 
ROJAS, J. C., LEE, J., JOHN, J. M. & GONZALEZ-LIMA, F. 2008. 
Neuroprotective effects of near-infrared light in an in vivo model of 
mitochondrial optic neuropathy. J Neurosci, 28, 13511-21. 
SAHARA, N., MAEDA, S., YOSHIIKE, Y., MIZOROKI, T., YAMASHITA, S., 
MURAYAMA, M., PARK, J. M., SAITO, Y., MURAYAMA, S. & 
TAKASHIMA, A. 2007. Molecular chaperone-mediated tau protein 
metabolism counteracts the formation of granular tau oligomers in human 
brain. J Neurosci Res, 85, 3098-108. 
 
 
359 
SAITO, Y., YAMAGISHI, N. & HATAYAMA, T. 2007. Different localization of 
Hsp105 family proteins in mammalian cells. Exp Cell Res, 313, 3707-17. 
SAITO, Y., YAMAGISHI, N. & HATAYAMA, T. 2009. Nuclear localization 
mechanism of Hsp105beta and its possible function in mammalian cells. 
J Biochem, 145, 185-91. 
SAMALI, A., HOLMBERG, C. I., SISTONEN, L. & ORRENIUS, S. 1999. 
Thermotolerance and cell death are distinct cellular responses to stress: 
dependence on heat shock proteins. FEBS Lett, 461, 306-10. 
SAMALI, A., ROBERTSON, J. D., PETERSON, E., MANERO, F., VAN ZEIJL, 
L., PAUL, C., COTGREAVE, I. A., ARRIGO, A. P. & ORRENIUS, S. 
2001. Hsp27 protects mitochondria of thermotolerant cells against 
apoptotic stimuli. Cell Stress Chaperones, 6, 49-58. 
SAWIN, E. R., RANGANATHAN, R. & HORVITZ, H. R. 2000. C. elegans 
locomotory rate is modulated by the environment through a dopaminergic 
pathway and by experience through a serotonergic pathway. Neuron, 26, 
619-31. 
SCHAFER, W. R. 2005. Deciphering the neural and molecular mechanisms of 
C. elegans behavior. Curr Biol, 15, R723-9. 
SCHEFFLER, I. E. 2001. A century of mitochondrial research: achievements 
and perspectives. Mitochondrion, 1, 3-31. 
SCHMITT, K., GRIMM, A., KAZMIERCZAK, A., STROSZNAJDER, J. B., GOTZ, 
J. & ECKERT, A. 2012. Insights into Mitochondrial Dysfunction: Aging, 
Amyloid-beta, and Tau-A Deleterious Trio. Antioxid Redox Signal, 16, 
1456-66. 
SCHOLZEN, T. & GERDES, J. 2000. The Ki-67 protein: from the known and the 
unknown. J Cell Physiol, 182, 311-22. 
SEKI, M., NAWA, H., MORIOKA, T., FUKUCHI, T., OITE, T., ABE, H. & TAKEI, 
N. 2002. Establishment of a novel enzyme-linked immunosorbent assay 
for Thy-1; quantitative assessment of neuronal degeneration. Neurosci 
Lett, 329, 185-8. 
SHAMMAS, S. L., WAUDBY, C. A., WANG, S., BUELL, A. K., KNOWLES, T. 
P., ECROYD, H., WELLAND, M. E., CARVER, J. A., DOBSON, C. M. & 
MEEHAN, S. 2011. Binding of the molecular chaperone alphaB-crystallin 
to Abeta amyloid fibrils inhibits fibril elongation. Biophys J, 101, 1681-9. 
SHANKAR, G. M., LI, S., MEHTA, T. H., GARCIA-MUNOZ, A., SHEPARDSON, 
N. E., SMITH, I., BRETT, F. M., FARRELL, M. A., ROWAN, M. J., 
LEMERE, C. A., REGAN, C. M., WALSH, D. M., SABATINI, B. L. & 
SELKOE, D. J. 2008. Amyloid-beta protein dimers isolated directly from 
Alzheimer's brains impair synaptic plasticity and memory. Nat Med, 14, 
837-42. 
SHARP, F. R., MASSA, S. M. & SWANSON, R. A. 1999. Heat-shock protein 
protection. Trends Neurosci, 22, 97-9. 
SHERMAN, M. Y. & GOLDBERG, A. L. 2001. Cellular defenses against 
unfolded proteins: a cell biologist thinks about neurodegenerative 
diseases. Neuron, 29, 15-32. 
SHIMURA, H., MIURA-SHIMURA, Y. & KOSIK, K. S. 2004. Binding of tau to 
heat shock protein 27 leads to decreased concentration of 
hyperphosphorylated tau and enhanced cell survival. J Biol Chem, 279, 
17957-62. 
 
 
360 
SHINOHARA, H., INAGUMA, Y., GOTO, S., INAGAKI, T. & KATO, K. 1993. 
Alpha B crystallin and HSP28 are enhanced in the cerebral cortex of 
patients with Alzheimer's disease. J Neurol Sci, 119, 203-8. 
SILVEIRA, P. C., SILVA, L. A., FRAGA, D. B., FREITAS, T. P., STRECK, E. L. 
& PINHO, R. 2009. Evaluation of mitochondrial respiratory chain activity 
in muscle healing by low-level laser therapy. J Photochem Photobiol B, 
95, 89-92. 
SILVEIRA, P. C., STRECK, E. L. & PINHO, R. A. 2007. Evaluation of 
mitochondrial respiratory chain activity in wound healing by low-level 
laser therapy. J Photochem Photobiol B, 86, 279-82. 
SIMPKINS, J. W., GREEN, P. S., GRIDLEY, K. E., SINGH, M., DE FIEBRE, N. 
C. & RAJAKUMAR, G. 1997. Role of estrogen replacement therapy in 
memory enhancement and the prevention of neuronal loss associated 
with Alzheimer's disease. Am J Med, 103, 19S-25S. 
SINGH, V. & ABALLAY, A. 2006. Heat-shock transcription factor (HSF)-1 
pathway required for Caenorhabditis elegans immunity. Proc Natl Acad 
Sci U S A, 103, 13092-7. 
SNUTCH, T. P. & BAILLIE, D. L. 1984. A high degree of DNA strain 
polymorphism associated with the major heat shock gene in 
Caenorhabditis elegans. Mol Gen Genet, 195, 329-35. 
SOMMER, A. P., BIESCHKE, J., FRIEDRICH, R. P., ZHU, D., WANKER, E. E., 
FECHT, H. J., MERELES, D. & HUNSTEIN, W. 2012. 670 nm laser light 
and EGCG complementarily reduce amyloid-beta aggregates in human 
neuroblastoma cells: basis for treatment of Alzheimer's disease? 
Photomed Laser Surg, 30, 54-60. 
SOMMER, A. P., PINHEIRO, A. L., MESTER, A. R., FRANKE, R. P. & 
WHELAN, H. T. 2001. Biostimulatory windows in low-intensity laser 
activation: lasers, scanners, and NASA's light-emitting diode array 
system. J Clin Laser Med Surg, 19, 29-33. 
SOO, E. T., NG, Y. K., BAY, B. H. & YIP, G. W. 2008. Heat shock proteins and 
neurodegenerative disorders. ScientificWorldJournal, 8, 270-4. 
SOTI, C. & CSERMELY, P. 2000. Molecular chaperones and the aging process. 
Biogerontology, 1, 225-33. 
SOTI, C. & CSERMELY, P. 2003. Aging and molecular chaperones. Exp 
Gerontol, 38, 1037-40. 
SOUIL, E., CAPON, A., MORDON, S., DINH-XUAN, A. T., POLLA, B. S. & 
BACHELET, M. 2001. Treatment with 815-nm diode laser induces long-
lasting expression of 72-kDa heat shock protein in normal rat skin. Br J 
Dermatol, 144, 260-6. 
STEGE, G. J., RENKAWEK, K., OVERKAMP, P. S., VERSCHUURE, P., VAN 
RIJK, A. F., REIJNEN-AALBERS, A., BOELENS, W. C., BOSMAN, G. J. 
& DE JONG, W. W. 1999. The molecular chaperone alphaB-crystallin 
enhances amyloid beta neurotoxicity. Biochem Biophys Res Commun, 
262, 152-6. 
STETLER, R. A., GAO, Y., SIGNORE, A. P., CAO, G. & CHEN, J. 2009. 
HSP27: mechanisms of cellular protection against neuronal injury. Curr 
Mol Med, 9, 863-72. 
STRINGHAM, E. G., DIXON, D. K., JONES, D. & CANDIDO, E. P. 1992. 
Temporal and spatial expression patterns of the small heat shock 
 
 
361 
(hsp16) genes in transgenic Caenorhabditis elegans. Mol Biol Cell, 3, 
221-33. 
SUDOH, S., KAWAMURA, Y., SATO, S., WANG, R., SAIDO, T. C., OYAMA, F., 
SAKAKI, Y., KOMANO, H. & YANAGISAWA, K. 1998. Presenilin 1 
mutations linked to familial Alzheimer's disease increase the intracellular 
levels of amyloid beta-protein 1-42 and its N-terminally truncated 
variant(s) which are generated at distinct sites. J Neurochem, 71, 1535-
43. 
SUN, W., QURESHI, H. Y., CAFFERTY, P. W., SOBUE, K., AGARWAL-
MAWAL, A., NEUFIELD, K. D. & PAUDEL, H. K. 2002. Glycogen 
synthase kinase-3beta is complexed with tau protein in brain 
microtubules. J Biol Chem, 277, 11933-40. 
SUN, Y. & MACRAE, T. H. 2005. The small heat shock proteins and their role in 
human disease. Febs J, 272, 2613-27. 
SWEETMAN, A. J. & WEETMAN, D. F. 1969. Polarographic assay of 
monoamine oxidase. Br J Pharmacol, 37, 550P. 
TABNER, B. J., EL-AGNAF, O. M., TURNBULL, S., GERMAN, M. J., 
PALEOLOGOU, K. E., HAYASHI, Y., COOPER, L. J., FULLWOOD, N. J. 
& ALLSOP, D. 2005. Hydrogen peroxide is generated during the very 
early stages of aggregation of the amyloid peptides implicated in 
Alzheimer disease and familial British dementia. J Biol Chem, 280, 
35789-92. 
TANIGUCHI, D., DAI, P., HOJO, T., YAMAOKA, Y., KUBO, T. & TAKAMATSU, 
T. 2009. Low-energy laser irradiation promotes synovial fibroblast 
proliferation by modulating p15 subcellular localization. Lasers Surg Med, 
41, 232-9. 
THORNBERRY, N. A. 1998. Caspases: key mediators of apoptosis. Chem Biol, 
5, R97-103. 
TRIMMER, P. A., SCHWARTZ, K. M., BORLAND, M. K., DE TABOADA, L., 
STREETER, J. & ORON, U. 2009. Reduced axonal transport in 
Parkinson's disease cybrid neurites is restored by light therapy. Mol 
Neurodegener, 4, 26. 
TSAI, C. L., CHEN, J. C. & WANG, W. J. 2001. Near-Infrared Absorption 
Property of Biological Soft Tissue Constituents. Journal of Medical and 
Biological Engineering, 21, 7-14. 
TURTURICI, G., SCONZO, G. & GERACI, F. 2011. Hsp70 and its molecular 
role in nervous system diseases. Biochem Res Int, 2011, 618127. 
UEDA, Y. & SHIMIZU, N. 2003. Effects of pulse frequency of low-level laser 
therapy (LLLT) on bone nodule formation in rat calvarial cells. J Clin 
Laser Med Surg, 21, 271-7. 
VANDENBERGHE, W., NICOLL, R. A. & BREDT, D. S. 2005. Stargazin is an 
AMPA receptor auxiliary subunit. Proc Natl Acad Sci U S A, 102, 485-90. 
VINCK, E. M., CAGNIE, B. J., CORNELISSEN, M. J., DECLERCQ, H. A. & 
CAMBIER, D. C. 2003. Increased fibroblast proliferation induced by light 
emitting diode and low power laser irradiation. Lasers Med Sci, 18, 95-9. 
VIRK, B., CORREIA, G., DIXON, D. P., FEYST, I., JIA, J., OBERLEITNER, N., 
BRIGGS, Z., HODGE, E., EDWARDS, R., WARD, J., GEMS, D. & 
WEINKOVE, D. 2012. Excessive folate synthesis limits lifespan in the C. 
elegans: E. coli aging model. BMC Biol, 10, 67. 
 
 
362 
VOISINE, C., PEDERSEN, J. S. & MORIMOTO, R. I. 2010. Chaperone 
networks: tipping the balance in protein folding diseases. Neurobiol Dis, 
40, 12-20. 
VOSS, K., COMBS, B., PATTERSON, K. R., BINDER, L. I. & GAMBLIN, T. C. 
2012. Hsp70 alters tau function and aggregation in an isoform specific 
manner. Biochemistry, 51, 888-98. 
VOSS, K. & GAMBLIN, T. C. 2009. GSK-3beta phosphorylation of functionally 
distinct tau isoforms has differential, but mild effects. Mol Neurodegener, 
4, 18. 
VOSS, M. R., STALLONE, J. N., LI, M., CORNELUSSEN, R. N., 
KNUEFERMANN, P. & KNOWLTON, A. A. 2003. Gender differences in 
the expression of heat shock proteins: the effect of estrogen. Am J 
Physiol Heart Circ Physiol, 285, H687-92. 
WALKER, G. A. & LITHGOW, G. J. 2003. Lifespan extension in C. elegans by a 
molecular chaperone dependent upon insulin-like signals. Aging Cell, 2, 
131-9. 
WAN, B., LANOUE, K. F., CHEUNG, J. Y. & SCADUTO, R. C., JR. 1989. 
Regulation of citric acid cycle by calcium. J Biol Chem, 264, 13430-9. 
WANG, J., DICKSON, D. W., TROJANOWSKI, J. Q. & LEE, V. M. 1999. The 
levels of soluble versus insoluble brain Abeta distinguish Alzheimer's 
disease from normal and pathologic aging. Exp Neurol, 158, 328-37. 
WELCH, W. J. 1992. Mammalian stress response: cell physiology, 
structure/function of stress proteins, and implications for medicine and 
disease. Physiol Rev, 72, 1063-81. 
WHELAN, H. T., SMITS, R. L., JR., BUCHMAN, E. V., WHELAN, N. T., 
TURNER, S. G., MARGOLIS, D. A., CEVENINI, V., STINSON, H., 
IGNATIUS, R., MARTIN, T., CWIKLINSKI, J., PHILIPPI, A. F., GRAF, W. 
R., HODGSON, B., GOULD, L., KANE, M., CHEN, G. & CAVINESS, J. 
2001. Effect of NASA light-emitting diode irradiation on wound healing. J 
Clin Laser Med Surg, 19, 305-14. 
WHITE, J. G., SOUTHGATE, E., THOMSON, J. N. & BRENNER, S. 1986. The 
structure of the nervous system of the nematode Caenorhabditis 
elegans. Philos Trans R Soc Lond B Biol Sci, 314, 1-340. 
WILHELMUS, M. M., BOELENS, W. C., OTTE-HOLLER, I., KAMPS, B., DE 
WAAL, R. M. & VERBEEK, M. M. 2006a. Small heat shock proteins 
inhibit amyloid-beta protein aggregation and cerebrovascular amyloid-
beta protein toxicity. Brain Res, 1089, 67-78. 
WILHELMUS, M. M., DE WAAL, R. M. & VERBEEK, M. M. 2007. Heat shock 
proteins and amateur chaperones in amyloid-Beta accumulation and 
clearance in Alzheimer's disease. Mol Neurobiol, 35, 203-16. 
WILHELMUS, M. M., OTTE-HOLLER, I., WESSELING, P., DE WAAL, R. M., 
BOELENS, W. C. & VERBEEK, M. M. 2006b. Specific association of 
small heat shock proteins with the pathological hallmarks of Alzheimer's 
disease brains. Neuropathol Appl Neurobiol, 32, 119-30. 
WINKLHOFER, K. F., TATZELT, J. & HAASS, C. 2008. The two faces of 
protein misfolding: gain- and loss-of-function in neurodegenerative 
diseases. EMBO J, 27, 336-49. 
WOGULIS, M., WRIGHT, S., CUNNINGHAM, D., CHILCOTE, T., POWELL, K. 
& RYDEL, R. E. 2005. Nucleation-dependent polymerization is an 
 
 
363 
essential component of amyloid-mediated neuronal cell death. J 
Neurosci, 25, 1071-80. 
WOLOZIN, B., GABEL, C., FERREE, A., GUILLILY, M. & EBATA, A. 2011. 
Watching worms whither: modeling neurodegeneration in C. elegans. 
Prog Mol Biol Transl Sci, 100, 499-514. 
WONG-RILEY, M. T., LIANG, H. L., EELLS, J. T., CHANCE, B., HENRY, M. M., 
BUCHMANN, E., KANE, M. & WHELAN, H. T. 2005. Photobiomodulation 
directly benefits primary neurons functionally inactivated by toxins: role of 
cytochrome c oxidase. J Biol Chem, 280, 4761-71. 
WOOD, W. B. 1988. The Nematode Caenorhabditis Elegans, Cold Spring 
Harbor Laboratory. 
WU, D., CYPSER, J. R., YASHIN, A. I. & JOHNSON, T. E. 2009. Multiple mild 
heat-shocks decrease the Gompertz component of mortality in 
Caenorhabditis elegans. Exp Gerontol, 44, 607-12. 
YAMAGISHI, N., FUJII, H., SAITO, Y. & HATAYAMA, T. 2009. Hsp105beta 
upregulates hsp70 gene expression through signal transducer and 
activator of transcription-3. Febs J, 276, 5870-80. 
YAMAGISHI, N., GOTO, K., NAKAGAWA, S., SAITO, Y. & HATAYAMA, T. 
2010. Hsp105 reduces the protein aggregation and cytotoxicity by 
expanded-polyglutamine proteins through the induction of Hsp70. Exp 
Cell Res, 316, 2424-33. 
YAMAGISHI, N., ISHIHARA, K. & HATAYAMA, T. 2004. Hsp105alpha 
suppresses Hsc70 chaperone activity by inhibiting Hsc70 ATPase 
activity. J Biol Chem, 279, 41727-33. 
YAMAGISHI, N., ISHIHARA, K., SAITO, Y. & HATAYAMA, T. 2003. Hsp105 but 
not Hsp70 family proteins suppress the aggregation of heat-denatured 
protein in the presence of ADP. FEBS Lett, 555, 390-6. 
YAMAGISHI, N., NISHIHORI, H., ISHIHARA, K., OHTSUKA, K. & HATAYAMA, 
T. 2000. Modulation of the chaperone activities of Hsc70/Hsp40 by 
Hsp105alpha and Hsp105beta. Biochem Biophys Res Commun, 272, 
850-5. 
YAMAGISHI, N., YOKOTA, M., YASUDA, K., SAITO, Y., NAGATA, K. & 
HATAYAMA, T. 2011. Characterization of stress sensitivity and 
chaperone activity of Hsp105 in mammalian cells. Biochem Biophys Res 
Commun, 409, 90-5. 
YASUDA, K., NAKAI, A., HATAYAMA, T. & NAGATA, K. 1995. Cloning and 
expression of murine high molecular mass heat shock proteins, HSP105. 
J Biol Chem, 270, 29718-23. 
YENARI, M. A., GIFFARD, R. G., SAPOLSKY, R. M. & STEINBERG, G. K. 
1999. The neuroprotective potential of heat shock protein 70 (HSP70). 
Mol Med Today, 5, 525-31. 
YENARI, M. A., LIU, J., ZHENG, Z., VEXLER, Z. S., LEE, J. E. & GIFFARD, R. 
G. 2005. Antiapoptotic and anti-inflammatory mechanisms of heat-shock 
protein protection. Ann N Y Acad Sci, 1053, 74-83. 
YING, R., LIANG, H. L., WHELAN, H. T., EELLS, J. T. & WONG-RILEY, M. T. 
2008. Pretreatment with near-infrared light via light-emitting diode 
provides added benefit against rotenone- and MPP+-induced 
neurotoxicity. Brain Res, 1243, 167-73. 
YONEDA, T., BENEDETTI, C., URANO, F., CLARK, S. G., HARDING, H. P. & 
RON, D. 2004. Compartment-specific perturbation of protein handling 
 
 
364 
activates genes encoding mitochondrial chaperones. J Cell Sci, 117, 
4055-66. 
YOO, B. C., KIM, S. H., CAIRNS, N., FOUNTOULAKIS, M. & LUBEC, G. 2001. 
Deranged expression of molecular chaperones in brains of patients with 
Alzheimer's disease. Biochem Biophys Res Commun, 280, 249-58. 
YOUNG, A. E., GERMON, T. J., BARNETT, N. J., MANARA, A. R. & NELSON, 
R. J. 2000. Behaviour of near-infrared light in the adult human head: 
implications for clinical near-infrared spectroscopy. Br J Anaesth, 84, 38-
42. 
ZARKOWER, D. 2006. WormBook. In: MEYER, B. J. (ed.) Somatic Sex 
Determination. The C.elegans Research Community. 
ZHANG, R., MIO, Y., PRATT, P. F., LOHR, N., WARLTIER, D. C., WHELAN, H. 
T., ZHU, D., JACOBS, E. R., MEDHORA, M. & BIENENGRAEBER, M. 
2009. Near infrared light protects cardiomyocytes from hypoxia and 
reoxygenation injury by a nitric oxide dependent mechanism. J Mol Cell 
Cardiol, 46, 4-14. 
ZHENG, H., JIANG, M., TRUMBAUER, M. E., SIRINATHSINGHJI, D. J., 
HOPKINS, R., SMITH, D. W., HEAVENS, R. P., DAWSON, G. R., 
BOYCE, S., CONNER, M. W., STEVENS, K. A., SLUNT, H. H., SISODA, 
S. S., CHEN, H. Y. & VAN DER PLOEG, L. H. 1995. beta-Amyloid 
precursor protein-deficient mice show reactive gliosis and decreased 
locomotor activity. Cell, 81, 525-31. 
 
 
